0001654954-23-011271.txt : 20230828 0001654954-23-011271.hdr.sgml : 20230828 20230828160646 ACCESSION NUMBER: 0001654954-23-011271 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 106 CONFORMED PERIOD OF REPORT: 20230531 FILED AS OF DATE: 20230828 DATE AS OF CHANGE: 20230828 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AEHR TEST SYSTEMS CENTRAL INDEX KEY: 0001040470 STANDARD INDUSTRIAL CLASSIFICATION: INSTRUMENTS FOR MEAS & TESTING OF ELECTRICITY & ELEC SIGNALS [3825] IRS NUMBER: 942424084 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22893 FILM NUMBER: 231215457 BUSINESS ADDRESS: STREET 1: 400 KATO TERRACE CITY: FREMONT STATE: CA ZIP: 94539 BUSINESS PHONE: 5106239400 MAIL ADDRESS: STREET 1: 400 KATO TERRACE CITY: FREMONT STATE: CA ZIP: 94539 10-K 1 aehr_10k.htm FORM 10-K aehr_10k.htm

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

FORM 10-K

 

(Mark One)

Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

For the fiscal year ended May 31, 2023

or

 

Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

For the transition period from ________________ to ________________

 

Commission file number: 000-22893.

 

AEHR TEST SYSTEMS

(Exact name of registrant as specified in its charter)

 

California

 

94-2424084

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification Number)

 

 

 

400 KATO TERRACE, FREMONT, CA

 

94539

(Address of principal executive offices)

 

(Zip Code)

   

Registrant’s telephone number, including area code: (510) 623-9400

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.01 per share

AEHR

The NASDAQ Capital Market

 

Securities registered pursuant to Section 12(g) of the Act:  None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ☐ Yes      ☒ No 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Act. ☐ Yes      ☒ No

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes      ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes      ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer

Accelerated filer  

☐ 

 

 

 

 

Non-accelerated filer

Smaller reporting company  

 

 

 

 

 

Emerging growth company

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐ Yes      ☒ No

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐ Yes      ☒ No

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes      ☒ No

 

The aggregate market value of the registrant’s common stock, par value $0.01 per share, held by non-affiliates of the registrant, based upon the closing price of $26.07 on November 30, 2022, as reported on the NASDAQ Capital Market, was $663,547,666. For purposes of this disclosure, shares of common stock held by persons who hold more than 5% of the outstanding shares of common stock (other than such persons of whom the Registrant became aware only through the filing of a Schedule 13G filed with the Securities and Exchange Commission) and shares held by officers and directors of the Registrant have been excluded because such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily conclusive for other purposes.

 

The number of shares of registrant’s common stock, par value $0.01 per share, outstanding at July 31, 2023 was 28,755,426.

 

DOCUMENTS INCORPORATED BY REFERENCE:

 

Portions of registrant’s Definitive Proxy Statement relating to the Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant’s fiscal year ended May 31, 2023.

 

 

 

 

AEHR TEST SYSTEMS

 

FORM 10-K

FISCAL YEAR ENDED MAY 31, 2023

 

TABLE OF CONTENTS

 

PART I

 

 

 

 

 

Item  1.

Business

 

3

 

Item  1A.

Risk Factors

 

10

 

Item  1B.

Unresolved Staff Comments

 

17

 

Item  2.

Properties

 

17

 

Item  3.

Legal Proceedings

 

17

 

Item  4.

Mine Safety Disclosures

 

17

 

 

 

 

 

 

PART II 

 

 

 

 

 

Item  5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

17

 

Item  6.

[Reserved]

 

18

 

Item  7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

18

 

Item  7A.

Quantitative and Qualitative Disclosures about Market Risk

 

24

 

Item  8.

Financial Statements and Supplementary Data

 

25

 

Item  9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

53

 

Item  9A.

Controls and Procedures

 

53

 

Item  9B.

Other Information

 

53

 

Item  9C.

Disclosure Regarding Foreign Jurisdiction that Prevent Inspections

 

53

 

 

 

 

 

 

PART III

 

 

 

 

 

Item 10.

Directors, Executive Officers and Corporate Governance

 

54

 

Item 11.

Executive Compensation

 

54

 

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

54

 

Item 13.

Certain Relationships and Related Transactions, and Director Independence

 

54

 

Item 14.

Principal Accountant Fees and Services

 

54

 

 

 

 

 

 

PART IV

 

 

 

 

 

Item 15.

Exhibits and Financial Statement Schedules

 

55

 

Item 16.

Form 10-K Summary

 

58

 

 

 

 

 

 

 

Signatures

 

59

 

 

 
2

Table of Contents

 

This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). All statements contained in this Annual Report on Form 10-K other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “plan,” “intend,” “expect,” “could,” “target,” “project,” “should,” “predict,” “potential,” “would,” “seek” and similar expressions and the negative of those expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. These risks include but are not limited to those factors identified in “Risk Factors” beginning on page 10 of this Annual Report on Form 10-K, those factors that we may from time to time identify in our periodic filings with the Securities and Exchange Commission, as well as other factors beyond our control. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. Unless the context requires otherwise, references in this Form 10-K to “Aehr Test,” the “Company,” “we,” “us” and “our” refer to Aehr Test Systems.

 

Investors and others should note that we announce material financial information to our investors using our investor relations website (https://www.aehr.com/investor-relations/), SEC filings, press releases, public conference calls and webcasts. We use these channels to communicate with our investors and the public about our company, our products and services and other issues. It is possible that the information we post on our investor relations website could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on our investor relations website.

 

PART I

 

Item 1. Business

 

THE COMPANY

 

Aehr Test Systems, Inc. (“Aehr Test,” “Aehr,” or “we”) was incorporated in the state of California on May 25, 1977 and is headquartered in Fremont, California. We are a leading provider of test solutions for testing, burning-in, and stabilizing semiconductor devices in wafer level, singulated die, and package part form, and have installed thousands of systems worldwide. Increasing quality, reliability, safety, and security needs of semiconductors used across multiple applications, including electric vehicles, electric vehicle charging infrastructure, solar and wind power, computing, data and telecommunications infrastructure, and solid-state memory storage, are driving additional test requirements, incremental capacity needs, and new opportunities for Aehr Test products and solutions. We have developed and introduced several innovative products including the FOX-PTM family of test and burn-in systems and FOX WaferPakTM Aligner, FOX WaferPak Contactor, FOX DiePak® Carrier and FOX DiePak Loader. The FOX-XP and FOX-NP systems are full wafer contact and singulated die/module test and burn-in systems that can test, burn-in, and stabilize a wide range of devices such as leading-edge silicon carbide-based and other power semiconductors, 2D and 3D sensors used in mobile phones, tablets, and other computing devices, memory semiconductors, processors, microcontrollers, systems-on-a-chip, and photonics and integrated optical devices. The FOX-CP system is a low-cost single-wafer compact test solution for logic, memory and photonic devices and the newest addition to the FOX-P product family. The FOX WaferPak Contactor contains a unique full wafer contactor capable of testing wafers up to 300mm that enables IC manufacturers to perform test, burn-in, and stabilization of full wafers on the FOX-P systems. The FOX DiePak Carrier allows testing, burn-in, and stabilization of singulated bare die and modules up to 1,024 devices in parallel per DiePak on the FOX-NP and FOX-XP systems up to nine DiePaks at a time.

 

INDUSTRY BACKGROUND

 

Semiconductor manufacturing is a complex, multi-step process, and defects or weaknesses that may result in the failure of a semiconductor device may be introduced at any process step. Failures may occur immediately or at any time during the operating life of the device, sometimes after several months of normal use. Semiconductor manufacturers rely on testing and reliability screening to identify and eliminate defects that occur during the manufacturing process.

 

Testing and reliability screening involve multiple steps. The first set of tests is typically performed by semiconductor device manufacturers before the processed semiconductor wafer is cut into individual die, in order to avoid the cost of packaging defective die into their packages. This “wafer probe” testing can be performed on one or many die at a time, including testing the entire wafer at once. Most leading-edge microprocessors, microcontrollers, digital signal processors, memory ICs, sensors, power and optical devices (such as vertical-cavity surface-emitting lasers, or VCSELs) then undergo an extensive reliability screening and stress testing procedure known as burn-in or cycling, depending on the application. This can either be done at the wafer level, before the die are packaged, or at the package level, after the die are packaged. The burn-in process screens for early failures by operating the device at elevated voltages and

 

 
3

Table of Contents

 

temperatures, at up to 150 degrees Celsius (302 degrees Fahrenheit) or higher. Depending upon the application, the burn-in times can range anywhere from minutes to hours or even days. A typical burn-in system can process thousands of devices simultaneously. After burn-in, the devices undergo a final test process using automatic test equipment, or testers. For example, this cycling process screens silicon carbide semiconductor devices used in electric vehicle engine controller inverters and their corresponding on-board battery chargers for failure to meet current carrying, power loss and leakage specifications, as well as endurance requirements.

    

MARKETS

 

The Company’s semiconductor test and reliability qualification solutions address multiple test and burn-in markets including Silicon Carbide (SiC) and Gallium Nitride (GaN) devices for power semiconductors, electric vehicles, electric vehicle charging infrastructure, solar and wind power, silicon photonics for data center infrastructure and worldwide 5G infrastructure, 2D/3D sensors for consumer electronics and automotive applications, and the data storage and memory markets.

 

Power Semiconductors (Silicon Carbide and Gallium Nitride)

 

Silicon carbide power semiconductors have emerged as the preferred technology for battery electric vehicle power conversion in on-board and off-board electric vehicle battery chargers, and the electric power conversion and control of the electric engines. These devices reduce power loss by as much as greater than 75% over power silicon alternatives like IGBT (Insulated-Gate Bipolar Transistor) devices, which has essentially changed the entire market dynamic. With this development, the Company sees most, if not every automotive company that is working on electric vehicles, moving to silicon carbide-based powertrain and charging systems in the near future.

 

The gallium nitride market appears to be a potentially significant growth driver for our systems and WaferPak full wafer Contactors, particularly for automotive and photovoltaic applications where burn-in appears to be critical for meeting the initial quality and reliability needs of those markets.

 

The Company’s FOX-P family of products are very cost-effective solutions for ensuring the critical quality and reliability of devices in this market, where performance and reliability can not only mean increased battery life, but also assurance against failure of a vehicle whose power semiconductor fails in the power train.

 

Silicon Photonics

 

The silicon photonics market is seeing increasing deployment of devices used in the expansion of bandwidth and infrastructure to meet the explosive growth of data center and 5G infrastructure.

 

The rapid growth of integrated optical devices in data centers and data center interconnect infrastructure, mobile devices, automotive applications, and wearable biosensor markets is driving substantially higher requirements for initial quality and long-term reliability, and they are increasing with every new product generation. The upcoming application of silicon photonics integrated circuits for use in optical chip-to-chip communication in addition to the current photonics as multiple companies have made announcements regarding their product roadmaps for co-packaged photonics integrated circuits with microprocessors, graphics processors, chip sets for computing as well as artificial intelligence applications.

 

Silicon photonics devices are highly integrated silicon-based semiconductors that have embedded or integrated the non-silicon-based laser transmitters and receivers to enable a smaller, lower cost, higher reliable alternative to traditional fiber optic transceivers currently used in data center and telecommunication infrastructure. These require a process step in manufacturing called stabilization where the devices are subjected to high temperatures and power to stabilize their output power. The Company’s solution makes it feasible to burn-in integrated silicon photonics devices while still in wafer form without adding the cost to the transceiver printed circuit board and other mechanical infrastructure of the final transceiver module, and that has both yield and significant cost savings. In the case of silicon photonics, the laser devices are bonded directly to a silicon-based device that has all the logic multiplexing and de-multiplexing, and other high-speed communication subsystems, all integrated into a silicon-based integrated circuit.

 

Mobile 2D and 3D Sensors

 

Sensors used in mobile devices such as smartphones, tablets, wearables such as watches and fitness bands, and audio devices have become pervasive. Initially, sensors on smartphones allowed basic functions we have all come to expect such as touchscreens, rotational sensors, and fingerprint sensors, but have gotten more complex with added capabilities such as 3D facial recognition and time of flight distance measurements. We will see the addition of health monitoring sensors, 3D measurement capability, and other advanced sensors in the future. As sensors become more pervasive and add critical new functionality to devices, it becomes more and more important that the data collected be accurate and

 

 
4

Table of Contents

 

reliable, which we believe will drive more and more requirements for our solutions for production test and burn-in of these sensors.

   

Automotive Semiconductors

 

In addition, the rapid growth and increasing demand for reliability in automotive sensor technologies is a key market driver for the Company. These technologies include ADAS (Advanced Driver Assistance Systems) capabilities such as collision avoidance systems using laser, LIDAR (Light Detection and Ranging), and RADAR (Radio Detection and Ranging) or other sensing technologies. More and more new vehicles now include as standard capabilities collision avoidance systems that detect obstacles and monitor the vehicle’s surroundings to notify the driver of dangerous conditions and take evasive action. In addition to autonomous vehicles that require extremely high reliability of the devices in these systems, more and more vehicles around the world are embedding these systems and sensors into their everyday driving features. The Company sees the rising tide of the increasing number of embedded sensors and electrical and optical systems in vehicles as a key driver of the increasing market need for more and more reliable semiconductors. This, in turn, is increasing the need for 100% production test and burn-in of devices in order to lower the infant mortality rate of devices and ensure that these devices and systems operate over the life of the vehicles.

 

Data Storage and Memory

 

The Company also sees the data storage and memory markets as critical new opportunities for its systems where these end markets and customers require devices to have extremely high levels of quality and long-term reliability.

 

PRODUCTS

 

The Company manufactures and markets full wafer contact test systems, test during burn-in systems, test fixtures and related accessories.

 

All of the Company’s systems are platform-based systems with a portfolio of current, voltage, digital and thermal capabilities, allowing them to be configured with optional features to meet customer requirements. Systems can be configured for use in production applications, where capacity, throughput and price are most important, or for reliability engineering and quality assurance applications, where performance and flexibility, such as extended temperature ranges, are essential.

 

FULL WAFER CONTACT SYSTEMS

 

Aehr’s FOX-XP test and burn-in platform allows for one of the key reliability screening tests to be completed on an entire wafer full of devices, testing all of them at one time, while also testing and monitoring every device for failures during the burn-in process to provide critical information on those devices. This is an enormously valuable capability, as it allows its customers to screen devices that would otherwise fail after they are packaged into multi-die modules where the yield impact is 10 times or even 100 times as costly.

 

The FOX-XP test and burn-in system, introduced in July 2016, is designed for devices in wafer, singulated die, and module form that require test and burn-in times typically measured in hours to days. The FOX-XP system can test and burn-in up to 18 wafers at a time. For high reliability applications, such as automotive, mobile devices, networking, telecommunications, sensors, power and solid-state devices, the FOX-XP system is a cost-effective solution for producing tested and burned-in die for use in multi-chip packages. Using Known-Good Die, or KGD, which are fully burned-in and tested die, in multi-chip/heterogeneous packages helps assure the reliability of the final product and lowers costs by increasing the yield of high-cost multi-chip packages. Wafer-level burn-in and test enables lower cost production of KGD for multi-chip modules, 3-D stacked packages and systems-in-a-package. The FOX-XP platform has been extended for burn-in and test of small multi-die modules by using DiePak Carriers. The DiePak Carrier with its multi-module sockets and high wattage dissipation capabilities has a capacity of hundreds of die or modules, much higher than the capacity of a traditional burn-in system with traditional single-device sockets and heat sinks. This capability was introduced in March 2017.

 

The FOX-NP was introduced in January 2019 and is a low-cost entry-level system to provide a configuration and price point for companies to initiate a new product introduction and production qualification, enabling an easier transition to the FOX-XP system for high volume production test. The FOX-NP system is 100% compatible with the FOX-XP system and is configurable with up to two slot assemblies per system compared to up to 18 slot assemblies in the FOX-XP system.

 

The FOX-CP was introduced in February 2019 and is a low-cost single-wafer compact test and reliability verification solution for logic, memory, power and photonic devices. The FOX-CP reduces test cost by functionally testing wafers during reliability screening to identify failing logic, memory, power or photonic die before the die are integrated into

 

 
5

Table of Contents

 

their final package, and is optimal for test times ranging from minutes to a few hours or where multiple touchdowns are required to test the entire wafer. The FOX-CP includes an integrated prober which is equipped with optics for automatic pattern recognition so that the wafer is aligned properly for the testing process. It complements the capabilities of the FOX-XP and FOX-NP systems, which are optimal when the test time is measured in hours or days and the full wafer can be tested in a single touchdown.

  

One of the key components of the FOX systems is the patented WaferPak Contactor. The WaferPak Contactor contains a full-wafer single-touchdown probe card which is easily removable from the system. Traditional probe cards often are only able to contact a portion of the wafer, requiring multiple touchdowns to test the entire wafer. Traditional probe cards also require the use of a dedicated wafer prober handler for each wafer in order to press the wafer up to make contact with the probe card. The need for a wafer prober per wafer is a significant cost adder to the cost of testing a wafer, and also creates the need for significant clean room space to facilitate the footprint of a wafer prober per wafer. The unique design of the WaferPak as well as the FOX-XP and FOX-NP systems remove the need for a dedicated wafer prober per wafer, allowing for better utilization of clean room space. A single FOX-XP system with a set of WaferPak Contactors can test up to 18 wafers at a time in the same footprint as a single-wafer wafer prober and test system offered by Aehr’s competitors. The WaferPak Contactor is intended to accommodate a wide range of contactor technologies so that the contactor technology can evolve along with the changing requirements of the customer’s wafers. The WaferPak Contactors are custom designed for each device type, each of which has a typical lifetime of two to seven years, depending on the device life cycle. Therefore, multiple sets of WaferPak Contactors could be purchased over the life of a FOX system.

 

Another key component of the FOX-XP and FOX-NP systems is the patented DiePak Carrier. The DiePak Carrier, which is easily removable from the system, contains many multi-module or die sockets with very fine-pitch probes. Traditional sockets contact only a single device, requiring multiple large numbers of sockets and burn-in boards to test a production lot of devices. The unique design accommodates a wide range of socket sizes and densities so that the DiePak Carrier technology can evolve along with the changing requirements of the customer’s devices. The DiePak Carriers are custom designed for each device type, each of which has a typical lifetime of two to seven years, depending on the device life cycle. Therefore, multiple sets of DiePak Carriers could be purchased over the life of a FOX-XP or FOX-NP system.

 

Another key component of our FOX-XP and FOX-NP and test solution is the WaferPak Aligner.  The WaferPak Aligner performs alignment of the customer’s wafer to the WaferPak Contactor so that the wafer can be tested and burned-in by the FOX-XP and FOX-NP systems.  The Company offers an automated aligner for high volume production applications, which can support several FOX-XP or FOX-NP systems or can be connected to a FOX-XP resulting in a fully integrated automated test cell, and a manual aligner for low volume production or engineering applications.  The latest generation Automated WaferPak Aligner supports industry standard Automated Material Handling System (AMHS), Automated Guided Vehicle (AGV), Overhead Hoist Transfer (OHT) and SEMI Equipment Communication Standard (SECS) and Generic Equipment Mode (GEM) Semi E84 factory integration enabling “Lights-out” fully automated wafer handling.  Supporting a wide range of wafer sizes (e.g. 100/200/300mm) allows a broad range of customers to implement fully automated wafer level test and burn-in factories.

 

Similar to the WaferPak Aligner for WaferPak Contactors, the Company offers the DiePak Loader for DiePak Carriers. The DiePak Loader performs automatic loading of the customer’s modules to the DiePak Carrier so that the modules can be tested and burned-in by the FOX-XP and FOX-NP system. Typically, one DiePak Loader can support several FOX-XP or FOX-NP systems.

  

Net sales of full wafer contact product lines, systems, WaferPak Contactors, DiePaks Carriers and services for fiscal 2023, 2022 and 2021 were $63.5 million, $48.9 million, and $15.0 million, respectively, and accounted for approximately 98%, 96% and 90% of the Company’s net sales in fiscal 2023, 2022 and 2021, respectively.

 

SYSTEMS FOR PACKAGED PARTS

 

Test during burn-in, or TDBI, systems consist of several subsystems: pattern generation and test electronics, control software, network interface and environmental chamber. The test pattern generator allows duplication of most of the functional tests performed by a traditional tester. Pin electronics at each burn-in board, or BIB, position are designed to provide accurate signals to the ICs being tested and detect whether a device is failing the test.

 

Devices being tested are placed on BIBs and loaded into environmental chambers which typically operate at temperatures from 25 degrees Celsius (77 degrees Fahrenheit) up to 150 degrees Celsius (302 degrees Fahrenheit). Using our optional chambers, our systems can produce temperatures as low as -55 degrees Celsius (-67 degrees Fahrenheit). A single BIB can hold up to several hundred ICs, and a production chamber holds up to 72 BIBs, resulting in thousands of memory or logic devices being tested in a single system.

 

 
6

Table of Contents

 

The Advanced Burn-in and Test System, or ABTS, was introduced in fiscal 2008. Several updates to the ABTS system have been made since its introduction, including the ABTS-P system released in 2012. The ABTS family of products is based on a hardware and software architecture that is intended to address not only today’s devices, but also future devices for many years to come. The ABTS system can test and burn-in both high-power logic and low-power ICs. It can be configured to provide individual device temperature control for devices up to 70W or more and with up to 320 I/O channels. The ABTS system is nearing the end of its lifecycle and limited shipments are expected in the future.

 

Net sales of packaged part product lines, systems and services for fiscal 2023, 2022 and 2021 were $1.4 million, $1.9 million, and $1.6 million, respectively, and accounted for approximately 2%, 4% and 10% of the Company’s net sales in fiscal 2023, 2022 and 2021, respectively.

 

CUSTOMERS

 

The Company markets and sells its products throughout the world to semiconductor manufacturers, semiconductor contract assemblers, electronics manufacturers and burn-in and test service companies.

 

Sales to the Company’s five largest customers accounted for approximately 97%, 98%, and 84% of its net sales in fiscal 2023, 2022 and 2021, respectively. During fiscal 2023, two customers accounted for approximately 79% and 10% of the Company’s net sales. During fiscal 2022, one customer accounted for approximately 82% of the Company’s net sales. During fiscal 2021, four customers accounted for approximately 24%, 23%, 20% and 10%, respectively, of the Company’s net sales. No other customers accounted for more than 10% of the Company’s net sales for any of these periods. The Company expects that sales of its products to a limited number of customers will continue to account for a high percentage of net sales for the foreseeable future. In addition, sales to particular customers may fluctuate significantly from quarter to quarter. Such fluctuations may result in changes in utilization of the Company’s facilities and resources. The loss of or reduction or delay in orders from a significant customer or a delay in collecting or failure to collect accounts receivable from a significant customer could materially and adversely affect the Company’s business, financial condition and operating results.

 

MARKETING, SALES AND CUSTOMER SUPPORT

 

The Company has sales and service operations in the United States, Germany, Philippines and Taiwan, dedicated service resources in China and South Korea, and has established a network of distributors and sales representatives in certain key parts of the world. See “REVENUE RECOGNITION” in Item 7 under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” for a further discussion of the Company’s relationship with distributors, and its effects on revenue recognition.

 

The Company’s customer service and support program includes system installation, system repair, applications engineering support, spare parts inventories, customer training and documentation. The Company has applications engineering and field service personnel located near and sometimes co-located at our customers and includes resources at the corporate headquarters in Fremont, California, at customer locations in Texas, at the Company’s subsidiaries in Germany and the Philippines, at its branch office in Taiwan, and also through third-party agreements in China and South Korea. The Company’s distributors provide applications and field service support in other parts of the world. The Company customarily provides a warranty on its products. The Company offers service contracts on its systems directly and through its subsidiaries, distributors and representatives. The Company believes that maintaining a close relationship with customers and providing them with ongoing engineering support improves customer satisfaction and will provide the Company with a competitive advantage in selling its products to the Company’s customers.

 

BACKLOG

 

At May 31, 2023, the Company’s backlog was $24.5 million compared with $11.1 million at May 31, 2022. The Company’s backlog consists of product orders for which confirmed purchase orders have been received and which are scheduled for shipment within 12 months. Due to the possibility of customer changes in delivery schedules or cancellations and potential delays in product shipments or development projects, the Company’s backlog as of a particular date may not be indicative of net sales for any succeeding period.

 

RESEARCH AND PRODUCT DEVELOPMENT

 

The Company historically has devoted a significant portion of its financial resources to research and development programs and expects to continue to allocate significant resources to these efforts. Certain research and development expenditures related to non-recurring engineering milestones have been transferred to cost of goods sold, reducing research and development expenses. The Company’s research and development expenses during fiscal 2023, 2022 and 2021 were $7.1 million, $5.8 million and $3.7 million, respectively.

 

 
7

Table of Contents

 

The Company conducts ongoing research and development to design new products and to support and enhance existing product lines.  Building upon the expertise gained in the development of its existing products, the Company has developed the FOX family of systems for performing test and burn-in of entire processed wafers, and burn-in of devices in singulated die and module form, including the FOX-NP and FOX-CP systems released during fiscal 2019, and the Automated WaferPak Aligner released during fiscal 2023.  The Company is developing enhancements to our packaged parts and wafer level burn-in products, intended to improve the capability and performance for testing and burn-in of future generation devices and provide the flexibility in a wide variety of applications.  

      

MANUFACTURING

 

The Company assembles its products from components and parts manufactured by others, including environmental chambers, power supplies, metal fabrications, printed circuit assemblies, ICs, burn-in sockets, high-density interconnects, wafer contactors and interconnect substrates. The Company’s strategy is to use in-house manufacturing only when necessary to protect a proprietary process or when a significant improvement in quality, cost or lead time can be achieved and relies on subcontractors to manufacture many of the components and subassemblies used in its products. Final assembly and testing are performed at the Company’s principal manufacturing facility located in Fremont, California.

 

COMPETITION

 

The semiconductor equipment industry is intensely competitive. Significant competitive factors in the semiconductor equipment market include price, technical capabilities, quality, flexibility, automation, cost of ownership, reliability, throughput, product availability and customer service. In each of the markets it serves, the Company faces competition from established competitors and potential new entrants, many of which have greater financial, engineering, manufacturing and marketing resources than the Company.

 

The Company expects its competitors to continue to improve the performance of their current products and to introduce new products with improved price and performance characteristics. New product introductions by the Company’s competitors or by new market entrants could cause a decline in sales or loss of market acceptance of the Company’s products. The Company has observed price competition in the systems market, particularly with respect to its less advanced products. Increased competitive pressure could also lead to intensified price-based competition, resulting in lower prices which could adversely affect the Company’s operating margins and results. The Company believes that to remain competitive it must invest significant financial resources in new product development and expand its customer service and support worldwide. There can be no assurance that the Company will be able to compete successfully in the future.

 

PROPRIETARY RIGHTS

 

The Company relies primarily on the technical and creative ability of its personnel, its proprietary software, and trade secrets and copyright protection, rather than on patents, to maintain its competitive position. The Company’s proprietary software is copyrighted and licensed to the Company’s customers. At May 31, 2023, the Company held 46 issued United States patents with expiration date ranges from 2023 to 2038 and had several additional United States patent applications and foreign patent applications pending.

 

The Company’s ability to compete successfully is dependent in part upon its ability to protect its proprietary technology and information. Although the Company attempts to protect its proprietary technology through patents, copyrights, trade secrets and other measures, there can be no assurance that these measures will be adequate or that competitors will not be able to develop similar technology independently. Further, there can be no assurance that claims allowed on any patent issued to the Company will be sufficiently broad to protect the Company’s technology, that any patent will be issued to the Company from any pending application or that foreign intellectual property laws will protect the Company’s intellectual property. Litigation may be necessary to enforce or determine the validity and scope of the Company’s proprietary rights, and there can be no assurance that the Company’s intellectual property rights, if challenged, will be upheld as valid. Any such litigation could result in substantial costs and diversion of resources and could have a material adverse effect on the Company’s business, financial condition and operating results, regardless of the outcome of the litigation. In addition, there can be no assurance that any of the patents issued to the Company will not be challenged, invalidated or circumvented or that the rights granted thereunder will provide competitive advantages to the Company. Also, there can be no assurance that the Company will have the financial resources to defend its patents from infringement or claims of invalidity.

 

There are currently no pending claims against the Company regarding infringement of any patents or other intellectual property rights of others. However, the Company may, from time to time, receive communications from third parties asserting intellectual property claims against the Company. Such claims could include assertions that the Company’s products infringe, or may infringe, the proprietary rights of third parties, requests for indemnification against

 

 
8

Table of Contents

 

such infringement or suggest the Company may be interested in acquiring a license from such third parties. There can be no assurance that any such claim made in the future will not result in litigation, which could involve significant expense to the Company, and, if the Company is required or deems it appropriate to obtain a license relating to one or more products or technologies, there can be no assurance that the Company would be able to do so on commercially reasonable terms, or at all.

  

ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG)

 

ENVIRONMENTAL

 

The Company focuses on clean technology such as the electrical vehicle (“EV”) and power semiconductors market. EV and power semiconductor revenues accounted for 85%, 82%, and 23% of total revenues in fiscal 2023, 2022 and 2021, respectively. We engineer our products to be more energy efficient by using more efficient electrical designs and thermally efficient cooling architectures using conductive heat transfer versus convection air cooled methods. Our technology and architectural design allow our products to take up only 5% of the test floor space compared to competitor’s products.

 

The Company improved our facility by replacing existing air conditioners and heat exchanger: with higher efficiency units that draw less power and produce less wasted energy. Our new headquarters facility upgrades include moving to high efficiency lighting, modernizing our electrical power and cooling infrastructure, and adding Electric Vehicle charging stations for employees, vendors, and customers.

 

SOCIAL

 

The Company reviews hiring and turnover quarterly and performs annual salary reviews, using independent third-party data, to ensure competitive compensation practices. The Company performs annual employee surveys to evaluate employee satisfaction. Glassdoor shows the Company at a 4.1 out of 5 rating as a great place to work.

 

The Company provides variable compensation on top of base salary for all employees including an employee profit sharing plan. The Company also provides equity awards including stock options, restricted stock units (“RSUs”), and participation in an employee stock purchase plan for regular full-time (“RFT”) employees, located in the U.S. The Company is restricted from issuing stock options or RSUs to non-U.S. employees in certain countries due to local regulations. For those employees who are unable to participate in the Company’s equity incentive plan, the Company maintains a stock appreciation bonus program to provide compensation linked to the Company’s stock price during a predetermined period. The Company also provides a 401k plan, and a non-contributory Employee Stock Ownership plan, for U.S. employees.

 

The Company provides recurring training in compliance with State of California ragulations including sexual harassment, prevention of violence in the workplace, and Diversity, Equality, and Inclusion (“DEI”) training. The Company promotes employee engagement through corporate events or activities and maintains a “First Years” group to encourage new hires to build comradery, and assist in recruiting efforts.

  

The Company provides health care coverage for all RFT employees, life insurance, continuing education assistance, and reimbursement of employee health club membership. The Company ensures compliance with International Organization for Standardization (ISO”) certification and maintains safety training.

  

GOVERNANCE

 

The Company’s Board satisfies the diversity objectives of Nasdaq Rule 5605(1)(2) for Smaller Reporting Companies with two directors who identify as female, representing 33% of the total six Board members. The Board members also include individuals with Native American origin and multi-ethnicity. As the Company pursues future Board recruitment efforts, the Nominating Committee will continue to seek candidates who can contribute to the diversity of views and perspectives of the Board. This includes seeking out individuals of diverse ethnicities, a balance in terms of gender, and individuals with diverse perspectives informed by other personal and professional experiences.

 

All employees and Board members sign a Code of Conduct and Ethics policy, and Insider Trading Policy upon hire. All employees are provided with the employee handbook which addresses sexual harassment, confidentiality, and Electronic Use Policy among others. Each of Company’s directors and officers completes a Director and Officer Questionnaire to identify conflicts of interest or areas of concern. The Company also maintains Audit, Compensation and Nominating and Governance Committees to provide corporate oversight.

 

 
9

Table of Contents

 

HUMAN CAPITAL RESOURCES

 

As of May 31, 2023, the Company, including its foreign subsidiaries and one branch office, employed 104 persons collectively, on a regular full-time basis, of whom 23 were engaged in research, development and related engineering, 31 were engaged in manufacturing, 39 were engaged in marketing, sales and customer support and 11 were engaged in general administration, finance and IT functions. In addition, the Company from time to time employs a number of contractors, temporary, and part-time employees, particularly to perform customer support and manufacturing.

 

The Company’s employees are dispersed across principal offices in the United States, Germany, Taiwan, and Philippines. In addition, our service and support organization has employees located worldwide, at or near customer facilities, to provide timely customer response. As of May 31, 2023 regular full-time employees were located in the following geographic areas: 80 United States, 1 Germany, 5 Taiwan, and 18 in the Philippines.

 

The Company’s success is in part dependent on its ability to attract and retain highly skilled workers, who are in high demand. None of the Company’s employees are represented by a union and the Company has never experienced a work stoppage. The Company’s management considers its relations with its employees to be good. The Company regularly evaluates its ability to attract and retain its employees. The Company has had relatively low turnover rates within its workforce, with 58% of its regular full-time workforce being with the Company for 5 years or more.

 

The Company believes that the investments we make in driving a strong, values-based culture and supporting its employees through programs, development, and competitive pay enhances its organizational capability. Company management quarterly reviews retention and turnover, employee communications, performance review status, and compensation and benefits to identify potential issues or opportunities. The Company periodically performs employee surveys to monitor employee satisfaction and the Company follows-up with an action planning process to actively respond to employee feedback.

 

BUSINESS SEGMENT DATA AND GEOGRAPHIC AREAS

 

The Company operates in one business segment, the designing, manufacturing, marketing and selling of advanced test and burn-in products to the semiconductor manufacturing industry in several geographic areas. Selected financial information, including net sales and property and equipment, net for each of the last three fiscal years, by geographic area is included in Part II, Item 8, Note 2, “Revenue” and Note 17, “Segment Information” and certain risks related to such operations are discussed in Part I, Item 1A, Risk Factors, under the heading “We sell our products and services worldwide, and our business is subject to risks inherent in conducting business activities in geographic regions outside of the United States.”

 

AVAILABLE INFORMATION

 

The Company’s common stock trades on the NASDAQ Capital Market under the symbol “AEHR.” The Company’s annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to these reports that are filed with the United States Securities and Exchange Commission, or SEC, pursuant to Section 13(a) or 15(d) of the Exchange Act, are available free of charge through the Company’s website at www.aehr.com as soon as reasonably practicable after we electronically file them with, or furnish them to the SEC.

 

The public may read and copy any materials filed by the Company with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Washington, DC 20549. The public may obtain information on the operations of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site, www.sec.gov, that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC.

 

In addition, information regarding the Company’s code of conduct and ethics and the charters of its Audit, Compensation and Nominating and Governance Committees, are available free of charge on the Company’s website listed above.

 

Item 1A. Risk Factors

 

You should carefully consider the risks described below. These risks are not the only risks that we may face. Additional risks and uncertainties that we are unaware of, or that we currently deem immaterial, also may become important factors that affect us. If any of the following risks occur, our business, financial condition or results of operations could be materially and adversely affected which could cause our actual operating results to differ materially from those indicated or suggested by forward-looking statements made in this Annual Report on Form 10-K or presented elsewhere by management from time to time.

 

 
10

Table of Contents

 

Risks Related to our Business and Industry

 

We generate a large portion of our sales from a small number of customers. If we were to lose one or more of our large customers, operating results could suffer dramatically.

 

The semiconductor manufacturing industry is highly concentrated, with a relatively small number of large semiconductor manufacturers and contract assemblers accounting for a substantial portion of the purchases of semiconductor equipment. Sales to our five largest customers accounted for approximately 97%, 98%, and 84% of our net sales in fiscal 2023, 2022 and 2021, respectively. During fiscal 2023, two customers accounted for approximately 79% and 10% of our net sales. During fiscal 2022, one customer accounted for approximately 82% of our net sales. During fiscal 2021, four customers accounted for approximately 24%, 23%, 20% and 10%, respectively, of our net sales. No other customers accounted for more than 10% of our net sales for any of these periods.

 

We expect that sales of our products to a limited number of customers will continue to account for a high percentage of our net sales for the foreseeable future. In addition, sales to particular customers may fluctuate significantly from quarter to quarter. The loss of, or reduction or delay of, an order or orders from a significant customer or customers, or a delay in collecting or failure to collect accounts receivable from a significant customer or customers, could adversely affect our business, financial condition and operating results.

 

The semiconductor equipment industry is intensely competitive. In each of the markets we serve, we face competition from established competitors and potential new entrants, many of which have greater financial, engineering, manufacturing and marketing resources than us.

 

Our FOX wafer-level and singulated die/module test and burn in systems face competition from larger systems manufacturers that have significant technological know-how and manufacturing capability. Some users of our systems, such as independent test labs, build their own burn-in systems, while others, particularly large IC manufacturers in Asia, acquire burn-in systems from captive or affiliated suppliers. Our WaferPak products are facing and are expected to face increasing competition. Several companies have developed or are developing full-wafer and single-touchdown probe cards. The Company expects that its DiePak products for burning-in and testing multiple singulated die and small modules face significant competition. The Company believes that several companies have developed or are developing products which are intended to enable test and burn-in of multiple bare die, and small modules.

 

We expect our competitors to continue to improve the performance of their current products and to introduce new products with improved price and performance characteristics. New product introductions by our competitors or by new market entrants could cause a decline in sales or loss of market acceptance of our products. We have observed price competition in the systems market, particularly with respect to its less advanced products. Increased competitive pressure could also lead to intensified price-based competition, resulting in lower prices which could adversely affect our operating margins and results. We believe that to remain competitive we must invest significant financial resources in new product development and expand our customer service and support worldwide. There can be no assurance that we will be able to compete successfully in the future.

 

We rely on increasing market acceptance for our FOX system, and we may not be successful in attracting new customers or maintaining our existing customers.

 

A principal element of our business strategy is to increase our presence in the test equipment market through system sales in our FOX wafer-level and singulated die/module test and burn-in product family. Market acceptance of the FOX system is subject to a number of risks. Before a customer will incorporate the FOX system into a production line, lengthy qualification and correlation tests must be performed. We anticipate that potential customers may be reluctant to change their procedures in order to transfer burn-in and test functions to the FOX system. Initial purchases are expected to be limited to systems used for these qualifications and for engineering studies. Market acceptance of the FOX system also may be affected by a reluctance of IC manufacturers to rely on relatively small suppliers such as us. As is common with new complex products incorporating leading-edge technologies, we may encounter reliability, design and manufacturing issues as we begin volume production and initial installations of FOX systems at customer sites. The failure of the FOX system to achieve increased market acceptance would have a material adverse effect on our future operating results, long-term prospects and our stock price.

  

A substantial portion of our net sales is generated by relatively small volume, high value transactions.

 

We derive a substantial portion of our net sales from the sale of a relatively small number of systems with high dollar value. As a result, the loss or deferral of a limited number of system sales could have a material adverse effect on our net sales and operating results in a particular period. Most customer purchase orders are subject to cancellation or rescheduling by the customer with limited penalties, and, therefore, backlog at any particular date is not necessarily indicative of actual sales for any succeeding period. From time to time, cancellations and rescheduling of customer

 

 
11

Table of Contents

 

orders have occurred, and delays by our suppliers in providing components or subassemblies to us have caused delays in our shipments of our own products. There can be no assurance that we will not be materially adversely affected by future cancellations or rescheduling by our customers or other delays in our shipments. For non-standard products where we have not effectively demonstrated the ability to meet specifications in the customer environment, we defer revenue until we have met such customer specifications. Any delay in meeting customer specifications could have a material adverse effect on our operating results. A substantial portion of net sales typically are realized near the end of each quarter. A delay or reduction in shipments near the end of a particular quarter, due, for example, to unanticipated shipment rescheduling, cancellations or deferrals by customers, customer credit issues, unexpected manufacturing difficulties experienced by us or delays in deliveries by suppliers, could cause net sales in a particular quarter to fall significantly.

 

We may experience increased costs associated with new product introductions.

 

As is common with new complex products incorporating leading-edge technologies, we have encountered reliability, design and manufacturing issues as we begin volume production and initial installations of certain products at customer sites. Some of these issues in the past have been related to components and subsystems supplied to us by third parties who have in some cases limited the ability of us to address such issues promptly. This process in the past required and in the future is likely to require us to incur un-reimbursed engineering expenses and to experience larger than anticipated warranty claims which could result in product returns. In the early stages of product development there can be no assurance that we will discover any reliability, design and manufacturing issues or, that if such issues arise, that they can be resolved to the customers’ satisfaction or that the resolution of such problems will not cause us to incur significant development costs or warranty expenses or to lose significant sales opportunities.

 

The Company is exposed to cybersecurity threats or incidents.

 

We collect, maintain, and transmit data on information systems. These systems include those owned and maintained by the Company or by third parties. In addition, we use cloud-based enterprise resource planning, ERP, software to manage the business integrating all facets of operations, including manufacturing, finance, and sales and marketing. The data maintained on these systems includes confidential and proprietary information belonging to us, our customers, suppliers, and others. While the Company devotes significant resources to protect its systems and data from unauthorized access or misuse, we are exposed to cybersecurity risks. Our systems are subject to computer viruses, data breach, phishing schemes, and other malicious software programs or attacks. We have experienced cyber threats and incidents in the past. Although past threats and incidents have not resulted in a material adverse effect, cybersecurity incidents may result in business disruption, loss of data, or unauthorized access to intellectual property which could adversely affect our business.

 

Our industry is subject to rapid technological change and our ability to remain competitive depends on our ability to introduce new products in a timely manner.

 

The semiconductor equipment industry is subject to rapid technological change and new product introductions and enhancements. Our ability to remain competitive depends in part upon our ability to develop new products and to introduce them at competitive prices and on a timely and cost-effective basis. Our success in developing new and enhanced products depends upon a variety of factors, including product selection, timely and efficient completion of product design, timely and efficient implementation of manufacturing and assembly processes, product performance in the field and effective sales and marketing. Because new product development commitments must be made well in advance of sales, new product decisions must anticipate both future demand and the technology that will be available to supply that demand. Furthermore, introductions of new and complex products typically involve a period in which design, engineering and reliability issues are identified and addressed by our suppliers and by us. There can be no assurance that we will be successful in selecting, developing, manufacturing and marketing new products that satisfy market demand. Any such failure would materially and adversely affect our business, financial condition and results of operations.

 

Because of the complexity of our products, significant delays can occur between a product’s introduction and the commencement of the volume production of such product. We have experienced, from time to time, significant delays in the introduction of, and technical and manufacturing difficulties with, certain of our products and may experience delays and technical and manufacturing difficulties in future introductions or volume production of our new products. Our inability to complete new product development, or to manufacture and ship products in time to meet customer requirements would materially adversely affect our business, financial condition and results of operations.

 

A decrease in customer device failure rates may result in a decrease in demand for our products.

 

Customer tool utilization is driven by many factors including failure rates of customer devices. Improvements in yield may result in customers decreasing test and burn-in times, or electing to perform sampling rather than 100% burn-in

 

 
12

Table of Contents

 

of their devices. Based upon data obtained from our systems customers may revise internal manufacturing processes to decrease failure rates. A decrease in customer tool utilization may result in a decrease in demand for our products impacting our business and results of operations.

  

Future changes in semiconductor technologies may make our products obsolete.

 

Future improvements in semiconductor design and manufacturing technology may reduce or eliminate the need for our products. For example, improvements in semiconductor process technology and improvements in conventional test systems, such as reduced cost or increased throughput, may significantly reduce or eliminate the market for one or more of our products. If we are not able to improve our products or develop new products or technologies quickly enough to maintain a competitive position in our markets, our business may decline.

 

Operational and Other Risks

 

Supply chain issues, including a shortage of critical components or contract manufacturing capacity, could result in a delay in fulfillment of customer orders, or an increase in costs, resulting in an adverse impact on our business and operating results.

 

Our sales growth depends on our ability to obtain timely deliveries of parts from our suppliers and contract manufacturers. There is currently a market shortage of semiconductor and other component supply which has affected, and could further affect, lead times, the cost of supply, and our ability to meet customer demand for our products. While we have taken steps to obtain an assurance of supply from our key suppliers, the market shortage of semiconductor supply may impact our ability to meet customer order fulfillments, or result in a significant increase in costs of our inventories. Manufacturing issues or capacity problems experienced by our suppliers or contract manufacturers could impact our ability to secure sufficient supply of critical components. Due to the market shortage of semiconductor supply, suppliers and contract manufacturers may commit their capacity to others, limiting our supplies or increasing costs. The failure to obtain timely delivery of supplies, or a significant increase in costs, could result in a material impact in our business and results from operations.

 

We sell our products and services worldwide, and our business is subject to risks inherent in conducting business activities in geographic regions outside of the United States.

 

Approximately 86%, 90%, and 68% of our net sales in fiscal 2023, 2022 and 2021, respectively, were attributable to sales to customers for delivery outside of the United States. We provide sales and service in North America and Taiwan, operate a sales organization in Germany and a service organization in the Philippines, as well as direct support through third party agreements in China and South Korea. We expect that sales of products for delivery outside of the United States will continue to represent a substantial portion of our future sales. Our future performance will depend, in significant part, upon our ability to continue to compete in foreign markets which in turn will depend, in part, upon a continuation of current trade relations between the United States and foreign countries in which semiconductor manufacturers or assemblers have operations. A change toward more protectionist trade legislation in either the United States or such foreign countries, such as a change in the current tariff structures, export compliance or other trade policies, could adversely affect our ability to sell our products in foreign markets. In addition, we are subject to other risks associated with doing business internationally, including longer receivable collection periods and greater difficulty in accounts receivable collection, the burden of complying with a variety of foreign laws, difficulty in staffing and managing global operations, risks of civil disturbance or other events which may limit or disrupt markets, international exchange restrictions, changing political conditions and monetary policies of foreign governments.

 

Our net sales for fiscal 2023 were primarily denominated in U.S. Dollars. However, because a substantial portion of our net sales is from sales of products for delivery outside the United States, an increase in the value of the U.S. Dollar relative to foreign currencies would increase the cost of our products compared to products sold by local companies in such markets. In addition, since the price is determined at the time a purchase order is accepted, we are exposed to the risks of fluctuations in the U.S. Dollar exchange rate during the lengthy period from the date a purchase order is received until payment is made. This exchange rate risk is partially offset to the extent our foreign operations incur expenses in the local currency. To date, we have not invested in any instruments designed to hedge currency risks. Our operating results could be adversely affected by fluctuations in the value of the U.S. Dollar relative to other currencies.

 

We purchase materials from suppliers worldwide, which subjects the Company to increased risk.

 

We purchase components, sub-assemblies, and chambers from suppliers outside the United States. Increases in tariffs, additional taxes, or trade barriers may result in an increase in our manufacturing costs. A decrease in the value of the U.S. Dollar relative to foreign currencies would increase the cost of our materials. Should the Company increase its sales prices to recover the increase in costs, this could result in a decrease in the competitiveness of our products. In addition, we are subject to other risks associated with purchasing materials from suppliers worldwide. Government

 

 
13

Table of Contents

 

authorities may also implement protectionist policies or impose limitations on the transfer of intellectual property. This may limit our ability to obtain products from certain geographic regions and require us to identify and qualify new suppliers. The process of qualifying suppliers could be lengthy, and no assurance can be given that any additional sources would be available to us on a timely basis. Changes in trade relations, currency fluctuations, or protectionist policies could have a material adverse effect on our business, financial condition or results of operations.

  

Global unrest may impact our ability to sell our products or obtain critical materials.

 

Global economic uncertainty and financial market volatility caused by political instability, changes in international trade relationships and conflicts, such as the conflict between Russia and Ukraine and the political climate in China and Taiwan may result in limited access to these markets for sales and material purchases. Periods of macroeconomic weakness or recession and heightened market volatility caused by adverse geopolitical developments could increase these risks, potentially resulting in adverse impacts on our business operations. Increased energy costs in Europe, resulting from Russia’s limiting energy supplies in the region, may result in an economic downturn or an increase in the cost of materials. The recent decline in relations between the United States and China, and relations between China and Taiwan, may result in the imposition of trade restrictions with China or Taiwan. While we have limited sales in Europe and Taiwan, and procurement from these regions, unrest in these areas may result in a decrease in sales of our products, or an increase in costs of materials and services.

 

Our dependence on subcontractors and sole source suppliers may prevent us from delivering our products on a timely basis and expose us to intellectual property infringement.

 

We rely on subcontractors to manufacture many of the components or subassemblies used in our products. Our FOX systems, WaferPak contactors, DiePak carriers, WaferPak Aligners, and DiePak Loaders contain several components, including environmental chambers, power supplies, high-density interconnects, wafer contactors, module contactors, signal distribution substrates, and certain ICs that are currently supplied by only one or a limited number of suppliers. Our reliance on subcontractors and single source suppliers involves a number of significant risks, including the loss of control over the manufacturing process, the potential absence of adequate capacity and reduced control over delivery schedules, manufacturing yields, quality and costs. In the event that any significant subcontractor or single source supplier is unable or unwilling to continue to manufacture subassemblies, components or parts in required volumes, we would have to identify and qualify acceptable replacements. The process of qualifying subcontractors and suppliers could be lengthy, and no assurance can be given that any additional sources would be available to us on a timely basis. Any delay, interruption or termination of a supplier relationship could adversely affect our ability to deliver products, which would harm our operating results.

 

Our suppliers manufacture components, tooling, and provide engineering services. During this process, our suppliers are allowed access to our intellectual property. While we maintain patents to protect from intellectual property infringement, there can be no assurance that technological information gained in the manufacture of our products will not be used to develop a new product, improve processes or techniques which compete against our products. Litigation may be necessary to enforce or determine the validity and scope of our proprietary rights, and there can be no assurance that our intellectual property rights, if challenged, will be upheld as valid.

 

Tightening of fiscal monetary policy, and periodic economic and semiconductor industry downturns could negatively affect our business, results of operations and financial condition.

 

Inflation reached a 40-year high during 2022, and market rates of interest have risen after a prolonged period at historical lows. The increase in inflation has resulted in a tightening of world-wide monetary policy, which in turn has resulted in an increase in the cost of credit. Financial turmoil in the banking system and financial markets has resulted, and may result in the future, in a tightening of the credit markets, disruption in the financial markets and global economy downturn. Periodic global economic and semiconductor industry downturns have negatively affected and could continue to negatively affect our business, results of operations, and financial condition. These events may contribute to significant slowdowns in the industry in which we operate. Difficulties in obtaining capital and deteriorating market conditions can pose the risk that some of our customers may not be able to obtain necessary financing on reasonable terms, which could result in lower sales. Customers with liquidity issues may lead to additional bad debt expense.

 

Turmoil in the international financial markets has resulted, and may result in the future, in dramatic currency devaluations, stock market declines, restriction of available credit and general financial weakness. In addition, flash memory and other similar device prices have historically declined and will likely do so again in the future. These developments may affect us in several ways. The market for semiconductors and semiconductor capital equipment has historically been cyclical, and we expect this to continue in the future. The uncertainty of the semiconductor market may cause some manufacturers in the future to further delay capital spending plans. Economic conditions may also affect the ability of our customers to meet their payment obligations, resulting in cancellations or deferrals of existing orders and limiting additional orders. In addition, some governments have subsidized portions of fabrication facility construction,

 

 
14

Table of Contents

 

and financial turmoil may reduce these governments’ willingness to continue such subsidies. Such developments could have a material adverse effect on our business, financial condition and results of operations.

  

The current economic conditions and uncertainty about future economic conditions make it challenging for us to forecast our operating results, make business decisions, and identify the risks that may affect our business, financial condition and results of operations. If such conditions recur, and we are not able to timely and appropriately adapt to changes resulting from the difficult macroeconomic environment, our business, financial condition or results of operations may be materially and adversely affected.

 

If we are not able to reduce our operating expenses sufficiently during periods of weak revenue, or if we utilize significant amounts of cash to support operating losses, we may erode our cash resources and may not have sufficient cash to operate our business.

 

We have in the past, in the face of a downturn in our business and a decline in our net sales, implemented a variety of cost controls and restructured our operations with the goal of reducing our operating costs to position ourselves to more effectively meet the needs of the then weak market for test and burn-in equipment. While we took significant steps to minimize our expense levels and to increase the likelihood that we would have sufficient cash to support operations during the downturn, we have experienced historical operating losses. We anticipate that our existing cash balance together with income from operations, collections of existing accounts receivable, revenue from our existing backlog of products, the sale of inventory on hand, and deposits and down payments against significant orders, and available balance under our ATM offering, will be adequate to meet our working capital and capital equipment requirements. Depending on our rate of growth and profitability, and our ability to obtain significant orders with down payments, we may require additional equity or debt financing to meet our working capital requirements or capital equipment needs. There can be no assurance that additional financing will be available when required, or if available, that such financing can be obtained on terms satisfactory to us.

 

We may be subject to litigation relating to intellectual property infringement which would be time-consuming, expensive and a distraction from our business.

 

If we do not adequately protect our intellectual property, competitors may be able to use our proprietary information to erode our competitive advantage, which could harm our business and operating results. Litigation may be necessary to enforce or determine the validity and scope of our proprietary rights, and there can be no assurance that our intellectual property rights, if challenged, will be upheld as valid. Such litigation could result in substantial costs and diversion of resources and could have a material adverse effect on our operating results, regardless of the outcome of the litigation. In addition, there can be no assurance that any of the patents issued to us will not be challenged, invalidated or circumvented or that the rights granted thereunder will provide competitive advantages to us.

 

There are no pending claims against us regarding infringement of any patents or other intellectual property rights of others. However, in the future we may receive communications from third parties asserting intellectual property claims against us. Such claims could include assertions that our products infringe, or may infringe, the proprietary rights of third parties, requests for indemnification against such infringement or suggestions that we may be interested in acquiring a license from such third parties. There can be no assurance that any such claim will not result in litigation, which could involve significant expense to us, and, if we are required or deem it appropriate to obtain a license relating to one or more products or technologies, there can be no assurance that we would be able to do so on commercially reasonable terms, or at all.

 

While we believe we have complied with all applicable environmental laws, our failure to do so could adversely affect our business as a result of having to pay substantial amounts in damages or fees.

 

Federal, state and local regulations impose various controls on the use, storage, discharge, handling, emission, generation, manufacture and disposal of toxic and other hazardous substances used in our operations. We believe that our activities conform in all material respects to current environmental and land use regulations applicable to our operations and our current facilities, and that we have obtained environmental permits necessary to conduct our business. Nevertheless, failure to comply with current or future regulations could result in substantial fines, suspension of production, alteration of our manufacturing processes or cessation of operations. Such regulations could require us to acquire expensive remediation equipment or to incur substantial expenses to comply with environmental regulations. Any failure to control the use, disposal or storage of or adequately restrict the discharge of, hazardous or toxic substances could subject us to significant liabilities.

 

 
15

Table of Contents

 

Risks Related to Ownership of our Common Stock

 

Our stock price may fluctuate.

 

The price of our common stock has fluctuated in the past and may fluctuate significantly in the future. We believe that factors such as announcements of developments related to our business, fluctuations in our operating results, general conditions in the semiconductor and semiconductor equipment industries as well as the worldwide economy, announcement of technological innovations, new systems or product enhancements by us or our competitors, fluctuations in the level of cooperative development funding, acquisitions, changes in governmental regulations, developments in patents or other intellectual property rights and changes in our relationships with customers and suppliers could cause the price of our common stock to fluctuate substantially. In addition, in recent years the stock market in general, and the market for small capitalization and high technology stocks in particular, have experienced extreme price fluctuations which have often been unrelated to the operating performance of the affected companies. Such fluctuations could adversely affect the market price of our common stock.

 

Increased scrutiny and changing expectations from stakeholders with respect to the Company’s ESG practices may result in additional costs or risks.

 

Companies across many industries are facing increasing scrutiny related to their ESG practices. Investor advocacy groups, certain institutional investors, investment funds and other influential investors are also increasingly focused on ESG practices and in recent years have placed increasing importance on the non-financial impacts of their investments. If our ESG practices do not meet investor or other industry stakeholder expectations, which continue to evolve, we may incur additional costs and our brand, ability to attract and retain qualified employees and business may be harmed.

 

Risks Related to our Legal/Organizational Structure

 

We depend on our key personnel and our success depends on our ability to attract and retain talented employees.

 

Our success depends to a significant extent upon the continued service of Gayn Erickson, our President and Chief Executive Officer, as well as other executive officers and key employees. We do not maintain key person life insurance for our benefit on any of our personnel, and none of our employees are subject to a non-competition agreement with us. The loss of the services of any of our executive officers or a group of key employees could have a material adverse effect on our business, financial condition and operating results. Our future success will depend in significant part upon our ability to attract and retain highly skilled technical, management, sales and marketing personnel. There are a limited number of personnel with the requisite skills to serve in these positions, and it has become increasingly difficult for us to hire such personnel. Competition for such personnel in the semiconductor equipment industry is intense, and there can be no assurance that we will be successful in attracting or retaining such personnel. Changes in management could disrupt our operations and adversely affect our operating results.

 

If we fail to maintain effective internal control over financial reporting in the future, the accuracy and timing of our financial reporting may be adversely affected.

 

We are required to comply with Section 404 of the Sarbanes-Oxley Act of 2002. The provisions of the act require, among other things, that we maintain effective internal control over financial reporting and disclosure controls and procedures. Preparing our financial statements involves a number of complex processes, many of which are done manually and are dependent upon individual data input or review. These processes include, but are not limited to, calculating revenue, deferred revenue and inventory costs. While we continue to automate our processes and enhance our review and put in place controls to reduce the likelihood for errors, we expect that for the foreseeable future, many of our processes will remain manually intensive and thus subject to human error.

 

The collapse of certain U.S. banks and potentially other financial institutions may have adverse impacts on our business.

 

On March 10, 2023, Silicon Valley Bank (“SVB”) was shut down, followed on March 11, 2023 by Signature Bank and the Federal Deposit Insurance Corporation was appointed as receiver for those banks. Since that time, there have been reports of instability at other U.S. banks. The Company’s cash and investment balances held at banks and brokerage firms may at time exceed federally insured levels. On March 15, 2023, the Company filed a Current Report on Form 8-K with the SEC, disclosing its exposure to SVB and stating that the Company did not expect a significant impact on its operations.

 

 
16

Table of Contents

 

Item 1B. Unresolved Staff Comments

 

None.

 

Item 2. Properties

 

The Company’s principal administrative and production facilities are located in Fremont, California, in a 51,289 square foot building. The Company’s lease was renewed in December 2022 and expires in September 2030. The Company leases a 492 square foot sales and support office in Utting, Germany. The lease, which began February 1, 1992 and expires on January 31, 2025, contains an automatic twelve months renewal, at rates to be determined, if no notice is given prior to six months from expiration. On November 18, 2020, the Company established a wholly owned subsidiary, Aehr Test Systems Philippines Inc., which has been in full operation since March 2021. The Company leases a facility in Philippines located in a 2,713 square foot building in Clark Freeport Zone, Pampanga. The lease, which began January 1, 2021 and expires on December 31, 2025, contains an option to renew for another three years at rates stipulated in the contract, notice for renewal is given six months from expiration. The Company periodically evaluates its global operations and facilities to bring its capacity in line with demand and to provide cost efficient services for its customers. In prior years, through this process, the Company has moved from certain facilities that exceeded the capacity required to satisfy its needs. The Company believes that its existing facilities in Fremont, California are adequate to meet its current and reasonably foreseeable requirements. The Company regularly evaluates its expected future facilities requirements and believes that alternate facilities would be available if needed.

 

Item 3. Legal Proceedings

 

None.

 

Item 4. Mine Safety Disclosures

 

Not Applicable

 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

The Company’s common stock is publicly traded on the NASDAQ Capital Market under the symbol “AEHR”. The following table sets forth, for the periods indicated, the high and low sale prices for the common stock on such market. These quotations represent prices between dealers and do not include retail markups, markdowns or commissions and may not necessarily represent actual transactions.

 

 

 

High

 

 

Low

 

Fiscal 2023:

 

 

 

 

 

 

First quarter ended August 31, 2022

 

$19.43

 

 

$6.71

 

Second quarter ended November 30, 2022

 

 

27.00

 

 

 

13.00

 

Third quarter ended February 28, 2023

 

 

37.57

 

 

 

17.05

 

Fourth quarter ended May 31, 2023

 

 

40.69

 

 

 

23.11

 

 

 

 

 

 

 

 

 

 

Fiscal 2022:

 

 

 

 

 

 

 

 

First quarter ended August 31, 2021

 

$8.60

 

 

$2.25

 

Second quarter ended November 30, 2021

 

 

27.09

 

 

 

6.83

 

Third quarter ended February 28, 2022

 

 

24.70

 

 

 

10.20

 

Fourth quarter ended May 31, 2022

 

 

13.94

 

 

 

6.86

 

 

At August 3, 2023, the Company had 86 holders of record of its common stock. A substantially greater number of holders of the Company’s common stock are “street name” or beneficial holders whose shares are held by banks, brokers and other financial institutions.

 

The Company has not paid cash dividends on its common stock or other securities. The Company currently anticipates that it will retain its future earnings, if any, for use in the expansion and operation of its business and does not anticipate paying any cash dividends on its common stock in the foreseeable future.

 

The Company did not repurchase any of its common stock during the fiscal year ended May 31, 2023.

 

 
17

Table of Contents

 

Item 6. [Reserved]

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis of the financial condition and results of operations should be read in conjunction with our “Selected Consolidated Financial Data” and our consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K.

 

OVERVIEW

 

Aehr Test Systems (“Aehr Test”, “Aehr” or “We”) is a leading provider of test solutions for testing, burning-in, and stabilizing semiconductor devices in wafer level, singulated die, and package part form, and has installed thousands of systems worldwide. Increasing quality, reliability, safety, and security needs of semiconductors used across multiple applications, including electric vehicles, electric vehicle charging infrastructure, solar and wind power, computing, data and telecommunications infrastructure, and solid-state memory and storage, are driving additional test requirements, incremental capacity needs, and new opportunities for Aehr Test products and solutions.

 

We have developed and introduced several innovative products including the FOX-P family of test and burn-in systems and FOX WaferPak Aligner, FOX WaferPak Contactor, FOX DiePak Carrier and FOX DiePak Loader. The FOX-XP and FOX-NP systems are full wafer contact and singulated die/module test and burn-in systems that can test, burn-in, and stabilize a wide range of devices such as leading-edge silicon carbide-based and other power semiconductors, 2D and 3D sensors used in mobile phones, tablets, and other computing devices, memory semiconductors, processors, microcontrollers, systems-on-a-chip, and photonics and integrated optical devices. The FOX-CP system is a low-cost single-wafer compact test solution for logic, memory and photonic devices and the newest addition to the FOX-P product family. The FOX WaferPak Contactor contains a unique full wafer contactor capable of testing wafers up to 300mm that enables Integrated Circuit manufacturers to perform test, burn-in, and stabilization of full wafers on the FOX-P systems. The FOX DiePak Carrier allows testing, burning in, and stabilization of singulated bare die and modules up to 1,024 devices in parallel per DiePak on the FOX-NP and FOX-XP systems up to nine DiePaks at a time.

 

Our net sales consist primarily of sales of FOX-P systems, WaferPak Aligners and DiePak Loaders, WaferPak contactors, DiePak carriers, test fixtures, upgrades and spare parts, service contracts revenues, and non-recurring engineering charges. Our selling arrangements may include contractual customer acceptance provisions, which are mostly deemed perfunctory or inconsequential, and installation of the product occurs after shipment, transfer of title and risk of loss.

 

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

 

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to customer programs and incentives, product returns, bad debts, inventories, investments, income taxes, financing operations, warranty obligations, and long-term service contracts, among others. Our estimates are derived from historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Those results form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our consolidated financial statements.

 

REVENUE RECOGNITION

 

The Company recognizes revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by following a five-step process: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price, and (5) recognize revenue when or as the Company satisfies a performance obligation, as further described below.

 

Performance obligations include sales of systems, contactors, spare parts, and services, as well as installation and training services included in customer contracts.

 

 
18

Table of Contents

 

A contract’s transaction price is allocated to each distinct performance obligation. In determining the transaction price, the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which the Company expects to be entitled. The Company generally does not grant return privileges, except for defective products during the warranty period.

 

For contracts that contain multiple performance obligations, the Company allocates the transaction price to the performance obligations on a relative standalone selling price basis. Standalone selling prices are based on multiple factors including, but not limited to, historical discounting trends for products and services and pricing practices in different geographies.

 

Revenue for systems and spares are recognized at a point in time, which is generally upon shipment or delivery. Revenue from services is recognized over time as services are completed or ratably over the contractual period of generally one year or less.

 

The Company has elected the practical expedient to not assess whether a contract has a significant financing component as the Company’s standard payment terms are less than one year.

 

We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors.

 

Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services.

 

ALLOWANCE FOR DOUBTFUL ACCOUNTS

 

We maintain an allowance for doubtful accounts to reserve for potentially uncollectible trade receivables. We also review our trade receivables by aging category to identify specific customers with known disputes or collection issues. We exercise judgment when determining the adequacy of these reserves as we evaluate historical bad debt trends, general economic conditions in the United States and internationally and changes in customer financial conditions. Uncollectible receivables are recorded as bad debt expense when all efforts to collect have been exhausted and recoveries are recognized when they are received.

 

WARRANTY OBLIGATIONS

 

We provide and record the estimated cost of product warranties at the time revenues are recognized on products shipped. While we engage in extensive product quality programs and processes, including actively monitoring and evaluating the quality of our component suppliers, our warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Our estimate of warranty reserve is based on management’s assessment of future warranty obligations and on historical warranty obligations. Should actual product failure rates, material usage or service delivery costs differ from our estimates, revisions to the estimated warranty liability would be required.

 

INVENTORY OBSOLESCENCE

 

In each of the last three fiscal years, we wrote down our inventory for estimated obsolescence or unmarketable inventory by an amount equal to the difference between the cost of inventory and the net realizable value based upon assumptions about future demand and market conditions, see Note 7, “Balance Sheet Detail.” If future market conditions are less favorable than those projected by management, additional inventory write-downs may be required.

 

INCOME TAXES

 

Income taxes are accounted for under the asset-and-liability method as required by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 740, Income Taxes (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. Under ASC 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.

 

As of May 31, 2023 the Company maintained a full valuation allowance against its deferred tax assets. We will continue to assess whether sufficient future taxable income will be generated to permit the use of deferred tax assets, and will reverse all or a portion of the allowance when there is sufficient evidence to support the reversal. Based upon our prior two fiscal years of profitability, the outlook for the next fiscal year, and absent any additional objective negative evidence, the Company anticipates adjusting the current valuation allowance position in fiscal 2024.

  

FASB ASC Subtopic 740-10, Accounting for Uncertainty of Income Taxes, (“ASC 740-10”) defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements

 

 
19

Table of Contents

 

prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company’s policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of income taxes.

 

STOCK-BASED COMPENSATION EXPENSE

 

Stock-based compensation expense consists of expenses for stock options, restricted stock units, or RSUs, and employee stock purchase plan, or ESPP, purchase rights. Stock-based compensation cost for stock options and ESPP purchase rights is measured at each grant date, based on the fair value of the award using the Black-Scholes option valuation model, and is recognized as expense over the employee’s requisite service period. This model was developed for use in estimating the value of publicly traded options that have no vesting restrictions and are fully transferable. Our employee stock options have characteristics significantly different from those of publicly traded options. For RSUs, stock-based compensation expense is based on the fair value of our common stock at the grant date, and is recognized as expense over the employee’s requisite service period. All of our stock-based compensation is accounted for as an equity instrument.

 

The fair value of each option grant and the right to purchase shares under our ESPP are estimated on the date of grant using the Black-Scholes option valuation model with assumptions concerning expected term, stock price volatility, expected dividend yield, risk-free interest rate and the expected life of the award. See Note 13 to our consolidated financial statements for detailed information relating to stock-based compensation and the stock option plan and the ESPP.

 

RESULTS OF OPERATIONS

 

The following table sets forth statements of operations data as a percentage of net sales for the periods indicated.

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

 

100.0%

 

 

100.0%

 

 

100.0%

Cost of sales

 

 

49.6

 

 

 

53.4

 

 

 

63.7

 

Gross profit

 

 

50.4

 

 

 

46.6

 

 

 

36.3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

18.8

 

 

 

19.8

 

 

 

39.5

 

Research and development

 

 

11.0

 

 

 

11.5

 

 

 

22.0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total operating expenses

 

 

29.8

 

 

 

31.3

 

 

 

61.5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) from operations

 

 

20.6

 

 

 

15.3

 

 

 

(25.2)

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income (expense), net

 

 

1.9

 

 

 

0.1

 

 

 

(0.3)

Net gain from dissolution of Aehr Test Systems Japan

 

 

--

 

 

 

--

 

 

 

13.2

 

Gain from forgiveness of PPP loan

 

 

--

 

 

 

3.3

 

 

 

--

 

Other (expense) income, net

 

 

--

 

 

 

0.1

 

 

 

(1.0)

 

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) before income tax (expense) benefit

 

 

22.5

 

 

 

18.8

 

 

 

(13.3)

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax (expense) benefit

 

 

(0.1)

 

 

(0.2)

 

 

1.1

 

Net income (loss)

 

 

22.4%

 

 

18.6%

 

 

(12.2)%

   

FISCAL YEAR ENDED MAY 31, 2023 COMPARED TO FISCAL YEAR ENDED MAY 31, 2022

 

NET SALES.  Net sales increased to $65.0 million for the fiscal year ended May 31, 2023 from $50.8 million for the fiscal year ended May 31, 2022, an increase of 27.8%.  The increase in net sales for the fiscal year ended May 31, 2023 was primarily due to the increases in net sales of our wafer-level test products.  Net sales of our wafer-level test products

 

 
20

Table of Contents

 

for fiscal 2023 were $63.5 million and increased approximately $14.6 million from fiscal 2022 due to strong demand for our FOX-P systems.  

 

GROSS PROFIT. Gross profit increased to $32.7 million for the fiscal year ended May 31, 2023 from $23.7 million for the fiscal year ended May 31, 2022, an increase of 38.4%. Gross margin increased to 50.4% for the fiscal year ended May 31, 2023 from 46.6% for the fiscal year ended May 31, 2022. The increase in gross margin was primarily the result of a decrease in other cost of sales of 1.6 percentage points primarily due to lower costs of provision for inventory reserves, a decrease in labor and overhead of 1.2 percentage points due to manufacturing efficiencies due to higher sales volume, and a benefit of 1.0 percentage points due to lower direct material costs.

 

SELLING, GENERAL AND ADMINISTRATIVE. SG&A expenses were $12.2 million for the fiscal year ended May 31, 2023, compared with $10.0 million for the fiscal year ended May 31, 2022, an increase of 21.8%. The increase in SG&A expenses was primarily the result of increased shareholder relation costs of $0.5 million, recruiting and relocation of $0.3 million, and employment-related expenses of $0.3 million to support our growing business.

 

RESEARCH AND DEVELOPMENT. R&D expenses were $7.1 million for the fiscal year ended May 31, 2023, compared with $5.8 million for the fiscal year ended May 31, 2022, an increase of 22.6%. The increase in R&D expenses was primarily due to increases in project expenses of $0.6 million and employment-related expenses of $0.5 million related to R&D initiatives during fiscal 2023.

 

INTEREST INCOME (EXPENSE), NET. Interest income, net was $1.2 million and $13,000 for the fiscal years ended May 31, 2023 and 2022, respectively. Higher interest income for the fiscal year ended May 31, 2023 was driven by higher cash deposits and higher interest rates in fiscal year ended May 31, 2023.

 

GAIN FROM FORGIVENESS OF PPP LOAN. On June 12, 2021, we received confirmation from SVB that on June 4, 2021, the Small Business Administration approved our Payroll Protection Program loan (“PPP Loan”) forgiveness application for the entire PPP Loan balance of $1,679,000 and interest totaling $19,000, and we recognized a gain of $1,698,000.

 

OTHER (EXPENSE) INCOME, NET. Other expense, net was $3,000 for the fiscal year ended May 31, 2023, compared with other income, net of $30,000 for the fiscal year ended May 31, 2022. The change in other (expense) income, net was primarily due to losses or gains realized in connection with the fluctuation in the value of the dollar compared to foreign currencies during the referenced periods.

 

INCOME TAX (EXPENSE) BENEFIT. Income tax expense was $60,000 and $91,000 for the fiscal years ended May 31, 2023 and 2022, respectively. Income tax expense for both fiscal years were related to income taxes incurred in foreign tax jurisdictions. Income tax expense was not significant due to available net operating loss and research and development credit carryforwards.

 

FISCAL YEAR ENDED MAY 31, 2022 COMPARED TO FISCAL YEAR ENDED MAY 31, 2021

 

NET SALES.  Net sales increased to $50.8 million for the fiscal year ended May 31, 2022 from $16.6 million for the fiscal year ended May 31, 2021, an increase of 206.2%.  The increase in net sales for the fiscal year ended May 31, 2022 was primarily due to the increases in net sales of our wafer-level products.  Net sales of our wafer-level products for fiscal 2022 were $48.9 million, and increased approximately $33.9 million from fiscal 2021 due to stronger demand related to silicon carbide applications. 

 

GROSS PROFIT. Gross profit increased to $23.7 million for the fiscal year ended May 31, 2022 from $6.0 million for the fiscal year ended May 31, 2021, an increase of 292.3%. Gross profit margin increased to 46.6% for the fiscal year ended May 31, 2022 from 36.3% for the fiscal year ended May 31, 2021. The increase in gross profit margin was primarily the result of manufacturing efficiencies due to an increase in net sales.

 

SELLING, GENERAL AND ADMINISTRATIVE. SG&A expenses were $10.0 million for the fiscal year ended May 31, 2022, compared with $6.6 million for the fiscal year ended May 31, 2021, an increase of 53.1%. The increase in SG&A expenses was primarily the result of increased bonuses, stock-based compensation, and commission expense due to an increase in net sales and profitability, and an increase in headcount.

 

RESEARCH AND DEVELOPMENT. R&D expenses were $5.8 million for the fiscal year ended May 31, 2022, compared with $3.7 million for the fiscal year ended May 31, 2021, an increase of 59.3%. The increase in R&D expenses was primarily due to increases in employment-related expenses of $1.7 million, outside services of $316,000, and project expenses of $155,000. The increase in employment-related expenses was primarily the result of increased bonuses and stock-based compensation due to an increase in net sales and profitability, and an increase in headcount.

 

 
21

Table of Contents

 

INTEREST INCOME (EXPENSE), NET. Interest income, net was $13,000 for the fiscal year ended May 31, 2022, compared with interest expense of $46,000 for the fiscal year ended May 31, 2021. The interest expense for the fiscal year ended May 31, 2021 was from the PPP Loan that we obtained on April 23, 2020.

 

NET GAIN FROM DISSOLUTION OF AEHR TEST SYSTEMS JAPAN. Net gain from dissolution of Aehr Test Systems Japan was $2.2 million for the fiscal year ended May 31, 2021, due to the release of the cumulative translation adjustment in connection with the complete liquidation of Aehr Test Systems Japan subsidiary in July 2020.

 

GAIN FROM FORGIVENESS OF PPP LOAN. On June 12, 2021, we received confirmation from SVB that on June 4, 2021, the Small Business Administration approved our PPP Loan forgiveness application for the entire PPP Loan balance of $1,679,000 and interest totaling $19,000, and we recognized a gain of $1,698,000.

 

OTHER (EXPENSE) INCOME, NET. Other income, net was $30,000 for the fiscal year ended May 31, 2022, compared with other expense, net of $162,000 for the fiscal year ended May 31, 2021. The change in other (expense) income, net was primarily due to gains or losses realized in connection with the fluctuation in the value of the dollar compared to foreign currencies during the referenced periods.

 

INCOME TAX (EXPENSE) BENEFIT. Income tax expense for the fiscal year ended May 31, 2022 was $91,000 compared with income tax benefit of $177,000 for the fiscal year ended May 31, 2021. During the fiscal year ended May 31, 2021, the currency translation adjustment balance was released and the residual income tax effect of $215,000 was recorded pursuant to the inter-period allocation rules in connection with the complete liquidation of Aehr Test Systems Japan subsidiary in July 2020.

 

LIQUIDITY AND CAPITAL RESOURCES

 

We consider cash, cash equivalents and short-term investments as liquid and available for use. As of May 31, 2023 and 2022, respectively, we had $30.2 million and $31.6 million in cash, cash equivalents and restricted cash. We also had $17.9 million in short-term investments as of May 31, 2023.

 

Net cash provided by operating activities was $10.0 million and $1.5 million for the fiscal year ended May 31, 2023 and 2022, respectively. For the fiscal year ended May 31, 2023, net cash provided by operating activities was primarily the result of net income of $14.6 million, net of a non-cash charge of stock-based compensation expense of $2.7 million, depreciation and amortization of $0.5 million, and accretion of investment discount of $0.6 million. Other changes in cash from operations primarily resulted from increases in inventories and trade and other accounts receivable of $9.5 million and $3.8 million, respectively, partially offset by increases in accounts payable, accrued expenses and customer deposits and deferred revenue of $5.0 million, $0.5 million and $0.4 million, respectively. The increase in inventory was to support expected future shipments for customer orders. The increase in trade and other accounts receivable was primarily due to higher revenues and lower customer deposits on shipments. The increase in accounts payable was primarily due to inventory purchases to support future shipments. For the fiscal year ended May 31, 2022, net cash provided by operating activities was primarily the result of net income of $9.5 million, as adjusted to exclude the effect of forgiveness of PPP loan of $1.7 million, and a non-cash charge of stock-based compensation expense of $3.0 million and depreciation and amortization of $356,000. Other changes in cash from operations primarily resulted from increases in accounts receivable and inventories of $7.8 million and $6.7 million, respectively, partially offset by increases in customer deposits and deferred revenue, accrued expenses, and accounts payable of $2.2 million, $1.5 million and $1.4 million, respectively. The increase in accounts receivable was primarily due to the increase in and timing of revenue generated toward the end of the fiscal year ended May 31, 2022. The increase in inventory was to support expected future shipments for customer orders. The increase in customer deposits and deferred revenue was primarily due to the receipt of additional down payments from certain customers. The increase in accrued expenses was primarily due to an increase in accrued employment related expenses including profit sharing, commissions, bonuses, and vacations. The increase in accounts payable was primarily due to inventory purchases to support future shipments.

 

Net cash used in investing activities was $18.7 million and $0.4 million for the fiscal years ended May 31, 2023 and 2022, respectively. During the fiscal year ended May 31, 2023, net cash used in investing activities was due to the purchases of U.S. treasury securities of $33.3 million, partially offset by proceeds from maturities of U.S. treasury securities of $16 million, and the purchases of property and equipment of $1.4 million. During the fiscal year ended May 31, 2022, net cash used in investing activities was due to purchases of property and equipment.

 

Financing activities provided cash of $7.3 million and $25.8 million for the fiscal years ended May 31, 2023 and 2022, respectively. Net cash provided by financing activities during the fiscal year ended May 31, 2023 was primarily due to the net proceeds from issuance of common stock from public offering of $6.8 million, and the proceeds from the issuance of common stock under employee benefit plans of $2.6 million, partially offset by the shares repurchased for tax withholdings on vesting of RSUs and PRSUs of $2.1 million. Net cash provided by financing activities during the fiscal year ended May 31, 2022 was primarily due to the net proceeds from issuance of common stock from public

 

 
22

Table of Contents

 

offering of $24.0 million, and the proceeds from the issuance of common stock under employee benefit plans of $3.6 million, partially offset by the shares repurchased for tax withholdings on vesting of RSUs of $0.4 million, and by the net payment of the line of credit of $1.4 million.

  

The effect of fluctuation in exchange rates decreased cash by $37,000 for the fiscal years ended May 31, 2023 and increased cash by $49,000 for the fiscal years ended May 31, 2022. The changes were due to the fluctuation in the value of the dollar compared to foreign currencies.

 

As of May 31, 2023 and 2022, we had working capital of $72.7 million and $49.0 million, respectively.

 

For the fiscal year ended May 31, 2021, net cash used in operating activities was primarily the result of the net loss of $2.0 million, as adjusted to exclude the effect of net gain from dissolution of Aehr Test Systems Japan of $2.4 million, including an income tax benefit of $215,000, a non-cash charge for stock-based compensation expense of $1.1 million and depreciation and amortization of $328,000. Net cash used in operations was also impacted by increases in accounts receivable and inventories of $1.4 million and $972,000, respectively, partially offset by increases in accounts payable and accrued expenses of $1.9 million and $732,000, respectively. The increase in accounts receivable was primarily due to higher shipment activities toward the end of fiscal year ended May 31, 2021. The increase in inventory was to support expected future shipments for customer orders. The increase in accounts payable was primarily due to inventory purchases to support future shipments. The increase in accrued expenses was primarily due to increases in warranty provision and accrued employment related expenses.

 

Net cash used in investing activities was $227,000 for the fiscal year ended May 31, 2021 was due to the purchase of property and equipment.

 

Net cash provided by financing activities was $2.0 million for the fiscal year ended May 31, 2021 was due to $1.4 million borrowing from our line of credit and $560,000 in proceeds from the issuance of common stock under employee plans.

 

The effect of fluctuation in exchange rates increased cash by $117,000 for the fiscal year ended May 31, 2021 due to the fluctuation in the value of the dollar compared to foreign currencies.

 

We lease our manufacturing and office space under operating leases. We entered into a non-cancelable operating lease agreement for our United States manufacturing and office facilities, which was renewed in December 2022 and expires in September 2030. As of May 31, 2023 our operating lease liabilities totaled $6,300,000. Under that lease agreement, we are responsible for payments of utilities, taxes and insurance.

 

From time to time, we evaluate potential acquisitions of businesses, products or technologies that complement our business. If consummated, any such transactions may use a portion of our working capital or require the issuance of equity. We have no present understandings, commitments or agreements with respect to any material acquisitions.

 

We anticipate that the existing cash balance and the available line of credit together with future income from operations, collections of existing accounts receivable, revenue from our existing backlog of products as of this filing date, the sale of inventory on hand, deposits and down payments against significant orders will be adequate to meet our working capital and capital equipment requirement needs over the next 12 months. Our future capital requirements will depend on many factors, including our growth rate, the timing and extent of our spending to support research and development activities, the timing and cost of establishing additional sales and marketing capabilities, the timing and cost to introduce new and enhanced products and the timing and cost to implement new manufacturing technologies. We successfully raised $25 million in an at-the-market (“ATM”) offering in October 2021 and $7.3 million in a follow on ATM offering in February 2023; however, in the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all. Any additional debt financing obtained by us in the future could also involve restrictive covenants relating to our capital-raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. Additionally, if we raise additional funds through further issuances of equity, convertible debt securities or other securities convertible into equity, our existing stockholders could suffer significant dilution in their percentage ownership of the Company, and any new equity securities we issue could have rights, preferences and privileges senior to those of holders of our common stock. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, our ability to continue to grow or support our business and to respond to business challenges could be significantly limited.

 

OFF-BALANCE SHEET FINANCING

 

We have not entered into any off-balance sheet financing arrangements and have not established any special purpose or variable interest entities.

 

 
23

Table of Contents

 

OVERVIEW OF CONTRACTUAL OBLIGATIONS

 

The following table provides a summary of such arrangements, or contractual obligations.

 

 

 

Payments Due by Period (in thousands)

 

 

 

 

 

 

Less than

 

 

1-3

 

 

4-5

 

 

More than

 

 

 

Total

 

 

1 year

 

 

years

 

 

years

 

 

5 years

 

Lease obligations

 

$8,429

 

 

$608

 

 

$2,317

 

 

$2,429

 

 

$3,075

 

Purchases (1)

 

 

26,318

 

 

 

26,318

 

 

 

--

 

 

 

--

 

 

 

--

 

Total

 

$34,747

 

 

$26,926

 

 

$2,317

 

 

$2,429

 

 

$3,075

 

 

(1) Shown above are our binding purchase obligations. The large majority of our purchase orders are cancelable by either party, which if canceled may result in a negotiation with the vendor to determine if there shall be any restocking or cancellation fees payable to the vendor.

 

In the normal course of business to facilitate sales of our products, we indemnify other parties, including customers, with respect to certain matters. We have agreed to hold the other party harmless against losses arising from a breach of representations or covenants, or from intellectual property infringement or other claims. These agreements may limit the time period within which an indemnification claim can be made and the amount of the claim. In addition, we have entered into indemnification agreements with our officers and directors, and our bylaws contain similar indemnification obligations to our agents.

 

It is not possible to determine the maximum potential amount under these indemnification agreements due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. To date, our payments under these agreements have not had a material impact on our operating results, financial position or cash flows.

 

RECENT ACCOUNTING PRONOUNCEMENTS

 

For a description of recent accounting pronouncements, including the expected dates of adoption and estimated effects, if any, on our consolidated financial statements, see Note 1, “Organization and Summary of Significant Accounting Policies,” of the Notes to Consolidated Financial Statements.

 

Item 7A. Quantitative and Qualitative Disclosures about Market Risk

 

As a Smaller Reporting Company, we are not required to provide information under Item 7A.

 

 
24

Table of Contents

   

Item 8. Financial Statements and Supplementary Data

 

INDEX

 

Consolidated Financial Statements of Aehr Test Systems

 

 

 

 

 

 

 

Report of Independent Registered Public Accounting Firm (Firm ID 207)

 

26

 

 

 

 

 

Consolidated Balance Sheets at May 31, 2023 and 2022

 

28

 

 

 

 

 

Consolidated Statements of Operations for the years ended May 31, 2023, 2022 and 2021

 

29

 

 

 

 

 

Consolidated Statements of Comprehensive Income (Loss) for the years ended May 31, 2023, 2022 and 2021

 

30

 

 

 

 

 

Consolidated Statements of Shareholders' Equity for the years ended May 31, 2023, 2022 and 2021

 

31

 

 

 

 

 

Consolidated Statements of Cash Flows for the years ended May 31, 2023, 2022 and 2021

 

32

 

 

 

 

 

Notes to Consolidated Financial Statements

 

33

 

 

Financial statement schedules not listed above are either omitted because they are not applicable or the required information is shown in the Consolidated Financial Statements or in the Notes thereto.

 

 
25

Table of Contents

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Stockholders and Board of Directors of

Aehr Test Systems

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheets of Aehr Test Systems and its subsidiaries (the “Company”) as of May 31, 2023 and 2022, the related consolidated statements of operations, comprehensive income (loss), shareholders’ equity, and cash flows for each of the three years in the period ended May 31, 2023, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of May 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended May 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.

 

Inventory Valuation – Adjustments for Excess or Obsolete Inventory

 

As described in Note 1 to the consolidated financial statements, the Company’s consolidated inventories balance was $23.9 million as of May 31, 2023. The Company’s inventory is stated at the lower of cost, which is determined on a standard cost basis on a first-in, first-out method, or net realizable value. The Company evaluates the net realizable value by considering obsolescence, excessive levels of inventory, deterioration and other factors. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolescence or impaired inventory. If actual demand were to be substantially lower than estimated, there could be a significant adverse impact on the carrying value of the inventory and results of operations.

 

The principal considerations for our determination that performing procedures relating to adjustments for excess or obsolete inventory is a critical audit matter are the significant amount of judgement by management in developing the assumptions of the forecasted product demand, which in turn led to significant auditor judgement, subjectivity, and effort in performing audit procedures and evaluating audit evidence relating to the forecasted product demand. Additionally, for certain new sales channels there may be limited historical data with which to evaluate forecasts.

 

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others, testing management’s

 

 
26

Table of Contents

 

process for developing the estimate of the adjustments for excess or obsolete inventory, testing the completeness and accuracy of the underlying data used in the estimate, and evaluating management’s assumptions of forecasted product demand. Evaluating management’s demand forecast for reasonableness involved considering historical sales of its products, comparing prior period estimates to actual results of the same period, and determining whether the demand forecast used was consistent with evidence obtained in other areas of the audit.

 

/s/ BPM LLP

 

We have served as the Company’s auditor since 2005.

 

San Jose, California

August 28, 2023

 

 
27

Table of Contents

  

AEHR TEST SYSTEMS AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT PER SHARE DATA)

 

 

 

May 31,

 

 

 

2023

 

 

2022

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$30,054

 

 

$31,484

 

Short-term investments

 

 

17,853

 

 

 

-

 

Trade and other accounts receivable, net

 

 

16,594

 

 

 

12,859

 

Inventories

 

 

23,908

 

 

 

15,051

 

Prepaid expenses and other current assets

 

 

621

 

 

 

613

 

 

 

 

 

 

 

 

 

 

Total current assets

 

 

89,030

 

 

 

60,007

 

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

2,759

 

 

 

1,203

 

Operating lease right-of-use assets

 

 

6,123

 

 

 

917

 

Other assets

 

 

231

 

 

 

201

 

 

 

 

 

 

 

 

 

 

Total assets

 

$98,143

 

 

$62,328

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$9,206

 

 

$4,195

 

Accrued expenses

 

 

4,143

 

 

 

3,610

 

Operating lease liabilities, short-term

 

 

137

 

 

 

794

 

Customer deposits and deferred revenue, short-term

 

 

2,822

 

 

 

2,415

 

 

 

 

 

 

 

 

 

 

Total current liabilities

 

 

16,308

 

 

 

11,014

 

 

 

 

 

 

 

 

 

 

Operating lease liabilities, long-term

 

 

6,163

 

 

 

212

 

Deferred revenue, long-term

 

 

31

 

 

 

69

 

Other long-term liabilities

 

 

41

 

 

 

44

 

 

 

 

 

 

 

 

 

 

Total liabilities

 

 

22,543

 

 

 

11,339

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies (Note 20)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shareholders' equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.01 par value: Authorized: 10,000 shares;

 

 

 

 

 

 

 

 

Issued and outstanding: none

 

 

-

 

 

 

-

 

Common stock, $0.01 par value: Authorized: 75,000 shares; Issued and outstanding: 28,539 shares and 27,120 shares at May 31, 2023 and 2022 respectively

 

 

285

 

 

 

271

 

Additional paid-in capital

 

 

127,776

 

 

 

117,686

 

Accumulated other comprehensive loss

 

 

(155)

 

 

(105)

Accumulated deficit

 

 

(52,306)

 

 

(66,863)

Total shareholders' equity

 

 

75,600

 

 

 

50,989

 

 

 

 

 

 

 

 

 

 

Total liabilities and shareholders' equity

 

$98,143

 

 

$62,328

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 
28

Table of Contents

 

AEHR TEST SYSTEMS AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS, EXCEPT PER SHARE DATA)

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$64,961

 

 

$50,829

 

 

$16,600

 

Cost of sales

 

 

32,215

 

 

 

27,164

 

 

 

10,568

 

Gross profit

 

 

32,746

 

 

 

23,665

 

 

 

6,032

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

12,237

 

 

 

10,047

 

 

 

6,562

 

Research and development

 

 

7,134

 

 

 

5,818

 

 

 

3,652

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total operating expenses

 

 

19,371

 

 

 

15,865

 

 

 

10,214

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) from operations

 

 

13,375

 

 

 

7,800

 

 

 

(4,182)

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income (expense), net

 

 

1,245

 

 

 

13

 

 

 

(46)

Net gain from dissolution of Aehr Test Systems Japan

 

 

-

 

 

 

-

 

 

 

2,186

 

Gain from forgiveness of PPP loan

 

 

-

 

 

 

1,698

 

 

 

-

 

Other (expense) income, net

 

 

(3)

 

 

30

 

 

 

(162)

 

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) before income tax (expense) benefit

 

 

14,617

 

 

 

9,541

 

 

 

(2,204)

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax (expense) benefit

 

 

(60)

 

 

(91)

 

 

177

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$14,557

 

 

$9,450

 

 

$(2,027)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (net loss) per share – basic

 

$0.52

 

 

$0.36

 

 

$(0.09)

Earnings (net loss) per share – diluted

 

$0.50

 

 

$0.34

 

 

$(0.09)

Shares used in per share calculation – basic

 

 

27,785

 

 

 

26,014

 

 

 

23,457

 

Shares used in per share calculation – diluted

 

 

29,215

 

 

 

27,774

 

 

 

23,457

 

 

                      The accompanying notes are an integral part of these consolidated financial statements.

 

 
29

Table of Contents

 

AEHR TEST SYSTEMS AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(IN THOUSANDS)

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$14,557

 

 

$9,450

 

 

$(2,027)

 

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive income (loss), net of tax:

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation (loss) income

 

 

(33)

 

 

(77)

 

 

160

 

Net change in unrealized loss on investments

 

 

(17)

 

 

-

 

 

 

-

 

Reclassification of cumulative translation adjustment as a result of dissolution of Aehr Test Systems Japan

 

 

-

 

 

 

-

 

 

 

(2,401)

 

 

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive income (loss)

 

 

14,507

 

 

 

9,373

 

 

 

(4,268)

 

 

 

 

 

 

 

 

 

 

 

 

 

Less: Comprehensive income attributable to noncontrolling interest

 

 

-

 

 

 

-

 

 

 

21

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive income (loss)

 

$14,507

 

 

$9,373

 

 

$(4,289)

 

                            The accompanying notes are an integral part of these consolidated financial statements.

 

 
30

Table of Contents

 

AEHR TEST SYSTEMS AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY

(IN THOUSANDS)

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Aehr

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

Test

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

Systems

 

 

 

 

 

Total 

 

 

 

Common Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Shareholders’

 

 

Noncontrolling

 

 

Stockholders' 

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income (loss)

 

 

Deficit

 

 

Equity

 

 

Interest

 

 

Equity

 

Balances, May 31, 2020

 

 

23,107

 

 

$231

 

 

$85,898

 

 

$2,234

 

 

$(74,286)

 

$14,077

 

 

$(21)

 

$14,056

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock under employee plans

 

 

627

 

 

 

6

 

 

 

574

 

 

 

-

 

 

 

-

 

 

 

580

 

 

 

-

 

 

 

580

 

Shares repurchased for tax withholdings on vesting of RSUs

 

 

(9

 

 

 -

 

 

 

(20

 

 

-

 

 

 

-

 

 

 

(20

 

 

- 

 

 

 

(20

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

1,101

 

 

 

-

 

 

 

-

 

 

 

1,101

 

 

 

-

 

 

 

1,101

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(2,027)

 

 

(2,027)

 

 

-

 

 

 

(2,027)

Reclassification of cumulative translation adjustment

 

-

 

 

 

-

 

 

 

-

 

 

(2,401

)

 

 

-

 

(2,401

 

 

-

 

 

 

(2,401)

Foreign currency translation adjustment

 

 

-

 

 

 

-

 

 

 

-

 

 

 

139

 

 

 

-

 

 

 

139

 

 

 

21

 

 

 

160

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, May 31, 2021

 

 

23,725

 

 

 

237

 

 

 

87,553

 

 

 

(28)

 

 

(76,313)

 

 

11,449

 

 

 

-

 

 

 

11,449

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock under employee plans

 

 

1,760

 

 

 

17

 

 

 

3,543

 

 

 

-

 

 

 

-

 

 

 

3,560

 

 

 

-

 

 

 

3,560

 

Shares repurchased for tax withholdings on vesting of RSUs

 

 

(62)

 

 

-

 

 

 

(429)

 

 

-

 

 

 

-

 

 

 

(429)

 

 

-

 

 

 

(429)

Proceeds from public offerings, net of issuance costs

 

 

1,697

 

 

 

17

 

 

 

24,013

 

 

 

-

 

 

 

-

 

 

24,030

 

 

 

-

 

 

 

24,030

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

3,006

 

 

 

-

 

 

 

-

 

 

 

3,006

 

 

 

-

 

 

 

3,006

 

Net income

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

9,450

 

 

 

9,450

 

 

 

-

 

 

 

9,450

 

Foreign currency translation adjustment

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(77)

 

 

-

 

 

 

(77)

 

 

-

 

 

 

(77)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, May 31, 2022

 

 

27,120

 

 

 

271

 

 

 

117,686

 

 

 

(105)

 

 

(66,863)

 

 

50,989

 

 

 

-

 

 

 

50,989

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock under employee plans

 

 

1,388

 

 

 

13

 

 

 

2,549

 

 

 

-

 

 

 

-

 

 

 

2,562

 

 

 

-

 

 

 

2,562

 

Shares repurchased for tax withholdings on vesting of RSUs

 

 

(178)

 

 

(1)

 

 

(2,059)

 

 

-

 

 

 

-

 

 

 

(2,060)

 

 

-

 

 

 

(2,060)

Proceeds from public offerings, net of issuance costs

 

 

209

 

 

 

2

 

 

 

6,818

 

 

 

-

 

 

 

-

 

 

 

6,820

 

 

 

-

 

 

 

6,820

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

2,782

 

 

 

-

 

 

 

-

 

 

 

2,782

 

 

 

-

 

 

 

2,782

 

Net income

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

14,557

 

 

 

14,557

 

 

 

-

 

 

 

14,557

 

Net unrealized loss on investments

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(17)

 

 

-

 

 

 

(17)

 

 

-

 

 

 

(17)

Foreign currency translation adjustment

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(33)

 

 

-

 

 

 

(33)

 

 

-

 

 

 

(33)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, May 31, 2023

 

 

28,539

 

 

$285

 

 

$127,776

 

 

$(155)

 

$(52,306)

 

$75,600

 

 

$-

 

 

$75,600

 

  

The accompanying notes are an integral part of these consolidated financial statements.

 

 
31

Table of Contents

 

AEHR TEST SYSTEMS AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$14,557

 

 

$9,450

 

 

$(2,027)

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

2,748

 

 

 

3,006

 

 

 

1,101

 

Provision for doubtful accounts

 

 

24

 

 

 

-

 

 

 

-

 

Depreciation and amortization

 

 

450

 

 

 

356

 

 

 

328

 

Non-cash operating lease expense

 

 

88

 

 

 

(49)

 

 

(18)

Accretion of investment discount

 

 

(576)

 

 

-

 

 

 

-

 

Net gain from dissolution of Aehr Test Systems Japan

 

 

-

 

 

 

-

 

 

 

(2,186)

Income tax benefit related to dissolution of Aehr Test Systems Japan

 

 

-

 

 

 

-

 

 

 

(215)

Gain from forgiveness of PPP loan

 

 

-

 

 

 

(1,698)

 

 

-

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Trade and other accounts receivable

 

 

(3,788)

 

 

(7,834)

 

 

(1,373)

Inventories

 

 

(9,469)

 

 

(6,674)

 

 

(972)

Prepaid expenses and other

 

 

28

 

 

 

(71)

 

 

(81)

Accounts payable

 

 

5,044

 

 

 

1,356

 

 

 

1,877

 

Accrued expenses

 

 

528

 

 

 

1,464

 

 

 

732

 

Customer deposits and deferred revenue

 

 

369

 

 

 

2,196

 

 

 

96

 

Other long-term liabilities

 

 

-

 

 

 

-

 

 

 

47

 

Income taxes payable

 

 

8

 

 

 

6

 

 

 

(10)

Net cash provided by (used in) operating activities

 

 

10,011

 

 

 

1,508

 

 

 

(2,701)

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Purchases of investments

 

 

(33,294)

 

 

-

 

 

 

-

 

Proceeds from maturities of investments

 

 

16,000

 

 

 

-

 

 

 

-

 

Purchases of property and equipment

 

 

(1,362)

 

 

(416)

 

 

(227)

Net cash used in investing activities

 

 

(18,656)

 

 

(416)

 

 

(227)

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Line of credit (repayments) borrowings, net

 

 

-

 

 

 

(1,400)

 

 

1,400

 

Proceeds from issuance of common stock under employee plans

 

 

2,562

 

 

 

3,560

 

 

 

580

 

Shares repurchased for tax withholdings on vesting of restricted stock units

 

 

(2,060)

 

 

(429)

 

 

(20)

Proceeds from issuance of common stock from public offering, net of issuance costs

 

 

6,820

 

 

 

24,030

 

 

 

-

 

Net cash provided by financing activities

 

 

7,322

 

 

 

25,761

 

 

 

1,960

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Effect of exchange rates on cash, cash equivalents and restricted cash

 

 

(37)

 

 

49

 

 

 

117

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (decrease) increase in cash, cash equivalents and restricted cash

 

 

(1,360)

 

 

26,902

 

 

 

(851)

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash, cash equivalents and restricted cash, beginning of year

 

 

31,564

 

 

 

4,662

 

 

 

5,513

 

Cash, cash equivalents and restricted cash, end of year

 

$30,204

 

 

$31,564

 

 

$4,662

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Supplemental cash flow information:

 

 

 

 

 

 

 

 

 

 

 

 

Cash paid during the year for:

 

 

 

 

 

 

 

 

 

 

 

 

Income taxes

 

$21

 

 

$4

 

 

$15

 

Interest

 

$15

 

 

$12

 

 

$6

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Supplemental disclosure of non-cash flow information:

 

 

 

 

 

 

 

 

 

 

 

 

Net transfer of equipment between inventory and property and equipment

 

$646

 

 

$472

 

 

$113

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 
32

Table of Contents

 

AEHR TEST SYSTEMS AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

 

BUSINESS:

 

Aehr Test Systems (the “Company”) was incorporated in California in May 1977 and primarily designs, engineers and manufactures test and burn-in equipment used in the semiconductor industry. The Company’s principal products are the FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak carrier, the WaferPak aligner, the DiePak autoloader, and test fixtures.

 

CONSOLIDATION:

 

The consolidated financial statements include the accounts of the Company and both its wholly-owned and majority-owned foreign subsidiaries. Intercompany accounts and transactions have been eliminated.

 

FOREIGN CURRENCY TRANSLATION AND TRANSACTIONS:

 

Assets and liabilities of the Company’s foreign subsidiaries and a branch office are translated into U.S. Dollars from their functional currencies of Euros, Philippines Peso and New Taiwan Dollars using the exchange rate in effect at the balance sheet date. Additionally, their net sales and expenses are translated using exchange rates approximating average rates prevailing during the fiscal year. Translation adjustments that arise from translating their financial statements from their local currencies to U.S. Dollars are accumulated and reflected as a separate component of shareholders’ equity.

 

Transaction gains and losses that arise from exchange rate changes denominated in currencies other than the local currency are included in the Consolidated Statements of Operations as incurred. See Note 15, “Other (Expense) Income, Net” for the detail of foreign exchange transaction gains and losses for all periods presented.

 

USE OF ESTIMATES:

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the Company’s consolidated financial statements include allowance for doubtful accounts, valuation of inventory at the lower of cost or net realizable value, and warranty reserves.

 

RECLASSIFICATIONS:

 

Certain reclassifications have been made to the previous year consolidated financial statements to conform to the current period presentation. The reclassifications had no impact on net income (loss), total assets, total liabilities, or shareholders’ equity.

 

CASH EQUIVALENTS:

 

Cash equivalents consist of money market instruments purchased with an original maturity of three months or less. These investments are reported at fair value.

 

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS:

 

Accounts receivable are derived from the sale of products throughout the world to semiconductor manufacturers, semiconductor contract assemblers, electronics manufacturers and burn-in and test service companies. Accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts to reserve for potentially uncollectible trade receivables. The Company also reviews its trade receivables by aging category to identify specific customers with known disputes or collection issues. The Company exercises judgment when determining the adequacy of these reserves as the Company evaluates historical bad debt trends, general economic conditions in the United States and internationally, and changes in customer financial conditions. Uncollectible receivables are recorded as bad debt expense when all efforts to collect have been exhausted and recoveries are recognized when they are received. During the fiscal year ended May 31, 2023, the Company recorded bad debt expense of $24,000. No significant adjustments to the allowance for doubtful accounts were recorded during the fiscal years ended May 31, 2022 or 2021.

 

 

 
33

Table of Contents

 

CONCENTRATION OF CREDIT RISK:

 

The Company sells its products primarily to semiconductor manufacturers in North America, Asia, and Europe. As of May 31, 2023, approximately 17% and 83% of gross accounts receivable were from customers located in North America and Asia, respectively. As of May 31, 2022, approximately 20% and 80% of gross accounts receivable were from customers located in North America and Asia, respectively. Two customers accounted for 82% and 17% of gross accounts receivable as of May 31, 2023. Three customers accounted for 68%, 18% and 11% of gross accounts receivable as of May 31, 2022. Two customers accounted for 79% and 10% of net sales in fiscal 2023, respectively. One customer accounted for 82% of net sales in fiscal 2022. The Company performs ongoing credit evaluations of its customers and generally does not require collateral. The Company uses letter of credit terms for some of its international customers.

 

The Company’s cash and cash equivalents are generally deposited with major financial institutions in the United States, Philippines, Germany and Taiwan. The Company invests its excess cash in money market funds and U.S. Treasury securities. The money market funds bear the risk associated with each fund. The money market funds have variable interest rates. The Company’s cash and investment balances held at banks and brokerage firms may at time exceed federally insured levels. The Company has not experienced any material losses on its money market funds or short-term cash deposits.

 

CONCENTRATION OF SUPPLY RISK:

 

The Company relies on subcontractors to manufacture many of the components and subassemblies used in its products. Quality or performance failures of the Company’s products or changes in its manufacturers’ financial or business condition could disrupt the Company’s ability to supply quality products to its customers and thereby have a material and adverse effect on its business and operating results. Some of the components and technologies used in the Company’s products are purchased and licensed from a single source or a limited number of sources. The loss of any of these suppliers may cause the Company to incur additional transition costs, result in delays in the manufacturing and delivery of its products, or cause it to carry excess or obsolete inventory and could cause it to redesign its products.

 

INVENTORIES:

 

Inventories include material, labor and overhead, and are stated at the lower of cost (first-in, first-out method) or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less costs of completion, disposal and transportation. Provisions for excess, obsolete and unusable inventories are made after management’s evaluation of future demand and market conditions. The Company adjusts inventory balances to approximate the lower of its manufacturing costs or net realizable value. If actual future demand or market conditions become less favorable than those projected by management, additional inventory write-downs may be required, and would be reflected in cost of sales in the period the revision is made. During fiscal 2023, 2022 and 2021 the Company recognized a provision for inventory reserves of $569,000, $1,031,000, and $176,000, respectively.

 

PROPERTY AND EQUIPMENT:

 

Property and equipment are stated at cost less accumulated depreciation and amortization. Major improvements are capitalized, while repairs and maintenance are expensed as incurred. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the related lease. Furniture and fixtures, machinery and equipment, and test equipment are depreciated on a straight-line basis over their estimated useful lives. The ranges of estimated useful lives are generally as follows:

 

Furniture and fixtures   

2 to 6 years

Machinery and equipment

3 to 6 years

Test equipment  

4 to 6 years

  

REVENUE RECOGNITION:

 

The Company recognizes revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by following a five-step process: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price, and (5) recognize revenue when or as the Company satisfies a performance obligation, as further described below.

 

Performance obligations include sales of systems, contactors, spare parts, and services, as well as installation and training services included in customer contracts.

 

 

 
34

Table of Contents

 

A contract’s transaction price is allocated to each distinct performance obligation. In determining the transaction price, the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which the Company expects to be entitled. The Company generally does not grant return privileges, except for defective products during the warranty period.

 

For contracts that contain multiple performance obligations, the Company allocates the transaction price to the performance obligations on a relative standalone selling price basis. Standalone selling prices are based on multiple factors including, but not limited to, historical discounting trends for products and services and pricing practices in different geographies.

 

Revenue for systems and spares are recognized at a point in time, which is generally upon shipment or delivery. Revenue from services is recognized over time as services are completed or ratably over the contractual period of generally one year or less.

 

The Company has elected the practical expedient to not assess whether a contract has a significant financing component as the Company’s standard payment terms are less than one year.

 

We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors.

 

Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services.

 

PRODUCT DEVELOPMENT COSTS AND CAPITALIZED SOFTWARE:

 

Costs incurred in the research and development of new products or systems are charged to operations as incurred. Costs incurred in the development of software programs for the Company’s products are charged to operations as incurred until technological feasibility of the software has been established. Generally, technological feasibility is established when the software module performs its primary functions described in its original specifications, contains features required for it to be usable in a production environment, is completely documented and the related hardware portion of the product is complete. After technological feasibility is established, any additional costs are capitalized. Capitalization of software costs ceases when the software is substantially complete and is ready for its intended use. Capitalized costs are amortized over the estimated life of the related software product using the greater of the units of sales or straight-line methods over ten years. No system software development costs were capitalized or amortized in fiscal 2023, 2022 and 2021.

 

IMPAIRMENT OF LONG-LIVED ASSETS:

 

In the event that facts and circumstances indicate that the carrying value of assets may be impaired, an evaluation of recoverability would be performed. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset would be compared to the asset’s carrying value to determine if a write-down is required.

 

ADVERTISING COSTS:

 

The Company expenses all advertising costs as incurred and the amounts were not material for all periods presented.

 

SHIPPING AND HANDLING OF PRODUCTS:

 

Amounts billed to customers for shipping and handling of products are included in net sales. Costs incurred related to shipping and handling of products are included in cost of sales.

 

INCOME TAXES:

 

Income taxes are accounted for under the asset-and-liability method as required by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 740, Income Taxes (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. Under ASC 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.

 

As of May 31, 2023 the Company maintained a full valuation allowance against its deferred tax assets. We will continue to assess whether sufficient future taxable income will be generated to permit the use of deferred tax assets, and will reverse all or a portion of the allowance when there is sufficient evidence to support the reversal. Based upon our prior two fiscal years of profitability, the outlook for the next fiscal year, and absent any additional objective negative evidence, the Company anticipates adjusting the current valuation allowance position in fiscal 2024.

 

 

 
35

Table of Contents

 

FASB ASC Subtopic 740-10, Accounting for Uncertainty of Income Taxes, (“ASC 740-10”) defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company’s policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of income taxes.

 

COMPREHENSIVE INCOME (LOSS):

 

Comprehensive income (loss) generally represents all changes in shareholders’ equity except those resulting from investments or contributions by shareholders. Unrealized gains and losses from available-for-sale securities and on foreign currency translation adjustments are included in the Company’s components of comprehensive income (loss), which are excluded from net income (loss). In fiscal 2021, the Company recognized a gain of $2,401,000 related to the completed liquidation of ATS-Japan, a majority owned subsidiary, which is deducted from net income (loss) when calculating comprehensive income (loss). Refer to Note 18, “Dissolution of Aehr Test Systems Japan,” for a further discussion of the transaction. Comprehensive income (loss) is included in the statements of comprehensive income (loss).

 

RECENT ACCOUNTING PRONOUNCEMENTS:

 

Accounting Standards Not Yet Adopted

 

In June 2016, the FASB issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326), that requires measurement and recognition of expected credit losses for financial assets held based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Due to a subsequent ASU in November 2019, the accounting standard will be effective for the Company beginning in the first quarter of fiscal 2024 on a modified retrospective basis. The Company does not expect a material impact of this accounting standard on its consolidated financial statements.

 

2. REVENUE:

 

Disaggregation of revenue

 

The following tables show revenues by major product categories. Within each product category, contract terms, conditions and economic factors affecting the nature, amount, timing and uncertainty around revenue recognition and cash flow are substantially similar.

 

The Company’s revenues by product category are as follows (in thousands):

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Type of good / service:

 

 

 

 

 

 

 

 

 

Systems

 

$38,844

 

 

$25,224

 

 

$7,250

 

Contactors

 

 

21,873

 

 

 

22,647

 

 

 

5,837

 

Services

 

 

4,244

 

 

 

2,958

 

 

 

3,513

 

 

 

$64,961

 

 

$50,829

 

 

$16,600

 

Product lines:

 

 

 

 

 

 

 

 

 

 

 

 

Wafer-level

 

$63,531

 

 

$48,926

 

 

$15,004

 

Test During Burn-In

 

 

1,430

 

 

 

1,903

 

 

 

1,596

 

 

 

$64,961

 

 

$50,829

 

 

$16,600

 

   

The following presents information about the Company’s operations in different geographic areas.  Net sales are based upon ship-to location (in thousands):

 

 
36

Table of Contents

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Geographic region:

 

 

 

 

 

 

 

 

 

United States

 

$9,289

 

 

$5,110

 

 

$5,386

 

Asia

 

 

55,609

 

 

 

45,700

 

 

 

11,074

 

Europe

 

 

63

 

 

 

19

 

 

 

140

 

 

 

$64,961

 

 

$50,829

 

 

$16,600

 

 

With the exception of the amount of service contracts and extended warranties, the Company’s product category revenues are recognized at point in time when control transfers to customers.  The following presents revenue based on timing of recognition (in thousands):

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Timing of revenue recognition (in thousands):

 

 

 

 

 

 

Products and services transferred at a point in time

 

$63,531

 

 

$49,441

 

 

$15,009

 

Services transferred over time

 

 

1,430

 

 

 

1,388

 

 

 

1,591

 

 

 

$64,961

 

 

$50,829

 

 

$16,600

 

 

Contract balances   

 

A receivable is recognized in the period the Company delivers goods or provides services or when the Company’s right to consideration is unconditional. The Company usually does not record contract assets because the Company has an unconditional right to payment upon satisfaction of the performance obligation, and therefore, a receivable is more commonly recorded than a contract asset.

 

Contract liabilities include payments received in advance of performance under a contract and are satisfied as the associated revenue is recognized. Contract liabilities are reported on the consolidated balance sheets at the end of each reporting period as a component of deferred revenue. Contract liabilities as of May 31, 2023 and 2022 were $2,853,000 and $2,484,000, respectively.  During the fiscal years ended May 31, 2023 and 2022, the Company recognized $2,179,000 and $189,000 of revenues that were included in contract liabilities as of May 31, 2022 and 2021, respectively.

 

Remaining performance obligations

 

On May 31, 2023, the Company had $163,000 of remaining performance obligations, exclusive of customer deposits, which were comprised of deferred service contracts and extended warranty contracts not yet delivered. The Company expects to recognize approximately 81% of its remaining performance obligations as revenue in fiscal 2024, and an additional 19% in fiscal 2025 and thereafter. The foregoing excludes the value of other remaining performance obligations as they have original durations of one year or less, and also excludes information about variable consideration allocated entirely to a wholly unsatisfied performance obligation.

 

Costs to obtain or fulfill a contract

 

The Company generally expenses sales commissions when incurred as a component of selling, general and administrative expense as the amortization period is typically less than one year. Additionally, the majority of the Company’s cost of fulfillment as a manufacturer of products is classified as inventory and fixed assets, which are accounted for under the respective guidance for those asset types. Other costs of contract fulfillment are immaterial due to the nature of the Company’s products and their respective manufacturing process.

 

3. EARNINGS PER SHARE (“EPS”):

 

Basic EPS is determined using the weighted average number of common shares outstanding during the period. Diluted EPS is determined using the weighted average number of common shares and potential common shares (representing the dilutive effect of stock options, restricted shares, restricted shares units, or RSUs, and ESPP shares) outstanding during the period using the treasury stock method.

  

The following table presents the computation of basic and diluted earnings (net loss) per share attributable to Aehr Test Systems common shareholders (in thousands, except per share data):

  

 
37

Table of Contents

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Numerator: Net income (net loss)

 

$14,557

 

 

$9,450

 

 

$(2,027)

 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator for basic earnings (net loss) per share:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

27,785

 

 

 

26,014

 

 

 

23,457

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares used in basic earnings (net loss) per share calculation  

 

 

27,785

 

 

 

26,014

 

 

 

23,457

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Effect of dilutive securities

 

 

1,430

 

 

 

1,760

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator for diluted earnings (net loss) per share

 

 

29,215

 

 

 

27,774

 

 

 

23,457

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic earnings (net loss) per share

 

$0.52

 

 

$0.36

 

 

$(0.09)

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted earnings (net loss) per share

 

$0.50

 

 

$0.34

 

 

$(0.09)

 

For the purpose of computing diluted earnings per share, weighted average potential common shares do not include stock options with an exercise price greater than the average fair value of the Company’s common stock for the period, as the effect would be anti-dilutive. Stock options to purchase 5,000 and 64,000 shares of common stock were outstanding as of May 31, 2023 and 2022, respectively, but were not included in the computation of diluted earnings per share, because the inclusion of such shares would be anti-dilutive. Stock options to purchase 2,766,000 shares of common stock were outstanding on May 31, 2021 but were not included in the computation of diluted net loss per share, because the inclusion of such shares would be anti-dilutive.  ESPP rights to purchase 239,000 ESPP shares and RSUs for 132,000 shares were outstanding on May 31, 2021 but were not included in the computation of diluted net loss per share, because the inclusion of such shares would be anti-dilutive.

 

4.  CASH, CASH EQUIVALENTS AND INVESTMENTS

 

The following table summarizes the Company’s cash, cash equivalents and investments by security type as of May 31, 2023 (in thousands):

 

 

 

Cost

 

 

Gross Unrealized Loss

 

 

Estimated Fair Value

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$3,182

 

 

$-

 

 

$3,182

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

 

26,872

 

 

 

-

 

 

 

26,872

 

Total cash and cash equivalents

 

$30,054

 

 

$-

 

 

$30,054

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

$17,870

 

 

$(17)

 

$17,853

 

Long-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$150

 

 

$-

 

 

$150

 

Total cash, cash equivalents and investments

 

$48,074

 

 

$(17)

 

$48,057

 

   

The following table summarizes the Company’s cash, cash equivalents and investments by security type as of May 31, 2022 (in thousands):

 

 

 
38

Table of Contents

 

 

 

Cost

 

 

Gross Unrealized Loss

 

 

Estimated Fair Value

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$2,955

 

 

$-

 

 

$2,955

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

 

28,529

 

 

 

-

 

 

 

28,529

 

Total cash and cash equivalents

 

$31,484

 

 

$-

 

 

$31,484

 

Long-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$80

 

 

$-

 

 

$80

 

Total cash, cash equivalents and investments

 

$31,564

 

 

$-

 

 

$31,564

 

 

Long-term investments are included in other assets on the accompanying consolidated balance sheets.

 

Unrealized gains and losses on investments classified as available-for-sale are included within accumulated other comprehensive loss, net of any related tax effect. Upon realization, those amounts are reclassified from accumulated other comprehensive loss to results of operations.

 

The unrealized loss of $17,000 as of May 31, 2023 is not considered other-than-temporary, and has been in an unrealized loss position for less than a year.

 

5. FAIR VALUE OF FINANCIAL INSTRUMENTS:

 

The Company’s financial instruments are measured at fair value consistent with authoritative guidance. This authoritative guidance defines fair value, establishes a framework for using fair value to measure assets and liabilities, and disclosures required related to fair value measurements.

 

The guidance establishes a fair value hierarchy based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources while unobservable inputs reflect a reporting entity’s pricing based upon their own market assumptions. The fair value hierarchy consists of the following three levels:

 

Level 1 - instrument valuations are obtained from real-time quotes for transactions in active exchange markets involving identical assets.

 

Level 2 - instrument valuations are obtained from readily-available pricing sources for comparable instruments.

 

Level 3 - instrument valuations are obtained without observable market values and require a high level of judgment to determine the fair value.

 

The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of May 31, 2023 (in thousands):

 

 

 

Balance as of

 

 

 

 

 

 

 

 

 

 

 

May 31, 2023

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Money market funds

 

$27,022

 

 

$27,022

 

 

$-

 

 

$-

 

U.S. treasury securities

 

 

17,853

 

 

 

17,853

 

 

 

 

 

 

 

 

 

Total

 

$44,875

 

 

$44,875

 

 

$-

 

 

$-

 

 

The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of May 31, 2022 (in thousands):

 

   

 

 

Balance as of

 

 

 

 

 

 

 

 

 

 

 

May 31, 2022

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Money market funds

 

$28,609

 

 

$28,609

 

 

$-

 

 

$-

 

Total

 

$28,609

 

 

$28,609

 

 

$-

 

 

$-

 

 

 
39

Table of Contents

 

 

Included in money market funds as of May 31, 2023 and 2022 was $150,000 and $80,000 of restricted cash, respectively, representing a security deposit for the Company’s United States manufacturing and office space lease which is included in other assets in the consolidated balance sheets.

 

There were no financial liabilities measured at fair value as of May 31, 2023 and 2022.

 

There were no transfers between Level 1 and Level 2 fair value measurements during the fiscal years ended May 31, 2023 and 2022.

 

The carrying amounts of financial instruments including cash equivalents, accounts receivables, accounts payable and certain other accrued liabilities, approximate fair value due to their short maturities.

 

6. TRADE AND OTHER ACCOUNTS RECEIVABLE, NET:

 

Accounts receivable comprise (in thousands):

 

 

 

May 31,

 

 

 

2023

 

 

2022

 

Accounts receivable

 

$16,594

 

 

$12,859

 

Less: Allowance for doubtful accounts

 

 

-

 

 

 

-

 

 

 

$16,594

 

 

$12,859

 

 

Accounts receivable represents customer trade receivables. As of May 31, 2023 and 2022, there were no allowances for doubtful accounts.

 

7. BALANCE SHEET DETAIL:

 

INVENTORIES:     

 

 May 31,

 

(In Thousands)

 

2023

 

 

2022

 

Raw materials and sub-assemblies

 

$15,953

 

 

$9,507

 

Work in process

 

 

5,764

 

 

 

5,461

 

Finished goods

 

 

2,191

 

 

 

83

 

 

 

$23,908

 

 

$15,051

 

 

PROPERTY AND EQUIPMENT, NET:  

 

 

 

 May 31,

 

(In Thousands)

 

2023

 

 

2022

 

Leasehold improvements

 

$1,310

 

 

$1,230

 

Furniture and fixtures

 

 

706

 

 

 

697

 

Machinery and equipment

 

 

5,445

 

 

 

4,013

 

Test equipment

 

 

2,998

 

 

 

2,523

 

 

 

 

10,459

 

 

 

8,463

 

Less: Accumulated depreciation and amortization

 

 

(7,700)

 

 

(7,260)

 

 

$2,759

 

 

$1,203

 

   

Depreciation expense was $450,000, $307,000 and $310,000 for fiscal 2023, 2022, and 2021, respectively.

 

 

 
40

Table of Contents

 

ACCRUED EXPENSES:

 

 

 

 May 31,

 

(In Thousands)

 

2023

 

 

2022

 

Commissions and bonuses

 

$1,728

 

 

$1,505

 

Payroll related

 

 

1,491

 

 

 

1,401

 

Warranty

 

 

267

 

 

 

410

 

Professional services

 

 

520

 

 

 

204

 

Investor relations

 

 

79

 

 

 

44

 

Taxes payable

 

 

22

 

 

 

13

 

Other

 

 

36

 

 

 

33

 

 

 

$4,143

 

 

$3,610

 

 

CUSTOMER DEPOSITS AND DEFERRED REVENUE, SHORT-TERM:   

 

 

 

 May 31,

 

(In Thousands)

 

2023

 

 

2022

 

Customer deposits

 

$2,690

 

 

$2,263

 

Deferred revenue  

 

 

132

 

 

 

152

 

 

 

$2,822

 

 

$2,415

 

 

8.  ACCUMULATED OTHER COMPREHENSIVE LOSS:

 

Changes in the components of accumulated other comprehensive loss, net of tax, were as follows (in thousands):

 

 

 

Cumulative Translation Adjustments

 

 

Unrealized Loss on Investments, Net

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

Balance as of May 31, 2021

 

$(28)

 

$-

 

 

$(28)

Other comprehensive loss before reclassifications

 

 

(77)

 

 

-

 

 

 

(77)

Balance as of May 31, 2022

 

 

(105)

 

 

-

 

 

 

(105)

Other comprehensive loss before reclassifications

 

 

(33)

 

 

(17)

 

 

(50)

Balance as of May 31, 2023

 

$(138)

 

$(17)

 

$(155)

 

9. INCOME TAXES:

 

Domestic and foreign components of income (loss) before income tax (expense) benefit are as follows (in thousands):

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Domestic

 

$14,541

 

 

$9,416

 

 

$(13,064)

Foreign

 

 

76

 

 

 

125

 

 

 

10,860

 

 

 

$14,617

 

 

$9,541

 

 

$(2,204)

 

 
41

Table of Contents

 

 

The income tax (expense) benefit consists of the following (in thousands):

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Federal income taxes:

 

 

 

 

 

 

 

 

 

Current

 

$(28)

 

$(59)

 

$163

 

Deferred

 

 

-

 

 

 

-

 

 

 

-

 

State income taxes:

 

 

 

 

 

 

 

 

 

 

 

 

Current

 

 

-

 

 

 

(5)

 

 

13

 

Deferred

 

 

-

 

 

 

-

 

 

 

-

 

Foreign income taxes:

 

 

 

 

 

 

 

 

 

 

 

 

Current

 

 

(32)

 

 

(27)

 

 

1

 

Deferred

 

 

-

 

 

 

-

 

 

 

-

 

 

 

$(60)

 

$(91)

 

$177

 

 

The Company’s effective tax rate differs from the U.S. federal statutory tax rate, as follows:

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

U.S. federal statutory tax rate

 

 

21.0%

 

 

21.0%

 

 

21.0%

State taxes, net of federal tax effect

 

 

-

 

 

 

0.1

 

 

 

0.6

 

Foreign rate differential

 

 

0.7

 

 

 

0.3

 

 

 

9.8

 

Stock-based compensation

 

 

(9.1)

 

 

(11.0)

 

 

(4.7)

Research and development credit

 

 

(2.3)

 

 

(1.3)

 

 

4.0

 

Change in valuation allowance

 

 

(9.3)

 

 

(4.7)

 

 

(32.1)

Controlled Foreign Corporation Liquidation. .

 

 

-

 

 

 

-

 

 

 

9.8

 

PPP Loan

 

 

-

 

 

 

(3.7)

 

 

-

 

Other

 

 

(0.6)

 

 

0.4

 

 

 

(0.4)

Effective tax rate

 

 

0.4%

 

 

1.1%

 

 

8.0%

 

The components of the net deferred tax assets and liabilities are as follows (in thousands):

 

 

 

Year Ended May 31,

 

 

 

         2023

 

 

2022

 

Deferred tax assets:

 

 

 

 

 

 

Net operating losses

 

$11,964

 

 

$14,912

 

Lease liability

 

 

1,335

 

 

 

218

 

Credit carryforwards

 

 

6,235

 

 

 

5,535

 

Inventory reserves

 

 

938

 

 

 

934

 

Reserves and accruals

 

 

1,200

 

 

 

1,360

 

Capitalized research and development

 

 

1,187

 

 

 

-

 

Other

 

 

297

 

 

 

220

 

Less: valuation allowance

 

 

(21,859)

 

 

(22,980)

 

 

 

1,297

 

 

 

199

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

Operating lease right-of-use assets

 

 

(1,297)

 

 

(199)

Net deferred tax assets (liabilities)

 

$-

 

 

$-

 

 

The valuation allowance decreased by $1,121,000 during fiscal 2023, decreased by $278,000 during fiscal 2022, and increased by $2,438,000 during fiscal 2021. As of May 31, 2023 and 2022, the Company provided a full valuation allowance against the deferred tax assets as it did not have enough objective evidence as required by GAAP to reverse its full valuation allowance. The Company will continue to evaluate the need for a valuation allowance against its deferred tax assets on a quarterly basis.

 

At May 31, 2023 and 2022, the Company has federal net operating loss carryforwards of approximately $46,967,000 and $61,068,000 respectively, to reduce future taxable income. A portion of the federal net operating losses will begin to expire in 2024. Federal net operating losses of $14,425,000 will carryforward indefinitely and would be subject to an 80% taxable income limitation in the year utilized. At May 31, 2023 and 2022, the Company has state net operating loss carryforwards of $30,203,000 and $30,043,000, respectively, to reduce future taxable income. The state net operating loss carryforwards will begin to expire in 2028.

 

 

 
42

Table of Contents

 

At May 31, 2023 and 2022, the Company has federal research and development credit carryforwards of approximately $2,923,000 and $2,362,000, respectively, to offset future tax liability. The federal credit carryforwards began to expire in 2022. At May 31, 2023 and 2022, the Company has state research and development credit carryforwards of approximately $6,623,000 and $6,152,000 respectively, to offset future tax liability. The state credit carryforwards are not subject to expiration. The Company also has alternative minimum tax credit carryforwards of $34,000 for state purposes. The credits may be used to offset regular tax and do not expire.

 

Internal Revenue Code of 1986, as amended (“IRC”) Section 382 (“§382”) limits the use of NOL and tax credit carryforwards in certain situations where changes occur in the stock ownership of a company. In general, if we experience a greater than 50% aggregate change in ownership over a three-year period, we are subject to an annual limitation under IRC §382 on the utilization of the Company’s pre-change NOL carryforwards. California and other states have similar laws. The annual limitation generally is determined by multiplying the value of the Company’s stock at the time of such ownership change (subject to certain adjustments) by the applicable long-term exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization.

 

The Company has made no provision for U.S. income taxes on undistributed earnings of certain foreign subsidiaries because it is the Company’s intention to permanently reinvest such earnings in its foreign subsidiaries. If such earnings were distributed, the Company would be subject to additional U.S. income tax expense.

 

The Company maintains liabilities for uncertain tax positions. These liabilities involve considerable judgment and estimation and are continuously monitored by management based on the best information available.

 

The aggregate changes in the balance of gross unrecognized tax benefits are as follows (in thousands):

 

Beginning balance as of May 31, 2020

 

$1,852

 

 

 

 

 

 

Increases related to prior year tax positions

 

 

11

 

Increases related to current year tax positions

 

 

65

 

 

 

 

 

 

Balance at May 31, 2021

 

 

1,928

 

 

 

 

 

 

Increases related to prior year tax positions

 

 

12

 

Increases related to current year tax positions

 

 

78

 

 

 

 

 

 

Balance at May 31, 2022

 

 

2,018

 

 

 

 

 

 

Increases related to prior year tax positions

 

 

90

 

Increases related to current year tax positions

 

 

168

 

 

 

 

 

 

Balance at May 31, 2023

 

$2,276

 

 

As of May 31, 2023 and 2022, the Company has not recorded interest and penalties associated with its unrecognized tax benefits. The Company’s unrecognized gross tax benefits would not reduce the annual effective tax rate if recognized because it has recorded a full valuation allowance on its deferred tax assets. The Company does not foresee any material changes to the gross unrecognized tax benefit within the next twelve months. The Company’s policy is to recognize interest and penalties in income tax expense.

 

The Company’s federal and state income tax returns are subject to possible examination by the taxing authorities until the expiration of the related statutes of limitations on those tax returns. In general, the federal income tax returns have a three-year statute of limitations, and the state income tax returns have a four-year statute of limitations. The Company’s foreign income tax returns are also subject to examination by the foreign tax authorities with the longest statute of limitations period of four-year.

   

10. LEASES

 

The Company leases its manufacturing and office space under operating leases. The principal administrative and production facility is located in Fremont, California, in a 51,289 square foot building. The Company entered into a non-cancelable operating lease agreement for its United States manufacturing and office facility, which was renewed in December 2022 and expires in September 2030. The Company leases a 492 square foot sales and support office in Utting, Germany. The lease, which began on February 1, 1992 and expires on January 31, 2025, contains an automatic twelve months renewal, at rates to be determined, if no notice is given prior to six months from expiration. The Company leases a facility in the Philippines located in a 2,713 square foot building in Clark Freeport Zone, Pampanga. The lease, which began on January 1, 2021 and expires on December 31, 2025, contains an option to renew for another three years at rates stipulated in the contract, notice for renewal is given six months from expiration. Under the lease agreements, the Company is responsible for payments of utilities, taxes and insurance.

 

 

 
43

Table of Contents

 

The Company has only operating leases for real estate including corporate offices, warehouse space and certain equipment. A lease with an initial term of 12 months or less is generally not recorded on the consolidated balance sheets, unless the arrangement includes an option to purchase the underlying asset, or renew the arrangement that the Company is reasonably certain to exercise (short-term leases). The Company recognizes lease expense on a straight-line basis over the lease term for short-term leases that the Company does not record on its balance sheets. The Company’s operating leases have remaining lease terms of one year to seven years.

 

The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.

 

In December 2022, the Company amended its lease agreement to extend the lease term of an existing office facility located in the United States, which is considered a lease modification not accounted for as a separate contract. The total commitments, net of tenant incentives expected to be received, under the modified lease are $8.6 million. The modified lease expires in fiscal 2031 and contains an option to further extend the lease. The lease modification resulted in an increase in the Company’s operating lease right-of-use assets and operating lease liabilities of $5.9 million each.

 

The weighted average remaining lease term for the Company’s operating leases was 7.3 years at May 31, 2023 and the weighted average discount rate was 7.5%.

 

The Company’s operating lease cost was $923,000, $766,000 and $761,000 for the years ended May 31, 2023, 2022 and 2021, respectively.

 

The following table presents supplemental cash flow information related to the Company’s operating leases (in thousands):

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Cash paid for amounts included in the measurement of operating lease liabilities:

 

 

 

 

 

 

 

 

 

Operating cash flows from operating leases

 

$835

 

 

$813

 

 

$779

 

 

    The following table presents the maturities of the Company’s operating lease liabilities as of May 31, 2023 (in thousands):

 

Fiscal year

 

Operating Leases

 

2024

 

$608

 

2025

 

 

1,143

 

2026

 

 

1,174

 

2027

 

 

1,195

 

2028

 

 

1,234

 

Thereafter

 

 

3,075

 

Total future minimum operating lease payments

 

 

8,429

 

Less: imputed interest

 

 

(2,129)

Present value of operating lease liabilities

 

$6,300

 

   

11. BORROWING AND FINANCING ARRANGEMENTS:

 

On January 16, 2020, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Silicon Valley Bank (“SVB”). Pursuant to the Loan Agreement, the Company may borrow up to (a) the lesser of (i) the revolving line of $4.0 million or (ii) the amount available under the borrowing base under a revolving line of credit which is collateralized by all the Company’s assets except intellectual property. The borrowing base is 80% of eligible accounts, as determined by SVB from the Company’s most recent borrowing base statement; provided, however, SVB has the right to decrease the foregoing percentage in its good faith business judgment to mitigate the impact of certain events or conditions, which may adversely affect the collateral or its value. Subject to an event of default, the principal amount outstanding under the revolving line of credit will accrue interest at a floating per annum rate equal to the greater of (a) the prime rate plus an additional percentage of up to 1%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 4.75%. Interest is payable monthly on the last calendar day of each month and the outstanding principal amount, the unpaid interest and all other obligations are due on the maturity date, which is 364 days from the effective date of January 13, 2020.

 

 
44

Table of Contents

 

 

On January 14, 2021, the Company entered into the First Amendment to Loan and Security Agreement (the “Amendment”) with SVB. The Amendment, among other things, extended the Revolving Line Maturity Date to July 14, 2021; provided, however, that if the Company achieved specified operating metrics on a consolidated basis on or prior to May 31, 2021 the Amended Revolving Line Maturity Date would be extended to January 13, 2022.

 

On January 11, 2022, the Company entered into the Second Amendment to the Loan and Security Agreement (the “Second Amendment”) with SVB. The Second Amendment, among other things, (A) increased the available amount of the line up to the lesser of (i) $10 million or (ii) the available amount under the borrowing base, under a revolving line of credit, (B) allowed for borrowing up to $3 million of the available balance based upon eligible customer purchase orders, (C) reduced the interest rate for account advances under the line to the greater of (a) prime rate plus an additional percentage up to 1.0%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 3.25%, reduces the interest rate for purchase order advances under the line to the greater of (a) prime rate plus an additional percentage up to 1.5%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 3.75%, and (D) extended the maturity date to January 13, 2023.

 

On January 10, 2023, the Company entered into the Third Amendment to the Loan and Security Agreement (the “Third Amendment”) with SVB. The Third Amendment, among other things, extends the Revolving Line Maturity Date to January 13, 2024, provided, however, that (i) if the Company submits a fiscal year 2024 plan of record that is generally acceptable to SVB, and (ii) the minimum net liquidity at the end of November 30, 2023 is at least $20.0 million, the Amended Revolving Line Maturity Date would be extended to January 13, 2025.

 

As of May 31, 2023 the Company had not drawn against the credit facility and was in compliance with all covenants related to obligations to meet reporting requirements. The balance available to borrow under the line as of May 31, 2023 was $8,004,000. There are no financial covenants in the agreement.

 

12. LONG-TERM DEBT:

 

On April 23, 2020, the Company obtained a Payroll Protection Program loan (“PPP Loan”) in the aggregate amount of $1,679,000 from SVB. The PPP Loan was evidenced by a promissory note dated April 23, 2020 (the “Note”) that matures on April 23, 2022 and bears interest at a rate of 1% per annum, payable monthly commencing on November 23, 2020. The PPP Loan proceeds were used for payroll, health care benefits, rent and utilities.

 

Under the terms of the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), PPP Loan recipients can apply for and be granted forgiveness for all or a portion of loans granted under the PPP Loan. On June 12, 2021, the Company received confirmation from the SVB that on June 4, 2021, the Small Business Administration approved the Company’s PPP Loan forgiveness application for the entire PPP Loan balance of $1,679,000 and interest totaling $19,000, and the Company recognized a gain on loan forgiveness of $1,698,000.

 

13. STOCK-BASED COMPENSATION:

 

Stock-based compensation expense consists of expenses for stock options, restricted stock units (“RSUs”), performance RSUs, or PRSUs, restricted shares, performance restricted shares and employee stock purchase plan, or ESPP, purchase rights. Stock-based compensation expense for stock options and ESPP purchase rights is measured at each grant date, based on the fair value of the award using the Black-Scholes option valuation model, and is recognized as expense over the employee’s requisite service period. This model was developed for use in estimating the value of publicly traded options that have no vesting restrictions and are fully transferable. The Company’s employee stock options have characteristics significantly different from those of publicly traded options. For RSUs, PRSUs, restricted shares and performance restricted shares, stock-based compensation expense is based on the fair value of the Company’s common stock at the grant date, and is recognized as expense over the employee’s requisite service period. All of the Company’s stock-based compensation is accounted for as equity instruments.

 

The following table summarizes the stock-based compensation expense for the fiscal years ended May 31, 2023, 2022 and 2021 (in thousands, except per share data):

 

 

 
45

Table of Contents

 

 

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Stock-based compensation in the form of stock options,

 

 

 

 

 

 

 

 

 

RSUs, and ESPP purchase rights, included in:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales

 

$331

 

 

$234

 

 

$70

 

Selling, general and administrative

 

 

1,711

 

 

 

1,721

 

 

 

816

 

Research and development

 

 

706

 

 

 

968

 

 

 

215

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net effect on net income (loss)

 

$2,748

 

 

$2,923

 

 

$1,101

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Effect on earnings (net loss) per share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$0.10

 

 

$0.11

 

 

$0.05

 

Diluted

 

$0.09

 

 

$0.11

 

 

$0.05

 

 

As of the years ended May 31, 2023, 2022 and 2021, stock-based compensation totaling $120,000, $83,000 and $0, respectively, was capitalized as part of inventory.

 

During fiscal 2023, 2022 and 2021, the Company recorded stock-based compensation related to stock options, RSUs, PRSUs, performance restricted shares and restricted shares of $1,988,000, $2,071,000 and $993,000, respectively. For PRSUs and performance restricted shares, the Company evaluates compensation expense quarterly and recognizes expense for performance-based awards only if it determines it is probable that performance criteria for the awards will be met.

 

As of May 31, 2023, the total compensation expense related to unvested stock-based awards under the Company’s 2016 Equity Incentive Plan, but not yet recognized, was $3,102,000 which is net of estimated forfeitures of $8,000. This expense will be amortized on a straight-line basis over a weighted average period of approximately 2.3 years.

 

During fiscal 2023, 2022 and 2021, the Company recorded stock-based compensation related to its ESPP of $760,000, $935,000 and $108,000, respectively.

 

As of May 31, 2023, the total compensation expense related to purchase rights under the ESPP but not yet recognized was $715,000. This expense will be amortized on a straight-line basis over a weighted average period of approximately 1.1 years.

 

Valuation Assumptions

 

Valuation and Amortization Method. The Company estimates the fair value of stock options granted using the Black-Scholes option valuation method and a single option award approach. The fair value under the single option approach is amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period.

 

Expected Term. The Company’s expected term represents the period that the Company’s stock-based awards are expected to be outstanding and was determined based on historical experience, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior as evidenced by changes to the terms of its stock-based awards.

 

Volatility. Volatility is a measure of the amounts by which a financial variable such as stock price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company uses the historical volatility for the past five to six years, based on weighted average of the expected term of option grants, to estimate expected volatility. Volatility for each of the ESPP’s four time periods of six months, twelve months, eighteen months, and twenty-four months is calculated separately and included in the overall stock-based compensation expense recorded.

 

Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes option valuation method on the implied yield in effect at the time of option grant on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of the stock awards including the ESPP.

  

Fair Value. The fair values of the Company’s stock options granted to employees in fiscal 2023, 2022 and 2021 were estimated using the following weighted average assumptions in the Black-Scholes option valuation method:

 

 

 
46

Table of Contents

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

Expected term (in years)

 

5 - 6

 

 

5 - 6

 

 

 

6

 

Volatility

 

 

86%

 

 

88%

 

 

72%

Risk-free interest rates

 

 

3.12%

 

 

1.50%

 

 

0.44%

Weighted average grant date fair value

 

$6.29

 

 

$4.01

 

 

$1.12

 

 

The fair value of our ESPP purchase rights for the fiscal 2023, 2022 and 2021 was estimated using the following weighted average assumptions:

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

Expected term (in years)

 

0.52.0

 

 

0.52.0

 

 

0.52.0

 

Volatility

 

91% – 203

 

101% – 272

 

74% – 88

%

Risk-free interest rates

 

3.97%–4.94

 

0.05%–2.44

 

0.04%–0.17

Weighted average grant date fair value

 

$13.60

 

 

$9.68

 

 

$1.03

 

 

EQUITY INCENTIVE PLAN:

 

In October 2006, the Company’s 2006 Equity Incentive Plan was approved by the shareholders, which provides for granting of incentive stock options, non-statutory stock options, restricted shares, RSUs, stock appreciation rights, PRSUs, performance restricted shares and other stock or cash awards as the Company’s Board of Directors may determine.

 

In October 2016, the Company’s 2016 Equity Incentive Plan was approved by the Company’s shareholders. The 2016 Equity Incentive Plan replaced our 2006 Equity Incentive Plan, which was scheduled to expire in October 2016, and will continue in effect until 2026. The exercise price of each stock option equals the market value of the Company's common stock on the date of grant. Options typically vest over four years, subject to the grantee’s continued service with the Company through the scheduled vesting date, and expire in seven years from the grant date. A total of 4,848,000 shares of common stock have been reserved for issuance under the Company’s 2016 Equity Incentive Plan, which includes 2,248,000 shares that remained available for issuance under the 2006 Equity Incentive Plan. Full value awards, which are equity awards other than options, stock appreciation rights or other awards that are based solely on an increase in value of the shares following the grant date, when granted or forfeited will be counted as two times the number of shares added or deducted to the remaining available shares for issuance under 2016 Equity Incentive Plan. See the Company’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on November 16, 2021 for further information regarding the 2016 Equity Incentive Plan.

  

The following tables summarize the Company’s stock option and RSU transactions during fiscal 2023, 2022 and 2021 (in thousands):

 

 
47

Table of Contents

 

Available

Shares

Balance, May 31, 2020

1,416

Options granted

(297)

RSUs granted

(680)

RSUs cancelled

2

Shares withheld for taxes and not issued

18

Options terminated

455

Options expired

(341)

Balance, May 31, 2021

573

Additional shares reserved

1,414

Options granted

(303)

RSUs granted

(1,044)

RSUs cancelled

20

Shares withheld for taxes and not issued

(30)

Options terminated

105

Balance, May 31, 2022

735

Options granted

(110)

RSUs granted

(674)

RSUs cancelled

60

Options terminated

16

Balance, May 31, 2023

27

 

The following table summarized the stock option transactions during fiscal 2023, 2022 and 2021 (in thousands, except per share data):

 

 

 

Outstanding Options

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

Number

 

 

Average

 

 

Aggregate

 

 

 

of

 

 

Exercise

 

 

Intrinsic

 

 

 

Shares

 

 

Price

 

 

Value

 

Balances, May 31, 2020

 

 

3,153

 

 

$2.17

 

 

$102

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options granted

 

 

297

 

 

$1.78

 

 

 

 

 

Options terminated

 

 

(455)

 

$2.31

 

 

 

 

 

Options exercised

 

 

(229)

 

$1.54

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, May 31, 2021

 

 

2,766

 

 

$2.16

 

 

$807

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options granted

 

 

303

 

 

$5.37

 

 

 

 

 

Options terminated

 

 

(105)

 

$1.59

 

 

 

 

 

Options exercised

 

 

(1,367)

 

$2.28

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, May 31, 2022

 

 

1,597

 

 

$2.70

 

 

$9,290

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options granted

 

 

110

 

 

$9.06

 

 

 

 

 

Options terminated

 

 

(16)

 

$5.42

 

 

 

 

 

Options exercised

 

 

(730)

 

$2.32

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, May 31, 2023

 

 

961

 

 

$3.67

 

 

$28,211

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options fully vested and expected to vest at May 31, 2023

 

 

947

 

 

$3.66

 

 

$27,796

 

 

 
48

Table of Contents

 

 

The options outstanding and exercisable at May 31, 2023 were in the following exercise price ranges (in thousands, except per share data):

 

 

 

 

Options Outstanding

 

 

                       Options Exercisable

 

 

 

 

at May 31, 2023

 

 

                           at May 31, 2023

 

Range of Exercise

Prices

 

 

Number Outstanding Shares

 

 

Weighted Average Remaining Contractual Life (Years)

 

 

Weighted Average Exercise Price

 

 

Number Exercisable Shares

 

 

Weighted Average Remaining Contractual Life (Years)

 

 

Weighted Average Exercise Price

 

 

Aggregate Intrinsic Value

 

$1.34

 

 

 

41

 

 

 

4.39

 

 

$1.34

 

 

 

41

 

 

 

4.39

 

 

$1.34

 

 

 

 

$1.64-$1.86

 

 

 

365

 

 

 

3.53

 

 

$1.72

 

 

 

291

 

 

 

3.45

 

 

$1.70

 

 

 

 

$2.03-$2.40

 

 

 

185

 

 

 

2.61

 

 

$2.14

 

 

 

175

 

 

 

2.48

 

 

$2.14

 

 

 

 

$2.93

 

 

 

139

 

 

 

5.12

 

 

$2.93

 

 

 

35

 

 

 

5.12

 

 

$2.93

 

 

 

 

$3.46-$3.93

 

 

 

37

 

 

 

1.11

 

 

$3.93

 

 

 

37

 

 

 

1.11

 

 

$3.93

 

 

 

 

$8.00-34.00

 

 

 

194

 

 

 

5.97

 

 

$9.77

 

 

 

41

 

 

 

5.90

 

 

$10.18

 

 

 

 

$1.34-34.00

 

 

 

961

 

 

 

4.02

 

 

$3.67

 

 

 

620

 

 

 

3.35

 

 

$2.56

 

 

$18,895

 

 

The total intrinsic values of options exercised were $17,088,000, $12,542,000 and $152,000 during fiscal 2023, 2022 and 2021, respectively. The weighted average contractual life of the options exercisable and expected to be exercisable at May 31, 2023 was 4.01 years.

 

Options to purchase 620,000, 1,042,000 and 2,045,000 shares were exercisable at May 31, 2023, 2022 and 2021, respectively. These exercisable options had weighted average exercise prices of $2.56, $2.22 and $2.26 as of May 31, 2023, 2022 and 2021, respectively.

 

The following table summarizes RSUs, PRSUs, restricted shares and performance restricted shares granted to employees and members of the Company’s Board of Directors during fiscal 2023, 2022 and 2021:

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Employees:

 

 

 

 

 

 

 

 

 

Annual RSUs granted

 

 

152,000

 

 

 

120,000

 

 

 

161,000

 

Weighted-average grant-date fair value of annual RSUs

 

$8.03

 

 

$3.17

 

 

$1.86

 

Annual restricted shares granted

 

 

8,000

 

 

 

-

 

 

 

-

 

Weighted-average grant-date fair value of annual restricted shares  

 

$8.00

 

 

 

-

 

 

 

-

 

RSUs granted in lieu of cash payment for salary reductions and bonus

 

 

-

 

 

 

89,000

 

 

 

18,000

 

Weighted-average grant-date value of RSU in lieu of cash payment

 

 

-

 

 

$2.50

 

 

$2.21

 

Maximum PRSUs to be vested if all revenue goals are achieved

 

 

80,000

 

 

 

270,000

 

 

 

-

 

Maximum Performance restricted shares to be vested if all revenue goals are achieved

 

 

24,000

 

 

 

-

 

 

 

-

 

Weighted-average grant-date fair value of PRSUs and performance restricted shares

 

$8.00

 

 

$3.41

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Members of Board of Directors:

 

 

 

 

 

 

 

 

 

 

 

 

RSUs granted

 

 

44,000

 

 

 

43,000

 

 

 

161,000

 

Weighted-average grant-date fair value of RSUs

 

$11.35

 

 

$8.02

 

 

$1.81

 

Maximum PRSUs granted to be vested if all revenue goals are achieved

 

 

25,000

 

 

 

-

 

 

 

-

 

Weighted-average grant-date fair value of PRSUs

 

$8.00

 

 

 

-

 

 

 

-

 

 

PRSUs were granted to key officers and members of Board of Directors based upon revenue target thresholds for fiscal 2023 and 2022.

 

 

 
49

Table of Contents

  

The following table summarizes the RSUs and PRSUs vested and unvested during fiscal 2023, 2022 and 2021:

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Net RSUs and PRSUs vested

 

 

240,000

 

 

 

96,000

 

 

 

207,000

 

Shares withheld to settle payroll taxes  

 

 

178,000

 

 

 

62,000

 

 

 

9,000

 

Weighted average grant-date fair value of vested RSUs and PRSUs

 

$4.47

 

 

$3.12

 

 

$1.90

 

RSUs and PRSUs cancelled

 

 

30,000

 

 

 

10,000

 

 

 

1,000

 

Weighted average grant-date fair value of cancelled RSUs and PRSUs

 

$8.56

 

 

$2.93

 

 

$3.46

 

RSUs and PRSUs unvested

 

 

345,000

 

 

 

185,000

 

 

 

132,000

 

Weighted average grant-date fair value of unvested RSUs and PRSUs

 

$6.40

 

 

$3.00

 

 

$1.88

 

Intrinsic value of unvested RSUs and PRSUs (in thousands)

 

$11,392

 

 

$1,554

 

 

$297

 

 

EMPLOYEE STOCK PURCHASE PLAN:

 

In October 2006, the Company’s shareholders approved the 2006 Employee Stock Purchase Plan. In October 2016, the Company’s shareholders approved the Company’s Amended and Restated 2006 Employee Stock Purchase Plan (the “Purchase Plan”), which amended and restated the 2006 Employee Stock Purchase Plan. The Purchase Plan extended the term of the 2006 Employee Stock Purchase Plan indefinitely. See the Company’s Registration Statements on Form S-8 filed with the Securities and Exchange Commission on November 18, 2020 and November 16, 2022 for further information regarding the Purchase Plan. The Purchase Plan has consecutive, overlapping, twenty-four month offering periods. Each twenty-four-month offering period includes four six-month purchase periods. The offering periods generally begin on the first trading day on or after April 1 and October 1 each year. All employees who work a minimum of 20 hours per week and are customarily employed by the Company (or an affiliate thereof) for at least five months per calendar year are eligible to participate. Under the Purchase Plan, shares are purchased through employee payroll deductions at exercise prices equal to 85% of the lesser of the fair market value of the Company’s common stock at either the first day of an offering period or the last day of the purchase period. If a participant’s rights to purchase stock under all employee stock purchase plans of the Company accrue at a rate which exceeds $25,000 worth of stock for a calendar year, such participant may not be granted an option to purchase stock under the Purchase Plan. The maximum number of shares a participant may purchase during a single purchase period is 3,000 shares. In October 2022, the Company’s shareholders approved an amendment to the Purchase Plan to increase the number of shares authorized for issuance thereunder by an additional 350,000 shares of the Company’s common stock. After such amendment, a total of 2,550,000 shares of the Company’s common stock have been authorized for issuance under the Purchase Plan. During the fiscal years ended May 31, 2023, 2022 and 2021, ESPP purchase rights of 77,000, 101,000, and 279,000 shares, respectively, were granted. For the fiscal years ended May 31, 2023, 2022 and 2021, approximately 211,000, 178,000 and 147,000 shares of common stock, respectively, were issued under the Purchase Plan. As of May 31, 2023, a total of 2,152,000 shares have been issued under the Purchase Plan, and 398,000 ESPP shares remain available for issuance.

 

14. EMPLOYEE BENEFIT PLANS:

 

EMPLOYEE STOCK OWNERSHIP PLAN:

 

The Company has a non-contributory, trusteed employee stock ownership plan for full-time employees who have completed three consecutive months of service and for part-time employees who have completed one year of service and have attained an age of 21. The Company can contribute either shares of the Company’s stock or cash to the plan. The contribution is determined annually by the Company and cannot exceed 15% of the annual aggregate salaries of those employees eligible for participation in the plan. On May 31, 2007, the Company converted the Aehr Test Systems Employee Stock Bonus Plan into the Aehr Test Systems Employee Stock Ownership Plan (the “Plan”). The stock bonus plan was converted to an employee stock ownership plan (“ESOP”) to enable the Plan to better comply with changes in the law regarding Company stock. Individuals’ account balances vest at a rate of 20% per year commencing upon completion of two years of service. Non-vested balances, which are forfeited following termination of employment, are allocated to the remaining employees in the Plan. Under the Plan provisions, each employee who reaches age fifty-five (55) and has been a participant in the Plan for ten years will be offered an election each year to direct the transfer of up to 25% of his/her ESOP account to the employee self-directed account in the Savings and Retirement Plan. For anyone who met the above prerequisites, the first election to diversify holdings was offered after May 31, 2008. In the sixth year, employees will be able to diversify up to 50% of their ESOP accounts. Contributions of $300,000 were authorized for the plan during fiscal 2023, $250,000 for 2022 and $60,000 for 2021. The contribution amounts are recorded as compensation expense in the period authorized and included in accrued expenses in the period authorized. Contributions of 29,832 shares were made to the ESOP during fiscal 2023 for fiscal 2022. Contributions of 26,666 shares were made to the ESOP during fiscal 2022 for fiscal 2021. Contributions of 36,000 shares were made to the ESOP during fiscal 2021 for fiscal 2020. The contribution for fiscal 2023 will be made in fiscal 2024. Shares held in the ESOP are included in the EPS calculation.

 

 
50

Table of Contents

 

 

401(K) PLAN:

 

The Company maintains a defined contribution savings plan (the “401(k) Plan”) to provide retirement income to all qualified employees of the Company. The 401(k) Plan is intended to be qualified under Section 401(k) of the Internal Revenue Code of 1986, as amended. The 401(k) Plan is funded by voluntary pre-tax contributions from employees. Contributions are invested, as directed by the participant, in investment funds available under the 401(k) Plan. The Company is not required to make, and did not make, any contributions to the 401(k) Plan during fiscal 2023, 2022 and 2021.

 

15. OTHER (EXPENSE) INCOME, NET:

 

Other (expense) income, net comprises the following (in thousands):

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Foreign exchange (loss) gain

 

$(3)

 

$32

 

 

$(111)

Other expense, net

 

 

-

 

 

(2)

 

 

(51)

 

 

$(3)

 

$30

 

 

$(162)

 

16. PRODUCT WARRANTIES:

 

The Company provides for the estimated cost of product warranties at the time revenues are recognized on the products shipped. While the Company engages in extensive product quality programs and processes, including actively monitoring and evaluating the quality of its component suppliers, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required.

 

The standard warranty period is one year for systems and ninety days for parts and service.

 

Following is a summary of changes in the Company’s liability for product warranties during the fiscal years ended May 31, 2023 and 2022 (in thousands):

 

 

 

 May 31,

 

 

 

2023

 

 

2022

 

 

 

 

 

 

 

 

Balance at the beginning of the year

 

$410

 

 

$494

 

Accruals for warranties issued during the year

 

 

420

 

 

 

465

 

Adjustment to previously existing warranty

 

 

61

 

 

 

98

 

Consumption of reserves

 

 

(624)

 

 

(647)

 

 

 

 

 

 

 

 

 

Balance at the end of the year

 

$267

 

 

$410

 

 

The accrued warranty balance is included in accrued expenses on the consolidated balance sheets.

 

17. SEGMENT INFORMATION:

 

The Company has only one reportable segment. The information for revenue category by type, product line, geography and timing of revenue recognition, is summarized in Note 2, “Revenue.”

 

Property and equipment information is based on the physical location of the assets. The following table presents property and equipment information for geographic areas (in thousands):

 

 
51

Table of Contents

 

 

 

May 31,

 

 

 

2023

 

 

2022

 

United States

 

$2,713

 

 

$1,156

 

Asia

 

 

44

 

 

 

47

 

Europe

 

 

2

 

 

 

-

 

 

 

$2,759

 

 

$1,203

 

 

As of May 31, 2023, operating lease right-of-use assets of $6,007,000, $70,000 and $45,000 were allocated in the United States, Asia and Europe, respectively. As of May 31, 2022, the operating lease right-of-use assets of $822,000 and $95,000 were allocated in the United States and Asia, respectively.

 

There were no revenues through distributors for the fiscal years ended May 31, 2023, 2022 and 2021.

 

18. DISSOLUTION OF AEHR TEST SYSTEMS JAPAN:

 

On July 31, 2020, the Company completed the liquidation of ATS-Japan, a majority owned subsidiary. Accordingly, the Company deconsolidated ATS-Japan and recognized an aggregate net gain of $2,401,000 for the period ended August 31, 2020. The net gain was mainly due to cumulative translation adjustment reclassified into earnings of $2,186,000 and the residual income tax effect in connection with the cumulative translation adjustment released into income tax benefits of $215,000.

 

19. EQUITY:

 

On August 25, 2021, the Board of Directors authorized management to take actions necessary for the execution of a $75 million shelf registration. A Registration Statement on Form S-3 was filed with the SEC on September 3, 2021. A Prospectus Supplement for an "At the Market" ("ATM") sale of $25 million of common stock was subsequently filed on September 17, 2021. On October 8, 2021, the Company executed the ATM offering by selling 1,696,729 shares of common stock at an average selling price of $14.73 per share. The gross proceeds to the Company were $25.0 million, before commission fees of $0.7 million and offering expenses of $0.3 million. Another Prospectus Supplement for an ATM sale of $25 million of common stock was subsequently filed on February 8, 2023. The Company partially executed the ATM offering by selling 208,917 shares of common stock at an average selling price of $34.78 per share. The gross proceeds to the Company were $7.3 million, before commissions of $0.2 million and offering expenses of $0.2 million.

 

20. COMMITMENTS AND CONTINGENCIES:

 

COMMITMENTS

 

As of May 31, 2023 and 2022, the Company had restricted money market funds of $150,000 and $80,000, respectively, held by a financial institution, representing a security deposit for its United States manufacturing and office space lease. This amount is included in other assets on the consolidated balance sheets.

 

PURCHASE OBLIGATIONS

 

The Company has purchase obligations to certain suppliers. In some cases, the products the Company purchases are unique and have provisions against cancellation of the order. At May 31, 2023, the Company had $26,318,000 of purchase obligations which are due within the following 12 months. This amount does not include contractual obligations recorded on the consolidated balance sheets as liabilities.

 

CONTINGENCIES

 

The Company may, from time to time, be involved in legal proceedings arising in the ordinary course of business. While there can be no assurances as to the ultimate outcome of any litigation involving the Company, management does not believe any pending legal proceedings will result in judgment or settlement that will have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

 

In the normal course of business to facilitate sales of its products, the Company indemnifies other parties, including customers, with respect to certain matters, for example, including against losses arising from a breach of representations or covenants, or from intellectual property infringement or other claims. These agreements may limit the time within which an indemnification claim can be made and the amount of the claim. In addition, the Company has entered into indemnification agreements with its officers and directors, and the Company’s bylaws contain similar indemnification obligations to the Company’s agents.

 

It is not possible to determine the maximum potential amount under these indemnification agreements due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. To date, payments made by the Company under these agreements have not had a material impact on the Company’s operating results, financial position or cash flow.

  

 
52

Table of Contents

 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

None.

  

Item 9A. Controls and Procedures

 

(a) Evaluation of disclosure controls and procedures.

 

Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this Annual Report on Form 10-K. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective to ensure that information we are required to disclose in reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow for timely decisions regarding required disclosure.

 

(b) Management’s report on internal control over financial reporting.

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) of the Exchange Act. Under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, our management conducted an evaluation of the effectiveness of our internal control over financial reporting based upon the framework in “Internal Control – Integrated Framework” (2013 Framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on that evaluation, management has concluded that the Company’s internal control over financial reporting was effective as of May 31, 2023.

 

(c) Changes in internal controls over financial reporting.

 

There were no changes in our internal controls over financial reporting that occurred during the period covered by this Annual Report on Form 10-K that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

 

Item 9B. Other Information

 

On March 28, 2023, Kenneth B. Spink, the Company’s Chief Financial Officer (“CFO”), notified the Company of his intention to retire after the end of current fiscal year end reporting. The Company has hired Chris Siu as CFO effective June 1, 2023. To facilitate an orderly transition, Mr. Spink intends to remain at the Company and continue to serve in his current role until August 31, 2023.

 

Item 9C. Disclosure Regarding Foreign Jurisdiction that Prevent Inspections

 

Not applicable.

 

 
53

Table of Contents

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance

 

The information required by this item is incorporated by reference to our Proxy Statement to be filed with the Securities and Exchange Commission in connection with our 2023 Annual Meeting of Shareholders.

 

Item 11. Executive Compensation

 

The information required by this item is incorporated by reference to our Proxy Statement to be filed with the Securities and Exchange Commission in connection with our 2023 Annual Meeting of Shareholders.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

The information required by this item is incorporated by reference to our Proxy Statement to be filed with the Securities and Exchange Commission in connection with our 2023 Annual Meeting of Shareholders.

 

Item 13. Certain Relationships and Related Transactions, and Director Independence

 

The information required by this item is incorporated by reference to our Proxy Statement to be filed with the Securities and Exchange Commission in connection with our 2023 Annual Meeting of Shareholders.

 

Item 14. Principal Accountant Fees and Services

 

The information required by this item is incorporated by reference to our Proxy Statement to be filed with the Securities and Exchange Commission in connection with our 2023 Annual Meeting of Shareholders.

 

 
54

Table of Contents

 

PART IV

 

Item 15. Exhibits and Financial Statement Schedules

 

(a) The following documents are filed as part of this Report:

 

 

1.

Financial Statements

 

 

 

 

 

See Index under Item 8.

 

 

 

 

2.

Financial Statement Schedule

 

 

 

 

 

See Index under Item 8.

 

 

 

 

3.

Exhibits

 

 

 

 

 

See Item 15(b) below.

 

 

 

(b) Exhibits

 

The following exhibits are filed as part of or incorporated by reference into this Report:

 

 
55

Table of Contents

 

Exhibit No.

 

Description

3.1(1)

 

Restated Articles of Incorporation of Registrant.

3.2(2)(25)(28)

 

Amended and Restated Bylaws of Registrant.

4.1(3)

 

Form of Common Stock certificate.

4.2(4)

 

Registration Rights Agreement by and among the Company and the Investors (as defined therein), dated as of September 22, 2016.

4.3(32)

 

Description of Securities

10.1(5)

 

2006 Equity Incentive Plan.*

10.2(6)

 

Amended and Restated 2006 Employee Stock Purchase Plan.*

10.3(7)

 

2016 Equity Incentive Plan.*

10.4(8)

 

Form of Indemnification Agreement entered into between Registrant and its directors and executive officers.*

10.5(9)

 

Form of Change of Control Agreement.*

10.6(10)

 

Lease dated August 3, 1999 for facilities located at Building C, 400 Kato Terrace, Fremont, California.

10.7(11)

 

First Amendment dated May 06, 2008 for facilities located at 400 Kato Terrace, Fremont, California.

10.8(12)

 

Second Amendment dated November 7, 2014 for facilities located at 400 Kato Terrace, Fremont, California.

10.9(13)

 

Third Amendment dated February 27, 2018 for facilities located at 400 Kato Terrace, Fremont, California.

10.10(14)

 

Offer Letter dated January 3, 2012, between the Company and Gayn Erickson.*

10.11(15)

 

Offer Letter dated March 5, 2013, between the Company and Rhea Posedel.*

10.12(16)

 

Change of Control Severance Agreement dated January 3, 2012, between the Company and Gayn Erickson.*

10.13(17)

 

Amended and Restated Change of Control Severance Agreement dated March 5, 2013, between the Company and Rhea J. Posedel.*

10.15(18)

 

Form of 2006 Equity Incentive Plan Stock Option Award Agreement.*

10.16(19)

 

Form of 2006 Equity Incentive Plan Restricted Stock Unit Award.*

10.17(20)

 

Form of 2016 Equity Incentive Plan Stock Option Award Agreement.*

10.18(21)

 

Form of 2016 Equity Incentive Plan Restricted Stock Unit Award.*

10.19(22)

 

Purchase Agreement by and among the Company and the Investors (as defined therein), dated as of September 22, 2016.

10.20(23)

 

Loan and Security Agreement, dated as of January 13, 2020 and effective on January 16, 2020, by and between Silicon Valley Bank and Aehr Test Systems.

10.21(24)

 

Promissory Note, dated April 23, 2020, with Silicon Valley Bank as Lender and Aehr Test Systems as Borrower.

10.22(26)

 

First Amendment, dated as of January 14, 2021, to Loan and Security Agreement by and between Silicon Valley Bank and Aehr Test Systems, dated January 13, 2020

10.23(27)

 

Equity Distribution Agreement, dated as of September 17, 2021, by and between Craig-Hallum Capital Group LLC and Aehr Test Systems

10.24(29)

 

Second Amendment, dated as of January 11, 2022, to Loan and Security Agreement by and between Silicon Valley Bank and Aehr Test Systems, dated January 13, 2020

10.25(30)

 

Third Amendment, dated as of January 10, 2023, to Loan and Security Agreement by and between Silicon Valley Bank and Aehr Test Systems, dated January 17, 2023

10.26(31)

 

Equity Distribution Agreement, dated as of February 7, 2023, by and among William Blair & Company L.L.C., Craig-Hallum Capital Group LLC and Aehr Test Systems

21.1(33)

 

Subsidiaries of the Company.

21.1

 

Subsidiaries of the Company (filed herewith).

23.1

 

Consent of BPM LLP - Independent Registered Public Accounting Firm (filed herewith).

24.1

 

Power of Attorney (incorporated by reference to the signature page of this Annual Report on Form 10-K).

31.1

 

Certification Statement of Chief Executive Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002 (filed herewith).

31.2

 

Certification Statement of Chief Financial Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002 (filed herewith).

32.1

 

Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).

101.INS

 

XBRL Instance Document

101.SCH

 

XBRL Taxonomy Extension Schema Document

101.CAL

 

XBRL Taxonomy Extension Calculation Linkbase Document

 

 
56

Table of Contents

 

101.DEF

 

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

 

XBRL Taxonomy Extension Label Linkbase Document

101.PRE

 

XBRL Taxonomy Extension Presentation Linkbase Document

___________________ 

(1) Incorporated by reference to the same-numbered exhibit previously filed with the Company’s Registration Statement on Form S-1 filed June 11, 1997 (File No. 333-28987).

(2) Incorporated by reference to the same-numbered exhibit previously filed with the Company’s Current Report on Form 8-K filed September 11, 2019 (File No. 000-22893).

(3) Incorporated by reference to the same-numbered exhibit previously filed with Amendment No.1 to the Company’s Registration Statement on Form S-1 filed July 17, 1997 (File No. 333-28987).

(4) Incorporated by reference to Exhibit 10.2 previously filed with the Company’s Current Report on Form 8-K filed September 28, 2016 (File No. 000-22893).

(5) Incorporated by reference to Exhibit 4.1 previously filed with the Company’s Registration Statement on Form S-8 filed October 27, 2006 (File No. 333-138249).

(6) Incorporated by reference to Exhibit 4.2 previously filed with the Company’s Registration Statement on Form S-8 filed November 14, 2016 (File No. 333-214589).

(7) Incorporated by reference to Appendix A of the Company’s Definitive Proxy Statement filed September 26, 2019 (File No. 333-214589).

(8) Incorporated by reference to Exhibit 10.4 previously filed with Amendment No.1 to the Company’s Registration Statement on Form S-1 filed July 17, 1997 (File No. 333-28987).

(9) Incorporated by reference to Exhibit 10.14 previously filed with the Company’s Form 10-K for the year ended May 31, 2001 filed August 29, 2001 (File No. 000-22893).

(10) Incorporated by reference to Exhibit 10.12 exhibit previously filed with the Company’s Form 10-K for the year ended May 31, 1999 filed August 30, 1999 (File No. 000-22893).

(11) Incorporated by reference to Exhibit 10.15 previously filed with the Company’s Current Report on Form 8-K filed May 9, 2008 (File No. 000-22893).

(12) Incorporated by reference to Exhibit 10.1 previously filed with the Company’s Current Report on Form 8-K filed November 12, 2014 (File No. 000-22893).

(13) Incorporated by reference to Exhibit 10.1 previously filed with the Company’s Current Report on Form 8-K filed March 2, 2018 (File No. 000-22893).

(14) Incorporated by reference to Exhibit No. 10.1 previously filed with the Company's Current Report on Form 8-K filed January 9, 2012 (File No. 000-22893).

(15) Incorporated by reference to Exhibit No. 10.1 previously filed with the Company's Current Report on Form 8-K filed March 8, 2013 (File No. 000-22893).

(16) Incorporated by reference to Exhibit No. 10.3 previously filed with the Company's Current Report on Form 8-K filed January 9, 2012 (File No. 000-22893).

(17) Incorporated by reference to Exhibit No. 10.2 previously filed with the Company's Current Report on Form 8-K filed March 8, 2013 (File No. 000-22893).

(18) Incorporated by reference to Exhibit 10.17 previously filed with the Company’s Annual Report on Form 10-K filed August 29, 2016 (File No. 000-22893).

(19) Incorporated by reference to Exhibit 10.18 previously filed with the Company’s Annual Report on Form 10-K filed August 29, 2016 (File No. 000-22893).

(20) Incorporated by reference to Exhibit 10.19 previously filed with the Company’s Annual Report on Form 10-K filed August 29, 2017 (File No. 000-22893).

(21) Incorporated by reference to Exhibit 10.20 previously filed with the Company’s Annual Report on Form 10-K filed August 29, 2017 (File No. 000-22893).

(22) Incorporated by reference to Exhibit 10.1 previously filed with the Company’s Current Report on Form 8-K filed September 28, 2016 (File No. 000-22893).

(23) Incorporated by references to Exhibit 10.1 previously filed with the Company’s Current Report on Form 8-K filed January 1, 2020 (File No. 000-22893).

(24) Incorporated by reference to Exhibit 10.1 previously filed with the Company’s Current Report on Form 8-K filed April 28, 2020 (File No. 000-22893).

(25) Incorporated by reference to Exhibit 3.1 previously filed with the Company’s Current Report on Form 8-K filed September 2, 2020 (File No. 000-22893).

(26) Incorporated by reference to Exhibit 10.1 previously filed with the Company’s Current Report on Form 8-K filed January 14, 2021 (File No. 000-22893).

(27) Incorporated by reference to Exhibit 1.1 previously filed with the Company’s Current Report on Form 8-K filed September 17, 2021 (File No. 000-22893).

(28) Incorporated by reference to Exhibit 3.1 previously filed with the Company’s Current Report on Form 8-K filed October 19, 2021 (File No. 000-22893).

(29) Incorporated by reference to Exhibit 10.1 previously filed with the Company’s Current Report on Form 8-K filed January 11, 2022 (File No. 000-22893).

 

 
57

Table of Contents

 

(30) Incorporated by reference to Exhibit 10.1 previously filed with the Company’s Current Report on Form 8-K filed January 17, 2023 (File No. 000-22893).

(31) Incorporated by reference to Exhibit 1.1 previously filed with the Company’s Current Report on Form 8-K filed February 8, 2023 (File No. 000-22893).

(32) Incorporated by reference to Exhibit 4.3 previously filed with the Company’s Annual Report on Form 10-K filed August 27, 2021 (File No. 000-22893).

(33) Incorporated by reference to Exhibit 21.1 previously filed with the Company’s Annual Report on Form 10-K filed August 27, 2021 (File No. 000-22893).

 

* Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.

 

Item 16. Form 10-K Summary

 

None.

 

 
58

Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: August 28, 2023

  

 

AEHR TEST SYSTEMS

    
By:/s/ GAYN ERICKSON

 

 

Gayn Erickson 
  PRESIDENT AND CHIEF EXECUTIVE OFFICER

(Principal Executive Officer)

 

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Gayn Erickson and Kenneth B. Spink, jointly and severally, his attorneys-in-fact, each with the power of substitution, for him in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

Signature

 

Title

 

Date

     
/s/ GAYN ERICKSON 

President, Chief Executive

Officer, and Director

(Principal Executive Officer)

 

August 28, 2023

Gayn Erickson    
     
/s/ KENNETH B. SPINK 

Vice President of Finance

and Chief Financial Officer

(Principal Financial and Accounting Officer)

 

August 28, 2023

Kenneth B. Spink    
     
/s/ FARIBA DANESH  Director 

August 28, 2023

Fariba Danesh

    

 

 

 

 

 

/s/ LAURA OLIPHANT

 

Director

 

August 28, 2023

Laura Oliphant

 

 

 

 

 

 

 

 

 

/s/ RHEA J. POSEDEL

 

Chairman

 

August 28, 2023

Rhea J. Posedel

 

 

 

 

 

 

 

 

 

/s/ GEOFFREY G. SCOTT

 

Director

 

August 28, 2023

Geoffrey G. Scott

 

 

 

 

 

 

 

 

 

/s/ HOWARD T. SLAYEN

 

Director

 

August 28, 2023

Howard T. Slayen

 

 

 

 

 

 

EX-23.1 2 aehr_ex231.htm CONSENT aehr_ex231.htm

 

EXHIBIT 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-259317, 333-216792, 333-214218 and 333-204008) and the Registration Statements on Form S-8 (No. 333-268413, 333-261147, 333-250175, 333-235105, 333-228509, 333-214589, 333-208130, 333-200442, 333-184865, 333-177954, 333-163100, 333-155389, 333-138249, 333-119636, 333-52592 and 333-40577) of Aehr Test Systems of our report dated August 28, 2023 relating to the consolidated financial statements, which appears in this Form 10-K.

 

/s/ BPM LLP

 

San Jose, California

 

August 28, 2023

EX-31.1 3 aehr_ex311.htm CERTIFICATION aehr_ex311.htm

 

EXHIBIT 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT

   

I, Gayn Erickson, certify that:

 

1. I have reviewed this annual report on Form 10-K of Aehr Test Systems;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 28, 2023

 

 

By: /s/ GAYN ERICKSON

 

 

Gayn Erickson  
   

President and Chief Executive Officer 

(Principal Executive Officer)

 

EX-31.2 4 aehr_ex312.htm CERTIFICATION aehr_ex312.htm

 

EXHIBIT 31.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT

 

I, Kenneth B. Spink, certify that:

 

1. I have reviewed this annual report on Form 10-K of Aehr Test Systems;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 28, 2023

 

 

By: /s/ KENNETH B. SPINK

 

 

Kenneth B. Spink  

 

 

Vice President of Finance and Chief Financial Officer

(Principal Financial and Accounting Officer)

 

EX-32.1 5 aehr_ex321.htm CERTIFICATION aehr_ex321.htm

EXHIBIT 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Gayn Erickson, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Aehr Test Systems on Form 10-K for the period ending May 31, 2023 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of Aehr Test Systems.

 

Date: August 28, 2023

 

By: /s/ GAYN ERICKSON

 

 

Gayn Erickson  
   

President and Chief Executive Officer 

(Principal Executive Officer)

 

 

I, Kenneth B. Spink, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Aehr Test Systems on Form 10-K for the period ending May 31, 2023 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of Aehr Test Systems.

 

Date: August 28, 2023

 

By: /s/ KENNETH B. SPINK

 

 

Kenneth B. Spink  
   

Vice President of Finance and Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 

The foregoing certifications are not deemed filed with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and are not to be incorporated by reference into any filing of Aehr Test Systems under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

EX-101.SCH 6 aehr-20230531.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - EARNINGS PER SHARE (EPS) link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - CASH, CASH EQUIVALENTS AND INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - TRADE AND OTHER ACCOUNTS RECEIVABLE, NET link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - BALANCE SHEET DETAIL link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - BORROWING AND FINANCING ARRANGEMENTS link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - LONGTERM DEBT link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - EMPLOYEE BENEFIT PLANS link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - OTHER INCOME (EXPENSE) NET link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - PRODUCT WARRANTIES link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - DISSOLUTION OF AEHR TEST SYSTEMS JAPAN link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - EQUITY link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - EARNINGS PER SHARE (EPS) (Tables) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - CASH, CASH EQUIVALENTS AND INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 000034 - Disclosure - TRADE AND OTHER ACCOUNTS RECEIVABLE, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 000035 - Disclosure - BALANCE SHEET DETAIL (Tables) link:presentationLink link:calculationLink link:definitionLink 000036 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) link:presentationLink link:calculationLink link:definitionLink 000037 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 000038 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 000039 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 000040 - Disclosure - OTHER INCOME (EXPENSE) NET (Tables) link:presentationLink link:calculationLink link:definitionLink 000041 - Disclosure - PRODUCT WARRANTIES (Tables) link:presentationLink link:calculationLink link:definitionLink 000042 - Disclosure - SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 000043 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 000044 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000045 - Disclosure - REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 000046 - Disclosure - REVENUE (Details 1) link:presentationLink link:calculationLink link:definitionLink 000047 - Disclosure - REVENUE (Details 2) link:presentationLink link:calculationLink link:definitionLink 000048 - Disclosure - REVENUE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000049 - Disclosure - EARNINGS PER SHARE (EPS) (Details) link:presentationLink link:calculationLink link:definitionLink 000050 - Disclosure - EARNINGS PER SHARE (EPS) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000051 - Disclosure - CASH CASH EQUIVALENTS AND INVESTMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 000052 - Disclosure - CASH CASH EQUIVALENTS AND INVESTMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000053 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 000054 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000055 - Disclosure - TRADE AND OTHER ACCOUNTS RECEIVABLE, NET (Details) link:presentationLink link:calculationLink link:definitionLink 000056 - Disclosure - BALANCE SHEET DETAIL (Details) link:presentationLink link:calculationLink link:definitionLink 000057 - Disclosure - BALANCE SHEET DETAIL (Details 1) link:presentationLink link:calculationLink link:definitionLink 000058 - Disclosure - BALANCE SHEET DETAIL (Details 2) link:presentationLink link:calculationLink link:definitionLink 000059 - Disclosure - BALANCE SHEET DETAIL (Details 3) link:presentationLink link:calculationLink link:definitionLink 000060 - Disclosure - BALANCE SHEET DETAIL (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000061 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) link:presentationLink link:calculationLink link:definitionLink 000062 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 000063 - Disclosure - INCOME TAXES (Details 1) link:presentationLink link:calculationLink link:definitionLink 000064 - Disclosure - INCOME TAXES (Details 2) link:presentationLink link:calculationLink link:definitionLink 000065 - Disclosure - INCOME TAXES (Details 3) link:presentationLink link:calculationLink link:definitionLink 000066 - Disclosure - INCOME TAXES (Details 4) link:presentationLink link:calculationLink link:definitionLink 000067 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000068 - Disclosure - LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 000069 - Disclosure - LEASES (Details 1) link:presentationLink link:calculationLink link:definitionLink 000070 - Disclosure - LEASES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000071 - Disclosure - BORROWING AND FINANCING ARRANGEMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000072 - Disclosure - LONGTERM DEBT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000073 - Disclosure - STOCK-BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 000074 - Disclosure - STOCK-BASED COMPENSATION (Details 1) link:presentationLink link:calculationLink link:definitionLink 000075 - Disclosure - STOCK-BASED COMPENSATION (Details 2) link:presentationLink link:calculationLink link:definitionLink 000076 - Disclosure - STOCK-BASED COMPENSATION (Details 3) link:presentationLink link:calculationLink link:definitionLink 000077 - Disclosure - STOCK-BASED COMPENSATION (Details 4) link:presentationLink link:calculationLink link:definitionLink 000078 - Disclosure - STOCK-BASED COMPENSATION (Details 5) link:presentationLink link:calculationLink link:definitionLink 000079 - Disclosure - STOCKBASED COMPENSATION (Details 6) link:presentationLink link:calculationLink link:definitionLink 000080 - Disclosure - STOCKBASED COMPENSATION (Details 7) link:presentationLink link:calculationLink link:definitionLink 000081 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000082 - Disclosure - EMPLOYEE BENEFIT PLANS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000083 - Disclosure - OTHER INCOME (EXPENSE) NET (Details) link:presentationLink link:calculationLink link:definitionLink 000084 - Disclosure - PRODUCT WARRANTIES (Details) link:presentationLink link:calculationLink link:definitionLink 000085 - Disclosure - SEGMENT INFORMATION (Details) link:presentationLink link:calculationLink link:definitionLink 000086 - Disclosure - SEGMENT INFORMATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000087 - Disclosure - DISSOLUTION OF AEHR TEST SYSTEMS JAPAN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000088 - Disclosure - EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000089 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 aehr-20230531_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Voluntary Filers Current Fiscal Year End Date Entity Well Known Seasoned Issuer Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Entity Public Float Document Annual Report Document Transition Report Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name Entity Interactive Data Current Icfr Auditor Attestation Flag Auditor Name Auditor Location Auditor Firm Id CONSOLIDATED BALANCE SHEETS ASSETS Current assets: Cash and cash equivalents Short-term investments Trade and other accounts receivable, net Inventories Prepaid expenses and other current assets Total current assets [Assets, Current] Property and equipment, net Operating lease right-of-use assets Other assets Total assets [Assets] LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable Accrued expenses Operating lease liabilities, short-term Customer deposits and deferred revenue, short-term Total current liabilities [Liabilities, Current] Operating lease liabilities, long-term Deferred revenue, long-term Other long-term liabilities Total liabilities [Liabilities] Commitments and contingencies (Note 20) Shareholders' equity: Preferred stock, $0.01 par value: Authorized: 10,000 shares; Issued and outstanding: none Common stock, $0.01 par value: Authorized: 75,000 shares; Issued and outstanding: 28,539 shares and 27,120 shares at May 31, 2023 and 2022 respectively Additional paid-in capital Accumulated other comprehensive loss [Accumulated Other Comprehensive Income (Loss), Net of Tax] Accumulated deficit Total shareholders' equity [Stockholders' Equity Attributable to Parent] Total liabilities and shareholders' equity [Liabilities and Equity] Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Net sales Cost of sales Gross profit [Gross Profit] Operating expenses: Selling, general and administrative Research and development Total operating expenses [Operating Expenses] Income (loss) from operations [Operating Income (Loss)] Interest income (expense), net Net gain from dissolution of Aehr Test Systems Japan Gain from forgiveness of PPP loan Other (expense) income, net Income (loss) before income tax (expense) benefit [Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest] Income tax (expense) benefit [Income Tax Expense (Benefit)] Net income (loss) [Net Income (Loss) Attributable to Parent] Earnings (net loss) per share - basic Earnings (net loss) per share - diluted Shares used in per share calculation - basic Shares used in per share calculation - diluted CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Net income (loss) Other comprehensive income (loss), net of tax: Foreign currency translation (loss) income Net change in unrealized loss on investments Reclassification of cumulative translation adjustment as a result of dissolution of Aehr Test Systems Japan Total comprehensive income (loss) [Other Comprehensive Income (Loss), Tax] Less: Comprehensive income attributable to noncontrolling interest Comprehensive income (loss) [Comprehensive Income (Loss), Net of Tax, Attributable to Parent] CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Statement [Table] Statement [Line Items] Equity Components [Axis] Common Stock Additional Paid-In Capital Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Retained Earnings (Accumulated Deficit) Noncontrolling Interest Aher Test Systems Share holders Equity Balance, shares [Shares, Issued] Balance, amount Shares repurchased for tax withholdings on vesting of RSUs, share Shares repurchased for tax withholdings on vesting of RSUs, amount Issuance of common stock under employee plans, share Issuance of common stock under employee plans, amount Stock-based compensation Net Income (Loss) Reclassification of cumulative translation adjustment Foreign currency translation adjustment Proceeds from public offerings, net of issuance costs, share Proceeds from public offerings, net of issuance costs, amount Net unrealized loss on investments Balance, shares Balance, amount CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Cash flows from operating activities: Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Stock-based compensation [Share-Based Payment Arrangement, Noncash Expense] Provision for doubtful accounts Depreciation and amortization Non-cash operating lease expense Accretion of investment discount Net gain from dissolution of Aehr Test Systems Japan [Net gain from dissolution of Aehr Test Systems Japan] Income tax benefit related to dissolution of Aehr Test Systems Japan Gain from forgiveness of PPP loan [Gain from forgiveness of PPP loan] Changes in operating assets and liabilities: Trade and other accounts receivable Inventories [Increase (Decrease) in Inventories] Prepaid expenses and other Accounts payable [Increase (Decrease) in Accounts Payable] Accrued expenses [Increase (Decrease) in Accrued Liabilities] Customer deposits and deferred revenue Other long-term liabilities [Increase (Decrease) in Other Noncurrent Liabilities] Income taxes payable Net cash provided by (used in) operating activities [Net Cash Provided by (Used in) Operating Activities] Cash flows from investing activities: Purchases of investments [Payments to Acquire Investments] Proceeds from maturities of investments Purchases of property and equipment [Payments to Acquire Property, Plant, and Equipment] Net cash used in investing activities [Net Cash Provided by (Used in) Investing Activities] Cash flows from financing activities: Line of credit (repayments)borrowings, net [Repayments of Lines of Credit] Proceeds from issuance of common stock under employee plans Shares repurchased for tax withholdings on vesting of restricted stock units [Payment, Tax Withholding, Share-Based Payment Arrangement] Proceeds from issuance of common stock from public offering, net of issuance costs Net cash provided by financing activities [Net Cash Provided by (Used in) Financing Activities] Effect of exchange rates on cash, cash equivalents and restricted cash Net (decrease) increase in cash, cash equivalents and restricted cash [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect] Cash, cash equivalents and restricted cash, beginning of year [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents] Cash, cash equivalents and restricted cash, end of year Supplemental cash flow information: Cash paid during the year for: Income taxes Interest Supplemental disclosure of non-cash flow information: Net transfer of equipment between inventory and property and equipment ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Description and Accounting Policies [Text Block] REVENUE REVENUE Revenue from Contract with Customer [Text Block] EARNINGS PER SHARE (EPS) EARNINGS PER SHARE (''EPS'') CASH, CASH EQUIVALENTS AND INVESTMENTS CASH, CASH EQUIVALENTS AND INVESTMENTS Cash, Cash Equivalents, and Short-Term Investments [Text Block] FAIR VALUE OF FINANCIAL INSTRUMENTS FAIR VALUE OF FINANCIAL INSTRUMENTS Fair Value Disclosures [Text Block] TRADE AND OTHER ACCOUNTS RECEIVABLE, NET TRADE AND OTHER ACCOUNTS RECEIVABLE, NET: BALANCE SHEET DETAIL BALANCE SHEET DETAIL Supplemental Balance Sheet Disclosures [Text Block] ACCUMULATED OTHER COMPREHENSIVE LOSS ACCUMULATED OTHER COMPREHENSIVE LOSS Comprehensive Income (Loss) Note [Text Block] INCOME TAXES INCOME TAXES Income Tax Disclosure [Text Block] LEASES LEASES Lessee, Operating Leases [Text Block] BORROWING AND FINANCING ARRANGEMENTS BORROWING AND FINANCING ARRANGEMENTS Debt Disclosure [Text Block] LONGTERM DEBT LONG-TERM DEBT STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] EMPLOYEE BENEFIT PLANS EMPLOYEE BENEFIT PLANS Compensation and Employee Benefit Plans [Text Block] OTHER INCOME (EXPENSE) NET OTHER INCOME (EXPENSE), NET PRODUCT WARRANTIES PRODUCT WARRANTIES Product Warranty Disclosure [Text Block] SEGMENT INFORMATION SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] DISSOLUTION OF AEHR TEST SYSTEMS JAPAN DISSOLUTION OF AEHR TEST SYSTEMS JAPAN [DISSOLUTION OF AEHR TEST SYSTEMS JAPAN] EQUITY EQUITY Stockholders' Equity Note Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] BUSINESS: CONSOLIDATION: FOREIGN CURRENCY TRANSLATION AND TRANSACTIONS: USE OF ESTIMATES: RECLASSIFICATIONS: CASH EQUIVALENTS: ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS: CONCENTRATION OF CREDIT RISK: CONCENTRATION OF SUPPLY RISK: INVENTORIES: PROPERTY AND EQUIPMENT: REVENUE RECOGNITION: PRODUCT DEVELOPMENT COSTS AND CAPITALIZED SOFTWARE: IMPAIRMENT OF LONG-LIVED ASSETS: ADVERTISING COSTS: SHIPPING AND HANDLING OF PRODUCTS: INCOME TAXES: COMPREHENSIVE INCOME (LOSS): RECENT ACCOUNTING PRONOUNCEMENTS: Useful life for property and equipment Disaggregation of revenue Earnings per share Cash, cash equivalents and investments by security type Fair value by hierarchy Accounts receivable Inventories Schedule of Inventory, Current [Table Text Block] Property and equipment, net Property, Plant and Equipment [Table Text Block] Accrued expenses Schedule of Accrued Liabilities [Table Text Block] Customer deposits and deferred revenue, short-term [Customer deposits and deferred revenue, short-term] Schedule of Changes in the components of accumulated other comprehensive loss, net of tax Domestic and foreign components of loss before income tax (expense) benefit Income tax (expense) benefit Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Income tax reconciliation Net deferred tax assets and liabilities Unrecognized tax benefits Supplemental cash flow information related to leases Maturity of operating lease liabilities Compensation costs related to the Company's stock-based compensation Fair value assumptions for Option Valuation Model Fair value assumption of the ESPP Purchase Rights Stock option and RSU transactions Stock option transactions Options outstanding RSUs, PRSUs, restricted shares and performance restricted shares granted RSUs and PRSUs vested and unvested Other income (expense), net Liability for product warranties Property and equipment by geographic region Range [Axis] Long-Lived Tangible Asset [Axis] Maximum Furniture and Fixtures Minimum Machinery and Equipment Test Equipment Useful life Concentration Risk By Type Axis Statement Business Segments Axis Geographical [Axis] Accounts Receivable Customer One Customer Two Customer Three Net Sales North America Asia Allowance for doubtful accounts Provision for inventory reserves Gain related to completed liquidation of ATS-Japan Concentration risk Product and Service [Axis] Systems [Member] Test During Burn-In. [Member] Wafer-level [Member] Services [Member] Contactors [Member] Total Product line [Member] Net sales [Revenue from Contract with Customer, Excluding Assessed Tax] Asia Europe United States Net sales Timing Of Transfer Of Good Or Service Axis Products And Services Transferred At A Point In Time [Member] Services Transferred over Time [Member] Statement Scenario Axis Scenario Forecast [Member] Contract liabilities Recognition of contract liabilities Remaining performance obligations Remaining performance obligation revenue recognition Weighted average shares outstanding Shares used in basic net income (loss) per share calculation Effect of dilutive securities Denominator for diluted net income (loss) per share Basic net income (loss) per share Diluted net income (loss) per share Award Type Axis Employee Stock Ownership Plan E S O P Disclosures By Plan Axis Stock Option Employee Stock Purchase Plan Restricted Stock Units Options not included in the computation of diluted net loss per share (in thousands) CASH CASH EQUIVALENTS AND INVESTMENTS (Details) Plan Name Axis Financial Instrument [Axis] Cost [Member] Gross Unrealized Loss Estimated Fair Value [Member] Money Market Funds U S Treasury Securities [Member] Cash equivalents Long-term investments Cash Total cash and cash equivalents Total cash, cash equivalents and investments Total cash, cash equivalents and investments Short-term Investments Short-term Investments Gross Unrealized Loss Net unrealized loss on investments Fair Value By Fair Value Hierarchy Level Axis Fair Value By Asset Class Axis Money Market Funds Level 1 [Member] Level 2 [Member] Level 3 [Member] U.S. treasury securities US Treasury Securities Assets [Member] Investment securities Transfer between Level 1 and Level 2 fair value measurements Restricted cash Financial liabilities at fair value Accounts receivable [Accounts Receivable, before Allowance for Credit Loss, Current] Less: Allowance for doubtful accounts [Accounts Receivable, Allowance for Credit Loss, Current] Accounts Receivable, net Raw materials and sub-assemblies Work in process Finished goods Inventories Leasehold improvements Furniture and fixtures Machinery and equipment Test equipment Property and equipment, gross Less: Accumulated depreciation and amortization [Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment] Property and equipment, net Commissions and bonuses Payroll related Warranty Professional services Investor relations Taxes payable Other Accrued expenses Customer deposits Deferred revenue Customer deposits and deferred revenue Depreciation expense Other Comprehensive Income Location Axis Cumulative Translation Adjustments [Member] Unrealized Loss on Investments Net [Member] Balance at the beginning of the year Other comprehensive loss before reclassifications Balance at the ending of the year Domestic Foreign Income (loss) before income tax (expense) benefit Federal income taxes: Current Deferred State income taxes: Current [Current State and Local Tax Expense (Benefit)] Deferred [Deferred State and Local Income Tax Expense (Benefit)] Foreign income taxes: Current [Current Foreign Tax Expense (Benefit)] Deferred [Deferred Foreign Income Tax Expense (Benefit)] U.S. federal statutory tax rate State taxes, net of federal tax effect Foreign rate differential Stock-based compensation [Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent] Research and development credit Change in valuation allowance Controlled Foreign Corporation Liquidation PPP Loan Other [Effective Income Tax Rate Reconciliation, Other Adjustments, Percent] Effective tax rate Deferred tax assets: Net operating losses Lease liability Credit carryforwards Inventory reserves Reserves and accruals Capitalized research and development Other [Deferred Tax Assets, Other] Less: Valuation allowance [Deferred Tax Assets, Valuation Allowance] Deferred tax assets Deferred tax liabilities: Operating lease right-of-use assets [Deferred Tax Liabilities, Other] Net deferred tax assets (liabilities) Unrecognized tax benefit, beginning [Unrecognized Tax Benefits] Increases related to prior year tax positions Increases related to current year tax positions Unrecognized tax benefit, ending Income Tax Authority [Axis] Federal State Valuation allowance Net operating loss carryforward [Operating Loss Carryforwards] Research and development tax credit carryforwards Alternative minimum tax credit carryforwards Cash paid for amounts included in measurement of operating lease liabilities: Operating cash flows for operating leases 2024 2025 2026 2027 2028 Thereafter Total future minimum operating lease payments Less: imputed interest [Lessee, Operating Lease, Liability, Undiscounted Excess Amount] Present value of operating lease liabilities Maximum [Member] Minimum [Member] Operating lease, weighted-average discount rate Operating lease, weighted-average remaining lease term Operating lease, cost Increase in operating lease liabilities Operating lease term Subsequent Event Type [Axis] Original Loan and Security Agreement Second Amendment To Loan And Security Agreement First Amendment to Loan and Security Agreement Third Amendment to Loan and Security Agreement Subsequent Event Line of Credit, maximum borrowing Balance available to borrow under the line of credit Variable interest rate Revolving line maturity date Minimum liquidity net Line Of Credit Facility Axis Silicon Valley Bank PPP loan Interest rate PPP Loan balance Total interest Recognized a gain on loan forgiveness Income Statement Location Axis Cost of Sales Selling, General and Administrative Research and Development Net stock-based compensation Effect on net loss per share, basic Effect on net loss per share, diluted Total stock-based compensation Expected term (in years) Volatility Risk-free interest rates Weighted-average grant date fair value Expected term (in years) Volatility Risk-free interest rates Weighted-average grant date fair value Stock Option and RSU Transactions Available shares, beginning (in thousands) [Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant] Additional shares reserved (in thousands) Options granted (in thousands) [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross] Annual RSUs granted [Stock Issued During Period, Shares, Restricted Stock Award, Gross] RSUs cancelled (in thousands) Shares withheld for tax and not issued (in thousands) Options terminated (in thousands) Options expired (in thousands) [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period] Available shares, ending (in thousands) Outstanding Options Stock Option Transactions Options outstanding, beginning (in thousands) [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number] Options granted (in thousands) Options terminated (in thousands) Options exercised (in thousands) [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period] Options outstanding, ending (in thousands) Options fully vested and expected to vest (in thousands) [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number] Weighted average exercise price outstanding, beginning [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price] Weighted average exercise price granted Weighted average exercise price terminated Weighted average exercise price exercised Weighted average exercise price outstanding, ending Weighted average exercise price fully vested and expected to vest [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price] Aggregate intrinsic value, beginning [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value] Aggregate intrinsic value, ending Aggregate intrinsic value for options fully vested and expected to vest [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value] Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Axis $1.34 $1.64-$1.86 $2.03-$2.40 $2.93 $3.46-$3.93 $8.00-34.00 $1.34-$34.00 Options outstanding, ending (in thousands) | shares Weighted average remaining contractual life (Years) options outstanding Weighted average exercise price for options outstanding | $ / shares Option exercisable shares (in thousands) Weighted average exercise price for options exercisable | $ / shares Weighted average remaining contractual life (Years) options exercisable [Weighted average remaining contractual life (Years) options exercisable] Weighted average remaining contractual life (Years) options exercisable [Weighted average remaining contractual life (Years) options exercisable 1] Weighted average remaining contractual life (Years) options exercisable [Weighted average remaining contractual life (Years) options exercisable 2] Weighted average remaining contractual life (Years) options exercisable [Weighted average remaining contractual life (Years) options exercisable 3] Weighted average remaining contractual life (Years) options exercisable [Weighted average remaining contractual life (Years) options exercisable 4] Weighted average remaining contractual options exercisable Weighted average remaining contractual life (Years) options exercisable Aggregate intrinsic value for options exercisable | STOCKBASED COMPENSATION (Details 6) Employees Member Board Of Directors Annual RSUs granted Weighted average market value on the date of the grant of annual RSUs Annual restricted shares granted Weighted average market value on the date of the grant of annual restricted shares RSUs granted in lieu of cash payment for salary reductions Weighted average market value on the date of the grant of RSU in lieu of cash payment PRSUs granted based on revenue target thresholds maximum Performance restricted shares granted based on revenue target thresholds maximum Weighted average market value on the date of the grant of PRSUs, performance restricted shares Weighted average market value on the date of the grant of PRSUs Net RSUs and PRSUs vested Shares withheld to settle payroll taxes Weighted average grant-date fair value of vested RSUs and PRSUs RSUs and PRSUs cancelled Weighted average grant-date fair value of cancelled RSUs RSUs and PRSUs unvested Weighted average grant-date fair value of unvested RSUs and PRSUs Intrinsic value of unvested RSUs and PRSUs (in thousands) Employee Stock Purchase Plan Stock Option, RSUs and PRSUs 2016 Equity Incentive Plan Total intrinsic values of options exercised Stock based compensation expenses Option exercisable shares (in thousands) [Option exercisable shares (in thousands)] Weighted average exercise price for options exercisable Stock-based compensation expense related to stock options and RSUs RSUs cancelled (in thousands) Unrecognized stock-based compensation Common stock reserved for issuance Remained available for issuance Estimated forfeitures of unvested stock based awards, amount Weighted average period for recognition of costs Purchase rights under the ESPP Weighted average period for recognition of costs [Weighted average period for recognition of costs] Stock-based compensation related to the ESPP Maximum calendar year contribution per employee Maximum number of shares a participant may purchase (in thousands) ESPP purchase right granted (in thousands) ESPP shares issued (in thousands) Total shares issued under ESPP plan (in thousands) ESPP Shares available for issuance (in thousands) Number of authorized shares increased Contributions to ESOP Shares contributed to the ESOP during fiscal year (in thousands) Defined contribution plan, description Foreign exchange gain (loss) Other income (expense), net [Other income (expense), net] Other income (expense), net Balance at the beginning of the period Accruals for warranties issued during the period Adjustments to previously existing warranty accruals Consumption of reserves [Standard and Extended Product Warranty Accrual, Decrease for Payments] Balance at the End of the period Property and equipment, net Operating lease right-of-use assets Deconsolidation net gain Net gain due to cumulative translation adjustment reclassiefied to earnings Income tax benefits Sale of common stock price per share Sale of common stock shares Gross proceeds Commission fees Offering expenses Shelf registration amount Restricted cash [Restricted Cash] Purchase obligation Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date. EX-101.CAL 8 aehr-20230531_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 9 aehr-20230531_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 10 aehr-20230531_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover - USD ($)
12 Months Ended
May 31, 2023
Aug. 16, 2023
Jan. 01, 2023
Cover [Abstract]      
Entity Registrant Name AEHR TEST SYSTEMS    
Entity Central Index Key 0001040470    
Document Type 10-K    
Amendment Flag false    
Entity Voluntary Filers No    
Current Fiscal Year End Date --05-31    
Entity Well Known Seasoned Issuer No    
Entity Small Business true    
Entity Shell Company false    
Entity Emerging Growth Company false    
Entity Current Reporting Status Yes    
Document Period End Date May 31, 2023    
Entity Filer Category Non-accelerated Filer    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2023    
Entity Common Stock Shares Outstanding   28,755,426  
Entity Public Float     $ 0
Document Annual Report true    
Document Transition Report false    
Entity File Number 000-22893    
Entity Incorporation State Country Code CA    
Entity Tax Identification Number 94-2424084    
Entity Address Address Line 1 400 KATO TERRACE    
Entity Address City Or Town FREMONT    
Entity Address State Or Province CA    
Entity Address Postal Zip Code 94539    
City Area Code 510    
Local Phone Number 623-9400    
Security 12b Title Common Stock, par value $0.01 per share    
Trading Symbol AEHR    
Security Exchange Name NASDAQ    
Entity Interactive Data Current Yes    
Icfr Auditor Attestation Flag false    
Auditor Name BPM LLP    
Auditor Location San Jose, California    
Auditor Firm Id 207    
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
May 31, 2023
May 31, 2022
Current assets:    
Cash and cash equivalents $ 30,054 $ 31,484
Short-term investments 17,853 0
Trade and other accounts receivable, net 16,594 12,859
Inventories 23,908 15,051
Prepaid expenses and other current assets 621 613
Total current assets 89,030 60,007
Property and equipment, net 2,759 1,203
Operating lease right-of-use assets 6,123 917
Other assets 231 201
Total assets 98,143 62,328
Current liabilities:    
Accounts payable 9,206 4,195
Accrued expenses 4,143 3,610
Operating lease liabilities, short-term 137 794
Customer deposits and deferred revenue, short-term 2,822 2,415
Total current liabilities 16,308 11,014
Operating lease liabilities, long-term 6,163 212
Deferred revenue, long-term 31 69
Other long-term liabilities 41 44
Total liabilities 22,543 11,339
Shareholders' equity:    
Preferred stock, $0.01 par value: Authorized: 10,000 shares; Issued and outstanding: none 0 0
Common stock, $0.01 par value: Authorized: 75,000 shares; Issued and outstanding: 28,539 shares and 27,120 shares at May 31, 2023 and 2022 respectively 285 271
Additional paid-in capital 127,776 117,686
Accumulated other comprehensive loss (155) (105)
Accumulated deficit (52,306) (66,863)
Total shareholders' equity 75,600 50,989
Total liabilities and shareholders' equity $ 98,143 $ 62,328
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
May 31, 2023
May 31, 2022
CONSOLIDATED BALANCE SHEETS    
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.01 $ 0.01
Common stock, shares authorized 75,000,000 75,000,000
Common stock, shares issued 28,539,000 27,120,000
Common stock, shares outstanding 28,539,000 27,120,000
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS      
Net sales $ 64,961 $ 50,829 $ 16,600
Cost of sales 32,215 27,164 10,568
Gross profit 32,746 23,665 6,032
Operating expenses:      
Selling, general and administrative 12,237 10,047 6,562
Research and development 7,134 5,818 3,652
Total operating expenses 19,371 15,865 10,214
Income (loss) from operations 13,375 7,800 (4,182)
Interest income (expense), net 1,245 13 (46)
Net gain from dissolution of Aehr Test Systems Japan 0 0 2,186
Gain from forgiveness of PPP loan 0 1,698 0
Other (expense) income, net (3) 30 (162)
Income (loss) before income tax (expense) benefit 14,617 9,541 (2,204)
Income tax (expense) benefit (60) (91) 177
Net income (loss) $ 14,557 $ 9,450 $ (2,027)
Earnings (net loss) per share - basic $ 0.52 $ 0.36 $ (0.09)
Earnings (net loss) per share - diluted $ 0.50 $ 0.34 $ (0.09)
Shares used in per share calculation - basic 27,785 26,014 23,457
Shares used in per share calculation - diluted 29,215 27,774 23,457
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Thousands
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME      
Net income (loss) $ 14,557 $ 9,450 $ (2,027)
Other comprehensive income (loss), net of tax:      
Foreign currency translation (loss) income (33) (77) 160
Net change in unrealized loss on investments (17) 0 0
Reclassification of cumulative translation adjustment as a result of dissolution of Aehr Test Systems Japan 0 0 (2,401)
Total comprehensive income (loss) 14,507 9,373 (4,268)
Less: Comprehensive income attributable to noncontrolling interest 0 0 21
Comprehensive income (loss) $ 14,507 $ 9,373 $ (4,289)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
shares in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated other comprehensive loss
Retained Earnings (Accumulated Deficit)
Noncontrolling Interest
Aher Test Systems Share holders Equity
Balance, shares at May. 31, 2020   23,107          
Balance, amount at May. 31, 2020 $ 14,056,000 $ 231,000 $ 85,898,000 $ 2,234,000 $ (74,286,000) $ (21,000) $ 14,077,000
Shares repurchased for tax withholdings on vesting of RSUs, share   (9)          
Shares repurchased for tax withholdings on vesting of RSUs, amount (20,000) $ 0 (20,000) 0 0 0 (20,000)
Issuance of common stock under employee plans, share   627          
Issuance of common stock under employee plans, amount 580,000 $ 6,000 574,000 0 0 0 580,000
Stock-based compensation 1,101,000 0 1,101,000 0 0 0 1,101,000
Net Income (Loss) (2,027,000) 0 0 0 (2,027,000) 0 (2,027,000)
Reclassification of cumulative translation adjustment (2,401,000) 0 0 (2,401,000) 0 0 (2,401,000)
Foreign currency translation adjustment 160,000 $ 0 0 139,000 0 21,000 139,000
Balance, shares at May. 31, 2021   23,725          
Balance, amount at May. 31, 2021 11,449,000 $ 237,000 87,553,000 (28,000) (76,313,000) 0 11,449,000
Shares repurchased for tax withholdings on vesting of RSUs, share   (62)          
Shares repurchased for tax withholdings on vesting of RSUs, amount (429,000) $ 0 (429,000) 0 0 0 (429,000)
Issuance of common stock under employee plans, share   1,760          
Issuance of common stock under employee plans, amount 3,560,000 $ 17,000 3,543,000 0 0 0 3,560,000
Stock-based compensation 3,006,000 0 3,006,000 0 0 0 3,006,000
Net Income (Loss) 9,450,000 0 0 0 9,450,000 0 9,450,000
Foreign currency translation adjustment (77,000) $ 0 0 (77,000) 0 0 (77,000)
Proceeds from public offerings, net of issuance costs, share   1,697          
Proceeds from public offerings, net of issuance costs, amount 24,030,000 $ 17,000 24,013,000 0 0 0 24,030,000
Balance, shares at May. 31, 2022   27,120          
Balance, amount at May. 31, 2022 50,989,000 $ 271,000 117,686,000 (105,000) (66,863,000) 0 50,989,000
Shares repurchased for tax withholdings on vesting of RSUs, share   (178)          
Shares repurchased for tax withholdings on vesting of RSUs, amount (2,060,000) $ (1,000) (2,059,000) 0 0 0 (2,060,000)
Issuance of common stock under employee plans, share   1,388          
Issuance of common stock under employee plans, amount 2,562,000 $ 13,000 2,549,000 0 0 0 2,562,000
Stock-based compensation 2,782,000 0 2,782,000 0 0 0 2,782,000
Net Income (Loss) 14,557,000 0 0 0 14,557,000 0 14,557,000
Foreign currency translation adjustment (33,000) $ 0 0 (33,000) 0 0 (33,000)
Proceeds from public offerings, net of issuance costs, share   209          
Proceeds from public offerings, net of issuance costs, amount 6,820,000 $ 2,000 6,818,000 0 0 0 6,820,000
Net unrealized loss on investments (17,000) $ 0 0 (17,000) 0 0 (17,000)
Balance, shares at May. 31, 2023   28,539          
Balance, amount at May. 31, 2023 $ 75,600,000 $ 285,000 $ 127,776,000 $ (155,000) $ (52,306,000) $ 0 $ 75,600,000
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
Cash flows from operating activities:      
Net Income (Loss) $ 14,557 $ 9,450 $ (2,027)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:      
Stock-based compensation 2,748 3,006 1,101
Provision for doubtful accounts 24 0 0
Depreciation and amortization 450 356 328
Non-cash operating lease expense 88 (49) (18)
Accretion of investment discount (576) 0 0
Net gain from dissolution of Aehr Test Systems Japan 0 0 (2,186)
Income tax benefit related to dissolution of Aehr Test Systems Japan 0 0 (215)
Gain from forgiveness of PPP loan 0 (1,698) 0
Changes in operating assets and liabilities:      
Trade and other accounts receivable (3,788) (7,834) (1,373)
Inventories (9,469) (6,674) (972)
Prepaid expenses and other 28 (71) (81)
Accounts payable 5,044 1,356 1,877
Accrued expenses 528 1,464 732
Customer deposits and deferred revenue 369 2,196 96
Other long-term liabilities 0 0 47
Income taxes payable 8 6 (10)
Net cash provided by (used in) operating activities 10,011 1,508 (2,701)
Cash flows from investing activities:      
Purchases of investments (33,294) 0 0
Proceeds from maturities of investments 16,000 0 0
Purchases of property and equipment (1,362) (416) (227)
Net cash used in investing activities (18,656) (416) (227)
Cash flows from financing activities:      
Line of credit (repayments)borrowings, net 0 (1,400) (1,400)
Proceeds from issuance of common stock under employee plans 2,562 3,560 580
Shares repurchased for tax withholdings on vesting of restricted stock units (2,060) (429) (20)
Proceeds from issuance of common stock from public offering, net of issuance costs 6,820 24,030 0
Net cash provided by financing activities 7,322 25,761 1,960
Effect of exchange rates on cash, cash equivalents and restricted cash (37) 49 117
Net (decrease) increase in cash, cash equivalents and restricted cash (1,360) 26,902 (851)
Cash, cash equivalents and restricted cash, beginning of year 31,564 4,662 5,513
Cash, cash equivalents and restricted cash, end of year 30,204 31,564 4,662
Cash paid during the year for:      
Income taxes 21 4 15
Interest 15 12 6
Supplemental disclosure of non-cash flow information:      
Net transfer of equipment between inventory and property and equipment $ 646 $ 472 $ 113
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.2
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended
May 31, 2023
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

 

BUSINESS:

 

Aehr Test Systems (the “Company”) was incorporated in California in May 1977 and primarily designs, engineers and manufactures test and burn-in equipment used in the semiconductor industry. The Company’s principal products are the FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak carrier, the WaferPak aligner, the DiePak autoloader, and test fixtures.

 

CONSOLIDATION:

 

The consolidated financial statements include the accounts of the Company and both its wholly-owned and majority-owned foreign subsidiaries. Intercompany accounts and transactions have been eliminated.

 

FOREIGN CURRENCY TRANSLATION AND TRANSACTIONS:

 

Assets and liabilities of the Company’s foreign subsidiaries and a branch office are translated into U.S. Dollars from their functional currencies of Euros, Philippines Peso and New Taiwan Dollars using the exchange rate in effect at the balance sheet date. Additionally, their net sales and expenses are translated using exchange rates approximating average rates prevailing during the fiscal year. Translation adjustments that arise from translating their financial statements from their local currencies to U.S. Dollars are accumulated and reflected as a separate component of shareholders’ equity.

 

Transaction gains and losses that arise from exchange rate changes denominated in currencies other than the local currency are included in the Consolidated Statements of Operations as incurred. See Note 15, “Other (Expense) Income, Net” for the detail of foreign exchange transaction gains and losses for all periods presented.

 

USE OF ESTIMATES:

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the Company’s consolidated financial statements include allowance for doubtful accounts, valuation of inventory at the lower of cost or net realizable value, and warranty reserves.

 

RECLASSIFICATIONS:

 

Certain reclassifications have been made to the previous year consolidated financial statements to conform to the current period presentation. The reclassifications had no impact on net income (loss), total assets, total liabilities, or shareholders’ equity.

 

CASH EQUIVALENTS:

 

Cash equivalents consist of money market instruments purchased with an original maturity of three months or less. These investments are reported at fair value.

 

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS:

 

Accounts receivable are derived from the sale of products throughout the world to semiconductor manufacturers, semiconductor contract assemblers, electronics manufacturers and burn-in and test service companies. Accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts to reserve for potentially uncollectible trade receivables. The Company also reviews its trade receivables by aging category to identify specific customers with known disputes or collection issues. The Company exercises judgment when determining the adequacy of these reserves as the Company evaluates historical bad debt trends, general economic conditions in the United States and internationally, and changes in customer financial conditions. Uncollectible receivables are recorded as bad debt expense when all efforts to collect have been exhausted and recoveries are recognized when they are received. During the fiscal year ended May 31, 2023, the Company recorded bad debt expense of $24,000. No significant adjustments to the allowance for doubtful accounts were recorded during the fiscal years ended May 31, 2022 or 2021.

 

CONCENTRATION OF CREDIT RISK:

 

The Company sells its products primarily to semiconductor manufacturers in North America, Asia, and Europe. As of May 31, 2023, approximately 17% and 83% of gross accounts receivable were from customers located in North America and Asia, respectively. As of May 31, 2022, approximately 20% and 80% of gross accounts receivable were from customers located in North America and Asia, respectively. Two customers accounted for 82% and 17% of gross accounts receivable as of May 31, 2023. Three customers accounted for 68%, 18% and 11% of gross accounts receivable as of May 31, 2022. Two customers accounted for 79% and 10% of net sales in fiscal 2023, respectively. One customer accounted for 82% of net sales in fiscal 2022. The Company performs ongoing credit evaluations of its customers and generally does not require collateral. The Company uses letter of credit terms for some of its international customers.

 

The Company’s cash and cash equivalents are generally deposited with major financial institutions in the United States, Philippines, Germany and Taiwan. The Company invests its excess cash in money market funds and U.S. Treasury securities. The money market funds bear the risk associated with each fund. The money market funds have variable interest rates. The Company’s cash and investment balances held at banks and brokerage firms may at time exceed federally insured levels. The Company has not experienced any material losses on its money market funds or short-term cash deposits.

 

CONCENTRATION OF SUPPLY RISK:

 

The Company relies on subcontractors to manufacture many of the components and subassemblies used in its products. Quality or performance failures of the Company’s products or changes in its manufacturers’ financial or business condition could disrupt the Company’s ability to supply quality products to its customers and thereby have a material and adverse effect on its business and operating results. Some of the components and technologies used in the Company’s products are purchased and licensed from a single source or a limited number of sources. The loss of any of these suppliers may cause the Company to incur additional transition costs, result in delays in the manufacturing and delivery of its products, or cause it to carry excess or obsolete inventory and could cause it to redesign its products.

 

INVENTORIES:

 

Inventories include material, labor and overhead, and are stated at the lower of cost (first-in, first-out method) or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less costs of completion, disposal and transportation. Provisions for excess, obsolete and unusable inventories are made after management’s evaluation of future demand and market conditions. The Company adjusts inventory balances to approximate the lower of its manufacturing costs or net realizable value. If actual future demand or market conditions become less favorable than those projected by management, additional inventory write-downs may be required, and would be reflected in cost of sales in the period the revision is made. During fiscal 2023, 2022 and 2021 the Company recognized a provision for inventory reserves of $569,000, $1,031,000, and $176,000, respectively.

 

PROPERTY AND EQUIPMENT:

 

Property and equipment are stated at cost less accumulated depreciation and amortization. Major improvements are capitalized, while repairs and maintenance are expensed as incurred. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the related lease. Furniture and fixtures, machinery and equipment, and test equipment are depreciated on a straight-line basis over their estimated useful lives. The ranges of estimated useful lives are generally as follows:

 

Furniture and fixtures   

2 to 6 years

Machinery and equipment

3 to 6 years

Test equipment  

4 to 6 years

  

REVENUE RECOGNITION:

 

The Company recognizes revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by following a five-step process: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price, and (5) recognize revenue when or as the Company satisfies a performance obligation, as further described below.

 

Performance obligations include sales of systems, contactors, spare parts, and services, as well as installation and training services included in customer contracts.

 

A contract’s transaction price is allocated to each distinct performance obligation. In determining the transaction price, the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which the Company expects to be entitled. The Company generally does not grant return privileges, except for defective products during the warranty period.

 

For contracts that contain multiple performance obligations, the Company allocates the transaction price to the performance obligations on a relative standalone selling price basis. Standalone selling prices are based on multiple factors including, but not limited to, historical discounting trends for products and services and pricing practices in different geographies.

 

Revenue for systems and spares are recognized at a point in time, which is generally upon shipment or delivery. Revenue from services is recognized over time as services are completed or ratably over the contractual period of generally one year or less.

 

The Company has elected the practical expedient to not assess whether a contract has a significant financing component as the Company’s standard payment terms are less than one year.

 

We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors.

 

Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services.

 

PRODUCT DEVELOPMENT COSTS AND CAPITALIZED SOFTWARE:

 

Costs incurred in the research and development of new products or systems are charged to operations as incurred. Costs incurred in the development of software programs for the Company’s products are charged to operations as incurred until technological feasibility of the software has been established. Generally, technological feasibility is established when the software module performs its primary functions described in its original specifications, contains features required for it to be usable in a production environment, is completely documented and the related hardware portion of the product is complete. After technological feasibility is established, any additional costs are capitalized. Capitalization of software costs ceases when the software is substantially complete and is ready for its intended use. Capitalized costs are amortized over the estimated life of the related software product using the greater of the units of sales or straight-line methods over ten years. No system software development costs were capitalized or amortized in fiscal 2023, 2022 and 2021.

 

IMPAIRMENT OF LONG-LIVED ASSETS:

 

In the event that facts and circumstances indicate that the carrying value of assets may be impaired, an evaluation of recoverability would be performed. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset would be compared to the asset’s carrying value to determine if a write-down is required.

 

ADVERTISING COSTS:

 

The Company expenses all advertising costs as incurred and the amounts were not material for all periods presented.

 

SHIPPING AND HANDLING OF PRODUCTS:

 

Amounts billed to customers for shipping and handling of products are included in net sales. Costs incurred related to shipping and handling of products are included in cost of sales.

 

INCOME TAXES:

 

Income taxes are accounted for under the asset-and-liability method as required by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 740, Income Taxes (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. Under ASC 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.

 

As of May 31, 2023 the Company maintained a full valuation allowance against its deferred tax assets. We will continue to assess whether sufficient future taxable income will be generated to permit the use of deferred tax assets, and will reverse all or a portion of the allowance when there is sufficient evidence to support the reversal. Based upon our prior two fiscal years of profitability, the outlook for the next fiscal year, and absent any additional objective negative evidence, the Company anticipates adjusting the current valuation allowance position in fiscal 2024.

 

FASB ASC Subtopic 740-10, Accounting for Uncertainty of Income Taxes, (“ASC 740-10”) defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company’s policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of income taxes.

 

COMPREHENSIVE INCOME (LOSS):

 

Comprehensive income (loss) generally represents all changes in shareholders’ equity except those resulting from investments or contributions by shareholders. Unrealized gains and losses from available-for-sale securities and on foreign currency translation adjustments are included in the Company’s components of comprehensive income (loss), which are excluded from net income (loss). In fiscal 2021, the Company recognized a gain of $2,401,000 related to the completed liquidation of ATS-Japan, a majority owned subsidiary, which is deducted from net income (loss) when calculating comprehensive income (loss). Refer to Note 18, “Dissolution of Aehr Test Systems Japan,” for a further discussion of the transaction. Comprehensive income (loss) is included in the statements of comprehensive income (loss).

 

RECENT ACCOUNTING PRONOUNCEMENTS:

 

Accounting Standards Not Yet Adopted

 

In June 2016, the FASB issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326), that requires measurement and recognition of expected credit losses for financial assets held based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Due to a subsequent ASU in November 2019, the accounting standard will be effective for the Company beginning in the first quarter of fiscal 2024 on a modified retrospective basis. The Company does not expect a material impact of this accounting standard on its consolidated financial statements.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.2
REVENUE
12 Months Ended
May 31, 2023
REVENUE  
REVENUE

2. REVENUE:

 

Disaggregation of revenue

 

The following tables show revenues by major product categories. Within each product category, contract terms, conditions and economic factors affecting the nature, amount, timing and uncertainty around revenue recognition and cash flow are substantially similar.

 

The Company’s revenues by product category are as follows (in thousands):

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Type of good / service:

 

 

 

 

 

 

 

 

 

Systems

 

$38,844

 

 

$25,224

 

 

$7,250

 

Contactors

 

 

21,873

 

 

 

22,647

 

 

 

5,837

 

Services

 

 

4,244

 

 

 

2,958

 

 

 

3,513

 

 

 

$64,961

 

 

$50,829

 

 

$16,600

 

Product lines:

 

 

 

 

 

 

 

 

 

 

 

 

Wafer-level

 

$63,531

 

 

$48,926

 

 

$15,004

 

Test During Burn-In

 

 

1,430

 

 

 

1,903

 

 

 

1,596

 

 

 

$64,961

 

 

$50,829

 

 

$16,600

 

   

The following presents information about the Company’s operations in different geographic areas.  Net sales are based upon ship-to location (in thousands):

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Geographic region:

 

 

 

 

 

 

 

 

 

United States

 

$9,289

 

 

$5,110

 

 

$5,386

 

Asia

 

 

55,609

 

 

 

45,700

 

 

 

11,074

 

Europe

 

 

63

 

 

 

19

 

 

 

140

 

 

 

$64,961

 

 

$50,829

 

 

$16,600

 

 

With the exception of the amount of service contracts and extended warranties, the Company’s product category revenues are recognized at point in time when control transfers to customers.  The following presents revenue based on timing of recognition (in thousands):

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Timing of revenue recognition (in thousands):

 

 

 

 

 

 

Products and services transferred at a point in time

 

$63,531

 

 

$49,441

 

 

$15,009

 

Services transferred over time

 

 

1,430

 

 

 

1,388

 

 

 

1,591

 

 

 

$64,961

 

 

$50,829

 

 

$16,600

 

 

Contract balances   

 

A receivable is recognized in the period the Company delivers goods or provides services or when the Company’s right to consideration is unconditional. The Company usually does not record contract assets because the Company has an unconditional right to payment upon satisfaction of the performance obligation, and therefore, a receivable is more commonly recorded than a contract asset.

 

Contract liabilities include payments received in advance of performance under a contract and are satisfied as the associated revenue is recognized. Contract liabilities are reported on the consolidated balance sheets at the end of each reporting period as a component of deferred revenue. Contract liabilities as of May 31, 2023 and 2022 were $2,853,000 and $2,484,000, respectively.  During the fiscal years ended May 31, 2023 and 2022, the Company recognized $2,179,000 and $189,000 of revenues that were included in contract liabilities as of May 31, 2022 and 2021, respectively.

 

Remaining performance obligations

 

On May 31, 2023, the Company had $163,000 of remaining performance obligations, exclusive of customer deposits, which were comprised of deferred service contracts and extended warranty contracts not yet delivered. The Company expects to recognize approximately 81% of its remaining performance obligations as revenue in fiscal 2024, and an additional 19% in fiscal 2025 and thereafter. The foregoing excludes the value of other remaining performance obligations as they have original durations of one year or less, and also excludes information about variable consideration allocated entirely to a wholly unsatisfied performance obligation.

 

Costs to obtain or fulfill a contract

 

The Company generally expenses sales commissions when incurred as a component of selling, general and administrative expense as the amortization period is typically less than one year. Additionally, the majority of the Company’s cost of fulfillment as a manufacturer of products is classified as inventory and fixed assets, which are accounted for under the respective guidance for those asset types. Other costs of contract fulfillment are immaterial due to the nature of the Company’s products and their respective manufacturing process.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.2
EARNINGS PER SHARE (EPS)
12 Months Ended
May 31, 2023
EARNINGS PER SHARE (EPS)  
EARNINGS PER SHARE (''EPS'')

3. EARNINGS PER SHARE (“EPS”):

 

Basic EPS is determined using the weighted average number of common shares outstanding during the period. Diluted EPS is determined using the weighted average number of common shares and potential common shares (representing the dilutive effect of stock options, restricted shares, restricted shares units, or RSUs, and ESPP shares) outstanding during the period using the treasury stock method.

  

The following table presents the computation of basic and diluted earnings (net loss) per share attributable to Aehr Test Systems common shareholders (in thousands, except per share data):

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Numerator: Net income (net loss)

 

$14,557

 

 

$9,450

 

 

$(2,027)

 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator for basic earnings (net loss) per share:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

27,785

 

 

 

26,014

 

 

 

23,457

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares used in basic earnings (net loss) per share calculation  

 

 

27,785

 

 

 

26,014

 

 

 

23,457

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Effect of dilutive securities

 

 

1,430

 

 

 

1,760

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator for diluted earnings (net loss) per share

 

 

29,215

 

 

 

27,774

 

 

 

23,457

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic earnings (net loss) per share

 

$0.52

 

 

$0.36

 

 

$(0.09)

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted earnings (net loss) per share

 

$0.50

 

 

$0.34

 

 

$(0.09)

 

For the purpose of computing diluted earnings per share, weighted average potential common shares do not include stock options with an exercise price greater than the average fair value of the Company’s common stock for the period, as the effect would be anti-dilutive. Stock options to purchase 5,000 and 64,000 shares of common stock were outstanding as of May 31, 2023 and 2022, respectively, but were not included in the computation of diluted earnings per share, because the inclusion of such shares would be anti-dilutive. Stock options to purchase 2,766,000 shares of common stock were outstanding on May 31, 2021 but were not included in the computation of diluted net loss per share, because the inclusion of such shares would be anti-dilutive.  ESPP rights to purchase 239,000 ESPP shares and RSUs for 132,000 shares were outstanding on May 31, 2021 but were not included in the computation of diluted net loss per share, because the inclusion of such shares would be anti-dilutive.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.2
CASH, CASH EQUIVALENTS AND INVESTMENTS
12 Months Ended
May 31, 2023
CASH, CASH EQUIVALENTS AND INVESTMENTS  
CASH, CASH EQUIVALENTS AND INVESTMENTS

4.  CASH, CASH EQUIVALENTS AND INVESTMENTS

 

The following table summarizes the Company’s cash, cash equivalents and investments by security type as of May 31, 2023 (in thousands):

 

 

 

Cost

 

 

Gross Unrealized Loss

 

 

Estimated Fair Value

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$3,182

 

 

$-

 

 

$3,182

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

 

26,872

 

 

 

-

 

 

 

26,872

 

Total cash and cash equivalents

 

$30,054

 

 

$-

 

 

$30,054

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

$17,870

 

 

$(17)

 

$17,853

 

Long-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$150

 

 

$-

 

 

$150

 

Total cash, cash equivalents and investments

 

$48,074

 

 

$(17)

 

$48,057

 

   

The following table summarizes the Company’s cash, cash equivalents and investments by security type as of May 31, 2022 (in thousands):

 

 

 

Cost

 

 

Gross Unrealized Loss

 

 

Estimated Fair Value

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$2,955

 

 

$-

 

 

$2,955

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

 

28,529

 

 

 

-

 

 

 

28,529

 

Total cash and cash equivalents

 

$31,484

 

 

$-

 

 

$31,484

 

Long-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$80

 

 

$-

 

 

$80

 

Total cash, cash equivalents and investments

 

$31,564

 

 

$-

 

 

$31,564

 

 

Long-term investments are included in other assets on the accompanying consolidated balance sheets.

 

Unrealized gains and losses on investments classified as available-for-sale are included within accumulated other comprehensive loss, net of any related tax effect. Upon realization, those amounts are reclassified from accumulated other comprehensive loss to results of operations.

 

The unrealized loss of $17,000 as of May 31, 2023 is not considered other-than-temporary, and has been in an unrealized loss position for less than a year.

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE OF FINANCIAL INSTRUMENTS
12 Months Ended
May 31, 2023
FAIR VALUE OF FINANCIAL INSTRUMENTS  
FAIR VALUE OF FINANCIAL INSTRUMENTS

5. FAIR VALUE OF FINANCIAL INSTRUMENTS:

 

The Company’s financial instruments are measured at fair value consistent with authoritative guidance. This authoritative guidance defines fair value, establishes a framework for using fair value to measure assets and liabilities, and disclosures required related to fair value measurements.

 

The guidance establishes a fair value hierarchy based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources while unobservable inputs reflect a reporting entity’s pricing based upon their own market assumptions. The fair value hierarchy consists of the following three levels:

 

Level 1 - instrument valuations are obtained from real-time quotes for transactions in active exchange markets involving identical assets.

 

Level 2 - instrument valuations are obtained from readily-available pricing sources for comparable instruments.

 

Level 3 - instrument valuations are obtained without observable market values and require a high level of judgment to determine the fair value.

 

The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of May 31, 2023 (in thousands):

 

 

 

Balance as of

 

 

 

 

 

 

 

 

 

 

 

May 31, 2023

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Money market funds

 

$27,022

 

 

$27,022

 

 

$-

 

 

$-

 

U.S. treasury securities

 

 

17,853

 

 

 

17,853

 

 

 

 

 

 

 

 

 

Total

 

$44,875

 

 

$44,875

 

 

$-

 

 

$-

 

 

The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of May 31, 2022 (in thousands):

 

   

 

 

Balance as of

 

 

 

 

 

 

 

 

 

 

 

May 31, 2022

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Money market funds

 

$28,609

 

 

$28,609

 

 

$-

 

 

$-

 

Total

 

$28,609

 

 

$28,609

 

 

$-

 

 

$-

 

 

Included in money market funds as of May 31, 2023 and 2022 was $150,000 and $80,000 of restricted cash, respectively, representing a security deposit for the Company’s United States manufacturing and office space lease which is included in other assets in the consolidated balance sheets.

 

There were no financial liabilities measured at fair value as of May 31, 2023 and 2022.

 

There were no transfers between Level 1 and Level 2 fair value measurements during the fiscal years ended May 31, 2023 and 2022.

 

The carrying amounts of financial instruments including cash equivalents, accounts receivables, accounts payable and certain other accrued liabilities, approximate fair value due to their short maturities.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.2
TRADE AND OTHER ACCOUNTS RECEIVABLE, NET
12 Months Ended
May 31, 2023
TRADE AND OTHER ACCOUNTS RECEIVABLE, NET  
TRADE AND OTHER ACCOUNTS RECEIVABLE, NET:

6. TRADE AND OTHER ACCOUNTS RECEIVABLE, NET:

 

Accounts receivable comprise (in thousands):

 

 

 

May 31,

 

 

 

2023

 

 

2022

 

Accounts receivable

 

$16,594

 

 

$12,859

 

Less: Allowance for doubtful accounts

 

 

-

 

 

 

-

 

 

 

$16,594

 

 

$12,859

 

 

Accounts receivable represents customer trade receivables. As of May 31, 2023 and 2022, there were no allowances for doubtful accounts.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.2
BALANCE SHEET DETAIL
12 Months Ended
May 31, 2023
BALANCE SHEET DETAIL  
BALANCE SHEET DETAIL

7. BALANCE SHEET DETAIL:

 

INVENTORIES:     

 

 May 31,

 

(In Thousands)

 

2023

 

 

2022

 

Raw materials and sub-assemblies

 

$15,953

 

 

$9,507

 

Work in process

 

 

5,764

 

 

 

5,461

 

Finished goods

 

 

2,191

 

 

 

83

 

 

 

$23,908

 

 

$15,051

 

 

PROPERTY AND EQUIPMENT, NET:  

 

 

 

 May 31,

 

(In Thousands)

 

2023

 

 

2022

 

Leasehold improvements

 

$1,310

 

 

$1,230

 

Furniture and fixtures

 

 

706

 

 

 

697

 

Machinery and equipment

 

 

5,445

 

 

 

4,013

 

Test equipment

 

 

2,998

 

 

 

2,523

 

 

 

 

10,459

 

 

 

8,463

 

Less: Accumulated depreciation and amortization

 

 

(7,700)

 

 

(7,260)

 

 

$2,759

 

 

$1,203

 

   

Depreciation expense was $450,000, $307,000 and $310,000 for fiscal 2023, 2022, and 2021, respectively.

 

ACCRUED EXPENSES:

 

 

 

 May 31,

 

(In Thousands)

 

2023

 

 

2022

 

Commissions and bonuses

 

$1,728

 

 

$1,505

 

Payroll related

 

 

1,491

 

 

 

1,401

 

Warranty

 

 

267

 

 

 

410

 

Professional services

 

 

520

 

 

 

204

 

Investor relations

 

 

79

 

 

 

44

 

Taxes payable

 

 

22

 

 

 

13

 

Other

 

 

36

 

 

 

33

 

 

 

$4,143

 

 

$3,610

 

 

CUSTOMER DEPOSITS AND DEFERRED REVENUE, SHORT-TERM:   

 

 

 

 May 31,

 

(In Thousands)

 

2023

 

 

2022

 

Customer deposits

 

$2,690

 

 

$2,263

 

Deferred revenue  

 

 

132

 

 

 

152

 

 

 

$2,822

 

 

$2,415

 

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.2
ACCUMULATED OTHER COMPREHENSIVE LOSS
12 Months Ended
May 31, 2023
ACCUMULATED OTHER COMPREHENSIVE LOSS  
ACCUMULATED OTHER COMPREHENSIVE LOSS

8.  ACCUMULATED OTHER COMPREHENSIVE LOSS:

 

Changes in the components of accumulated other comprehensive loss, net of tax, were as follows (in thousands):

 

 

 

Cumulative Translation Adjustments

 

 

Unrealized Loss on Investments, Net

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

Balance as of May 31, 2021

 

$(28)

 

$-

 

 

$(28)

Other comprehensive loss before reclassifications

 

 

(77)

 

 

-

 

 

 

(77)

Balance as of May 31, 2022

 

 

(105)

 

 

-

 

 

 

(105)

Other comprehensive loss before reclassifications

 

 

(33)

 

 

(17)

 

 

(50)

Balance as of May 31, 2023

 

$(138)

 

$(17)

 

$(155)
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.2
INCOME TAXES
12 Months Ended
May 31, 2023
INCOME TAXES  
INCOME TAXES

9. INCOME TAXES:

 

Domestic and foreign components of income (loss) before income tax (expense) benefit are as follows (in thousands):

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Domestic

 

$14,541

 

 

$9,416

 

 

$(13,064)

Foreign

 

 

76

 

 

 

125

 

 

 

10,860

 

 

 

$14,617

 

 

$9,541

 

 

$(2,204)

 

The income tax (expense) benefit consists of the following (in thousands):

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Federal income taxes:

 

 

 

 

 

 

 

 

 

Current

 

$(28)

 

$(59)

 

$163

 

Deferred

 

 

-

 

 

 

-

 

 

 

-

 

State income taxes:

 

 

 

 

 

 

 

 

 

 

 

 

Current

 

 

-

 

 

 

(5)

 

 

13

 

Deferred

 

 

-

 

 

 

-

 

 

 

-

 

Foreign income taxes:

 

 

 

 

 

 

 

 

 

 

 

 

Current

 

 

(32)

 

 

(27)

 

 

1

 

Deferred

 

 

-

 

 

 

-

 

 

 

-

 

 

 

$(60)

 

$(91)

 

$177

 

 

The Company’s effective tax rate differs from the U.S. federal statutory tax rate, as follows:

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

U.S. federal statutory tax rate

 

 

21.0%

 

 

21.0%

 

 

21.0%

State taxes, net of federal tax effect

 

 

-

 

 

 

0.1

 

 

 

0.6

 

Foreign rate differential

 

 

0.7

 

 

 

0.3

 

 

 

9.8

 

Stock-based compensation

 

 

(9.1)

 

 

(11.0)

 

 

(4.7)

Research and development credit

 

 

(2.3)

 

 

(1.3)

 

 

4.0

 

Change in valuation allowance

 

 

(9.3)

 

 

(4.7)

 

 

(32.1)

Controlled Foreign Corporation Liquidation. .

 

 

-

 

 

 

-

 

 

 

9.8

 

PPP Loan

 

 

-

 

 

 

(3.7)

 

 

-

 

Other

 

 

(0.6)

 

 

0.4

 

 

 

(0.4)

Effective tax rate

 

 

0.4%

 

 

1.1%

 

 

8.0%

 

The components of the net deferred tax assets and liabilities are as follows (in thousands):

 

 

 

Year Ended May 31,

 

 

 

         2023

 

 

2022

 

Deferred tax assets:

 

 

 

 

 

 

Net operating losses

 

$11,964

 

 

$14,912

 

Lease liability

 

 

1,335

 

 

 

218

 

Credit carryforwards

 

 

6,235

 

 

 

5,535

 

Inventory reserves

 

 

938

 

 

 

934

 

Reserves and accruals

 

 

1,200

 

 

 

1,360

 

Capitalized research and development

 

 

1,187

 

 

 

-

 

Other

 

 

297

 

 

 

220

 

Less: valuation allowance

 

 

(21,859)

 

 

(22,980)

 

 

 

1,297

 

 

 

199

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

Operating lease right-of-use assets

 

 

(1,297)

 

 

(199)

Net deferred tax assets (liabilities)

 

$-

 

 

$-

 

 

The valuation allowance decreased by $1,121,000 during fiscal 2023, decreased by $278,000 during fiscal 2022, and increased by $2,438,000 during fiscal 2021. As of May 31, 2023 and 2022, the Company provided a full valuation allowance against the deferred tax assets as it did not have enough objective evidence as required by GAAP to reverse its full valuation allowance. The Company will continue to evaluate the need for a valuation allowance against its deferred tax assets on a quarterly basis.

 

At May 31, 2023 and 2022, the Company has federal net operating loss carryforwards of approximately $46,967,000 and $61,068,000 respectively, to reduce future taxable income. A portion of the federal net operating losses will begin to expire in 2024. Federal net operating losses of $14,425,000 will carryforward indefinitely and would be subject to an 80% taxable income limitation in the year utilized. At May 31, 2023 and 2022, the Company has state net operating loss carryforwards of $30,203,000 and $30,043,000, respectively, to reduce future taxable income. The state net operating loss carryforwards will begin to expire in 2028.

 

At May 31, 2023 and 2022, the Company has federal research and development credit carryforwards of approximately $2,923,000 and $2,362,000, respectively, to offset future tax liability. The federal credit carryforwards began to expire in 2022. At May 31, 2023 and 2022, the Company has state research and development credit carryforwards of approximately $6,623,000 and $6,152,000 respectively, to offset future tax liability. The state credit carryforwards are not subject to expiration. The Company also has alternative minimum tax credit carryforwards of $34,000 for state purposes. The credits may be used to offset regular tax and do not expire.

 

Internal Revenue Code of 1986, as amended (“IRC”) Section 382 (“§382”) limits the use of NOL and tax credit carryforwards in certain situations where changes occur in the stock ownership of a company. In general, if we experience a greater than 50% aggregate change in ownership over a three-year period, we are subject to an annual limitation under IRC §382 on the utilization of the Company’s pre-change NOL carryforwards. California and other states have similar laws. The annual limitation generally is determined by multiplying the value of the Company’s stock at the time of such ownership change (subject to certain adjustments) by the applicable long-term exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization.

 

The Company has made no provision for U.S. income taxes on undistributed earnings of certain foreign subsidiaries because it is the Company’s intention to permanently reinvest such earnings in its foreign subsidiaries. If such earnings were distributed, the Company would be subject to additional U.S. income tax expense.

 

The Company maintains liabilities for uncertain tax positions. These liabilities involve considerable judgment and estimation and are continuously monitored by management based on the best information available.

 

The aggregate changes in the balance of gross unrecognized tax benefits are as follows (in thousands):

 

Beginning balance as of May 31, 2020

 

$1,852

 

 

 

 

 

 

Increases related to prior year tax positions

 

 

11

 

Increases related to current year tax positions

 

 

65

 

 

 

 

 

 

Balance at May 31, 2021

 

 

1,928

 

 

 

 

 

 

Increases related to prior year tax positions

 

 

12

 

Increases related to current year tax positions

 

 

78

 

 

 

 

 

 

Balance at May 31, 2022

 

 

2,018

 

 

 

 

 

 

Increases related to prior year tax positions

 

 

90

 

Increases related to current year tax positions

 

 

168

 

 

 

 

 

 

Balance at May 31, 2023

 

$2,276

 

 

As of May 31, 2023 and 2022, the Company has not recorded interest and penalties associated with its unrecognized tax benefits. The Company’s unrecognized gross tax benefits would not reduce the annual effective tax rate if recognized because it has recorded a full valuation allowance on its deferred tax assets. The Company does not foresee any material changes to the gross unrecognized tax benefit within the next twelve months. The Company’s policy is to recognize interest and penalties in income tax expense.

 

The Company’s federal and state income tax returns are subject to possible examination by the taxing authorities until the expiration of the related statutes of limitations on those tax returns. In general, the federal income tax returns have a three-year statute of limitations, and the state income tax returns have a four-year statute of limitations. The Company’s foreign income tax returns are also subject to examination by the foreign tax authorities with the longest statute of limitations period of four-year.

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.2
LEASES
12 Months Ended
May 31, 2023
LEASES  
LEASES

10. LEASES

 

The Company leases its manufacturing and office space under operating leases. The principal administrative and production facility is located in Fremont, California, in a 51,289 square foot building. The Company entered into a non-cancelable operating lease agreement for its United States manufacturing and office facility, which was renewed in December 2022 and expires in September 2030. The Company leases a 492 square foot sales and support office in Utting, Germany. The lease, which began on February 1, 1992 and expires on January 31, 2025, contains an automatic twelve months renewal, at rates to be determined, if no notice is given prior to six months from expiration. The Company leases a facility in the Philippines located in a 2,713 square foot building in Clark Freeport Zone, Pampanga. The lease, which began on January 1, 2021 and expires on December 31, 2025, contains an option to renew for another three years at rates stipulated in the contract, notice for renewal is given six months from expiration. Under the lease agreements, the Company is responsible for payments of utilities, taxes and insurance.

 

The Company has only operating leases for real estate including corporate offices, warehouse space and certain equipment. A lease with an initial term of 12 months or less is generally not recorded on the consolidated balance sheets, unless the arrangement includes an option to purchase the underlying asset, or renew the arrangement that the Company is reasonably certain to exercise (short-term leases). The Company recognizes lease expense on a straight-line basis over the lease term for short-term leases that the Company does not record on its balance sheets. The Company’s operating leases have remaining lease terms of one year to seven years.

 

The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.

 

In December 2022, the Company amended its lease agreement to extend the lease term of an existing office facility located in the United States, which is considered a lease modification not accounted for as a separate contract. The total commitments, net of tenant incentives expected to be received, under the modified lease are $8.6 million. The modified lease expires in fiscal 2031 and contains an option to further extend the lease. The lease modification resulted in an increase in the Company’s operating lease right-of-use assets and operating lease liabilities of $5.9 million each.

 

The weighted average remaining lease term for the Company’s operating leases was 7.3 years at May 31, 2023 and the weighted average discount rate was 7.5%.

 

The Company’s operating lease cost was $923,000, $766,000 and $761,000 for the years ended May 31, 2023, 2022 and 2021, respectively.

 

The following table presents supplemental cash flow information related to the Company’s operating leases (in thousands):

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Cash paid for amounts included in the measurement of operating lease liabilities:

 

 

 

 

 

 

 

 

 

Operating cash flows from operating leases

 

$835

 

 

$813

 

 

$779

 

 

    The following table presents the maturities of the Company’s operating lease liabilities as of May 31, 2023 (in thousands):

 

Fiscal year

 

Operating Leases

 

2024

 

$608

 

2025

 

 

1,143

 

2026

 

 

1,174

 

2027

 

 

1,195

 

2028

 

 

1,234

 

Thereafter

 

 

3,075

 

Total future minimum operating lease payments

 

 

8,429

 

Less: imputed interest

 

 

(2,129)

Present value of operating lease liabilities

 

$6,300

 

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.2
BORROWING AND FINANCING ARRANGEMENTS
12 Months Ended
May 31, 2023
BORROWING AND FINANCING ARRANGEMENTS  
BORROWING AND FINANCING ARRANGEMENTS

11. BORROWING AND FINANCING ARRANGEMENTS:

 

On January 16, 2020, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Silicon Valley Bank (“SVB”). Pursuant to the Loan Agreement, the Company may borrow up to (a) the lesser of (i) the revolving line of $4.0 million or (ii) the amount available under the borrowing base under a revolving line of credit which is collateralized by all the Company’s assets except intellectual property. The borrowing base is 80% of eligible accounts, as determined by SVB from the Company’s most recent borrowing base statement; provided, however, SVB has the right to decrease the foregoing percentage in its good faith business judgment to mitigate the impact of certain events or conditions, which may adversely affect the collateral or its value. Subject to an event of default, the principal amount outstanding under the revolving line of credit will accrue interest at a floating per annum rate equal to the greater of (a) the prime rate plus an additional percentage of up to 1%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 4.75%. Interest is payable monthly on the last calendar day of each month and the outstanding principal amount, the unpaid interest and all other obligations are due on the maturity date, which is 364 days from the effective date of January 13, 2020.

 

On January 14, 2021, the Company entered into the First Amendment to Loan and Security Agreement (the “Amendment”) with SVB. The Amendment, among other things, extended the Revolving Line Maturity Date to July 14, 2021; provided, however, that if the Company achieved specified operating metrics on a consolidated basis on or prior to May 31, 2021 the Amended Revolving Line Maturity Date would be extended to January 13, 2022.

 

On January 11, 2022, the Company entered into the Second Amendment to the Loan and Security Agreement (the “Second Amendment”) with SVB. The Second Amendment, among other things, (A) increased the available amount of the line up to the lesser of (i) $10 million or (ii) the available amount under the borrowing base, under a revolving line of credit, (B) allowed for borrowing up to $3 million of the available balance based upon eligible customer purchase orders, (C) reduced the interest rate for account advances under the line to the greater of (a) prime rate plus an additional percentage up to 1.0%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 3.25%, reduces the interest rate for purchase order advances under the line to the greater of (a) prime rate plus an additional percentage up to 1.5%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 3.75%, and (D) extended the maturity date to January 13, 2023.

 

On January 10, 2023, the Company entered into the Third Amendment to the Loan and Security Agreement (the “Third Amendment”) with SVB. The Third Amendment, among other things, extends the Revolving Line Maturity Date to January 13, 2024, provided, however, that (i) if the Company submits a fiscal year 2024 plan of record that is generally acceptable to SVB, and (ii) the minimum net liquidity at the end of November 30, 2023 is at least $20.0 million, the Amended Revolving Line Maturity Date would be extended to January 13, 2025.

 

As of May 31, 2023 the Company had not drawn against the credit facility and was in compliance with all covenants related to obligations to meet reporting requirements. The balance available to borrow under the line as of May 31, 2023 was $8,004,000. There are no financial covenants in the agreement.

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.2
LONGTERM DEBT
12 Months Ended
May 31, 2023
LONGTERM DEBT  
LONG-TERM DEBT

12. LONG-TERM DEBT:

 

On April 23, 2020, the Company obtained a Payroll Protection Program loan (“PPP Loan”) in the aggregate amount of $1,679,000 from SVB. The PPP Loan was evidenced by a promissory note dated April 23, 2020 (the “Note”) that matures on April 23, 2022 and bears interest at a rate of 1% per annum, payable monthly commencing on November 23, 2020. The PPP Loan proceeds were used for payroll, health care benefits, rent and utilities.

 

Under the terms of the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), PPP Loan recipients can apply for and be granted forgiveness for all or a portion of loans granted under the PPP Loan. On June 12, 2021, the Company received confirmation from the SVB that on June 4, 2021, the Small Business Administration approved the Company’s PPP Loan forgiveness application for the entire PPP Loan balance of $1,679,000 and interest totaling $19,000, and the Company recognized a gain on loan forgiveness of $1,698,000.

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK-BASED COMPENSATION
12 Months Ended
May 31, 2023
STOCK-BASED COMPENSATION  
STOCK-BASED COMPENSATION

13. STOCK-BASED COMPENSATION:

 

Stock-based compensation expense consists of expenses for stock options, restricted stock units (“RSUs”), performance RSUs, or PRSUs, restricted shares, performance restricted shares and employee stock purchase plan, or ESPP, purchase rights. Stock-based compensation expense for stock options and ESPP purchase rights is measured at each grant date, based on the fair value of the award using the Black-Scholes option valuation model, and is recognized as expense over the employee’s requisite service period. This model was developed for use in estimating the value of publicly traded options that have no vesting restrictions and are fully transferable. The Company’s employee stock options have characteristics significantly different from those of publicly traded options. For RSUs, PRSUs, restricted shares and performance restricted shares, stock-based compensation expense is based on the fair value of the Company’s common stock at the grant date, and is recognized as expense over the employee’s requisite service period. All of the Company’s stock-based compensation is accounted for as equity instruments.

 

The following table summarizes the stock-based compensation expense for the fiscal years ended May 31, 2023, 2022 and 2021 (in thousands, except per share data):

 

 

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Stock-based compensation in the form of stock options,

 

 

 

 

 

 

 

 

 

RSUs, and ESPP purchase rights, included in:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales

 

$331

 

 

$234

 

 

$70

 

Selling, general and administrative

 

 

1,711

 

 

 

1,721

 

 

 

816

 

Research and development

 

 

706

 

 

 

968

 

 

 

215

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net effect on net income (loss)

 

$2,748

 

 

$2,923

 

 

$1,101

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Effect on earnings (net loss) per share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$0.10

 

 

$0.11

 

 

$0.05

 

Diluted

 

$0.09

 

 

$0.11

 

 

$0.05

 

 

As of the years ended May 31, 2023, 2022 and 2021, stock-based compensation totaling $120,000, $83,000 and $0, respectively, was capitalized as part of inventory.

 

During fiscal 2023, 2022 and 2021, the Company recorded stock-based compensation related to stock options, RSUs, PRSUs, performance restricted shares and restricted shares of $1,988,000, $2,071,000 and $993,000, respectively. For PRSUs and performance restricted shares, the Company evaluates compensation expense quarterly and recognizes expense for performance-based awards only if it determines it is probable that performance criteria for the awards will be met.

 

As of May 31, 2023, the total compensation expense related to unvested stock-based awards under the Company’s 2016 Equity Incentive Plan, but not yet recognized, was $3,102,000 which is net of estimated forfeitures of $8,000. This expense will be amortized on a straight-line basis over a weighted average period of approximately 2.3 years.

 

During fiscal 2023, 2022 and 2021, the Company recorded stock-based compensation related to its ESPP of $760,000, $935,000 and $108,000, respectively.

 

As of May 31, 2023, the total compensation expense related to purchase rights under the ESPP but not yet recognized was $715,000. This expense will be amortized on a straight-line basis over a weighted average period of approximately 1.1 years.

 

Valuation Assumptions

 

Valuation and Amortization Method. The Company estimates the fair value of stock options granted using the Black-Scholes option valuation method and a single option award approach. The fair value under the single option approach is amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period.

 

Expected Term. The Company’s expected term represents the period that the Company’s stock-based awards are expected to be outstanding and was determined based on historical experience, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior as evidenced by changes to the terms of its stock-based awards.

 

Volatility. Volatility is a measure of the amounts by which a financial variable such as stock price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company uses the historical volatility for the past five to six years, based on weighted average of the expected term of option grants, to estimate expected volatility. Volatility for each of the ESPP’s four time periods of six months, twelve months, eighteen months, and twenty-four months is calculated separately and included in the overall stock-based compensation expense recorded.

 

Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes option valuation method on the implied yield in effect at the time of option grant on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of the stock awards including the ESPP.

  

Fair Value. The fair values of the Company’s stock options granted to employees in fiscal 2023, 2022 and 2021 were estimated using the following weighted average assumptions in the Black-Scholes option valuation method:

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

Expected term (in years)

 

5 - 6

 

 

5 - 6

 

 

 

6

 

Volatility

 

 

86%

 

 

88%

 

 

72%

Risk-free interest rates

 

 

3.12%

 

 

1.50%

 

 

0.44%

Weighted average grant date fair value

 

$6.29

 

 

$4.01

 

 

$1.12

 

 

The fair value of our ESPP purchase rights for the fiscal 2023, 2022 and 2021 was estimated using the following weighted average assumptions:

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

Expected term (in years)

 

0.5 – 2.0

 

 

0.5 – 2.0

 

 

0.5 – 2.0

 

Volatility

 

91% – 203

 

101% – 272

 

74% – 88

%

Risk-free interest rates

 

3.97%–4.94

 

0.05%–2.44

 

0.04%–0.17

Weighted average grant date fair value

 

$13.60

 

 

$9.68

 

 

$1.03

 

 

EQUITY INCENTIVE PLAN:

 

In October 2006, the Company’s 2006 Equity Incentive Plan was approved by the shareholders, which provides for granting of incentive stock options, non-statutory stock options, restricted shares, RSUs, stock appreciation rights, PRSUs, performance restricted shares and other stock or cash awards as the Company’s Board of Directors may determine.

 

In October 2016, the Company’s 2016 Equity Incentive Plan was approved by the Company’s shareholders. The 2016 Equity Incentive Plan replaced our 2006 Equity Incentive Plan, which was scheduled to expire in October 2016, and will continue in effect until 2026. The exercise price of each stock option equals the market value of the Company's common stock on the date of grant. Options typically vest over four years, subject to the grantee’s continued service with the Company through the scheduled vesting date, and expire in seven years from the grant date. A total of 4,848,000 shares of common stock have been reserved for issuance under the Company’s 2016 Equity Incentive Plan, which includes 2,248,000 shares that remained available for issuance under the 2006 Equity Incentive Plan. Full value awards, which are equity awards other than options, stock appreciation rights or other awards that are based solely on an increase in value of the shares following the grant date, when granted or forfeited will be counted as two times the number of shares added or deducted to the remaining available shares for issuance under 2016 Equity Incentive Plan. See the Company’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on November 16, 2021 for further information regarding the 2016 Equity Incentive Plan.

  

The following tables summarize the Company’s stock option and RSU transactions during fiscal 2023, 2022 and 2021 (in thousands):

Available

Shares

Balance, May 31, 2020

1,416

Options granted

(297)

RSUs granted

(680)

RSUs cancelled

2

Shares withheld for taxes and not issued

18

Options terminated

455

Options expired

(341)

Balance, May 31, 2021

573

Additional shares reserved

1,414

Options granted

(303)

RSUs granted

(1,044)

RSUs cancelled

20

Shares withheld for taxes and not issued

(30)

Options terminated

105

Balance, May 31, 2022

735

Options granted

(110)

RSUs granted

(674)

RSUs cancelled

60

Options terminated

16

Balance, May 31, 2023

27

 

The following table summarized the stock option transactions during fiscal 2023, 2022 and 2021 (in thousands, except per share data):

 

 

 

Outstanding Options

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

Number

 

 

Average

 

 

Aggregate

 

 

 

of

 

 

Exercise

 

 

Intrinsic

 

 

 

Shares

 

 

Price

 

 

Value

 

Balances, May 31, 2020

 

 

3,153

 

 

$2.17

 

 

$102

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options granted

 

 

297

 

 

$1.78

 

 

 

 

 

Options terminated

 

 

(455)

 

$2.31

 

 

 

 

 

Options exercised

 

 

(229)

 

$1.54

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, May 31, 2021

 

 

2,766

 

 

$2.16

 

 

$807

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options granted

 

 

303

 

 

$5.37

 

 

 

 

 

Options terminated

 

 

(105)

 

$1.59

 

 

 

 

 

Options exercised

 

 

(1,367)

 

$2.28

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, May 31, 2022

 

 

1,597

 

 

$2.70

 

 

$9,290

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options granted

 

 

110

 

 

$9.06

 

 

 

 

 

Options terminated

 

 

(16)

 

$5.42

 

 

 

 

 

Options exercised

 

 

(730)

 

$2.32

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, May 31, 2023

 

 

961

 

 

$3.67

 

 

$28,211

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options fully vested and expected to vest at May 31, 2023

 

 

947

 

 

$3.66

 

 

$27,796

 

 

The options outstanding and exercisable at May 31, 2023 were in the following exercise price ranges (in thousands, except per share data):

 

 

 

 

Options Outstanding

 

 

                       Options Exercisable

 

 

 

 

at May 31, 2023

 

 

                           at May 31, 2023

 

Range of Exercise

Prices

 

 

Number Outstanding Shares

 

 

Weighted Average Remaining Contractual Life (Years)

 

 

Weighted Average Exercise Price

 

 

Number Exercisable Shares

 

 

Weighted Average Remaining Contractual Life (Years)

 

 

Weighted Average Exercise Price

 

 

Aggregate Intrinsic Value

 

$1.34

 

 

 

41

 

 

 

4.39

 

 

$1.34

 

 

 

41

 

 

 

4.39

 

 

$1.34

 

 

 

 

$1.64-$1.86

 

 

 

365

 

 

 

3.53

 

 

$1.72

 

 

 

291

 

 

 

3.45

 

 

$1.70

 

 

 

 

$2.03-$2.40

 

 

 

185

 

 

 

2.61

 

 

$2.14

 

 

 

175

 

 

 

2.48

 

 

$2.14

 

 

 

 

$2.93

 

 

 

139

 

 

 

5.12

 

 

$2.93

 

 

 

35

 

 

 

5.12

 

 

$2.93

 

 

 

 

$3.46-$3.93

 

 

 

37

 

 

 

1.11

 

 

$3.93

 

 

 

37

 

 

 

1.11

 

 

$3.93

 

 

 

 

$8.00-34.00

 

 

 

194

 

 

 

5.97

 

 

$9.77

 

 

 

41

 

 

 

5.90

 

 

$10.18

 

 

 

 

$1.34-34.00

 

 

 

961

 

 

 

4.02

 

 

$3.67

 

 

 

620

 

 

 

3.35

 

 

$2.56

 

 

$18,895

 

 

The total intrinsic values of options exercised were $17,088,000, $12,542,000 and $152,000 during fiscal 2023, 2022 and 2021, respectively. The weighted average contractual life of the options exercisable and expected to be exercisable at May 31, 2023 was 4.01 years.

 

Options to purchase 620,000, 1,042,000 and 2,045,000 shares were exercisable at May 31, 2023, 2022 and 2021, respectively. These exercisable options had weighted average exercise prices of $2.56, $2.22 and $2.26 as of May 31, 2023, 2022 and 2021, respectively.

 

The following table summarizes RSUs, PRSUs, restricted shares and performance restricted shares granted to employees and members of the Company’s Board of Directors during fiscal 2023, 2022 and 2021:

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Employees:

 

 

 

 

 

 

 

 

 

Annual RSUs granted

 

 

152,000

 

 

 

120,000

 

 

 

161,000

 

Weighted-average grant-date fair value of annual RSUs

 

$8.03

 

 

$3.17

 

 

$1.86

 

Annual restricted shares granted

 

 

8,000

 

 

 

-

 

 

 

-

 

Weighted-average grant-date fair value of annual restricted shares  

 

$8.00

 

 

 

-

 

 

 

-

 

RSUs granted in lieu of cash payment for salary reductions and bonus

 

 

-

 

 

 

89,000

 

 

 

18,000

 

Weighted-average grant-date value of RSU in lieu of cash payment

 

 

-

 

 

$2.50

 

 

$2.21

 

Maximum PRSUs to be vested if all revenue goals are achieved

 

 

80,000

 

 

 

270,000

 

 

 

-

 

Maximum Performance restricted shares to be vested if all revenue goals are achieved

 

 

24,000

 

 

 

-

 

 

 

-

 

Weighted-average grant-date fair value of PRSUs and performance restricted shares

 

$8.00

 

 

$3.41

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Members of Board of Directors:

 

 

 

 

 

 

 

 

 

 

 

 

RSUs granted

 

 

44,000

 

 

 

43,000

 

 

 

161,000

 

Weighted-average grant-date fair value of RSUs

 

$11.35

 

 

$8.02

 

 

$1.81

 

Maximum PRSUs granted to be vested if all revenue goals are achieved

 

 

25,000

 

 

 

-

 

 

 

-

 

Weighted-average grant-date fair value of PRSUs

 

$8.00

 

 

 

-

 

 

 

-

 

 

PRSUs were granted to key officers and members of Board of Directors based upon revenue target thresholds for fiscal 2023 and 2022.

 

The following table summarizes the RSUs and PRSUs vested and unvested during fiscal 2023, 2022 and 2021:

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Net RSUs and PRSUs vested

 

 

240,000

 

 

 

96,000

 

 

 

207,000

 

Shares withheld to settle payroll taxes  

 

 

178,000

 

 

 

62,000

 

 

 

9,000

 

Weighted average grant-date fair value of vested RSUs and PRSUs

 

$4.47

 

 

$3.12

 

 

$1.90

 

RSUs and PRSUs cancelled

 

 

30,000

 

 

 

10,000

 

 

 

1,000

 

Weighted average grant-date fair value of cancelled RSUs and PRSUs

 

$8.56

 

 

$2.93

 

 

$3.46

 

RSUs and PRSUs unvested

 

 

345,000

 

 

 

185,000

 

 

 

132,000

 

Weighted average grant-date fair value of unvested RSUs and PRSUs

 

$6.40

 

 

$3.00

 

 

$1.88

 

Intrinsic value of unvested RSUs and PRSUs (in thousands)

 

$11,392

 

 

$1,554

 

 

$297

 

 

EMPLOYEE STOCK PURCHASE PLAN:

 

In October 2006, the Company’s shareholders approved the 2006 Employee Stock Purchase Plan. In October 2016, the Company’s shareholders approved the Company’s Amended and Restated 2006 Employee Stock Purchase Plan (the “Purchase Plan”), which amended and restated the 2006 Employee Stock Purchase Plan. The Purchase Plan extended the term of the 2006 Employee Stock Purchase Plan indefinitely. See the Company’s Registration Statements on Form S-8 filed with the Securities and Exchange Commission on November 18, 2020 and November 16, 2022 for further information regarding the Purchase Plan. The Purchase Plan has consecutive, overlapping, twenty-four month offering periods. Each twenty-four-month offering period includes four six-month purchase periods. The offering periods generally begin on the first trading day on or after April 1 and October 1 each year. All employees who work a minimum of 20 hours per week and are customarily employed by the Company (or an affiliate thereof) for at least five months per calendar year are eligible to participate. Under the Purchase Plan, shares are purchased through employee payroll deductions at exercise prices equal to 85% of the lesser of the fair market value of the Company’s common stock at either the first day of an offering period or the last day of the purchase period. If a participant’s rights to purchase stock under all employee stock purchase plans of the Company accrue at a rate which exceeds $25,000 worth of stock for a calendar year, such participant may not be granted an option to purchase stock under the Purchase Plan. The maximum number of shares a participant may purchase during a single purchase period is 3,000 shares. In October 2022, the Company’s shareholders approved an amendment to the Purchase Plan to increase the number of shares authorized for issuance thereunder by an additional 350,000 shares of the Company’s common stock. After such amendment, a total of 2,550,000 shares of the Company’s common stock have been authorized for issuance under the Purchase Plan. During the fiscal years ended May 31, 2023, 2022 and 2021, ESPP purchase rights of 77,000, 101,000, and 279,000 shares, respectively, were granted. For the fiscal years ended May 31, 2023, 2022 and 2021, approximately 211,000, 178,000 and 147,000 shares of common stock, respectively, were issued under the Purchase Plan. As of May 31, 2023, a total of 2,152,000 shares have been issued under the Purchase Plan, and 398,000 ESPP shares remain available for issuance.

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.2
EMPLOYEE BENEFIT PLANS
12 Months Ended
May 31, 2023
EMPLOYEE BENEFIT PLANS  
EMPLOYEE BENEFIT PLANS

14. EMPLOYEE BENEFIT PLANS:

 

EMPLOYEE STOCK OWNERSHIP PLAN:

 

The Company has a non-contributory, trusteed employee stock ownership plan for full-time employees who have completed three consecutive months of service and for part-time employees who have completed one year of service and have attained an age of 21. The Company can contribute either shares of the Company’s stock or cash to the plan. The contribution is determined annually by the Company and cannot exceed 15% of the annual aggregate salaries of those employees eligible for participation in the plan. On May 31, 2007, the Company converted the Aehr Test Systems Employee Stock Bonus Plan into the Aehr Test Systems Employee Stock Ownership Plan (the “Plan”). The stock bonus plan was converted to an employee stock ownership plan (“ESOP”) to enable the Plan to better comply with changes in the law regarding Company stock. Individuals’ account balances vest at a rate of 20% per year commencing upon completion of two years of service. Non-vested balances, which are forfeited following termination of employment, are allocated to the remaining employees in the Plan. Under the Plan provisions, each employee who reaches age fifty-five (55) and has been a participant in the Plan for ten years will be offered an election each year to direct the transfer of up to 25% of his/her ESOP account to the employee self-directed account in the Savings and Retirement Plan. For anyone who met the above prerequisites, the first election to diversify holdings was offered after May 31, 2008. In the sixth year, employees will be able to diversify up to 50% of their ESOP accounts. Contributions of $300,000 were authorized for the plan during fiscal 2023, $250,000 for 2022 and $60,000 for 2021. The contribution amounts are recorded as compensation expense in the period authorized and included in accrued expenses in the period authorized. Contributions of 29,832 shares were made to the ESOP during fiscal 2023 for fiscal 2022. Contributions of 26,666 shares were made to the ESOP during fiscal 2022 for fiscal 2021. Contributions of 36,000 shares were made to the ESOP during fiscal 2021 for fiscal 2020. The contribution for fiscal 2023 will be made in fiscal 2024. Shares held in the ESOP are included in the EPS calculation.

 

401(K) PLAN:

 

The Company maintains a defined contribution savings plan (the “401(k) Plan”) to provide retirement income to all qualified employees of the Company. The 401(k) Plan is intended to be qualified under Section 401(k) of the Internal Revenue Code of 1986, as amended. The 401(k) Plan is funded by voluntary pre-tax contributions from employees. Contributions are invested, as directed by the participant, in investment funds available under the 401(k) Plan. The Company is not required to make, and did not make, any contributions to the 401(k) Plan during fiscal 2023, 2022 and 2021.

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.2
OTHER INCOME (EXPENSE) NET
12 Months Ended
May 31, 2023
OTHER INCOME (EXPENSE) NET  
OTHER INCOME (EXPENSE), NET

15. OTHER (EXPENSE) INCOME, NET:

 

Other (expense) income, net comprises the following (in thousands):

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Foreign exchange (loss) gain

 

$(3)

 

$32

 

 

$(111)

Other expense, net

 

 

-

 

 

(2)

 

 

(51)

 

 

$(3)

 

$30

 

 

$(162)
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.2
PRODUCT WARRANTIES
12 Months Ended
May 31, 2023
PRODUCT WARRANTIES  
PRODUCT WARRANTIES

16. PRODUCT WARRANTIES:

 

The Company provides for the estimated cost of product warranties at the time revenues are recognized on the products shipped. While the Company engages in extensive product quality programs and processes, including actively monitoring and evaluating the quality of its component suppliers, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required.

 

The standard warranty period is one year for systems and ninety days for parts and service.

 

Following is a summary of changes in the Company’s liability for product warranties during the fiscal years ended May 31, 2023 and 2022 (in thousands):

 

 

 

 May 31,

 

 

 

2023

 

 

2022

 

 

 

 

 

 

 

 

Balance at the beginning of the year

 

$410

 

 

$494

 

Accruals for warranties issued during the year

 

 

420

 

 

 

465

 

Adjustment to previously existing warranty

 

 

61

 

 

 

98

 

Consumption of reserves

 

 

(624)

 

 

(647)

 

 

 

 

 

 

 

 

 

Balance at the end of the year

 

$267

 

 

$410

 

 

The accrued warranty balance is included in accrued expenses on the consolidated balance sheets.

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.2
SEGMENT INFORMATION
12 Months Ended
May 31, 2023
SEGMENT INFORMATION  
SEGMENT INFORMATION

17. SEGMENT INFORMATION:

 

The Company has only one reportable segment. The information for revenue category by type, product line, geography and timing of revenue recognition, is summarized in Note 2, “Revenue.”

 

Property and equipment information is based on the physical location of the assets. The following table presents property and equipment information for geographic areas (in thousands):

 

 

May 31,

 

 

 

2023

 

 

2022

 

United States

 

$2,713

 

 

$1,156

 

Asia

 

 

44

 

 

 

47

 

Europe

 

 

2

 

 

 

-

 

 

 

$2,759

 

 

$1,203

 

 

As of May 31, 2023, operating lease right-of-use assets of $6,007,000, $70,000 and $45,000 were allocated in the United States, Asia and Europe, respectively. As of May 31, 2022, the operating lease right-of-use assets of $822,000 and $95,000 were allocated in the United States and Asia, respectively.

 

There were no revenues through distributors for the fiscal years ended May 31, 2023, 2022 and 2021.

XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.2
DISSOLUTION OF AEHR TEST SYSTEMS JAPAN
12 Months Ended
May 31, 2023
DISSOLUTION OF AEHR TEST SYSTEMS JAPAN  
DISSOLUTION OF AEHR TEST SYSTEMS JAPAN

18. DISSOLUTION OF AEHR TEST SYSTEMS JAPAN:

 

On July 31, 2020, the Company completed the liquidation of ATS-Japan, a majority owned subsidiary. Accordingly, the Company deconsolidated ATS-Japan and recognized an aggregate net gain of $2,401,000 for the period ended August 31, 2020. The net gain was mainly due to cumulative translation adjustment reclassified into earnings of $2,186,000 and the residual income tax effect in connection with the cumulative translation adjustment released into income tax benefits of $215,000.

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.2
EQUITY
12 Months Ended
May 31, 2023
EQUITY  
EQUITY

19. EQUITY:

 

On August 25, 2021, the Board of Directors authorized management to take actions necessary for the execution of a $75 million shelf registration. A Registration Statement on Form S-3 was filed with the SEC on September 3, 2021. A Prospectus Supplement for an "At the Market" ("ATM") sale of $25 million of common stock was subsequently filed on September 17, 2021. On October 8, 2021, the Company executed the ATM offering by selling 1,696,729 shares of common stock at an average selling price of $14.73 per share. The gross proceeds to the Company were $25.0 million, before commission fees of $0.7 million and offering expenses of $0.3 million. Another Prospectus Supplement for an ATM sale of $25 million of common stock was subsequently filed on February 8, 2023. The Company partially executed the ATM offering by selling 208,917 shares of common stock at an average selling price of $34.78 per share. The gross proceeds to the Company were $7.3 million, before commissions of $0.2 million and offering expenses of $0.2 million.

XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.2
COMMITMENTS AND CONTINGENCIES
12 Months Ended
May 31, 2023
Commitments and contingencies (Note 20)  
COMMITMENTS AND CONTINGENCIES

20. COMMITMENTS AND CONTINGENCIES:

 

COMMITMENTS

 

As of May 31, 2023 and 2022, the Company had restricted money market funds of $150,000 and $80,000, respectively, held by a financial institution, representing a security deposit for its United States manufacturing and office space lease. This amount is included in other assets on the consolidated balance sheets.

 

PURCHASE OBLIGATIONS

 

The Company has purchase obligations to certain suppliers. In some cases, the products the Company purchases are unique and have provisions against cancellation of the order. At May 31, 2023, the Company had $26,318,000 of purchase obligations which are due within the following 12 months. This amount does not include contractual obligations recorded on the consolidated balance sheets as liabilities.

 

CONTINGENCIES

 

The Company may, from time to time, be involved in legal proceedings arising in the ordinary course of business. While there can be no assurances as to the ultimate outcome of any litigation involving the Company, management does not believe any pending legal proceedings will result in judgment or settlement that will have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

 

In the normal course of business to facilitate sales of its products, the Company indemnifies other parties, including customers, with respect to certain matters, for example, including against losses arising from a breach of representations or covenants, or from intellectual property infringement or other claims. These agreements may limit the time within which an indemnification claim can be made and the amount of the claim. In addition, the Company has entered into indemnification agreements with its officers and directors, and the Company’s bylaws contain similar indemnification obligations to the Company’s agents.

 

It is not possible to determine the maximum potential amount under these indemnification agreements due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. To date, payments made by the Company under these agreements have not had a material impact on the Company’s operating results, financial position or cash flow.

XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.2
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
12 Months Ended
May 31, 2023
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
BUSINESS:

Aehr Test Systems (the “Company”) was incorporated in California in May 1977 and primarily designs, engineers and manufactures test and burn-in equipment used in the semiconductor industry. The Company’s principal products are the FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak carrier, the WaferPak aligner, the DiePak autoloader, and test fixtures.

CONSOLIDATION:

The consolidated financial statements include the accounts of the Company and both its wholly-owned and majority-owned foreign subsidiaries. Intercompany accounts and transactions have been eliminated.

FOREIGN CURRENCY TRANSLATION AND TRANSACTIONS:

Assets and liabilities of the Company’s foreign subsidiaries and a branch office are translated into U.S. Dollars from their functional currencies of Euros, Philippines Peso and New Taiwan Dollars using the exchange rate in effect at the balance sheet date. Additionally, their net sales and expenses are translated using exchange rates approximating average rates prevailing during the fiscal year. Translation adjustments that arise from translating their financial statements from their local currencies to U.S. Dollars are accumulated and reflected as a separate component of shareholders’ equity.

 

Transaction gains and losses that arise from exchange rate changes denominated in currencies other than the local currency are included in the Consolidated Statements of Operations as incurred. See Note 15, “Other (Expense) Income, Net” for the detail of foreign exchange transaction gains and losses for all periods presented.

USE OF ESTIMATES:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the Company’s consolidated financial statements include allowance for doubtful accounts, valuation of inventory at the lower of cost or net realizable value, and warranty reserves.

RECLASSIFICATIONS:

Certain reclassifications have been made to the previous year consolidated financial statements to conform to the current period presentation. The reclassifications had no impact on net income (loss), total assets, total liabilities, or shareholders’ equity.

CASH EQUIVALENTS:

Cash equivalents consist of money market instruments purchased with an original maturity of three months or less. These investments are reported at fair value.

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS:

Accounts receivable are derived from the sale of products throughout the world to semiconductor manufacturers, semiconductor contract assemblers, electronics manufacturers and burn-in and test service companies. Accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts to reserve for potentially uncollectible trade receivables. The Company also reviews its trade receivables by aging category to identify specific customers with known disputes or collection issues. The Company exercises judgment when determining the adequacy of these reserves as the Company evaluates historical bad debt trends, general economic conditions in the United States and internationally, and changes in customer financial conditions. Uncollectible receivables are recorded as bad debt expense when all efforts to collect have been exhausted and recoveries are recognized when they are received. During the fiscal year ended May 31, 2023, the Company recorded bad debt expense of $24,000. No significant adjustments to the allowance for doubtful accounts were recorded during the fiscal years ended May 31, 2022 or 2021.

 

CONCENTRATION OF CREDIT RISK:

The Company sells its products primarily to semiconductor manufacturers in North America, Asia, and Europe. As of May 31, 2023, approximately 17% and 83% of gross accounts receivable were from customers located in North America and Asia, respectively. As of May 31, 2022, approximately 20% and 80% of gross accounts receivable were from customers located in North America and Asia, respectively. Two customers accounted for 82% and 17% of gross accounts receivable as of May 31, 2023. Three customers accounted for 68%, 18% and 11% of gross accounts receivable as of May 31, 2022. Two customers accounted for 79% and 10% of net sales in fiscal 2023, respectively. One customer accounted for 82% of net sales in fiscal 2022. The Company performs ongoing credit evaluations of its customers and generally does not require collateral. The Company uses letter of credit terms for some of its international customers.

 

The Company’s cash and cash equivalents are generally deposited with major financial institutions in the United States, Philippines, Germany and Taiwan. The Company invests its excess cash in money market funds and U.S. Treasury securities. The money market funds bear the risk associated with each fund. The money market funds have variable interest rates. The Company’s cash and investment balances held at banks and brokerage firms may at time exceed federally insured levels. The Company has not experienced any material losses on its money market funds or short-term cash deposits.

CONCENTRATION OF SUPPLY RISK:

The Company relies on subcontractors to manufacture many of the components and subassemblies used in its products. Quality or performance failures of the Company’s products or changes in its manufacturers’ financial or business condition could disrupt the Company’s ability to supply quality products to its customers and thereby have a material and adverse effect on its business and operating results. Some of the components and technologies used in the Company’s products are purchased and licensed from a single source or a limited number of sources. The loss of any of these suppliers may cause the Company to incur additional transition costs, result in delays in the manufacturing and delivery of its products, or cause it to carry excess or obsolete inventory and could cause it to redesign its products.

INVENTORIES:

Inventories include material, labor and overhead, and are stated at the lower of cost (first-in, first-out method) or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less costs of completion, disposal and transportation. Provisions for excess, obsolete and unusable inventories are made after management’s evaluation of future demand and market conditions. The Company adjusts inventory balances to approximate the lower of its manufacturing costs or net realizable value. If actual future demand or market conditions become less favorable than those projected by management, additional inventory write-downs may be required, and would be reflected in cost of sales in the period the revision is made. During fiscal 2023, 2022 and 2021 the Company recognized a provision for inventory reserves of $569,000, $1,031,000, and $176,000, respectively.

PROPERTY AND EQUIPMENT:

Property and equipment are stated at cost less accumulated depreciation and amortization. Major improvements are capitalized, while repairs and maintenance are expensed as incurred. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the related lease. Furniture and fixtures, machinery and equipment, and test equipment are depreciated on a straight-line basis over their estimated useful lives. The ranges of estimated useful lives are generally as follows:

 

Furniture and fixtures   

2 to 6 years

Machinery and equipment

3 to 6 years

Test equipment  

4 to 6 years

REVENUE RECOGNITION:

The Company recognizes revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by following a five-step process: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price, and (5) recognize revenue when or as the Company satisfies a performance obligation, as further described below.

 

Performance obligations include sales of systems, contactors, spare parts, and services, as well as installation and training services included in customer contracts.

 

A contract’s transaction price is allocated to each distinct performance obligation. In determining the transaction price, the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which the Company expects to be entitled. The Company generally does not grant return privileges, except for defective products during the warranty period.

 

For contracts that contain multiple performance obligations, the Company allocates the transaction price to the performance obligations on a relative standalone selling price basis. Standalone selling prices are based on multiple factors including, but not limited to, historical discounting trends for products and services and pricing practices in different geographies.

 

Revenue for systems and spares are recognized at a point in time, which is generally upon shipment or delivery. Revenue from services is recognized over time as services are completed or ratably over the contractual period of generally one year or less.

 

The Company has elected the practical expedient to not assess whether a contract has a significant financing component as the Company’s standard payment terms are less than one year.

 

We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors.

 

Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services.

PRODUCT DEVELOPMENT COSTS AND CAPITALIZED SOFTWARE:

Costs incurred in the research and development of new products or systems are charged to operations as incurred. Costs incurred in the development of software programs for the Company’s products are charged to operations as incurred until technological feasibility of the software has been established. Generally, technological feasibility is established when the software module performs its primary functions described in its original specifications, contains features required for it to be usable in a production environment, is completely documented and the related hardware portion of the product is complete. After technological feasibility is established, any additional costs are capitalized. Capitalization of software costs ceases when the software is substantially complete and is ready for its intended use. Capitalized costs are amortized over the estimated life of the related software product using the greater of the units of sales or straight-line methods over ten years. No system software development costs were capitalized or amortized in fiscal 2023, 2022 and 2021.

IMPAIRMENT OF LONG-LIVED ASSETS:

In the event that facts and circumstances indicate that the carrying value of assets may be impaired, an evaluation of recoverability would be performed. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset would be compared to the asset’s carrying value to determine if a write-down is required.

ADVERTISING COSTS:

The Company expenses all advertising costs as incurred and the amounts were not material for all periods presented.

SHIPPING AND HANDLING OF PRODUCTS:

Amounts billed to customers for shipping and handling of products are included in net sales. Costs incurred related to shipping and handling of products are included in cost of sales.

INCOME TAXES:

Income taxes are accounted for under the asset-and-liability method as required by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 740, Income Taxes (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. Under ASC 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.

 

As of May 31, 2023 the Company maintained a full valuation allowance against its deferred tax assets. We will continue to assess whether sufficient future taxable income will be generated to permit the use of deferred tax assets, and will reverse all or a portion of the allowance when there is sufficient evidence to support the reversal. Based upon our prior two fiscal years of profitability, the outlook for the next fiscal year, and absent any additional objective negative evidence, the Company anticipates adjusting the current valuation allowance position in fiscal 2024.

 

FASB ASC Subtopic 740-10, Accounting for Uncertainty of Income Taxes, (“ASC 740-10”) defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company’s policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of income taxes.

COMPREHENSIVE INCOME (LOSS):

Comprehensive income (loss) generally represents all changes in shareholders’ equity except those resulting from investments or contributions by shareholders. Unrealized gains and losses from available-for-sale securities and on foreign currency translation adjustments are included in the Company’s components of comprehensive income (loss), which are excluded from net income (loss). In fiscal 2021, the Company recognized a gain of $2,401,000 related to the completed liquidation of ATS-Japan, a majority owned subsidiary, which is deducted from net income (loss) when calculating comprehensive income (loss). Refer to Note 18, “Dissolution of Aehr Test Systems Japan,” for a further discussion of the transaction. Comprehensive income (loss) is included in the statements of comprehensive income (loss).

RECENT ACCOUNTING PRONOUNCEMENTS:

Accounting Standards Not Yet Adopted

 

In June 2016, the FASB issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326), that requires measurement and recognition of expected credit losses for financial assets held based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Due to a subsequent ASU in November 2019, the accounting standard will be effective for the Company beginning in the first quarter of fiscal 2024 on a modified retrospective basis. The Company does not expect a material impact of this accounting standard on its consolidated financial statements.

XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.2
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
May 31, 2023
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Useful life for property and equipment

Furniture and fixtures   

2 to 6 years

Machinery and equipment

3 to 6 years

Test equipment  

4 to 6 years

XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.2
REVENUE (Tables)
12 Months Ended
May 31, 2023
REVENUE  
Disaggregation of revenue

The Company’s revenues by product category are as follows (in thousands):

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Type of good / service:

 

 

 

 

 

 

 

 

 

Systems

 

$38,844

 

 

$25,224

 

 

$7,250

 

Contactors

 

 

21,873

 

 

 

22,647

 

 

 

5,837

 

Services

 

 

4,244

 

 

 

2,958

 

 

 

3,513

 

 

 

$64,961

 

 

$50,829

 

 

$16,600

 

Product lines:

 

 

 

 

 

 

 

 

 

 

 

 

Wafer-level

 

$63,531

 

 

$48,926

 

 

$15,004

 

Test During Burn-In

 

 

1,430

 

 

 

1,903

 

 

 

1,596

 

 

 

$64,961

 

 

$50,829

 

 

$16,600

 

The following presents information about the Company’s operations in different geographic areas.  Net sales are based upon ship-to location (in thousands):

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Geographic region:

 

 

 

 

 

 

 

 

 

United States

 

$9,289

 

 

$5,110

 

 

$5,386

 

Asia

 

 

55,609

 

 

 

45,700

 

 

 

11,074

 

Europe

 

 

63

 

 

 

19

 

 

 

140

 

 

 

$64,961

 

 

$50,829

 

 

$16,600

 

With the exception of the amount of service contracts and extended warranties, the Company’s product category revenues are recognized at point in time when control transfers to customers.  The following presents revenue based on timing of recognition (in thousands):

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Timing of revenue recognition (in thousands):

 

 

 

 

 

 

Products and services transferred at a point in time

 

$63,531

 

 

$49,441

 

 

$15,009

 

Services transferred over time

 

 

1,430

 

 

 

1,388

 

 

 

1,591

 

 

 

$64,961

 

 

$50,829

 

 

$16,600

 

XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.2
EARNINGS PER SHARE (EPS) (Tables)
12 Months Ended
May 31, 2023
EARNINGS PER SHARE (EPS)  
Earnings per share

The following table presents the computation of basic and diluted earnings (net loss) per share attributable to Aehr Test Systems common shareholders (in thousands, except per share data):

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Numerator: Net income (net loss)

 

$14,557

 

 

$9,450

 

 

$(2,027)

 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator for basic earnings (net loss) per share:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

27,785

 

 

 

26,014

 

 

 

23,457

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares used in basic earnings (net loss) per share calculation  

 

 

27,785

 

 

 

26,014

 

 

 

23,457

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Effect of dilutive securities

 

 

1,430

 

 

 

1,760

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator for diluted earnings (net loss) per share

 

 

29,215

 

 

 

27,774

 

 

 

23,457

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic earnings (net loss) per share

 

$0.52

 

 

$0.36

 

 

$(0.09)

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted earnings (net loss) per share

 

$0.50

 

 

$0.34

 

 

$(0.09)
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.2
CASH, CASH EQUIVALENTS AND INVESTMENTS (Tables)
12 Months Ended
May 31, 2023
CASH, CASH EQUIVALENTS AND INVESTMENTS  
Cash, cash equivalents and investments by security type

The following table summarizes the Company’s cash, cash equivalents and investments by security type as of May 31, 2023 (in thousands):

 

 

Cost

 

 

Gross Unrealized Loss

 

 

Estimated Fair Value

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$3,182

 

 

$-

 

 

$3,182

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

 

26,872

 

 

 

-

 

 

 

26,872

 

Total cash and cash equivalents

 

$30,054

 

 

$-

 

 

$30,054

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

$17,870

 

 

$(17)

 

$17,853

 

Long-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$150

 

 

$-

 

 

$150

 

Total cash, cash equivalents and investments

 

$48,074

 

 

$(17)

 

$48,057

 

The following table summarizes the Company’s cash, cash equivalents and investments by security type as of May 31, 2022 (in thousands):

 

 

 

Cost

 

 

Gross Unrealized Loss

 

 

Estimated Fair Value

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$2,955

 

 

$-

 

 

$2,955

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

 

28,529

 

 

 

-

 

 

 

28,529

 

Total cash and cash equivalents

 

$31,484

 

 

$-

 

 

$31,484

 

Long-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$80

 

 

$-

 

 

$80

 

Total cash, cash equivalents and investments

 

$31,564

 

 

$-

 

 

$31,564

 

XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)
12 Months Ended
May 31, 2023
FAIR VALUE OF FINANCIAL INSTRUMENTS  
Fair value by hierarchy

The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of May 31, 2023 (in thousands):

 

 

Balance as of

 

 

 

 

 

 

 

 

 

 

 

May 31, 2023

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Money market funds

 

$27,022

 

 

$27,022

 

 

$-

 

 

$-

 

U.S. treasury securities

 

 

17,853

 

 

 

17,853

 

 

 

 

 

 

 

 

 

Total

 

$44,875

 

 

$44,875

 

 

$-

 

 

$-

 

The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of May 31, 2022 (in thousands):

 

 

 

Balance as of

 

 

 

 

 

 

 

 

 

 

 

May 31, 2022

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Money market funds

 

$28,609

 

 

$28,609

 

 

$-

 

 

$-

 

Total

 

$28,609

 

 

$28,609

 

 

$-

 

 

$-

 

XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.2
TRADE AND OTHER ACCOUNTS RECEIVABLE, NET (Tables)
12 Months Ended
May 31, 2023
TRADE AND OTHER ACCOUNTS RECEIVABLE, NET  
Accounts receivable

Accounts receivable comprise (in thousands):

 

 

May 31,

 

 

 

2023

 

 

2022

 

Accounts receivable

 

$16,594

 

 

$12,859

 

Less: Allowance for doubtful accounts

 

 

-

 

 

 

-

 

 

 

$16,594

 

 

$12,859

 

XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.2
BALANCE SHEET DETAIL (Tables)
12 Months Ended
May 31, 2023
BALANCE SHEET DETAIL  
Inventories

INVENTORIES:     

 May 31,

 

(In Thousands)

 

2023

 

 

2022

 

Raw materials and sub-assemblies

 

$15,953

 

 

$9,507

 

Work in process

 

 

5,764

 

 

 

5,461

 

Finished goods

 

 

2,191

 

 

 

83

 

 

 

$23,908

 

 

$15,051

 

Property and equipment, net

PROPERTY AND EQUIPMENT, NET:  

 

 

 May 31,

 

(In Thousands)

 

2023

 

 

2022

 

Leasehold improvements

 

$1,310

 

 

$1,230

 

Furniture and fixtures

 

 

706

 

 

 

697

 

Machinery and equipment

 

 

5,445

 

 

 

4,013

 

Test equipment

 

 

2,998

 

 

 

2,523

 

 

 

 

10,459

 

 

 

8,463

 

Less: Accumulated depreciation and amortization

 

 

(7,700)

 

 

(7,260)

 

 

$2,759

 

 

$1,203

 

Accrued expenses

ACCRUED EXPENSES:

 

 

 May 31,

 

(In Thousands)

 

2023

 

 

2022

 

Commissions and bonuses

 

$1,728

 

 

$1,505

 

Payroll related

 

 

1,491

 

 

 

1,401

 

Warranty

 

 

267

 

 

 

410

 

Professional services

 

 

520

 

 

 

204

 

Investor relations

 

 

79

 

 

 

44

 

Taxes payable

 

 

22

 

 

 

13

 

Other

 

 

36

 

 

 

33

 

 

 

$4,143

 

 

$3,610

 

Customer deposits and deferred revenue, short-term

CUSTOMER DEPOSITS AND DEFERRED REVENUE, SHORT-TERM:   

 

 

 May 31,

 

(In Thousands)

 

2023

 

 

2022

 

Customer deposits

 

$2,690

 

 

$2,263

 

Deferred revenue  

 

 

132

 

 

 

152

 

 

 

$2,822

 

 

$2,415

 

XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.2
ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)
12 Months Ended
May 31, 2023
ACCUMULATED OTHER COMPREHENSIVE LOSS  
Schedule of Changes in the components of accumulated other comprehensive loss, net of tax

Changes in the components of accumulated other comprehensive loss, net of tax, were as follows (in thousands):

 

 

Cumulative Translation Adjustments

 

 

Unrealized Loss on Investments, Net

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

Balance as of May 31, 2021

 

$(28)

 

$-

 

 

$(28)

Other comprehensive loss before reclassifications

 

 

(77)

 

 

-

 

 

 

(77)

Balance as of May 31, 2022

 

 

(105)

 

 

-

 

 

 

(105)

Other comprehensive loss before reclassifications

 

 

(33)

 

 

(17)

 

 

(50)

Balance as of May 31, 2023

 

$(138)

 

$(17)

 

$(155)
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.2
INCOME TAXES (Tables)
12 Months Ended
May 31, 2023
INCOME TAXES  
Domestic and foreign components of loss before income tax (expense) benefit

Domestic and foreign components of income (loss) before income tax (expense) benefit are as follows (in thousands):

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Domestic

 

$14,541

 

 

$9,416

 

 

$(13,064)

Foreign

 

 

76

 

 

 

125

 

 

 

10,860

 

 

 

$14,617

 

 

$9,541

 

 

$(2,204)
Income tax (expense) benefit

 

The income tax (expense) benefit consists of the following (in thousands):

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Federal income taxes:

 

 

 

 

 

 

 

 

 

Current

 

$(28)

 

$(59)

 

$163

 

Deferred

 

 

-

 

 

 

-

 

 

 

-

 

State income taxes:

 

 

 

 

 

 

 

 

 

 

 

 

Current

 

 

-

 

 

 

(5)

 

 

13

 

Deferred

 

 

-

 

 

 

-

 

 

 

-

 

Foreign income taxes:

 

 

 

 

 

 

 

 

 

 

 

 

Current

 

 

(32)

 

 

(27)

 

 

1

 

Deferred

 

 

-

 

 

 

-

 

 

 

-

 

 

 

$(60)

 

$(91)

 

$177

 

Income tax reconciliation

The Company’s effective tax rate differs from the U.S. federal statutory tax rate, as follows:

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

U.S. federal statutory tax rate

 

 

21.0%

 

 

21.0%

 

 

21.0%

State taxes, net of federal tax effect

 

 

-

 

 

 

0.1

 

 

 

0.6

 

Foreign rate differential

 

 

0.7

 

 

 

0.3

 

 

 

9.8

 

Stock-based compensation

 

 

(9.1)

 

 

(11.0)

 

 

(4.7)

Research and development credit

 

 

(2.3)

 

 

(1.3)

 

 

4.0

 

Change in valuation allowance

 

 

(9.3)

 

 

(4.7)

 

 

(32.1)

Controlled Foreign Corporation Liquidation. .

 

 

-

 

 

 

-

 

 

 

9.8

 

PPP Loan

 

 

-

 

 

 

(3.7)

 

 

-

 

Other

 

 

(0.6)

 

 

0.4

 

 

 

(0.4)

Effective tax rate

 

 

0.4%

 

 

1.1%

 

 

8.0%
Net deferred tax assets and liabilities

The components of the net deferred tax assets and liabilities are as follows (in thousands):

 

 

Year Ended May 31,

 

 

 

         2023

 

 

2022

 

Deferred tax assets:

 

 

 

 

 

 

Net operating losses

 

$11,964

 

 

$14,912

 

Lease liability

 

 

1,335

 

 

 

218

 

Credit carryforwards

 

 

6,235

 

 

 

5,535

 

Inventory reserves

 

 

938

 

 

 

934

 

Reserves and accruals

 

 

1,200

 

 

 

1,360

 

Capitalized research and development

 

 

1,187

 

 

 

-

 

Other

 

 

297

 

 

 

220

 

Less: valuation allowance

 

 

(21,859)

 

 

(22,980)

 

 

 

1,297

 

 

 

199

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

Operating lease right-of-use assets

 

 

(1,297)

 

 

(199)

Net deferred tax assets (liabilities)

 

$-

 

 

$-

 

Unrecognized tax benefits

The aggregate changes in the balance of gross unrecognized tax benefits are as follows (in thousands):

 

Beginning balance as of May 31, 2020

 

$1,852

 

 

 

 

 

 

Increases related to prior year tax positions

 

 

11

 

Increases related to current year tax positions

 

 

65

 

 

 

 

 

 

Balance at May 31, 2021

 

 

1,928

 

 

 

 

 

 

Increases related to prior year tax positions

 

 

12

 

Increases related to current year tax positions

 

 

78

 

 

 

 

 

 

Balance at May 31, 2022

 

 

2,018

 

 

 

 

 

 

Increases related to prior year tax positions

 

 

90

 

Increases related to current year tax positions

 

 

168

 

 

 

 

 

 

Balance at May 31, 2023

 

$2,276

 

XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.2
LEASES (Tables)
12 Months Ended
May 31, 2023
LEASES  
Supplemental cash flow information related to leases

The following table presents supplemental cash flow information related to the Company’s operating leases (in thousands):

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Cash paid for amounts included in the measurement of operating lease liabilities:

 

 

 

 

 

 

 

 

 

Operating cash flows from operating leases

 

$835

 

 

$813

 

 

$779

 

Maturity of operating lease liabilities

    The following table presents the maturities of the Company’s operating lease liabilities as of May 31, 2023 (in thousands):

Fiscal year

 

Operating Leases

 

2024

 

$608

 

2025

 

 

1,143

 

2026

 

 

1,174

 

2027

 

 

1,195

 

2028

 

 

1,234

 

Thereafter

 

 

3,075

 

Total future minimum operating lease payments

 

 

8,429

 

Less: imputed interest

 

 

(2,129)

Present value of operating lease liabilities

 

$6,300

 

XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK-BASED COMPENSATION (Tables)
12 Months Ended
May 31, 2023
STOCK-BASED COMPENSATION  
Compensation costs related to the Company's stock-based compensation

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Stock-based compensation in the form of stock options,

 

 

 

 

 

 

 

 

 

RSUs, and ESPP purchase rights, included in:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales

 

$331

 

 

$234

 

 

$70

 

Selling, general and administrative

 

 

1,711

 

 

 

1,721

 

 

 

816

 

Research and development

 

 

706

 

 

 

968

 

 

 

215

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net effect on net income (loss)

 

$2,748

 

 

$2,923

 

 

$1,101

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Effect on earnings (net loss) per share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$0.10

 

 

$0.11

 

 

$0.05

 

Diluted

 

$0.09

 

 

$0.11

 

 

$0.05

 

Fair value assumptions for Option Valuation Model

Fair Value. The fair values of the Company’s stock options granted to employees in fiscal 2023, 2022 and 2021 were estimated using the following weighted average assumptions in the Black-Scholes option valuation method:

 

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

Expected term (in years)

 

5 - 6

 

 

5 - 6

 

 

 

6

 

Volatility

 

 

86%

 

 

88%

 

 

72%

Risk-free interest rates

 

 

3.12%

 

 

1.50%

 

 

0.44%

Weighted average grant date fair value

 

$6.29

 

 

$4.01

 

 

$1.12

 

Fair value assumption of the ESPP Purchase Rights

The fair value of our ESPP purchase rights for the fiscal 2023, 2022 and 2021 was estimated using the following weighted average assumptions:

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

Expected term (in years)

 

0.5 – 2.0

 

 

0.5 – 2.0

 

 

0.5 – 2.0

 

Volatility

 

91% – 203

 

101% – 272

 

74% – 88

%

Risk-free interest rates

 

3.97%–4.94

 

0.05%–2.44

 

0.04%–0.17

Weighted average grant date fair value

 

$13.60

 

 

$9.68

 

 

$1.03

 

Stock option and RSU transactions

The following tables summarize the Company’s stock option and RSU transactions during fiscal 2023, 2022 and 2021 (in thousands):

Available

Shares

Balance, May 31, 2020

1,416

Options granted

(297)

RSUs granted

(680)

RSUs cancelled

2

Shares withheld for taxes and not issued

18

Options terminated

455

Options expired

(341)

Balance, May 31, 2021

573

Additional shares reserved

1,414

Options granted

(303)

RSUs granted

(1,044)

RSUs cancelled

20

Shares withheld for taxes and not issued

(30)

Options terminated

105

Balance, May 31, 2022

735

Options granted

(110)

RSUs granted

(674)

RSUs cancelled

60

Options terminated

16

Balance, May 31, 2023

27
Stock option transactions

The following table summarized the stock option transactions during fiscal 2023, 2022 and 2021 (in thousands, except per share data):

 

 

Outstanding Options

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

Number

 

 

Average

 

 

Aggregate

 

 

 

of

 

 

Exercise

 

 

Intrinsic

 

 

 

Shares

 

 

Price

 

 

Value

 

Balances, May 31, 2020

 

 

3,153

 

 

$2.17

 

 

$102

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options granted

 

 

297

 

 

$1.78

 

 

 

 

 

Options terminated

 

 

(455)

 

$2.31

 

 

 

 

 

Options exercised

 

 

(229)

 

$1.54

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, May 31, 2021

 

 

2,766

 

 

$2.16

 

 

$807

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options granted

 

 

303

 

 

$5.37

 

 

 

 

 

Options terminated

 

 

(105)

 

$1.59

 

 

 

 

 

Options exercised

 

 

(1,367)

 

$2.28

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, May 31, 2022

 

 

1,597

 

 

$2.70

 

 

$9,290

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options granted

 

 

110

 

 

$9.06

 

 

 

 

 

Options terminated

 

 

(16)

 

$5.42

 

 

 

 

 

Options exercised

 

 

(730)

 

$2.32

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, May 31, 2023

 

 

961

 

 

$3.67

 

 

$28,211

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options fully vested and expected to vest at May 31, 2023

 

 

947

 

 

$3.66

 

 

$27,796

 

Options outstanding

 

The options outstanding and exercisable at May 31, 2023 were in the following exercise price ranges (in thousands, except per share data):

 

 

 

Options Outstanding

 

 

                       Options Exercisable

 

 

 

 

at May 31, 2023

 

 

                           at May 31, 2023

 

Range of Exercise

Prices

 

 

Number Outstanding Shares

 

 

Weighted Average Remaining Contractual Life (Years)

 

 

Weighted Average Exercise Price

 

 

Number Exercisable Shares

 

 

Weighted Average Remaining Contractual Life (Years)

 

 

Weighted Average Exercise Price

 

 

Aggregate Intrinsic Value

 

$1.34

 

 

 

41

 

 

 

4.39

 

 

$1.34

 

 

 

41

 

 

 

4.39

 

 

$1.34

 

 

 

 

$1.64-$1.86

 

 

 

365

 

 

 

3.53

 

 

$1.72

 

 

 

291

 

 

 

3.45

 

 

$1.70

 

 

 

 

$2.03-$2.40

 

 

 

185

 

 

 

2.61

 

 

$2.14

 

 

 

175

 

 

 

2.48

 

 

$2.14

 

 

 

 

$2.93

 

 

 

139

 

 

 

5.12

 

 

$2.93

 

 

 

35

 

 

 

5.12

 

 

$2.93

 

 

 

 

$3.46-$3.93

 

 

 

37

 

 

 

1.11

 

 

$3.93

 

 

 

37

 

 

 

1.11

 

 

$3.93

 

 

 

 

$8.00-34.00

 

 

 

194

 

 

 

5.97

 

 

$9.77

 

 

 

41

 

 

 

5.90

 

 

$10.18

 

 

 

 

$1.34-34.00

 

 

 

961

 

 

 

4.02

 

 

$3.67

 

 

 

620

 

 

 

3.35

 

 

$2.56

 

 

$18,895

 

RSUs, PRSUs, restricted shares and performance restricted shares granted

The following table summarizes RSUs, PRSUs, restricted shares and performance restricted shares granted to employees and members of the Company’s Board of Directors during fiscal 2023, 2022 and 2021:

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Employees:

 

 

 

 

 

 

 

 

 

Annual RSUs granted

 

 

152,000

 

 

 

120,000

 

 

 

161,000

 

Weighted-average grant-date fair value of annual RSUs

 

$8.03

 

 

$3.17

 

 

$1.86

 

Annual restricted shares granted

 

 

8,000

 

 

 

-

 

 

 

-

 

Weighted-average grant-date fair value of annual restricted shares  

 

$8.00

 

 

 

-

 

 

 

-

 

RSUs granted in lieu of cash payment for salary reductions and bonus

 

 

-

 

 

 

89,000

 

 

 

18,000

 

Weighted-average grant-date value of RSU in lieu of cash payment

 

 

-

 

 

$2.50

 

 

$2.21

 

Maximum PRSUs to be vested if all revenue goals are achieved

 

 

80,000

 

 

 

270,000

 

 

 

-

 

Maximum Performance restricted shares to be vested if all revenue goals are achieved

 

 

24,000

 

 

 

-

 

 

 

-

 

Weighted-average grant-date fair value of PRSUs and performance restricted shares

 

$8.00

 

 

$3.41

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Members of Board of Directors:

 

 

 

 

 

 

 

 

 

 

 

 

RSUs granted

 

 

44,000

 

 

 

43,000

 

 

 

161,000

 

Weighted-average grant-date fair value of RSUs

 

$11.35

 

 

$8.02

 

 

$1.81

 

Maximum PRSUs granted to be vested if all revenue goals are achieved

 

 

25,000

 

 

 

-

 

 

 

-

 

Weighted-average grant-date fair value of PRSUs

 

$8.00

 

 

 

-

 

 

 

-

 

RSUs and PRSUs vested and unvested

The following table summarizes the RSUs and PRSUs vested and unvested during fiscal 2023, 2022 and 2021:

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Net RSUs and PRSUs vested

 

 

240,000

 

 

 

96,000

 

 

 

207,000

 

Shares withheld to settle payroll taxes  

 

 

178,000

 

 

 

62,000

 

 

 

9,000

 

Weighted average grant-date fair value of vested RSUs and PRSUs

 

$4.47

 

 

$3.12

 

 

$1.90

 

RSUs and PRSUs cancelled

 

 

30,000

 

 

 

10,000

 

 

 

1,000

 

Weighted average grant-date fair value of cancelled RSUs and PRSUs

 

$8.56

 

 

$2.93

 

 

$3.46

 

RSUs and PRSUs unvested

 

 

345,000

 

 

 

185,000

 

 

 

132,000

 

Weighted average grant-date fair value of unvested RSUs and PRSUs

 

$6.40

 

 

$3.00

 

 

$1.88

 

Intrinsic value of unvested RSUs and PRSUs (in thousands)

 

$11,392

 

 

$1,554

 

 

$297

 

XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.2
OTHER INCOME (EXPENSE) NET (Tables)
12 Months Ended
May 31, 2023
OTHER INCOME (EXPENSE) NET  
Other income (expense), net

Other (expense) income, net comprises the following (in thousands):

 

 

Year Ended May 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Foreign exchange (loss) gain

 

$(3)

 

$32

 

 

$(111)

Other expense, net

 

 

-

 

 

(2)

 

 

(51)

 

 

$(3)

 

$30

 

 

$(162)
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.2
PRODUCT WARRANTIES (Tables)
12 Months Ended
May 31, 2023
PRODUCT WARRANTIES  
Liability for product warranties

Following is a summary of changes in the Company’s liability for product warranties during the fiscal years ended May 31, 2023 and 2022 (in thousands):

 

 

 May 31,

 

 

 

2023

 

 

2022

 

 

 

 

 

 

 

 

Balance at the beginning of the year

 

$410

 

 

$494

 

Accruals for warranties issued during the year

 

 

420

 

 

 

465

 

Adjustment to previously existing warranty

 

 

61

 

 

 

98

 

Consumption of reserves

 

 

(624)

 

 

(647)

 

 

 

 

 

 

 

 

 

Balance at the end of the year

 

$267

 

 

$410

 

XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.2
SEGMENT INFORMATION (Tables)
12 Months Ended
May 31, 2023
SEGMENT INFORMATION  
Property and equipment by geographic region

Property and equipment information is based on the physical location of the assets. The following table presents property and equipment information for geographic areas (in thousands):

 

 

May 31,

 

 

 

2023

 

 

2022

 

United States

 

$2,713

 

 

$1,156

 

Asia

 

 

44

 

 

 

47

 

Europe

 

 

2

 

 

 

-

 

 

 

$2,759

 

 

$1,203

 

XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.2
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)
May 31, 2023
Maximum | Furniture and Fixtures  
Useful life 6 years
Maximum | Machinery and Equipment  
Useful life 6 years
Maximum | Test Equipment  
Useful life 6 years
Minimum | Furniture and Fixtures  
Useful life 2 years
Minimum | Machinery and Equipment  
Useful life 3 years
Minimum | Test Equipment  
Useful life 4 years
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.2
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
Allowance for doubtful accounts $ 24,000 $ 0 $ 0
Provision for inventory reserves $ 569,000 $ 1,031,000 176,000
Gain related to completed liquidation of ATS-Japan     $ 2,401,000
Accounts Receivable | North America      
Concentration risk 17.00% 20.00%  
Accounts Receivable | Asia      
Concentration risk 83.00% 80.00%  
Accounts Receivable | Customer One      
Concentration risk 82.00% 68.00%  
Accounts Receivable | Customer Two      
Concentration risk 17.00% 18.00%  
Accounts Receivable | Customer Three      
Concentration risk   11.00%  
Net Sales | Customer One      
Concentration risk 79.00% 82.00%  
Net Sales | Customer Two      
Concentration risk 10.00%    
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.2
REVENUE (Details) - USD ($)
$ in Thousands
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
Net sales $ 64,961 $ 50,829 $ 16,600
Systems [Member]      
Net sales 38,844 25,224 7,250
Test During Burn-In. [Member]      
Net sales 1,430 1,903 1,596
Wafer-level [Member]      
Net sales 63,531 48,926 15,004
Services [Member]      
Net sales 4,244 2,958 3,513
Contactors [Member]      
Net sales 21,873 22,647 5,837
Total Product line [Member]      
Net sales $ 64,961 $ 50,829 $ 16,600
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.2
REVENUE (Details 1) - USD ($)
$ in Thousands
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
Net sales $ 64,961 $ 50,829 $ 16,600
Asia      
Net sales 55,609 45,700 11,074
Europe      
Net sales 63 19 140
United States      
Net sales $ 9,289 $ 5,110 $ 5,386
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.2
REVENUE (Details 2) - USD ($)
$ in Thousands
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
Net sales $ 64,961 $ 50,829 $ 16,600
Products And Services Transferred At A Point In Time [Member]      
Net sales 63,531 49,441 15,009
Services Transferred over Time [Member]      
Net sales $ 1,430 $ 1,388 $ 1,591
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.2
REVENUE (Details Narrative) - USD ($)
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2025
May 31, 2024
Contract liabilities $ 2,853,000 $ 2,484,000    
Recognition of contract liabilities 2,179,000 $ 189,000    
Remaining performance obligations $ 163,000      
Scenario Forecast [Member]        
Remaining performance obligation revenue recognition     19.00% 81.00%
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.2
EARNINGS PER SHARE (EPS) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
EARNINGS PER SHARE (EPS)      
Net Income (Loss) $ 14,557 $ 9,450 $ (2,027)
Weighted average shares outstanding 27,785 26,014 23,457
Shares used in basic net income (loss) per share calculation 27,785 26,014 23,457
Effect of dilutive securities 1,430 1,760  
Denominator for diluted net income (loss) per share 29,215 27,774 23,457
Basic net income (loss) per share $ 0.52 $ 0.36 $ (0.09)
Diluted net income (loss) per share $ 0.50 $ 0.34 $ (0.09)
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.2
EARNINGS PER SHARE (EPS) (Details Narrative) - shares
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
Employee Stock Purchase Plan      
Options not included in the computation of diluted net loss per share (in thousands)     239,000
Stock Option      
Options not included in the computation of diluted net loss per share (in thousands) 5,000 64,000 2,766,000
Restricted Stock Units      
Options not included in the computation of diluted net loss per share (in thousands)     132,000
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.2
CASH CASH EQUIVALENTS AND INVESTMENTS (Details) - USD ($)
$ in Thousands
May 31, 2023
May 31, 2022
Total cash and cash equivalents $ 30,054 $ 31,484
Cost [Member]    
Cash 3,182 2,955
Total cash and cash equivalents 30,054 31,484
Total cash, cash equivalents and investments 48,074 31,564
Total cash, cash equivalents and investments (48,074) (31,564)
Cost [Member] | Money Market Funds    
Cash equivalents 26,872 28,529
Long-term investments 150 80
Cost [Member] | U S Treasury Securities [Member]    
Short-term Investments 17,870  
Short-term Investments (17,870)  
Gross Unrealized Loss    
Cash 0 0
Total cash and cash equivalents 0 0
Total cash, cash equivalents and investments 17 0
Total cash, cash equivalents and investments (17) 0
Gross Unrealized Loss | Money Market Funds    
Cash equivalents 0 0
Long-term investments 0 0
Gross Unrealized Loss | U S Treasury Securities [Member]    
Short-term Investments 17  
Short-term Investments (17)  
Estimated Fair Value [Member]    
Cash 3,182 2,955
Total cash and cash equivalents 30,054 31,484
Total cash, cash equivalents and investments 48,057 31,564
Total cash, cash equivalents and investments (48,057) (31,564)
Estimated Fair Value [Member] | Money Market Funds    
Cash equivalents 26,872 28,529
Long-term investments 150 $ 80
Estimated Fair Value [Member] | U S Treasury Securities [Member]    
Short-term Investments 17,853  
Short-term Investments $ (17,853)  
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.2
CASH CASH EQUIVALENTS AND INVESTMENTS (Details Narrative)
12 Months Ended
May 31, 2023
USD ($)
Net unrealized loss on investments $ (17,000)
Gross Unrealized Loss  
Net unrealized loss on investments $ 17,000
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($)
May 31, 2023
May 31, 2022
Assets [Member]    
Investment securities $ 44,875,000 $ 28,609,000
U.S. treasury securities    
Investment securities 17,853,000  
Level 1 [Member] | Assets [Member]    
Investment securities 44,875,000 28,609,000
Level 2 [Member] | Assets [Member]    
Investment securities 0 0
Level 3 [Member] | Assets [Member]    
Investment securities 0 0
Money Market Funds    
Investment securities 27,022,000 28,609,000
Money Market Funds | Level 1 [Member]    
Investment securities 27,022,000 28,609,000
Money Market Funds | Level 2 [Member]    
Investment securities 0 0
Money Market Funds | Level 3 [Member]    
Investment securities 0 $ 0
US Treasury Securities | Level 1 [Member]    
Investment securities 17,853,000  
US Treasury Securities | Level 2 [Member]    
Investment securities 0  
US Treasury Securities | Level 3 [Member]    
Investment securities $ 0  
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE OF FINANCIAL INSTRUMENTS (Details Narrative) - USD ($)
May 31, 2023
May 31, 2022
FAIR VALUE OF FINANCIAL INSTRUMENTS    
Transfer between Level 1 and Level 2 fair value measurements $ 0 $ 0
Restricted cash 150,000 80,000
Financial liabilities at fair value $ 0 $ 0
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.23.2
TRADE AND OTHER ACCOUNTS RECEIVABLE, NET (Details) - USD ($)
$ in Thousands
May 31, 2023
May 31, 2022
TRADE AND OTHER ACCOUNTS RECEIVABLE, NET    
Accounts receivable $ 16,594 $ 12,859
Less: Allowance for doubtful accounts 0 0
Accounts Receivable, net $ 16,594 $ 12,859
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.2
BALANCE SHEET DETAIL (Details) - USD ($)
$ in Thousands
May 31, 2023
May 31, 2022
BALANCE SHEET DETAIL    
Raw materials and sub-assemblies $ 15,953 $ 9,507
Work in process 5,764 5,461
Finished goods 2,191 83
Inventories $ 23,908 $ 15,051
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.23.2
BALANCE SHEET DETAIL (Details 1) - USD ($)
$ in Thousands
May 31, 2023
May 31, 2022
BALANCE SHEET DETAIL    
Leasehold improvements $ 1,310 $ 1,230
Furniture and fixtures 706 697
Machinery and equipment 5,445 4,013
Test equipment 2,998 2,523
Property and equipment, gross 10,459 8,463
Less: Accumulated depreciation and amortization (7,700) (7,260)
Property and equipment, net $ 2,759 $ 1,203
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.23.2
BALANCE SHEET DETAIL (Details 2) - USD ($)
$ in Thousands
May 31, 2023
May 31, 2022
May 31, 2021
BALANCE SHEET DETAIL      
Commissions and bonuses $ 1,728 $ 1,505  
Payroll related 1,491 1,401  
Warranty 267 410 $ 494
Professional services 520 204  
Investor relations 79 44  
Taxes payable 22 13  
Other 36 33  
Accrued expenses $ 4,143 $ 3,610  
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.23.2
BALANCE SHEET DETAIL (Details 3) - USD ($)
$ in Thousands
May 31, 2023
May 31, 2022
BALANCE SHEET DETAIL    
Customer deposits $ 2,690 $ 2,263
Deferred revenue 132 152
Customer deposits and deferred revenue $ 2,822 $ 2,415
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.23.2
BALANCE SHEET DETAIL (Details Narrative) - USD ($)
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
BALANCE SHEET DETAIL      
Depreciation expense $ 450,000 $ 307,000 $ 310,000
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.23.2
ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) - USD ($)
$ in Thousands
12 Months Ended
May 31, 2023
May 31, 2022
Balance at the beginning of the year $ (105) $ (28)
Other comprehensive loss before reclassifications (50) (77)
Balance at the ending of the year (155) (105)
Unrealized Loss on Investments Net [Member]    
Balance at the beginning of the year 0 0
Other comprehensive loss before reclassifications (17) 0
Balance at the ending of the year (17) 0
Cumulative Translation Adjustments [Member]    
Balance at the beginning of the year (105) (28)
Other comprehensive loss before reclassifications (33) (77)
Balance at the ending of the year $ (138) $ (105)
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.23.2
INCOME TAXES (Details) - USD ($)
$ in Thousands
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
INCOME TAXES      
Domestic $ 14,541 $ 9,416 $ (13,064)
Foreign 76 125 10,860
Income (loss) before income tax (expense) benefit $ 14,617 $ 9,541 $ (2,204)
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.23.2
INCOME TAXES (Details 1) - USD ($)
$ in Thousands
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
Federal income taxes:      
Current $ (28) $ (59) $ 163
Deferred 0 0 0
State income taxes:      
Current 0 (5) 13
Deferred 0 0 0
Foreign income taxes:      
Current (32) (27) 1
Deferred 0 0 0
Income tax (expense) benefit $ (60) $ (91) $ 177
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.23.2
INCOME TAXES (Details 2)
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
INCOME TAXES      
U.S. federal statutory tax rate 21.00% 21.00% 21.00%
State taxes, net of federal tax effect 0.00% 0.10% 0.60%
Foreign rate differential 0.70% 0.30% 9.80%
Stock-based compensation (9.10%) (11.00%) (4.70%)
Research and development credit (2.30%) (1.30%) 4.00%
Change in valuation allowance (9.30%) (4.70%) (32.10%)
Controlled Foreign Corporation Liquidation 0.00% 0.00% 9.80%
PPP Loan 0.00% (3.70%) 0.00%
Other (0.60%) 0.40% (0.40%)
Effective tax rate 0.40% 1.10% 8.00%
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.23.2
INCOME TAXES (Details 3) - USD ($)
$ in Thousands
May 31, 2023
May 31, 2022
Deferred tax assets:    
Net operating losses $ 11,964 $ 14,912
Lease liability 1,335 218
Credit carryforwards 6,235 5,535
Inventory reserves 938 934
Reserves and accruals 1,200 1,360
Capitalized research and development 1,187 0
Other 297 220
Less: Valuation allowance (21,859) (22,980)
Deferred tax assets 1,297 199
Deferred tax liabilities:    
Operating lease right-of-use assets 1,297 199
Net deferred tax assets (liabilities) $ 0 $ 0
XML 76 R66.htm IDEA: XBRL DOCUMENT v3.23.2
INCOME TAXES (Details 4) - USD ($)
$ in Thousands
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
INCOME TAXES      
Unrecognized tax benefit, beginning $ 2,018 $ 1,928 $ 1,852
Increases related to prior year tax positions 90 12 11
Increases related to current year tax positions 168 78 65
Unrecognized tax benefit, ending $ 2,276 $ 2,018 $ 1,928
XML 77 R67.htm IDEA: XBRL DOCUMENT v3.23.2
INCOME TAXES (Details Narrative) - USD ($)
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
Valuation allowance $ (1,121,000) $ (278,000) $ 2,438,000
Federal      
Net operating loss carryforward (46,967,000) (61,068,000)  
Research and development tax credit carryforwards 2,923,000 2,362,000  
Alternative minimum tax credit carryforwards 14,425,000    
State      
Net operating loss carryforward (30,203,000) (30,043,000)  
Research and development tax credit carryforwards 6,623,000 $ 6,152,000  
Alternative minimum tax credit carryforwards $ 34,000    
XML 78 R68.htm IDEA: XBRL DOCUMENT v3.23.2
LEASES (Details) - USD ($)
$ in Thousands
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
Cash paid for amounts included in measurement of operating lease liabilities:      
Operating cash flows for operating leases $ 835 $ 813 $ 779
XML 79 R69.htm IDEA: XBRL DOCUMENT v3.23.2
LEASES (Details 1)
$ in Thousands
May 31, 2023
USD ($)
LEASES  
2024 $ 608
2025 1,143
2026 1,174
2027 1,195
2028 1,234
Thereafter 3,075
Total future minimum operating lease payments 8,429
Less: imputed interest (2,129)
Present value of operating lease liabilities $ 6,300
XML 80 R70.htm IDEA: XBRL DOCUMENT v3.23.2
LEASES (Details Narrative) - USD ($)
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
Operating lease, weighted-average discount rate 7.50%    
Operating lease, weighted-average remaining lease term 7 years 3 months 18 days    
Operating lease, cost $ 923,000 $ 766,000 $ 761,000
Increase in operating lease liabilities $ 5,900,000    
Maximum [Member]      
Operating lease term 1 year    
Minimum [Member]      
Operating lease term 7 years    
XML 81 R71.htm IDEA: XBRL DOCUMENT v3.23.2
BORROWING AND FINANCING ARRANGEMENTS (Details Narrative) - USD ($)
12 Months Ended
May 31, 2023
Nov. 30, 2023
Original Loan and Security Agreement    
Line of Credit, maximum borrowing $ 4,000,000.0  
Balance available to borrow under the line of credit $ 8,004,000  
Variable interest rate the greater of (a) the prime rate plus an additional percentage of up to 1%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 4.75%  
Second Amendment To Loan And Security Agreement    
Line of Credit, maximum borrowing $ 10,000,000  
Variable interest rate the greater of (a) prime rate plus an additional percentage up to 1.0%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 3.25%,  
Revolving line maturity date Jan. 13, 2023  
First Amendment to Loan and Security Agreement    
Revolving line maturity date Jan. 13, 2022  
Third Amendment to Loan and Security Agreement    
Revolving line maturity date Jan. 13, 2025  
Third Amendment to Loan and Security Agreement | Subsequent Event    
Minimum liquidity net   $ 20,000,000
XML 82 R72.htm IDEA: XBRL DOCUMENT v3.23.2
LONGTERM DEBT (Details Narrative) - Silicon Valley Bank - USD ($)
Jun. 12, 2021
Apr. 23, 2020
PPP loan   $ 1,679,000
Interest rate   1.00%
PPP Loan balance $ 1,679,000  
Total interest 19,000  
Recognized a gain on loan forgiveness $ 1,698,000  
XML 83 R73.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK-BASED COMPENSATION (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
Net stock-based compensation $ 2,748 $ 2,923 $ 1,101
Effect on net loss per share, basic $ 0.10 $ 0.11 $ 0.05
Effect on net loss per share, diluted $ 0.09 $ 0.11 $ 0.05
Cost of Sales      
Total stock-based compensation $ 331 $ 234 $ 70
Selling, General and Administrative      
Total stock-based compensation 1,711 1,721 816
Research and Development      
Total stock-based compensation $ 706 $ 968 $ 215
XML 84 R74.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK-BASED COMPENSATION (Details 1) - Stock Option - $ / shares
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
Expected term (in years)     6 years
Volatility 86.00% 88.00% 72.00%
Risk-free interest rates 3.12% 1.50% 0.44%
Weighted-average grant date fair value $ 6.29 $ 4.01 $ 1.12
Minimum [Member]      
Expected term (in years) 5 years 5 years  
Maximum [Member]      
Expected term (in years) 6 years 6 years  
XML 85 R75.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK-BASED COMPENSATION (Details 2) - Employee Stock Purchase Plan - $ / shares
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
Weighted-average grant date fair value $ 13.60 $ 9.68 $ 1.03
Minimum [Member]      
Expected term (in years) 6 months 6 months 6 months
Volatility 91.00% 101.00% 74.00%
Risk-free interest rates 3.97% 0.05% 0.04%
Maximum [Member]      
Expected term (in years) 2 years 2 years 2 years
Volatility 203.00% 272.00% 88.00%
Risk-free interest rates 4.94% 2.44% 0.17%
XML 86 R76.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK-BASED COMPENSATION (Details 3) - shares
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
Shares withheld for tax and not issued (in thousands) 178,000 62,000 9,000
Stock Option and RSU Transactions      
Available shares, beginning (in thousands) 735,000 573,000 1,416,000
Additional shares reserved (in thousands)   1,414,000  
Options granted (in thousands) (110,000) (303,000) (297,000)
Annual RSUs granted (674,000) (1,044,000) (680,000)
RSUs cancelled (in thousands) 60,000 20,000 2,000
Shares withheld for tax and not issued (in thousands)   (30,000) 18,000
Options terminated (in thousands) 16,000 105,000 455,000
Options expired (in thousands)     (341,000)
Available shares, ending (in thousands) 27,000 735,000 573,000
XML 87 R77.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK-BASED COMPENSATION (Details 4) - Outstanding Options Stock Option Transactions - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
Options outstanding, beginning (in thousands) 1,597 2,766 3,153
Options granted (in thousands) 110 303 297
Options terminated (in thousands) (16) (105) (455)
Options exercised (in thousands) (730) (1,367) (229)
Options outstanding, ending (in thousands) 961 1,597 2,766
Options fully vested and expected to vest (in thousands) 947    
Weighted average exercise price outstanding, beginning $ 2.70 $ 2.16 $ 2.17
Weighted average exercise price granted 9.06 5.37 1.78
Weighted average exercise price terminated 5.42 1.59 2.31
Weighted average exercise price exercised 2.32 2.28 1.54
Weighted average exercise price outstanding, ending 3.67 $ 2.70 $ 2.16
Weighted average exercise price fully vested and expected to vest $ 3.66    
Aggregate intrinsic value, beginning $ 9,290 $ 807 $ 102
Aggregate intrinsic value, ending 28,211 $ 9,290 $ 807
Aggregate intrinsic value for options fully vested and expected to vest $ 27,796    
XML 88 R78.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK-BASED COMPENSATION (Details 5)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
May 31, 2023
USD ($)
$ / shares
shares
$1.34  
Options outstanding, ending (in thousands) | shares | shares 41
Weighted average remaining contractual life (Years) options outstanding 4 years 4 months 20 days
Weighted average exercise price for options outstanding | $ / shares | $ / shares $ 1.34
Option exercisable shares (in thousands) | shares 41
Weighted average exercise price for options exercisable | $ / shares | $ / shares $ 1.34
Weighted average remaining contractual life (Years) options exercisable 4 years 4 months 20 days
$1.64-$1.86  
Options outstanding, ending (in thousands) | shares | shares 365
Weighted average remaining contractual life (Years) options outstanding 3 years 6 months 10 days
Weighted average exercise price for options outstanding | $ / shares | $ / shares $ 1.72
Option exercisable shares (in thousands) | shares 291
Weighted average exercise price for options exercisable | $ / shares | $ / shares $ 1.70
Weighted average remaining contractual life (Years) options exercisable 3 years 5 months 12 days
$2.03-$2.40  
Options outstanding, ending (in thousands) | shares | shares 185
Weighted average remaining contractual life (Years) options outstanding 2 years 7 months 9 days
Weighted average exercise price for options outstanding | $ / shares | $ / shares $ 2.14
Option exercisable shares (in thousands) | shares 175
Weighted average exercise price for options exercisable | $ / shares | $ / shares $ 2.14
Weighted average remaining contractual life (Years) options exercisable 2 years 5 months 23 days
$2.93  
Options outstanding, ending (in thousands) | shares | shares 139
Weighted average remaining contractual life (Years) options outstanding 5 years 1 month 13 days
Weighted average exercise price for options outstanding | $ / shares | $ / shares $ 2.93
Option exercisable shares (in thousands) | shares 35
Weighted average exercise price for options exercisable | $ / shares | $ / shares $ 2.93
Weighted average remaining contractual life (Years) options exercisable 5 years 1 month 13 days
$3.46-$3.93  
Options outstanding, ending (in thousands) | shares | shares 37
Weighted average remaining contractual life (Years) options outstanding 1 year 1 month 9 days
Weighted average exercise price for options outstanding | $ / shares | $ / shares $ 3.93
Option exercisable shares (in thousands) | shares 37
Weighted average exercise price for options exercisable | $ / shares | $ / shares $ 3.93
Weighted average remaining contractual life (Years) options exercisable 1 year 1 month 9 days
$8.00-34.00  
Options outstanding, ending (in thousands) | shares | shares 194
Weighted average remaining contractual life (Years) options outstanding 5 years 11 months 19 days
Weighted average exercise price for options outstanding | $ / shares | $ / shares $ 9.77
Option exercisable shares (in thousands) | shares 41
Weighted average exercise price for options exercisable | $ / shares | $ / shares $ 10.18
Weighted average remaining contractual options exercisable 5 years 10 months 24 days
$1.34-$34.00  
Options outstanding, ending (in thousands) | shares | shares 961
Weighted average remaining contractual life (Years) options outstanding 4 years 7 days
Weighted average exercise price for options outstanding | $ / shares | $ / shares $ 3.67
Option exercisable shares (in thousands) | shares 620
Weighted average exercise price for options exercisable | $ / shares | $ / shares $ 2.56
Weighted average remaining contractual life (Years) options exercisable 3 years 4 months 6 days
Aggregate intrinsic value for options exercisable | | $ $ 18,895
XML 89 R79.htm IDEA: XBRL DOCUMENT v3.23.2
STOCKBASED COMPENSATION (Details 6) - $ / shares
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
Employees Member      
Annual RSUs granted 152,000 120,000 161,000
Weighted average market value on the date of the grant of annual RSUs $ 8.03 $ 3.17 $ 1.86
Annual restricted shares granted 8,000 0  
Weighted average market value on the date of the grant of annual restricted shares $ 8.00 $ 0 $ 0
RSUs granted in lieu of cash payment for salary reductions   89,000 18,000
Weighted average market value on the date of the grant of RSU in lieu of cash payment $ 0 $ 2.50 $ 2.21
PRSUs granted based on revenue target thresholds maximum 80,000 270,000  
Performance restricted shares granted based on revenue target thresholds maximum 24,000    
Weighted average market value on the date of the grant of PRSUs, performance restricted shares $ 8.00 $ 3.41 $ 0
Board Of Directors      
Annual RSUs granted 44,000 43,000 161,000
Weighted average market value on the date of the grant of annual RSUs $ 11.35 $ 8.02 $ 1.81
PRSUs granted based on revenue target thresholds maximum 25,000    
Weighted average market value on the date of the grant of PRSUs $ 8.00 $ 0 $ 0
XML 90 R80.htm IDEA: XBRL DOCUMENT v3.23.2
STOCKBASED COMPENSATION (Details 7) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
STOCKBASED COMPENSATION (Details 6)      
Net RSUs and PRSUs vested 240,000 96,000 207,000
Shares withheld to settle payroll taxes 178,000 62,000 9,000
Weighted average grant-date fair value of vested RSUs and PRSUs $ 4.47 $ 3.12 $ 1.90
RSUs and PRSUs cancelled 30,000 10,000 1,000
Weighted average grant-date fair value of cancelled RSUs $ 8.56 $ 2.93 $ 3.46
RSUs and PRSUs unvested 345,000 185,000 132,000
Weighted average grant-date fair value of unvested RSUs and PRSUs $ 6.40 $ 3.00 $ 1.88
Intrinsic value of unvested RSUs and PRSUs (in thousands) $ 11,392 $ 1,554 $ 297
XML 91 R81.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK-BASED COMPENSATION (Details Narrative) - USD ($)
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
Total intrinsic values of options exercised $ 17,088,000 $ 12,542,000 $ 152,000
Stock based compensation expenses $ 120,000 $ 83,000 $ 0
Option exercisable shares (in thousands) 620,000 1,042,000 2,045,000
Weighted average exercise price for options exercisable $ 2.56 $ 2.22 $ 2.26
Stock Option, RSUs and PRSUs      
Stock-based compensation expense related to stock options and RSUs $ 1,988,000 $ 2,071,000 $ 993,000
RSUs cancelled (in thousands) 0    
2016 Equity Incentive Plan      
Unrecognized stock-based compensation $ 3,102,000    
Common stock reserved for issuance 4,848,000    
Remained available for issuance 2,248,000    
Estimated forfeitures of unvested stock based awards, amount $ 8,000    
Weighted average period for recognition of costs 2 years 3 months 18 days    
Employee Stock Purchase Plan      
Common stock reserved for issuance 2,550,000    
Purchase rights under the ESPP $ 715,000    
Weighted average period for recognition of costs 1 year 1 month 6 days    
Stock-based compensation related to the ESPP $ 760,000 935,000 108,000
Maximum calendar year contribution per employee $ 25,000 $ 25,000 $ 25,000
Maximum number of shares a participant may purchase (in thousands) 3,000 3,000 3,000
ESPP purchase right granted (in thousands) 77,000 101,000 279,000
ESPP shares issued (in thousands) 211,000 178,000 147,000
Total shares issued under ESPP plan (in thousands) 2,152,000    
ESPP Shares available for issuance (in thousands) 398,000    
Number of authorized shares increased 350,000    
XML 92 R82.htm IDEA: XBRL DOCUMENT v3.23.2
EMPLOYEE BENEFIT PLANS (Details Narrative) - USD ($)
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
EMPLOYEE BENEFIT PLANS      
Contributions to ESOP $ 300,000 $ 250,000 $ 60,000
Shares contributed to the ESOP during fiscal year (in thousands) 29,832 26,666 36,000
Defined contribution plan, description The stock bonus plan was converted to an employee stock ownership plan (“ESOP”) to enable the Plan to better comply with changes in the law regarding Company stock. Individuals’ account balances vest at a rate of 20% per year commencing upon completion of two years of service    
XML 93 R83.htm IDEA: XBRL DOCUMENT v3.23.2
OTHER INCOME (EXPENSE) NET (Details) - USD ($)
$ in Thousands
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
OTHER INCOME (EXPENSE) NET      
Foreign exchange gain (loss) $ (3) $ 32 $ (111)
Other income (expense), net   (2) (51)
Other income (expense), net $ (3) $ 30 $ (162)
XML 94 R84.htm IDEA: XBRL DOCUMENT v3.23.2
PRODUCT WARRANTIES (Details) - USD ($)
$ in Thousands
12 Months Ended
May 31, 2023
May 31, 2022
PRODUCT WARRANTIES    
Balance at the beginning of the period $ 410 $ 494
Accruals for warranties issued during the period 420 465
Adjustments to previously existing warranty accruals 61 98
Consumption of reserves (624) (647)
Balance at the End of the period $ 267 $ 410
XML 95 R85.htm IDEA: XBRL DOCUMENT v3.23.2
SEGMENT INFORMATION (Details) - USD ($)
$ in Thousands
May 31, 2023
May 31, 2022
Property and equipment, net $ 2,759 $ 1,203
Asia    
Property and equipment, net 44 47
Europe    
Property and equipment, net 2 0
United States    
Property and equipment, net $ 2,713 $ 1,156
XML 96 R86.htm IDEA: XBRL DOCUMENT v3.23.2
SEGMENT INFORMATION (Details Narrative) - USD ($)
$ in Thousands
May 31, 2023
May 31, 2022
Operating lease right-of-use assets $ 6,123 $ 917
Asia    
Operating lease right-of-use assets 70 95
Europe    
Operating lease right-of-use assets 45  
United States    
Operating lease right-of-use assets $ 6,007 $ 822
XML 97 R87.htm IDEA: XBRL DOCUMENT v3.23.2
DISSOLUTION OF AEHR TEST SYSTEMS JAPAN (Details Narrative) - USD ($)
12 Months Ended
May 31, 2023
May 31, 2022
May 31, 2021
DISSOLUTION OF AEHR TEST SYSTEMS JAPAN      
Deconsolidation net gain   $ 0 $ 2,401,000
Net gain due to cumulative translation adjustment reclassiefied to earnings $ 0 0 2,186,000
Income tax benefits $ 0 $ 0 $ 215,000
XML 98 R88.htm IDEA: XBRL DOCUMENT v3.23.2
EQUITY (Details Narrative) - USD ($)
$ / shares in Units, $ in Millions
Feb. 08, 2023
Oct. 08, 2021
Aug. 25, 2021
EQUITY      
Sale of common stock price per share $ 34.78 $ 14.73  
Sale of common stock shares 208,917 1,696,729  
Gross proceeds $ 7.3 $ 25.0  
Commission fees 0.2 0.7  
Offering expenses $ 0.2 $ 0.3  
Shelf registration amount     $ 75.0
XML 99 R89.htm IDEA: XBRL DOCUMENT v3.23.2
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
May 31, 2023
May 31, 2022
Commitments and contingencies (Note 20)    
Restricted cash $ 150,000 $ 80,000
Purchase obligation $ 26,318,000  
XML 100 aehr_10k_htm.xml IDEA: XBRL DOCUMENT 0001040470 2022-06-01 2023-05-31 0001040470 2021-08-25 0001040470 2023-02-01 2023-02-08 0001040470 2021-10-01 2021-10-08 0001040470 2023-02-08 0001040470 2021-10-08 0001040470 srt:EuropeMember 2022-05-31 0001040470 srt:EuropeMember 2023-05-31 0001040470 srt:AsiaMember 2022-05-31 0001040470 srt:AsiaMember 2023-05-31 0001040470 country:US 2022-05-31 0001040470 country:US 2023-05-31 0001040470 us-gaap:EmployeeStockMember 2021-05-31 0001040470 us-gaap:EmployeeStockMember 2022-05-31 0001040470 aehr:EquityIncentivePlan2016Member 2022-06-01 2023-05-31 0001040470 us-gaap:EmployeeStockMember 2023-05-31 0001040470 aehr:EquityIncentivePlan2016Member 2023-05-31 0001040470 aehr:StockOptionRSUsAndPRSUsMember 2020-06-01 2021-05-31 0001040470 aehr:StockOptionRSUsAndPRSUsMember 2021-06-01 2022-05-31 0001040470 aehr:StockOptionRSUsAndPRSUsMember 2022-06-01 2023-05-31 0001040470 aehr:BoardOfDirectorsMember 2021-06-01 2022-05-31 0001040470 aehr:BoardOfDirectorsMember 2020-06-01 2021-05-31 0001040470 aehr:BoardOfDirectorsMember 2022-06-01 2023-05-31 0001040470 aehr:EmployeesMember 2022-06-01 2023-05-31 0001040470 aehr:EmployeesMember 2021-06-01 2022-05-31 0001040470 aehr:EmployeesMember 2020-06-01 2021-05-31 0001040470 aehr:RangeTotalMember 2022-06-01 2023-05-31 0001040470 aehr:RangeSixMember 2022-06-01 2023-05-31 0001040470 aehr:Range5Member 2022-06-01 2023-05-31 0001040470 aehr:RangeFourMember 2022-06-01 2023-05-31 0001040470 aehr:RangeThreeMember 2022-06-01 2023-05-31 0001040470 aehr:Range2Member 2022-06-01 2023-05-31 0001040470 aehr:RangeTotalMember 2023-05-31 0001040470 aehr:RangeSixMember 2023-05-31 0001040470 aehr:Range5Member 2023-05-31 0001040470 aehr:RangeFourMember 2023-05-31 0001040470 aehr:RangeThreeMember 2023-05-31 0001040470 aehr:Range2Member 2023-05-31 0001040470 aehr:Range1Member 2022-06-01 2023-05-31 0001040470 aehr:Range1Member 2023-05-31 0001040470 aehr:OutstandingOptionsStockOptionTransactionsMember 2023-05-31 0001040470 aehr:OutstandingOptionsStockOptionTransactionsMember 2021-06-01 2022-05-31 0001040470 aehr:OutstandingOptionsStockOptionTransactionsMember 2020-06-01 2021-05-31 0001040470 aehr:OutstandingOptionsStockOptionTransactionsMember 2022-06-01 2023-05-31 0001040470 aehr:OutstandingOptionsStockOptionTransactionsMember 2021-05-31 0001040470 aehr:OutstandingOptionsStockOptionTransactionsMember 2022-05-31 0001040470 aehr:OutstandingOptionsStockOptionTransactionsMember 2020-05-31 0001040470 aehr:StockOptionAndRSUTransactionsMember 2023-05-31 0001040470 aehr:StockOptionAndRSUTransactionsMember 2020-06-01 2021-05-31 0001040470 aehr:StockOptionAndRSUTransactionsMember 2022-06-01 2023-05-31 0001040470 aehr:StockOptionAndRSUTransactionsMember 2021-06-01 2022-05-31 0001040470 aehr:StockOptionAndRSUTransactionsMember 2021-05-31 0001040470 aehr:StockOptionAndRSUTransactionsMember 2020-05-31 0001040470 aehr:StockOptionAndRSUTransactionsMember 2022-05-31 0001040470 us-gaap:EmployeeStockMember 2022-06-01 2023-05-31 0001040470 us-gaap:EmployeeStockMember 2021-06-01 2022-05-31 0001040470 srt:MaximumMember us-gaap:EmployeeStockMember 2022-06-01 2023-05-31 0001040470 srt:MinimumMember us-gaap:EmployeeStockMember 2022-06-01 2023-05-31 0001040470 srt:MaximumMember us-gaap:EmployeeStockMember 2020-06-01 2021-05-31 0001040470 srt:MinimumMember us-gaap:EmployeeStockMember 2020-06-01 2021-05-31 0001040470 srt:MaximumMember us-gaap:EmployeeStockMember 2021-06-01 2022-05-31 0001040470 srt:MinimumMember us-gaap:EmployeeStockMember 2021-06-01 2022-05-31 0001040470 srt:MinimumMember us-gaap:StockOptionMember 2022-06-01 2023-05-31 0001040470 srt:MaximumMember us-gaap:StockOptionMember 2022-06-01 2023-05-31 0001040470 srt:MaximumMember us-gaap:StockOptionMember 2021-06-01 2022-05-31 0001040470 srt:MinimumMember us-gaap:StockOptionMember 2021-06-01 2022-05-31 0001040470 us-gaap:ResearchAndDevelopmentExpenseMember 2022-06-01 2023-05-31 0001040470 us-gaap:ResearchAndDevelopmentExpenseMember 2020-06-01 2021-05-31 0001040470 us-gaap:ResearchAndDevelopmentExpenseMember 2021-06-01 2022-05-31 0001040470 us-gaap:GeneralAndAdministrativeExpenseMember 2022-06-01 2023-05-31 0001040470 us-gaap:GeneralAndAdministrativeExpenseMember 2020-06-01 2021-05-31 0001040470 us-gaap:GeneralAndAdministrativeExpenseMember 2021-06-01 2022-05-31 0001040470 us-gaap:CostOfSalesMember 2022-06-01 2023-05-31 0001040470 us-gaap:CostOfSalesMember 2020-06-01 2021-05-31 0001040470 us-gaap:CostOfSalesMember 2021-06-01 2022-05-31 0001040470 aehr:SiliconValleyBankMember 2021-06-12 0001040470 aehr:SiliconValleyBankMember 2020-04-23 0001040470 aehr:ThirdAmendmentToLoanAndSecurityAgreementMember us-gaap:SubsequentEventMember 2023-11-30 0001040470 aehr:ThirdAmendmentToLoanAndSecurityAgreementMember 2022-06-01 2023-05-31 0001040470 aehr:FirstAmendmentToLoanAndSecurityAgreementMember 2022-06-01 2023-05-31 0001040470 aehr:SecondAmendmentToLoanAndSecurityAgreementMember 2022-06-01 2023-05-31 0001040470 aehr:OriginalLoanAndSecurityAgreementMember 2022-06-01 2023-05-31 0001040470 aehr:SecondAmendmentToLoanAndSecurityAgreementMember 2023-05-31 0001040470 aehr:OriginalLoanAndSecurityAgreementMember 2023-05-31 0001040470 srt:MinimumMember 2022-06-01 2023-05-31 0001040470 srt:MaximumMember 2022-06-01 2023-05-31 0001040470 us-gaap:DomesticCountryMember 2022-06-01 2023-05-31 0001040470 us-gaap:StateAndLocalJurisdictionMember 2022-06-01 2023-05-31 0001040470 us-gaap:StateAndLocalJurisdictionMember 2021-06-01 2022-05-31 0001040470 us-gaap:DomesticCountryMember 2021-06-01 2022-05-31 0001040470 us-gaap:StateAndLocalJurisdictionMember 2023-05-31 0001040470 us-gaap:StateAndLocalJurisdictionMember 2022-05-31 0001040470 us-gaap:DomesticCountryMember 2023-05-31 0001040470 us-gaap:DomesticCountryMember 2022-05-31 0001040470 aehr:UnrealizedLossOnInvestmentsMember 2023-05-31 0001040470 aehr:CumulativeTranslationAdjustmentsMember 2023-05-31 0001040470 aehr:UnrealizedLossOnInvestmentsMember 2021-06-01 2022-05-31 0001040470 aehr:UnrealizedLossOnInvestmentsMember 2022-06-01 2023-05-31 0001040470 aehr:CumulativeTranslationAdjustmentsMember 2022-06-01 2023-05-31 0001040470 aehr:CumulativeTranslationAdjustmentsMember 2021-06-01 2022-05-31 0001040470 aehr:UnrealizedLossOnInvestmentsMember 2021-05-31 0001040470 aehr:UnrealizedLossOnInvestmentsMember 2022-05-31 0001040470 aehr:CumulativeTranslationAdjustmentsMember 2021-05-31 0001040470 aehr:CumulativeTranslationAdjustmentsMember 2022-05-31 0001040470 us-gaap:FairValueInputsLevel3Member aehr:MoneyMarketFundMember 2022-05-31 0001040470 us-gaap:FairValueInputsLevel2Member aehr:MoneyMarketFundMember 2022-05-31 0001040470 us-gaap:FairValueInputsLevel1Member aehr:MoneyMarketFundMember 2022-05-31 0001040470 aehr:MoneyMarketFundMember 2022-05-31 0001040470 us-gaap:AssetsMember us-gaap:FairValueInputsLevel3Member 2022-05-31 0001040470 us-gaap:AssetsMember us-gaap:FairValueInputsLevel3Member 2023-05-31 0001040470 us-gaap:AssetsMember us-gaap:FairValueInputsLevel2Member 2022-05-31 0001040470 us-gaap:AssetsMember us-gaap:FairValueInputsLevel2Member 2023-05-31 0001040470 us-gaap:AssetsMember us-gaap:FairValueInputsLevel1Member 2022-05-31 0001040470 us-gaap:AssetsMember us-gaap:FairValueInputsLevel1Member 2023-05-31 0001040470 us-gaap:AssetsMember 2022-05-31 0001040470 us-gaap:AssetsMember 2023-05-31 0001040470 us-gaap:FairValueInputsLevel3Member aehr:USTreasurySecurityMember 2023-05-31 0001040470 us-gaap:FairValueInputsLevel2Member aehr:USTreasurySecurityMember 2023-05-31 0001040470 us-gaap:FairValueInputsLevel1Member aehr:USTreasurySecurityMember 2023-05-31 0001040470 aehr:UStreasurysecuritiesMember 2023-05-31 0001040470 us-gaap:FairValueInputsLevel3Member aehr:MoneyMarketFundMember 2023-05-31 0001040470 us-gaap:FairValueInputsLevel2Member aehr:MoneyMarketFundMember 2023-05-31 0001040470 us-gaap:FairValueInputsLevel1Member aehr:MoneyMarketFundMember 2023-05-31 0001040470 aehr:MoneyMarketFundMember 2023-05-31 0001040470 aehr:GrossUnrealizedLossMember 2022-06-01 2023-05-31 0001040470 aehr:UnitedStateTreasurySecuritiesMember aehr:EstimatedFairValueMember 2023-05-31 0001040470 aehr:UnitedStateTreasurySecuritiesMember aehr:GrossUnrealizedLossMember 2023-05-31 0001040470 aehr:UnitedStateTreasurySecuritiesMember aehr:CostMember 2023-05-31 0001040470 aehr:EstimatedFairValueMember 2022-05-31 0001040470 aehr:EstimatedFairValueMember 2023-05-31 0001040470 aehr:GrossUnrealizedLossMember 2022-05-31 0001040470 aehr:GrossUnrealizedLossMember 2023-05-31 0001040470 aehr:CostMember 2022-05-31 0001040470 aehr:CostMember 2023-05-31 0001040470 aehr:MoneyMarketFundMember aehr:EstimatedFairValueMember 2022-05-31 0001040470 aehr:MoneyMarketFundMember aehr:GrossUnrealizedLossMember 2022-05-31 0001040470 aehr:MoneyMarketFundMember aehr:EstimatedFairValueMember 2023-05-31 0001040470 aehr:MoneyMarketFundMember aehr:GrossUnrealizedLossMember 2023-05-31 0001040470 aehr:MoneyMarketFundMember aehr:CostMember 2022-05-31 0001040470 aehr:MoneyMarketFundMember aehr:CostMember 2023-05-31 0001040470 us-gaap:RestrictedStockUnitsRSUMember 2020-06-01 2021-05-31 0001040470 us-gaap:EmployeeStockMember 2020-06-01 2021-05-31 0001040470 us-gaap:StockOptionMember 2022-06-01 2023-05-31 0001040470 us-gaap:StockOptionMember 2020-06-01 2021-05-31 0001040470 us-gaap:StockOptionMember 2021-06-01 2022-05-31 0001040470 srt:ScenarioForecastMember 2025-05-31 0001040470 srt:ScenarioForecastMember 2024-05-31 0001040470 aehr:ServicesTransferredOverTimeMember 2022-06-01 2023-05-31 0001040470 aehr:ServicesTransferredOverTimeMember 2020-06-01 2021-05-31 0001040470 aehr:ServicesTransferredOverTimeMember 2021-06-01 2022-05-31 0001040470 aehr:ProductsAndServicesTransferredAtAPointInTimeMember 2022-06-01 2023-05-31 0001040470 aehr:ProductsAndServicesTransferredAtAPointInTimeMember 2020-06-01 2021-05-31 0001040470 aehr:ProductsAndServicesTransferredAtAPointInTimeMember 2021-06-01 2022-05-31 0001040470 srt:AsiaMember 2021-06-01 2022-05-31 0001040470 srt:EuropeMember 2021-06-01 2022-05-31 0001040470 country:US 2021-06-01 2022-05-31 0001040470 srt:AsiaMember 2020-06-01 2021-05-31 0001040470 srt:EuropeMember 2020-06-01 2021-05-31 0001040470 country:US 2020-06-01 2021-05-31 0001040470 srt:AsiaMember 2022-06-01 2023-05-31 0001040470 srt:EuropeMember 2022-06-01 2023-05-31 0001040470 country:US 2022-06-01 2023-05-31 0001040470 aehr:TestDuringBurnInMember 2020-06-01 2021-05-31 0001040470 aehr:WaferLevelMember 2020-06-01 2021-05-31 0001040470 aehr:ServicesMember 2020-06-01 2021-05-31 0001040470 aehr:ContactorsMember 2020-06-01 2021-05-31 0001040470 aehr:SystemsMember 2020-06-01 2021-05-31 0001040470 aehr:TestDuringBurnInMember 2021-06-01 2022-05-31 0001040470 aehr:WaferLevelMember 2021-06-01 2022-05-31 0001040470 aehr:ServicesMember 2021-06-01 2022-05-31 0001040470 aehr:ContactorsMember 2021-06-01 2022-05-31 0001040470 aehr:SystemsMember 2021-06-01 2022-05-31 0001040470 aehr:ContactorsMember 2022-06-01 2023-05-31 0001040470 aehr:ServicesMember 2022-06-01 2023-05-31 0001040470 aehr:WaferLevelMember 2022-06-01 2023-05-31 0001040470 aehr:TestDuringBurnInMember 2022-06-01 2023-05-31 0001040470 aehr:SystemsMember 2022-06-01 2023-05-31 0001040470 aehr:ProductLineNetMember 2021-06-01 2022-05-31 0001040470 aehr:ProductLineNetMember 2022-06-01 2023-05-31 0001040470 aehr:ProductLineNetMember 2020-06-01 2021-05-31 0001040470 us-gaap:SalesMember aehr:TwoCustomerMember 2022-06-01 2023-05-31 0001040470 us-gaap:SalesMember aehr:OneCustomerMember 2022-06-01 2023-05-31 0001040470 us-gaap:SalesMember aehr:OneCustomerMember 2021-06-01 2022-05-31 0001040470 us-gaap:AccountsReceivableMember aehr:TwoCustomerMember 2022-06-01 2023-05-31 0001040470 us-gaap:AccountsReceivableMember aehr:OneCustomerMember 2022-06-01 2023-05-31 0001040470 us-gaap:AccountsReceivableMember aehr:CustomerThreeMember 2021-06-01 2022-05-31 0001040470 us-gaap:AccountsReceivableMember aehr:TwoCustomerMember 2021-06-01 2022-05-31 0001040470 us-gaap:AccountsReceivableMember aehr:OneCustomerMember 2021-06-01 2022-05-31 0001040470 srt:AsiaMember us-gaap:AccountsReceivableMember 2022-06-01 2023-05-31 0001040470 srt:NorthAmericaMember us-gaap:AccountsReceivableMember 2022-06-01 2023-05-31 0001040470 srt:AsiaMember us-gaap:AccountsReceivableMember 2021-06-01 2022-05-31 0001040470 srt:NorthAmericaMember us-gaap:AccountsReceivableMember 2021-06-01 2022-05-31 0001040470 srt:MaximumMember us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember 2023-05-31 0001040470 srt:MinimumMember us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember 2023-05-31 0001040470 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2023-05-31 0001040470 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2023-05-31 0001040470 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2023-05-31 0001040470 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2023-05-31 0001040470 us-gaap:NoncontrollingInterestMember 2023-05-31 0001040470 aehr:AherTestSystemsShareholdersEquityMember 2023-05-31 0001040470 us-gaap:RetainedEarningsMember 2023-05-31 0001040470 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-05-31 0001040470 us-gaap:AdditionalPaidInCapitalMember 2023-05-31 0001040470 us-gaap:CommonStockMember 2023-05-31 0001040470 us-gaap:NoncontrollingInterestMember 2022-06-01 2023-05-31 0001040470 aehr:AherTestSystemsShareholdersEquityMember 2022-06-01 2023-05-31 0001040470 us-gaap:RetainedEarningsMember 2022-06-01 2023-05-31 0001040470 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-01 2023-05-31 0001040470 us-gaap:AdditionalPaidInCapitalMember 2022-06-01 2023-05-31 0001040470 us-gaap:CommonStockMember 2022-06-01 2023-05-31 0001040470 us-gaap:NoncontrollingInterestMember 2022-05-31 0001040470 aehr:AherTestSystemsShareholdersEquityMember 2022-05-31 0001040470 us-gaap:RetainedEarningsMember 2022-05-31 0001040470 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-05-31 0001040470 us-gaap:AdditionalPaidInCapitalMember 2022-05-31 0001040470 us-gaap:CommonStockMember 2022-05-31 0001040470 us-gaap:NoncontrollingInterestMember 2021-06-01 2022-05-31 0001040470 aehr:AherTestSystemsShareholdersEquityMember 2021-06-01 2022-05-31 0001040470 us-gaap:RetainedEarningsMember 2021-06-01 2022-05-31 0001040470 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-01 2022-05-31 0001040470 us-gaap:AdditionalPaidInCapitalMember 2021-06-01 2022-05-31 0001040470 us-gaap:CommonStockMember 2021-06-01 2022-05-31 0001040470 2021-05-31 0001040470 us-gaap:NoncontrollingInterestMember 2021-05-31 0001040470 aehr:AherTestSystemsShareholdersEquityMember 2021-05-31 0001040470 us-gaap:RetainedEarningsMember 2021-05-31 0001040470 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-05-31 0001040470 us-gaap:AdditionalPaidInCapitalMember 2021-05-31 0001040470 us-gaap:CommonStockMember 2021-05-31 0001040470 us-gaap:NoncontrollingInterestMember 2020-06-01 2021-05-31 0001040470 aehr:AherTestSystemsShareholdersEquityMember 2020-06-01 2021-05-31 0001040470 us-gaap:RetainedEarningsMember 2020-06-01 2021-05-31 0001040470 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-01 2021-05-31 0001040470 us-gaap:AdditionalPaidInCapitalMember 2020-06-01 2021-05-31 0001040470 us-gaap:CommonStockMember 2020-06-01 2021-05-31 0001040470 2020-05-31 0001040470 us-gaap:NoncontrollingInterestMember 2020-05-31 0001040470 aehr:AherTestSystemsShareholdersEquityMember 2020-05-31 0001040470 us-gaap:RetainedEarningsMember 2020-05-31 0001040470 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-05-31 0001040470 us-gaap:AdditionalPaidInCapitalMember 2020-05-31 0001040470 us-gaap:CommonStockMember 2020-05-31 0001040470 2020-06-01 2021-05-31 0001040470 2021-06-01 2022-05-31 0001040470 2022-05-31 0001040470 2023-05-31 0001040470 2023-08-16 0001040470 2023-01-01 iso4217:USD shares iso4217:USD shares pure 0001040470 false --05-31 FY 2023 0 0.01 10000000 0 0 0 0 0.01 75000000 28539000 27120000 0 0 0 0 0 0 0 0 P1Y P7Y 0 0 25000 25000 3000 3000 29832 36000 26666 0 0 0 0 0 10-K true 2023-05-31 false 000-22893 AEHR TEST SYSTEMS CA 94-2424084 400 KATO TERRACE FREMONT CA 94539 510 623-9400 Common Stock, par value $0.01 per share AEHR NASDAQ No No Yes Yes Non-accelerated Filer true false false false 28755426 207 BPM LLP San Jose, California 30054000 31484000 17853000 0 16594000 12859000 23908000 15051000 621000 613000 89030000 60007000 2759000 1203000 6123000 917000 231000 201000 98143000 62328000 9206000 4195000 4143000 3610000 137000 794000 2822000 2415000 16308000 11014000 6163000 212000 31000 69000 41000 44000 22543000 11339000 0.01 10000000 0 0 0.01 75000000 28539000 27120000 285000 271000 127776000 117686000 -155000 -105000 -52306000 -66863000 75600000 50989000 98143000 62328000 64961000 50829000 16600000 32215000 27164000 10568000 32746000 23665000 6032000 12237000 10047000 6562000 7134000 5818000 3652000 19371000 15865000 10214000 13375000 7800000 -4182000 1245000 13000 -46000 0 0 2186000 0 1698000 0 -3000 30000 -162000 14617000 9541000 -2204000 60000 91000 -177000 14557000 9450000 -2027000 0.52 0.36 -0.09 0.50 0.34 -0.09 27785000 26014000 23457000 29215000 27774000 23457000 14557000 9450000 -2027000 -33000 -77000 160000 -17000 0 0 0 0 -2401000 14507000 9373000 -4268000 0 0 21000 14507000 9373000 -4289000 23107000 231000 85898000 2234000 -74286000 14077000 -21000 14056000 627000 6000 574000 0 0 580000 0 580000 -9000 0 -20000 0 0 -20000 0 -20000 0 1101000 0 0 1101000 0 1101000 0 0 0 -2027000 -2027000 0 -2027000 0 0 -2401000 0 -2401000 0 -2401000 0 0 139000 0 139000 21000 160000 23725000 237000 87553000 -28000 -76313000 11449000 0 11449000 1760000 17000 3543000 0 0 3560000 0 3560000 -62000 0 -429000 0 0 -429000 0 -429000 1697000 17000 24013000 0 0 24030000 0 24030000 0 3006000 0 0 3006000 0 3006000 0 0 0 9450000 9450000 0 9450000 0 0 -77000 0 -77000 0 -77000 27120000 271000 117686000 -105000 -66863000 50989000 0 50989000 1388000 13000 2549000 0 0 2562000 0 2562000 -178000 -1000 -2059000 0 0 -2060000 0 -2060000 209000 2000 6818000 0 0 6820000 0 6820000 0 2782000 0 0 2782000 0 2782000 0 0 0 14557000 14557000 0 14557000 0 0 -17000 0 -17000 0 -17000 0 0 -33000 0 -33000 0 -33000 28539000 285000 127776000 -155000 -52306000 75600000 0 75600000 14557000 9450000 -2027000 2748000 3006000 1101000 24000 0 0 450000 356000 328000 88000 -49000 -18000 -576000 0 0 0 0 -2186000 0 0 -215000 0 -1698000 0 -3788000 -7834000 -1373000 -9469000 -6674000 -972000 28000 -71000 -81000 5044000 1356000 1877000 528000 1464000 732000 369000 2196000 96000 0 0 47000 8000 6000 -10000 10011000 1508000 -2701000 33294000 0 0 16000000 0 0 1362000 416000 227000 -18656000 -416000 -227000 0 1400000 1400000 2562000 3560000 580000 2060000 429000 20000 6820000 24030000 0 7322000 25761000 1960000 -37000 49000 117000 -1360000 26902000 -851000 31564000 4662000 5513000 30204000 31564000 4662000 21000 4000 15000 15000 12000 6000 646000 472000 113000 <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">BUSINESS:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Aehr Test Systems (the “Company”) was incorporated in California in May 1977 and primarily designs, engineers and manufactures test and burn-in equipment used in the semiconductor industry. The Company’s principal products are the FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak carrier, the WaferPak aligner, the DiePak autoloader, and test fixtures.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">CONSOLIDATION:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The consolidated financial statements include the accounts of the Company and both its wholly-owned and majority-owned foreign subsidiaries. Intercompany accounts and transactions have been eliminated.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">FOREIGN CURRENCY TRANSLATION AND TRANSACTIONS:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Assets and liabilities of the Company’s foreign subsidiaries and a branch office are translated into U.S. Dollars from their functional currencies of Euros, Philippines Peso and New Taiwan Dollars using the exchange rate in effect at the balance sheet date. Additionally, their net sales and expenses are translated using exchange rates approximating average rates prevailing during the fiscal year. Translation adjustments that arise from translating their financial statements from their local currencies to U.S. Dollars are accumulated and reflected as a separate component of shareholders’ equity.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Transaction gains and losses that arise from exchange rate changes denominated in currencies other than the local currency are included in the Consolidated Statements of Operations as incurred. See Note 15, “Other (Expense) Income, Net” for the detail of foreign exchange transaction gains and losses for all periods presented.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">USE OF ESTIMATES:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the Company’s consolidated financial statements include allowance for doubtful accounts, valuation of inventory at the lower of cost or net realizable value, and warranty reserves.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0cm">RECLASSIFICATIONS:</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0cm">  </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0cm;text-indent:45px">Certain reclassifications have been made to the previous year consolidated financial statements to conform to the current period presentation. The reclassifications had no impact on net income (loss), total assets, total liabilities, or shareholders’ equity.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH EQUIVALENTS:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Cash equivalents consist of money market instruments purchased with an original maturity of three months or less. These investments are reported at fair value.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Accounts receivable are derived from the sale of products throughout the world to semiconductor manufacturers, semiconductor contract assemblers, electronics manufacturers and burn-in and test service companies. Accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts to reserve for potentially uncollectible trade receivables. The Company also reviews its trade receivables by aging category to identify specific customers with known disputes or collection issues. The Company exercises judgment when determining the adequacy of these reserves as the Company evaluates historical bad debt trends, general economic conditions in the United States and internationally, and changes in customer financial conditions. Uncollectible receivables are recorded as bad debt expense when all efforts to collect have been exhausted and recoveries are recognized when they are received. During the fiscal year ended May 31, 2023, the Company recorded bad debt expense of $24,000. No significant adjustments to the allowance for doubtful accounts were recorded during the fiscal years ended May 31, 2022 or 2021.</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">CONCENTRATION OF CREDIT RISK:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company sells its products primarily to semiconductor manufacturers in North America, Asia, and Europe. As of May 31, 2023, approximately 17% and 83% of gross accounts receivable were from customers located in North America and Asia, respectively. As of May 31, 2022, approximately 20% and 80% of gross accounts receivable were from customers located in North America and Asia, respectively. Two customers accounted for 82% and 17% of gross accounts receivable as of May 31, 2023. Three customers accounted for 68%, 18% and 11% of gross accounts receivable as of May 31, 2022. Two customers accounted for 79% and 10% of net sales in fiscal 2023, respectively. One customer accounted for 82% of net sales in fiscal 2022. The Company performs ongoing credit evaluations of its customers and generally does not require collateral. The Company uses letter of credit terms for some of its international customers.</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company’s cash and cash equivalents are generally deposited with major financial institutions in the United States, Philippines, Germany and Taiwan. The Company invests its excess cash in money market funds and U.S. Treasury securities. The money market funds bear the risk associated with each fund. The money market funds have variable interest rates. The Company’s cash and investment balances held at banks and brokerage firms may at time exceed federally insured levels. The Company has not experienced any material losses on its money market funds or short-term cash deposits.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">CONCENTRATION OF SUPPLY RISK:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company relies on subcontractors to manufacture many of the components and subassemblies used in its products. Quality or performance failures of the Company’s products or changes in its manufacturers’ financial or business condition could disrupt the Company’s ability to supply quality products to its customers and thereby have a material and adverse effect on its business and operating results. Some of the components and technologies used in the Company’s products are purchased and licensed from a single source or a limited number of sources. The loss of any of these suppliers may cause the Company to incur additional transition costs, result in delays in the manufacturing and delivery of its products, or cause it to carry excess or obsolete inventory and could cause it to redesign its products.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">INVENTORIES:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Inventories include material, labor and overhead, and are stated at the lower of cost (first-in, first-out method) or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less costs of completion, disposal and transportation. Provisions for excess, obsolete and unusable inventories are made after management’s evaluation of future demand and market conditions. The Company adjusts inventory balances to approximate the lower of its manufacturing costs or net realizable value. If actual future demand or market conditions become less favorable than those projected by management, additional inventory write-downs may be required, and would be reflected in cost of sales in the period the revision is made. During fiscal 2023, 2022 and 2021 the Company recognized a provision for inventory reserves of $569,000, $1,031,000, and $176,000, respectively.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">PROPERTY AND EQUIPMENT:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Property and equipment are stated at cost less accumulated depreciation and amortization. Major improvements are capitalized, while repairs and maintenance are expensed as incurred. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the related lease. Furniture and fixtures, machinery and equipment, and test equipment are depreciated on a straight-line basis over their estimated useful lives. The ranges of estimated useful lives are generally as follows:</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">  </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:50%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Furniture and fixtures   </p></td><td style="width:15%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2 to 6 years</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Machinery and equipment</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3 to 6 years</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Test equipment   </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">4 to 6 years</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">   </p><p style="font-size:10pt;font-family:times new roman;margin:0px">REVENUE RECOGNITION: </p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company recognizes revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by following a five-step process: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price, and (5) recognize revenue when or as the Company satisfies a performance obligation, as further described below.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Performance obligations include sales of systems, contactors, spare parts, and services, as well as installation and training services included in customer contracts.</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">A contract’s transaction price is allocated to each distinct performance obligation. In determining the transaction price, the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which the Company expects to be entitled. The Company generally does not grant return privileges, except for defective products during the warranty period.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">For contracts that contain multiple performance obligations, the Company allocates the transaction price to the performance obligations on a relative standalone selling price basis. Standalone selling prices are based on multiple factors including, but not limited to, historical discounting trends for products and services and pricing practices in different geographies.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Revenue for systems and spares are recognized at a point in time, which is generally upon shipment or delivery. Revenue from services is recognized over time as services are completed or ratably over the contractual period of generally one year or less.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company has elected the practical expedient to not assess whether a contract has a significant financing component as the Company’s standard payment terms are less than one year.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">PRODUCT DEVELOPMENT COSTS AND CAPITALIZED SOFTWARE:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Costs incurred in the research and development of new products or systems are charged to operations as incurred. Costs incurred in the development of software programs for the Company’s products are charged to operations as incurred until technological feasibility of the software has been established. Generally, technological feasibility is established when the software module performs its primary functions described in its original specifications, contains features required for it to be usable in a production environment, is completely documented and the related hardware portion of the product is complete. After technological feasibility is established, any additional costs are capitalized. Capitalization of software costs ceases when the software is substantially complete and is ready for its intended use. Capitalized costs are amortized over the estimated life of the related software product using the greater of the units of sales or straight-line methods over ten years. No system software development costs were capitalized or amortized in fiscal 2023, 2022 and 2021.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">IMPAIRMENT OF LONG-LIVED ASSETS:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">In the event that facts and circumstances indicate that the carrying value of assets may be impaired, an evaluation of recoverability would be performed. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset would be compared to the asset’s carrying value to determine if a write-down is required.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">ADVERTISING COSTS:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company expenses all advertising costs as incurred and the amounts were not material for all periods presented.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">SHIPPING AND HANDLING OF PRODUCTS:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Amounts billed to customers for shipping and handling of products are included in net sales. Costs incurred related to shipping and handling of products are included in cost of sales.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">INCOME TAXES:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Income taxes are accounted for under the asset-and-liability method as required by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 740, Income Taxes (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. Under ASC 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">  </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">As of May 31, 2023 the Company maintained a full valuation allowance against its deferred tax assets. We will continue to assess whether sufficient future taxable income will be generated to permit the use of deferred tax assets, and will reverse all or a portion of the allowance when there is sufficient evidence to support the reversal. Based upon our prior two fiscal years of profitability, the outlook for the next fiscal year, and absent any additional objective negative evidence, the Company anticipates adjusting the current valuation allowance position in fiscal 2024.</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">FASB ASC Subtopic 740-10, Accounting for Uncertainty of Income Taxes, (“ASC 740-10”) defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company’s policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of income taxes.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">COMPREHENSIVE INCOME (LOSS):</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Comprehensive income (loss) generally represents all changes in shareholders’ equity except those resulting from investments or contributions by shareholders. Unrealized gains and losses from available-for-sale securities and on foreign currency translation adjustments are included in the Company’s components of comprehensive income (loss), which are excluded from net income (loss). In fiscal 2021, the Company recognized a gain of $2,401,000 related to the completed liquidation of ATS-Japan, a majority owned subsidiary, which is deducted from net income (loss) when calculating comprehensive income (loss). Refer to Note 18, “Dissolution of Aehr Test Systems Japan,” for a further discussion of the transaction. Comprehensive income (loss) is included in the statements of comprehensive income (loss).</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">RECENT ACCOUNTING PRONOUNCEMENTS:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Accounting Standards Not Yet Adopted</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">In June 2016, the FASB issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326), that requires measurement and recognition of expected credit losses for financial assets held based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Due to a subsequent ASU in November 2019, the accounting standard will be effective for the Company beginning in the first quarter of fiscal 2024 on a modified retrospective basis. The Company does not expect a material impact of this accounting standard on its consolidated financial statements.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Aehr Test Systems (the “Company”) was incorporated in California in May 1977 and primarily designs, engineers and manufactures test and burn-in equipment used in the semiconductor industry. The Company’s principal products are the FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak carrier, the WaferPak aligner, the DiePak autoloader, and test fixtures.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The consolidated financial statements include the accounts of the Company and both its wholly-owned and majority-owned foreign subsidiaries. Intercompany accounts and transactions have been eliminated.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Assets and liabilities of the Company’s foreign subsidiaries and a branch office are translated into U.S. Dollars from their functional currencies of Euros, Philippines Peso and New Taiwan Dollars using the exchange rate in effect at the balance sheet date. Additionally, their net sales and expenses are translated using exchange rates approximating average rates prevailing during the fiscal year. Translation adjustments that arise from translating their financial statements from their local currencies to U.S. Dollars are accumulated and reflected as a separate component of shareholders’ equity.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Transaction gains and losses that arise from exchange rate changes denominated in currencies other than the local currency are included in the Consolidated Statements of Operations as incurred. See Note 15, “Other (Expense) Income, Net” for the detail of foreign exchange transaction gains and losses for all periods presented.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the Company’s consolidated financial statements include allowance for doubtful accounts, valuation of inventory at the lower of cost or net realizable value, and warranty reserves.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0cm;text-indent:45px">Certain reclassifications have been made to the previous year consolidated financial statements to conform to the current period presentation. The reclassifications had no impact on net income (loss), total assets, total liabilities, or shareholders’ equity.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Cash equivalents consist of money market instruments purchased with an original maturity of three months or less. These investments are reported at fair value.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Accounts receivable are derived from the sale of products throughout the world to semiconductor manufacturers, semiconductor contract assemblers, electronics manufacturers and burn-in and test service companies. Accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts to reserve for potentially uncollectible trade receivables. The Company also reviews its trade receivables by aging category to identify specific customers with known disputes or collection issues. The Company exercises judgment when determining the adequacy of these reserves as the Company evaluates historical bad debt trends, general economic conditions in the United States and internationally, and changes in customer financial conditions. Uncollectible receivables are recorded as bad debt expense when all efforts to collect have been exhausted and recoveries are recognized when they are received. During the fiscal year ended May 31, 2023, the Company recorded bad debt expense of $24,000. No significant adjustments to the allowance for doubtful accounts were recorded during the fiscal years ended May 31, 2022 or 2021.</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p> 24000 <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company sells its products primarily to semiconductor manufacturers in North America, Asia, and Europe. As of May 31, 2023, approximately 17% and 83% of gross accounts receivable were from customers located in North America and Asia, respectively. As of May 31, 2022, approximately 20% and 80% of gross accounts receivable were from customers located in North America and Asia, respectively. Two customers accounted for 82% and 17% of gross accounts receivable as of May 31, 2023. Three customers accounted for 68%, 18% and 11% of gross accounts receivable as of May 31, 2022. Two customers accounted for 79% and 10% of net sales in fiscal 2023, respectively. One customer accounted for 82% of net sales in fiscal 2022. The Company performs ongoing credit evaluations of its customers and generally does not require collateral. The Company uses letter of credit terms for some of its international customers.</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company’s cash and cash equivalents are generally deposited with major financial institutions in the United States, Philippines, Germany and Taiwan. The Company invests its excess cash in money market funds and U.S. Treasury securities. The money market funds bear the risk associated with each fund. The money market funds have variable interest rates. The Company’s cash and investment balances held at banks and brokerage firms may at time exceed federally insured levels. The Company has not experienced any material losses on its money market funds or short-term cash deposits.</p> 0.17 0.83 0.20 0.80 0.82 0.17 0.68 0.18 0.11 0.79 0.10 0.82 <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company relies on subcontractors to manufacture many of the components and subassemblies used in its products. Quality or performance failures of the Company’s products or changes in its manufacturers’ financial or business condition could disrupt the Company’s ability to supply quality products to its customers and thereby have a material and adverse effect on its business and operating results. Some of the components and technologies used in the Company’s products are purchased and licensed from a single source or a limited number of sources. The loss of any of these suppliers may cause the Company to incur additional transition costs, result in delays in the manufacturing and delivery of its products, or cause it to carry excess or obsolete inventory and could cause it to redesign its products.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Inventories include material, labor and overhead, and are stated at the lower of cost (first-in, first-out method) or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less costs of completion, disposal and transportation. Provisions for excess, obsolete and unusable inventories are made after management’s evaluation of future demand and market conditions. The Company adjusts inventory balances to approximate the lower of its manufacturing costs or net realizable value. If actual future demand or market conditions become less favorable than those projected by management, additional inventory write-downs may be required, and would be reflected in cost of sales in the period the revision is made. During fiscal 2023, 2022 and 2021 the Company recognized a provision for inventory reserves of $569,000, $1,031,000, and $176,000, respectively.</p> 569000 1031000 176000 <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Property and equipment are stated at cost less accumulated depreciation and amortization. Major improvements are capitalized, while repairs and maintenance are expensed as incurred. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the related lease. Furniture and fixtures, machinery and equipment, and test equipment are depreciated on a straight-line basis over their estimated useful lives. The ranges of estimated useful lives are generally as follows:</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">  </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:50%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Furniture and fixtures   </p></td><td style="width:15%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2 to 6 years</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Machinery and equipment</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3 to 6 years</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Test equipment   </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">4 to 6 years</p></td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:50%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Furniture and fixtures   </p></td><td style="width:15%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2 to 6 years</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Machinery and equipment</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3 to 6 years</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Test equipment   </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">4 to 6 years</p></td></tr></tbody></table> P2Y P6Y P3Y P6Y P4Y P6Y <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company recognizes revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by following a five-step process: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price, and (5) recognize revenue when or as the Company satisfies a performance obligation, as further described below.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Performance obligations include sales of systems, contactors, spare parts, and services, as well as installation and training services included in customer contracts.</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">A contract’s transaction price is allocated to each distinct performance obligation. In determining the transaction price, the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which the Company expects to be entitled. The Company generally does not grant return privileges, except for defective products during the warranty period.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">For contracts that contain multiple performance obligations, the Company allocates the transaction price to the performance obligations on a relative standalone selling price basis. Standalone selling prices are based on multiple factors including, but not limited to, historical discounting trends for products and services and pricing practices in different geographies.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Revenue for systems and spares are recognized at a point in time, which is generally upon shipment or delivery. Revenue from services is recognized over time as services are completed or ratably over the contractual period of generally one year or less.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company has elected the practical expedient to not assess whether a contract has a significant financing component as the Company’s standard payment terms are less than one year.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Costs incurred in the research and development of new products or systems are charged to operations as incurred. Costs incurred in the development of software programs for the Company’s products are charged to operations as incurred until technological feasibility of the software has been established. Generally, technological feasibility is established when the software module performs its primary functions described in its original specifications, contains features required for it to be usable in a production environment, is completely documented and the related hardware portion of the product is complete. After technological feasibility is established, any additional costs are capitalized. Capitalization of software costs ceases when the software is substantially complete and is ready for its intended use. Capitalized costs are amortized over the estimated life of the related software product using the greater of the units of sales or straight-line methods over ten years. No system software development costs were capitalized or amortized in fiscal 2023, 2022 and 2021.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">In the event that facts and circumstances indicate that the carrying value of assets may be impaired, an evaluation of recoverability would be performed. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset would be compared to the asset’s carrying value to determine if a write-down is required.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company expenses all advertising costs as incurred and the amounts were not material for all periods presented.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Amounts billed to customers for shipping and handling of products are included in net sales. Costs incurred related to shipping and handling of products are included in cost of sales.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Income taxes are accounted for under the asset-and-liability method as required by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 740, Income Taxes (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. Under ASC 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">  </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">As of May 31, 2023 the Company maintained a full valuation allowance against its deferred tax assets. We will continue to assess whether sufficient future taxable income will be generated to permit the use of deferred tax assets, and will reverse all or a portion of the allowance when there is sufficient evidence to support the reversal. Based upon our prior two fiscal years of profitability, the outlook for the next fiscal year, and absent any additional objective negative evidence, the Company anticipates adjusting the current valuation allowance position in fiscal 2024.</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">FASB ASC Subtopic 740-10, Accounting for Uncertainty of Income Taxes, (“ASC 740-10”) defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company’s policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of income taxes.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Comprehensive income (loss) generally represents all changes in shareholders’ equity except those resulting from investments or contributions by shareholders. Unrealized gains and losses from available-for-sale securities and on foreign currency translation adjustments are included in the Company’s components of comprehensive income (loss), which are excluded from net income (loss). In fiscal 2021, the Company recognized a gain of $2,401,000 related to the completed liquidation of ATS-Japan, a majority owned subsidiary, which is deducted from net income (loss) when calculating comprehensive income (loss). Refer to Note 18, “Dissolution of Aehr Test Systems Japan,” for a further discussion of the transaction. Comprehensive income (loss) is included in the statements of comprehensive income (loss).</p> 2401000 <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Accounting Standards Not Yet Adopted</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">In June 2016, the FASB issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326), that requires measurement and recognition of expected credit losses for financial assets held based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Due to a subsequent ASU in November 2019, the accounting standard will be effective for the Company beginning in the first quarter of fiscal 2024 on a modified retrospective basis. The Company does not expect a material impact of this accounting standard on its consolidated financial statements.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>2. REVENUE:</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Disaggregation of revenue</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following tables show revenues by major product categories. Within each product category, contract terms, conditions and economic factors affecting the nature, amount, timing and uncertainty around revenue recognition and cash flow are substantially similar.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company’s revenues by product category are as follows (in thousands):</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Type of good / service:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Systems</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">38,844</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,224</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Contactors </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,873</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,647</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,837</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Services </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,244</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,958</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,513</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">64,961</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">50,829</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">16,600</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Product lines:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Wafer-level</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">63,531</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">48,926</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,004</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Test During Burn-In</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,430</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,903</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,596</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">64,961</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">50,829</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">16,600</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">   </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following presents information about the Company’s operations in different geographic areas.  Net sales are based upon ship-to location (in thousands):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geographic region:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">United States </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,289</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,110</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,386</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Asia</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">55,609</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">45,700</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,074</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Europe </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">63</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">19</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">140</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">64,961</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">50,829</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">16,600</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">With the exception of the amount of service contracts and extended warranties, the Company’s product category revenues are recognized at point in time when control transfers to customers.  The following presents revenue based on timing of recognition (in thousands):</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Timing of revenue recognition (in thousands):</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Products and services transferred at a point in time</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">63,531</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">49,441</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,009</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Services transferred over time </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,430</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,388</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,591</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">64,961</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">50,829</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">16,600</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Contract balances    </em></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">A receivable is recognized in the period the Company delivers goods or provides services or when the Company’s right to consideration is unconditional. The Company usually does not record contract assets because the Company has an unconditional right to payment upon satisfaction of the performance obligation, and therefore, a receivable is more commonly recorded than a contract asset.</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Contract liabilities include payments received in advance of performance under a contract and are satisfied as the associated revenue is recognized. Contract liabilities are reported on the consolidated balance sheets at the end of each reporting period as a component of deferred revenue. Contract liabilities as of May 31, 2023 and 2022 were $2,853,000 and $2,484,000, respectively.  During the fiscal years ended May 31, 2023 and 2022, the Company recognized $2,179,000 and $189,000 of revenues that were included in contract liabilities as of May 31, 2022 and 2021, respectively.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Remaining performance obligations</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">On May 31, 2023, the Company had $163,000 of remaining performance obligations, exclusive of customer deposits, which were comprised of deferred service contracts and extended warranty contracts not yet delivered. The Company expects to recognize approximately 81% of its remaining performance obligations as revenue in fiscal 2024, and an additional 19% in fiscal 2025 and thereafter. The foregoing excludes the value of other remaining performance obligations as they have original durations of one year or less, and also excludes information about variable consideration allocated entirely to a wholly unsatisfied performance obligation.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Costs to obtain or fulfill a contract</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company generally expenses sales commissions when incurred as a component of selling, general and administrative expense as the amortization period is typically less than one year. Additionally, the majority of the Company’s cost of fulfillment as a manufacturer of products is classified as inventory and fixed assets, which are accounted for under the respective guidance for those asset types. Other costs of contract fulfillment are immaterial due to the nature of the Company’s products and their respective manufacturing process.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company’s revenues by product category are as follows (in thousands):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Type of good / service:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Systems</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">38,844</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,224</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Contactors </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,873</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,647</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,837</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Services </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,244</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,958</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,513</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">64,961</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">50,829</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">16,600</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Product lines:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Wafer-level</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">63,531</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">48,926</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,004</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Test During Burn-In</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,430</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,903</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,596</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">64,961</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">50,829</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">16,600</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following presents information about the Company’s operations in different geographic areas.  Net sales are based upon ship-to location (in thousands):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geographic region:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">United States </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,289</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,110</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,386</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Asia</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">55,609</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">45,700</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,074</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Europe </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">63</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">19</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">140</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">64,961</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">50,829</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">16,600</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">With the exception of the amount of service contracts and extended warranties, the Company’s product category revenues are recognized at point in time when control transfers to customers.  The following presents revenue based on timing of recognition (in thousands):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Timing of revenue recognition (in thousands):</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Products and services transferred at a point in time</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">63,531</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">49,441</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,009</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Services transferred over time </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,430</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,388</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,591</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">64,961</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">50,829</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">16,600</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 38844000 25224000 7250000 21873000 22647000 5837000 4244000 2958000 3513000 64961000 50829000 16600000 63531000 48926000 15004000 1430000 1903000 1596000 64961000 50829000 16600000 9289000 5110000 5386000 55609000 45700000 11074000 63000 19000 140000 64961000 50829000 16600000 63531000 49441000 15009000 1430000 1388000 1591000 64961000 50829000 16600000 2853000 2484000 2179000 189000 163000 0.81 0.19 <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>3. EARNINGS PER SHARE (“EPS”):</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Basic EPS is determined using the weighted average number of common shares outstanding during the period. Diluted EPS is determined using the weighted average number of common shares and potential common shares (representing the dilutive effect of stock options, restricted shares, restricted shares units, or RSUs, and ESPP shares) outstanding during the period using the treasury stock method.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">  </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following table presents the computation of basic and diluted earnings (net loss) per share attributable to Aehr Test Systems common shareholders (in thousands, except per share data):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Numerator: Net income (net loss)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,557</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,450</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(2,027</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Denominator for basic earnings (net loss) per share:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Weighted average shares outstanding</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">27,785</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,014</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">23,457</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Shares used in basic earnings (net loss) per share calculation  </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,785</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,014</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,457</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effect of dilutive securities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,430</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,760</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Denominator for diluted earnings (net loss) per share </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">29,215</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">27,774</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">23,457</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Basic earnings (net loss) per share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.52</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.36</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.09</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Diluted earnings (net loss) per share </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.50</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.34</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.09</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">For the purpose of computing diluted earnings per share, weighted average potential common shares do not include stock options with an exercise price greater than the average fair value of the Company’s common stock for the period, as the effect would be anti-dilutive. Stock options to purchase 5,000 and 64,000 shares of common stock were outstanding as of May 31, 2023 and 2022, respectively, but were not included in the computation of diluted earnings per share, because the inclusion of such shares would be anti-dilutive. Stock options to purchase 2,766,000 shares of common stock were outstanding on May 31, 2021 but were not included in the computation of diluted net loss per share, because the inclusion of such shares would be anti-dilutive.  ESPP rights to purchase 239,000 ESPP shares and RSUs for 132,000 shares were outstanding on May 31, 2021 but were not included in the computation of diluted net loss per share, because the inclusion of such shares would be anti-dilutive. </p> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following table presents the computation of basic and diluted earnings (net loss) per share attributable to Aehr Test Systems common shareholders (in thousands, except per share data):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Numerator: Net income (net loss)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,557</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,450</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(2,027</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Denominator for basic earnings (net loss) per share:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Weighted average shares outstanding</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">27,785</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,014</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">23,457</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Shares used in basic earnings (net loss) per share calculation  </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,785</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,014</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,457</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effect of dilutive securities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,430</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,760</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Denominator for diluted earnings (net loss) per share </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">29,215</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">27,774</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">23,457</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Basic earnings (net loss) per share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.52</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.36</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.09</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Diluted earnings (net loss) per share </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.50</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.34</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.09</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> 14557000 9450000 -2027000 27785000 26014000 23457000 27785000 26014000 23457000 1430000 1760000 29215000 27774000 23457000 0.52 0.36 -0.09 0.50 0.34 -0.09 5000 64000 2766000 239000 132000 <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>4.  CASH, CASH EQUIVALENTS AND INVESTMENTS</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following table summarizes the Company’s cash, cash equivalents and investments by security type as of May 31, 2023 (in thousands):</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Cost</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Gross Unrealized Loss</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Estimated Fair Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,182</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,182</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash equivalents:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,872</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,872</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">30,054</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">30,054</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Short-term investments:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">U.S. treasury securities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">17,870</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(17</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">17,853</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Long-term investments:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">150</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">150</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total cash, cash equivalents and investments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">48,074</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(17</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">48,057</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">   </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following table summarizes the Company’s cash, cash equivalents and investments by security type as of May 31, 2022 (in thousands):</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Cost</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Gross Unrealized Loss</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Estimated Fair Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,955</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,955</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash equivalents:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">28,529</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">28,529</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">31,484</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">31,484</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Long-term investments:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">80</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">80</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total cash, cash equivalents and investments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">31,564</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">31,564</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Long-term investments are included in other assets on the accompanying consolidated balance sheets.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Unrealized gains and losses on investments classified as available-for-sale are included within accumulated other comprehensive loss, net of any related tax effect. Upon realization, those amounts are reclassified from accumulated other comprehensive loss to results of operations.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The unrealized loss of $17,000 as of May 31, 2023 is not considered other-than-temporary, and has been in an unrealized loss position for less than a year.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following table summarizes the Company’s cash, cash equivalents and investments by security type as of May 31, 2023 (in thousands):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Cost</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Gross Unrealized Loss</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Estimated Fair Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,182</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,182</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash equivalents:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,872</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,872</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">30,054</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">30,054</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Short-term investments:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">U.S. treasury securities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">17,870</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(17</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">17,853</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Long-term investments:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">150</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">150</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total cash, cash equivalents and investments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">48,074</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(17</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">48,057</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following table summarizes the Company’s cash, cash equivalents and investments by security type as of May 31, 2022 (in thousands):</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Cost</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Gross Unrealized Loss</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Estimated Fair Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,955</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,955</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash equivalents:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">28,529</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">28,529</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">31,484</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">31,484</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Long-term investments:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">80</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">80</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total cash, cash equivalents and investments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">31,564</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">31,564</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 3182000 0 3182000 26872000 0 26872000 30054000 0 30054000 17870000 17000 17853000 150000 0 150000 48074000 17000 48057000 2955000 0 2955000 28529000 0 28529000 31484000 0 31484000 80000 0 80000 31564000 0 31564000 17000 <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>5. FAIR VALUE OF FINANCIAL INSTRUMENTS:</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company’s financial instruments are measured at fair value consistent with authoritative guidance. This authoritative guidance defines fair value, establishes a framework for using fair value to measure assets and liabilities, and disclosures required related to fair value measurements.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The guidance establishes a fair value hierarchy based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources while unobservable inputs reflect a reporting entity’s pricing based upon their own market assumptions. The fair value hierarchy consists of the following three levels:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Level 1 - instrument valuations are obtained from real-time quotes for transactions in active exchange markets involving identical assets.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Level 2 - instrument valuations are obtained from readily-available pricing sources for comparable instruments.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Level 3 - instrument valuations are obtained without observable market values and require a high level of judgment to determine the fair value.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of May 31, 2023 (in thousands):</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Balance as of</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">May 31, 2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 1</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 2</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 3</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,022</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,022</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">U.S. treasury securities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">17,853</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">17,853</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">44,875</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">44,875</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">  </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of May 31, 2022 (in thousands):</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">   </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Balance as of</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">May 31, 2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 1</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 2</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 3</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">28,609</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">28,609</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">28,609</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">28,609</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Included in money market funds as of May 31, 2023 and 2022 was $150,000 and $80,000 of restricted cash, respectively, representing a security deposit for the Company’s United States manufacturing and office space lease which is included in other assets in the consolidated balance sheets.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">There were no financial liabilities measured at fair value as of May 31, 2023 and 2022.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">There were no transfers between Level 1 and Level 2 fair value measurements during the fiscal years ended May 31, 2023 and 2022.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The carrying amounts of financial instruments including cash equivalents, accounts receivables, accounts payable and certain other accrued liabilities, approximate fair value due to their short maturities.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of May 31, 2023 (in thousands):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Balance as of</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">May 31, 2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 1</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 2</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 3</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,022</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,022</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">U.S. treasury securities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">17,853</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">17,853</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">44,875</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">44,875</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of May 31, 2022 (in thousands):</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Balance as of</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">May 31, 2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 1</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 2</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 3</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">28,609</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">28,609</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">28,609</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">28,609</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 27022000 27022000 0 0 17853000 17853000 44875000 44875000 0 0 28609000 28609000 0 0 28609000 28609000 0 0 150000 80000 <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>6. TRADE AND OTHER ACCOUNTS RECEIVABLE, NET:</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Accounts receivable comprise (in thousands):</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px">May 31, </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accounts receivable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,594</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,859</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: Allowance for doubtful accounts </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">16,594</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">12,859</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Accounts receivable represents customer trade receivables. As of May 31, 2023 and 2022, there were no allowances for doubtful accounts. </p> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Accounts receivable comprise (in thousands):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px">May 31, </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accounts receivable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,594</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,859</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: Allowance for doubtful accounts </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">16,594</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">12,859</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 16594000 12859000 0 0 16594000 12859000 <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>7. BALANCE SHEET DETAIL:</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">INVENTORIES:     </p><p style="font-size:10pt;font-family:times new roman;margin:0px">  </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td></td><td></td><td colspan="6" style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> May 31,</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(In Thousands)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Raw materials and sub-assemblies</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">15,953</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">9,507</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Work in process</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:9%;vertical-align:bottom;text-align:right;">5,764</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:9%;vertical-align:bottom;text-align:right;">5,461</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finished goods</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,191</td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">83</td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">23,908</td><td style="PADDING-BOTTOM: 3px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,051</td><td style="PADDING-BOTTOM: 3px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">  </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">PROPERTY AND EQUIPMENT, NET:   </p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(In Thousands)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Leasehold improvements</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,310</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,230</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Furniture and fixtures </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">706</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">697</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Machinery and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,445</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,013</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Test equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,998</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,523</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,459</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,463</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: Accumulated depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,700</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,260</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,759</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,203</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">   </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Depreciation expense was $450,000, $307,000 and $310,000 for fiscal 2023, 2022, and 2021, respectively.</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">ACCRUED EXPENSES:</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">  </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(In Thousands)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Commissions and bonuses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,728</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,505</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payroll related</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,491</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,401</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warranty</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">267</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">410</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Professional services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">520</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">204</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Investor relations </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Taxes payable </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">36</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">33</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,143</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,610</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">CUSTOMER DEPOSITS AND DEFERRED REVENUE, SHORT-TERM:    </p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(In Thousands)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Customer deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,690</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,263</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deferred revenue  </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">132</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">152</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,822</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,415</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">INVENTORIES:     </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td></td><td></td><td colspan="6" style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> May 31,</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(In Thousands)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Raw materials and sub-assemblies</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">15,953</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">9,507</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Work in process</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:9%;vertical-align:bottom;text-align:right;">5,764</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:9%;vertical-align:bottom;text-align:right;">5,461</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finished goods</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,191</td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">83</td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">23,908</td><td style="PADDING-BOTTOM: 3px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,051</td><td style="PADDING-BOTTOM: 3px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 15953000 9507000 5764000 5461000 2191000 83000 23908000 15051000 <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">PROPERTY AND EQUIPMENT, NET:   </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(In Thousands)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Leasehold improvements</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,310</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,230</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Furniture and fixtures </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">706</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">697</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Machinery and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,445</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,013</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Test equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,998</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,523</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,459</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,463</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: Accumulated depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,700</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,260</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,759</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,203</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 1310000 1230000 706000 697000 5445000 4013000 2998000 2523000 10459000 8463000 7700000 7260000 2759000 1203000 450000 307000 310000 <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">ACCRUED EXPENSES:</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(In Thousands)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Commissions and bonuses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,728</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,505</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payroll related</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,491</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,401</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warranty</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">267</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">410</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Professional services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">520</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">204</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Investor relations </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Taxes payable </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">36</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">33</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,143</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,610</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 1728000 1505000 1491000 1401000 267000 410000 520000 204000 79000 44000 22000 13000 36000 33000 4143000 3610000 <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">CUSTOMER DEPOSITS AND DEFERRED REVENUE, SHORT-TERM:    </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(In Thousands)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Customer deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,690</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,263</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deferred revenue  </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">132</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">152</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,822</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,415</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 2690000 2263000 132000 152000 2822000 2415000 <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>8.  ACCUMULATED OTHER COMPREHENSIVE LOSS:</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Changes in the components of accumulated other comprehensive loss, net of tax, were as follows (in thousands):</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Cumulative Translation Adjustments</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Unrealized Loss on Investments, Net</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance as of May 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(28</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(28</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Other comprehensive loss before reclassifications</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(77</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(77</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance as of May 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(105</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(105</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Other comprehensive loss before reclassifications</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(33</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(17</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(50</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance as of May 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(138</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(17</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(155</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Changes in the components of accumulated other comprehensive loss, net of tax, were as follows (in thousands):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Cumulative Translation Adjustments</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Unrealized Loss on Investments, Net</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance as of May 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(28</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(28</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Other comprehensive loss before reclassifications</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(77</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(77</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance as of May 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(105</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(105</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Other comprehensive loss before reclassifications</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(33</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(17</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(50</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance as of May 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(138</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(17</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(155</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> -28000 0 -28000 -77000 0 -77000 -105000 0 -105000 -33000 -17000 -50000 -138000 -17000 -155000 <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>9. INCOME TAXES:</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Domestic and foreign components of income (loss) before income tax (expense) benefit are as follows (in thousands):</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Domestic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,541</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,416</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(13,064</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Foreign </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">76</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">125</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,860</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,617</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,541</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(2,204</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The income tax (expense) benefit consists of the following (in thousands):</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Federal income taxes:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Current </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(28</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(59</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">163</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Deferred </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">State income taxes:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Current </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Deferred </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Foreign income taxes:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Current </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(32</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(27</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Deferred </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(60</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(91</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">177</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company’s effective tax rate differs from the U.S. federal statutory tax rate, as follows:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">U.S. federal statutory tax rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">State taxes, net of federal tax effect</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.1</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.6</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Foreign rate differential</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.7</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.3</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.8</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(9.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(11.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4.7</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research and development credit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2.3</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.3</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.0</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Change in valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(9.3</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4.7</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(32.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Controlled Foreign Corporation Liquidation. .</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.8</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">PPP Loan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3.7</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.6</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.4</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.4</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effective tax rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.4</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1.1</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8.0</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The components of the net deferred tax assets and liabilities are as follows (in thousands):</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px">         2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deferred tax assets:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net operating losses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,964</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,912</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,335</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">218</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Credit carryforwards</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,235</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,535</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Inventory reserves</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">938</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">934</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Reserves and accruals</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,360</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Capitalized research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,187</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">297</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">220</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: valuation allowance </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(21,859</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(22,980</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,297</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">199</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deferred tax liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating lease right-of-use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,297</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(199</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net deferred tax assets (liabilities)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The valuation allowance decreased by $1,121,000 during fiscal 2023, decreased by $278,000 during fiscal 2022, and increased by $2,438,000 during fiscal 2021. As of May 31, 2023 and 2022, the Company provided a full valuation allowance against the deferred tax assets as it did not have enough objective evidence as required by GAAP to reverse its full valuation allowance. The Company will continue to evaluate the need for a valuation allowance against its deferred tax assets on a quarterly basis.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">At May 31, 2023 and 2022, the Company has federal net operating loss carryforwards of approximately $46,967,000 and $61,068,000 respectively, to reduce future taxable income. A portion of the federal net operating losses will begin to expire in 2024. Federal net operating losses of $14,425,000 will carryforward indefinitely and would be subject to an 80% taxable income limitation in the year utilized. At May 31, 2023 and 2022, the Company has state net operating loss carryforwards of $30,203,000 and $30,043,000, respectively, to reduce future taxable income. The state net operating loss carryforwards will begin to expire in 2028.</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">At May 31, 2023 and 2022, the Company has federal research and development credit carryforwards of approximately $2,923,000 and $2,362,000, respectively, to offset future tax liability. The federal credit carryforwards began to expire in 2022. At May 31, 2023 and 2022, the Company has state research and development credit carryforwards of approximately $6,623,000 and $6,152,000 respectively, to offset future tax liability. The state credit carryforwards are not subject to expiration. The Company also has alternative minimum tax credit carryforwards of $34,000 for state purposes. The credits may be used to offset regular tax and do not expire.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Internal Revenue Code of 1986, as amended (“IRC”) Section 382 (“§382”) limits the use of NOL and tax credit carryforwards in certain situations where changes occur in the stock ownership of a company. In general, if we experience a greater than 50% aggregate change in ownership over a three-year period, we are subject to an annual limitation under IRC §382 on the utilization of the Company’s pre-change NOL carryforwards. California and other states have similar laws. The annual limitation generally is determined by multiplying the value of the Company’s stock at the time of such ownership change (subject to certain adjustments) by the applicable long-term exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company has made no provision for U.S. income taxes on undistributed earnings of certain foreign subsidiaries because it is the Company’s intention to permanently reinvest such earnings in its foreign subsidiaries. If such earnings were distributed, the Company would be subject to additional U.S. income tax expense.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company maintains liabilities for uncertain tax positions. These liabilities involve considerable judgment and estimation and are continuously monitored by management based on the best information available. </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The aggregate changes in the balance of gross unrecognized tax benefits are as follows (in thousands):</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Beginning balance as of May 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,852</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Increases related to prior year tax positions</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Increases related to current year tax positions</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">65</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at May 31, 2021 </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,928</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Increases related to prior year tax positions</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Increases related to current year tax positions</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">78</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at May 31, 2022 </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,018</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Increases related to prior year tax positions</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Increases related to current year tax positions</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">168</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at May 31, 2023 </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,276</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">As of May 31, 2023 and 2022, the Company has not recorded interest and penalties associated with its unrecognized tax benefits. The Company’s unrecognized gross tax benefits would not reduce the annual effective tax rate if recognized because it has recorded a full valuation allowance on its deferred tax assets. The Company does not foresee any material changes to the gross unrecognized tax benefit within the next twelve months. The Company’s policy is to recognize interest and penalties in income tax expense.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company’s federal and state income tax returns are subject to possible examination by the taxing authorities until the expiration of the related statutes of limitations on those tax returns. In general, the federal income tax returns have a three-year statute of limitations, and the state income tax returns have a four-year statute of limitations. The Company’s foreign income tax returns are also subject to examination by the foreign tax authorities with the longest statute of limitations period of four-year.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Domestic and foreign components of income (loss) before income tax (expense) benefit are as follows (in thousands):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Domestic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,541</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,416</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(13,064</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Foreign </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">76</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">125</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,860</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,617</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,541</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(2,204</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> 14541000 9416000 -13064000 76000 125000 10860000 14617000 9541000 -2204000 <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The income tax (expense) benefit consists of the following (in thousands):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Federal income taxes:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Current </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(28</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(59</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">163</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Deferred </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">State income taxes:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Current </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Deferred </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Foreign income taxes:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Current </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(32</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(27</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Deferred </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(60</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(91</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">177</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> -28000 -59000 163000 0 0 0 0 -5000 13000 0 0 0 -32000 -27000 1000 0 0 0 60000 91000 -177000 <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company’s effective tax rate differs from the U.S. federal statutory tax rate, as follows:</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">U.S. federal statutory tax rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">State taxes, net of federal tax effect</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.1</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.6</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Foreign rate differential</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.7</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.3</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.8</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(9.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(11.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4.7</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research and development credit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2.3</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.3</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.0</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Change in valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(9.3</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4.7</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(32.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Controlled Foreign Corporation Liquidation. .</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.8</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">PPP Loan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3.7</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.6</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.4</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.4</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effective tax rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.4</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1.1</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8.0</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table> 0.210 0.210 0.210 0 0.001 0.006 0.007 0.003 0.098 -0.091 -0.110 -0.047 -0.023 -0.013 0.040 -0.093 -0.047 -0.321 0 0 0.098 0 -0.037 0 -0.006 0.004 -0.004 0.004 0.011 0.080 <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The components of the net deferred tax assets and liabilities are as follows (in thousands):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px">         2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deferred tax assets:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net operating losses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,964</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,912</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,335</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">218</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Credit carryforwards</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,235</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,535</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Inventory reserves</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">938</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">934</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Reserves and accruals</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,360</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Capitalized research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,187</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">297</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">220</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: valuation allowance </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(21,859</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(22,980</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,297</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">199</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deferred tax liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating lease right-of-use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,297</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(199</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net deferred tax assets (liabilities)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 11964000 14912000 1335000 218000 6235000 5535000 938000 934000 1200000 1360000 1187000 0 297000 220000 21859000 22980000 1297000 199000 -1297000 -199000 0 0 -1121000 -278000 2438000 46967000 61068000 14425000 30203000 30043000 2923000 2362000 6623000 6152000 34000 <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The aggregate changes in the balance of gross unrecognized tax benefits are as follows (in thousands):</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Beginning balance as of May 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,852</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Increases related to prior year tax positions</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Increases related to current year tax positions</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">65</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at May 31, 2021 </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,928</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Increases related to prior year tax positions</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Increases related to current year tax positions</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">78</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at May 31, 2022 </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,018</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Increases related to prior year tax positions</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Increases related to current year tax positions</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">168</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at May 31, 2023 </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,276</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 1852000 11000 65000 1928000 12000 78000 2018000 90000 168000 2276000 <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>10. LEASES</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company leases its manufacturing and office space under operating leases. The principal administrative and production facility is located in Fremont, California, in a 51,289 square foot building. The Company entered into a non-cancelable operating lease agreement for its United States manufacturing and office facility, which was renewed in December 2022 and expires in September 2030. The Company leases a 492 square foot sales and support office in Utting, Germany. The lease, which began on February 1, 1992 and expires on January 31, 2025, contains an automatic twelve months renewal, at rates to be determined, if no notice is given prior to six months from expiration. The Company leases a facility in the Philippines located in a 2,713 square foot building in Clark Freeport Zone, Pampanga. The lease, which began on January 1, 2021 and expires on December 31, 2025, contains an option to renew for another three years at rates stipulated in the contract, notice for renewal is given six months from expiration. Under the lease agreements, the Company is responsible for payments of utilities, taxes and insurance.</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company has only operating leases for real estate including corporate offices, warehouse space and certain equipment. A lease with an initial term of 12 months or less is generally not recorded on the consolidated balance sheets, unless the arrangement includes an option to purchase the underlying asset, or renew the arrangement that the Company is reasonably certain to exercise (short-term leases). The Company recognizes lease expense on a straight-line basis over the lease term for short-term leases that the Company does not record on its balance sheets. The Company’s operating leases have remaining lease terms of one year to seven years.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">In December 2022, the Company amended its lease agreement to extend the lease term of an existing office facility located in the United States, which is considered a lease modification not accounted for as a separate contract. The total commitments, net of tenant incentives expected to be received, under the modified lease are $8.6 million. The modified lease expires in fiscal 2031 and contains an option to further extend the lease. The lease modification resulted in an increase in the Company’s operating lease right-of-use assets and operating lease liabilities of $5.9 million each.</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The weighted average remaining lease term for the Company’s operating leases was 7.3 years at May 31, 2023 and the weighted average discount rate was 7.5%.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company’s operating lease cost was $923,000, $766,000 and $761,000 for the years ended May 31, 2023, 2022 and 2021, respectively.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following table presents supplemental cash flow information related to the Company’s operating leases (in thousands):</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31, </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash paid for amounts included in the measurement of operating lease liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating cash flows from operating leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">835</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">813</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">779</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">    The following table presents the maturities of the Company’s operating lease liabilities as of May 31, 2023 (in thousands):</p><p style="font-size:10pt;font-family:times new roman;margin:0px">  </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fiscal year</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Operating Leases</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">608</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,143</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,174</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,195</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,234</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,075</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum operating lease payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,429</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: imputed interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,129</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Present value of operating lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6,300</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 5900000 P7Y3M18D 0.075 923000 766000 761000 <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following table presents supplemental cash flow information related to the Company’s operating leases (in thousands):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31, </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash paid for amounts included in the measurement of operating lease liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating cash flows from operating leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">835</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">813</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">779</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 835000 813000 779000 <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">    The following table presents the maturities of the Company’s operating lease liabilities as of May 31, 2023 (in thousands):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fiscal year</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Operating Leases</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">608</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,143</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,174</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,195</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,234</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,075</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum operating lease payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,429</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: imputed interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,129</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Present value of operating lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6,300</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 608000 1143000 1174000 1195000 1234000 3075000 8429000 2129000 6300000 <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>11. BORROWING AND FINANCING ARRANGEMENTS:</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">On January 16, 2020, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Silicon Valley Bank (“SVB”). Pursuant to the Loan Agreement, the Company may borrow up to (a) the lesser of (i) the revolving line of $4.0 million or (ii) the amount available under the borrowing base under a revolving line of credit which is collateralized by all the Company’s assets except intellectual property. The borrowing base is 80% of eligible accounts, as determined by SVB from the Company’s most recent borrowing base statement; provided, however, SVB has the right to decrease the foregoing percentage in its good faith business judgment to mitigate the impact of certain events or conditions, which may adversely affect the collateral or its value. Subject to an event of default, the principal amount outstanding under the revolving line of credit will accrue interest at a floating per annum rate equal to the greater of (a) the prime rate plus an additional percentage of up to 1%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 4.75%. Interest is payable monthly on the last calendar day of each month and the outstanding principal amount, the unpaid interest and all other obligations are due on the maturity date, which is 364 days from the effective date of January 13, 2020.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">On January 14, 2021, the Company entered into the First Amendment to Loan and Security Agreement (the “Amendment”) with SVB. The Amendment, among other things, extended the Revolving Line Maturity Date to July 14, 2021; provided, however, that if the Company achieved specified operating metrics on a consolidated basis on or prior to May 31, 2021 the Amended Revolving Line Maturity Date would be extended to January 13, 2022.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">On January 11, 2022, the Company entered into the Second Amendment to the Loan and Security Agreement (the “Second Amendment”) with SVB. The Second Amendment, among other things, (A) increased the available amount of the line up to the lesser of (i) $10 million or (ii) the available amount under the borrowing base, under a revolving line of credit, (B) allowed for borrowing up to $3 million of the available balance based upon eligible customer purchase orders, (C) reduced the interest rate for account advances under the line to the greater of (a) prime rate plus an additional percentage up to 1.0%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 3.25%, reduces the interest rate for purchase order advances under the line to the greater of (a) prime rate plus an additional percentage up to 1.5%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 3.75%, and (D) extended the maturity date to January 13, 2023.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">On January 10, 2023, the Company entered into the Third Amendment to the Loan and Security Agreement (the “Third Amendment”) with SVB. The Third Amendment, among other things, extends the Revolving Line Maturity Date to January 13, 2024, provided, however, that (i) if the Company submits a fiscal year 2024 plan of record that is generally acceptable to SVB, and (ii) the minimum net liquidity at the end of November 30, 2023 is at least $20.0 million, the Amended Revolving Line Maturity Date would be extended to January 13, 2025.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">As of May 31, 2023 the Company had not drawn against the credit facility and was in compliance with all covenants related to obligations to meet reporting requirements. The balance available to borrow under the line as of May 31, 2023 was $8,004,000. There are no financial covenants in the agreement.</p> 4000000.0 the greater of (a) the prime rate plus an additional percentage of up to 1%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 4.75% 2022-01-13 10000000 the greater of (a) prime rate plus an additional percentage up to 1.0%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 3.25%, 2023-01-13 20000000 2025-01-13 8004000 <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>12. LONG-TERM DEBT:</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">On April 23, 2020, the Company obtained a Payroll Protection Program loan (“PPP Loan”) in the aggregate amount of $1,679,000 from SVB. The PPP Loan was evidenced by a promissory note dated April 23, 2020 (the “Note”) that matures on April 23, 2022 and bears interest at a rate of 1% per annum, payable monthly commencing on November 23, 2020. The PPP Loan proceeds were used for payroll, health care benefits, rent and utilities.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Under the terms of the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), PPP Loan recipients can apply for and be granted forgiveness for all or a portion of loans granted under the PPP Loan. On June 12, 2021, the Company received confirmation from the SVB that on June 4, 2021, the Small Business Administration approved the Company’s PPP Loan forgiveness application for the entire PPP Loan balance of $1,679,000 and interest totaling $19,000, and the Company recognized a gain on loan forgiveness of $1,698,000.</p> 1679000 0.01 1679000 19000 1698000 <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>13. STOCK-BASED COMPENSATION:</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Stock-based compensation expense consists of expenses for stock options, restricted stock units (“RSUs”), performance RSUs, or PRSUs, restricted shares, performance restricted shares and employee stock purchase plan, or ESPP, purchase rights. Stock-based compensation expense for stock options and ESPP purchase rights is measured at each grant date, based on the fair value of the award using the Black-Scholes option valuation model, and is recognized as expense over the employee’s requisite service period. This model was developed for use in estimating the value of publicly traded options that have no vesting restrictions and are fully transferable. The Company’s employee stock options have characteristics significantly different from those of publicly traded options. For RSUs, PRSUs, restricted shares and performance restricted shares, stock-based compensation expense is based on the fair value of the Company’s common stock at the grant date, and is recognized as expense over the employee’s requisite service period. All of the Company’s stock-based compensation is accounted for as equity instruments.</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following table summarizes the stock-based compensation expense for the fiscal years ended May 31, 2023, 2022 and 2021 (in thousands, except per share data):</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation in the form of stock options,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">RSUs, and ESPP purchase rights, included in:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cost of sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">331</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">234</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">70</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Selling, general and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,711</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,721</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">816</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research and development </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">706</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">968</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">215</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net effect on net income (loss)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,748</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,923</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,101</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effect on earnings (net loss) per share:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.10</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.11</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.05</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.11</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.05</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">As of the years ended May 31, 2023, 2022 and 2021, stock-based compensation totaling $120,000, $83,000 and $0, respectively, was capitalized as part of inventory.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">During fiscal 2023, 2022 and 2021, the Company recorded stock-based compensation related to stock options, RSUs, PRSUs, performance restricted shares and restricted shares of $1,988,000, $2,071,000 and $993,000, respectively. For PRSUs and performance restricted shares, the Company evaluates compensation expense quarterly and recognizes expense for performance-based awards only if it determines it is probable that performance criteria for the awards will be met.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">As of May 31, 2023, the total compensation expense related to unvested stock-based awards under the Company’s 2016 Equity Incentive Plan, but not yet recognized, was $3,102,000 which is net of estimated forfeitures of $8,000. This expense will be amortized on a straight-line basis over a weighted average period of approximately 2.3 years.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">During fiscal 2023, 2022 and 2021, the Company recorded stock-based compensation related to its ESPP of $760,000, $935,000 and $108,000, respectively.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">As of May 31, 2023, the total compensation expense related to purchase rights under the ESPP but not yet recognized was $715,000. This expense will be amortized on a straight-line basis over a weighted average period of approximately 1.1 years.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Valuation Assumptions</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Valuation and Amortization Method. The Company estimates the fair value of stock options granted using the Black-Scholes option valuation method and a single option award approach. The fair value under the single option approach is amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Expected Term. The Company’s expected term represents the period that the Company’s stock-based awards are expected to be outstanding and was determined based on historical experience, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior as evidenced by changes to the terms of its stock-based awards.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Volatility. Volatility is a measure of the amounts by which a financial variable such as stock price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company uses the historical volatility for the past five to six years, based on weighted average of the expected term of option grants, to estimate expected volatility. Volatility for each of the ESPP’s four time periods of six months, twelve months, eighteen months, and twenty-four months is calculated separately and included in the overall stock-based compensation expense recorded.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes option valuation method on the implied yield in effect at the time of option grant on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of the stock awards including the ESPP.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">  </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Fair Value. The fair values of the Company’s stock options granted to employees in fiscal 2023, 2022 and 2021 were estimated using the following weighted average assumptions in the Black-Scholes option valuation method:</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected term (in years)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5 - 6</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5 - 6</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">86</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">88</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">72</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Risk-free interest rates</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.12</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.50</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.44</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average grant date fair value</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.29</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.01</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.12</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The fair value of our ESPP purchase rights for the fiscal 2023, 2022 and 2021 was estimated using the following weighted average assumptions:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">  </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31, </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected term (in years) </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.5 – 2.0</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.5 – 2.0</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.5 – 2.0</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Volatility</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">91% – 203</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">% </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">101% – 272</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">% </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">74% – 88</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Risk-free interest rates</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3.97%–4.94</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">% </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.05%–2.44</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">% </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.04%–0.17</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">% </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average grant date fair value</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.60</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.68</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.03</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">EQUITY INCENTIVE PLAN:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">In October 2006, the Company’s 2006 Equity Incentive Plan was approved by the shareholders, which provides for granting of incentive stock options, non-statutory stock options, restricted shares, RSUs, stock appreciation rights, PRSUs, performance restricted shares and other stock or cash awards as the Company’s Board of Directors may determine.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">In October 2016, the Company’s 2016 Equity Incentive Plan was approved by the Company’s shareholders. The 2016 Equity Incentive Plan replaced our 2006 Equity Incentive Plan, which was scheduled to expire in October 2016, and will continue in effect until 2026. The exercise price of each stock option equals the market value of the Company's common stock on the date of grant. Options typically vest over four years, subject to the grantee’s continued service with the Company through the scheduled vesting date, and expire in seven years from the grant date. A total of 4,848,000 shares of common stock have been reserved for issuance under the Company’s 2016 Equity Incentive Plan, which includes 2,248,000 shares that remained available for issuance under the 2006 Equity Incentive Plan. Full value awards, which are equity awards other than options, stock appreciation rights or other awards that are based solely on an increase in value of the shares following the grant date, when granted or forfeited will be counted as two times the number of shares added or deducted to the remaining available shares for issuance under 2016 Equity Incentive Plan. See the Company’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on November 16, 2021 for further information regarding the 2016 Equity Incentive Plan.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">  </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following tables summarize the Company’s stock option and RSU transactions during fiscal 2023, 2022 and 2021 (in thousands):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td></td><td style="white-space: nowrap;"></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Available</p></td><td style="white-space: nowrap;"></td></tr><tr style="height:15px"><td></td><td style="white-space: nowrap;"></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance, May 31, 2020</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,416</td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#ffffff"><td></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;"></td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Options granted</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(297</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">RSUs granted</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(680</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">RSUs cancelled</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Shares withheld for taxes and not issued</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18</td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Options terminated </p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">455</td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Options expired</p></td><td style="width:1%;white-space: nowrap;"></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(341</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;"></td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance, May 31, 2021 </p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">573</td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#cceeff"><td></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;"></td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Additional shares reserved</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,414</td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Options granted</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(303</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">RSUs granted</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,044</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">RSUs cancelled</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20</td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Shares withheld for taxes and not issued</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(30</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Options terminated </p></td><td style="width:1%;white-space: nowrap;"></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">105</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#ffffff"><td></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;"></td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance, May 31, 2022 </p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">735</td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#ffffff"><td></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;"></td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Options granted</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(110</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">RSUs granted</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(674</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">RSUs cancelled</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">60</td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Options terminated </p></td><td style="width:1%;white-space: nowrap;"></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">16</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#cceeff"><td></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;"></td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance, May 31, 2023 </p></td><td style="width:1%;white-space: nowrap;"></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">27</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following table summarized the stock option transactions during fiscal 2023, 2022 and 2021 (in thousands, except per share data):</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Outstanding Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Aggregate</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Intrinsic</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balances, May 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,153</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.17</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">102</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">297</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.78</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Options terminated </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(455</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.31</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(229</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.54</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balances, May 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,766</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.16</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">807</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">303</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.37</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Options terminated </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(105</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.59</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,367</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.28</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balances, May 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,597</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.70</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,290</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">110</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.06</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Options terminated </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(16</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.42</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(730</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.32</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balances, May 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">961</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.67</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,211</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options fully vested and expected to vest at May 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">947</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.66</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,796</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The options outstanding and exercisable at May 31, 2023 were in the following exercise price ranges (in thousands, except per share data):</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options Outstanding</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="14" style="width:6%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px">                       Options Exercisable</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">at May 31, 2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px">                           at May 31, 2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Range of Exercise</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Prices</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number Outstanding Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Remaining Contractual Life (Years)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number Exercisable Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Remaining Contractual Life (Years)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Aggregate Intrinsic Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td>1.34</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">41</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.39</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1.34</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">41</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.39</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1.34</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$1.64-$1.86</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">365</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3.53</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1.72</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">291</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3.45</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1.70</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$2.03-$2.40</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">185</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2.14</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">175</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2.48</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2.14</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td>2.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">139</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.12</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.12</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$3.46-$3.93</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">37</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1.11</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">37</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1.11</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$8.00-34.00</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">194</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.97</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9.77</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">41</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.90</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">10.18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$1.34-34.00</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">961</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.02</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3.67</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">620</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2.56</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">18,895</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The total intrinsic values of options exercised were $17,088,000, $12,542,000 and $152,000 during fiscal 2023, 2022 and 2021, respectively. The weighted average contractual life of the options exercisable and expected to be exercisable at May 31, 2023 was 4.01 years.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Options to purchase 620,000, 1,042,000 and 2,045,000 shares were exercisable at May 31, 2023, 2022 and 2021, respectively. These exercisable options had weighted average exercise prices of $2.56, $2.22 and $2.26 as of May 31, 2023, 2022 and 2021, respectively.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following table summarizes RSUs, PRSUs, restricted shares and performance restricted shares granted to employees and members of the Company’s Board of Directors during fiscal 2023, 2022 and 2021:</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">  </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Employees:</em></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Annual RSUs granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">152,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">161,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted-average grant-date fair value of annual RSUs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.03</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.17</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Annual restricted shares granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted-average grant-date fair value of annual restricted shares   </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">RSUs granted in lieu of cash payment for salary reductions and bonus</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">89,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted-average grant-date value of RSU in lieu of cash payment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.21</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Maximum PRSUs to be vested if all revenue goals are achieved</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">80,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">270,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Maximum Performance restricted shares to be vested if all revenue goals are achieved</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted-average grant-date fair value of PRSUs and performance restricted shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.41</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Members of Board of Directors:</em></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">RSUs granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">161,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted-average grant-date fair value of RSUs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.02</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.81</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Maximum PRSUs granted to be vested if all revenue goals are achieved</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted-average grant-date fair value of PRSUs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">PRSUs were granted to key officers and members of Board of Directors based upon revenue target thresholds for fiscal 2023 and 2022.</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following table summarizes the RSUs and PRSUs vested and unvested during fiscal 2023, 2022 and 2021:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net RSUs and PRSUs vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">240,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">96,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">207,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Shares withheld to settle payroll taxes  </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">178,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">62,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average grant-date fair value of vested RSUs and PRSUs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.47</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.12</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.90</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">RSUs and PRSUs cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average grant-date fair value of cancelled RSUs and PRSUs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.56</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.46</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">RSUs and PRSUs unvested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">345,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">185,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">132,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average grant-date fair value of unvested RSUs and PRSUs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.40</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.88</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Intrinsic value of unvested RSUs and PRSUs (in thousands)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,392</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,554</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">297</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">EMPLOYEE STOCK PURCHASE PLAN:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">In October 2006, the Company’s shareholders approved the 2006 Employee Stock Purchase Plan. In October 2016, the Company’s shareholders approved the Company’s Amended and Restated 2006 Employee Stock Purchase Plan (the “Purchase Plan”), which amended and restated the 2006 Employee Stock Purchase Plan. The Purchase Plan extended the term of the 2006 Employee Stock Purchase Plan indefinitely. See the Company’s Registration Statements on Form S-8 filed with the Securities and Exchange Commission on November 18, 2020 and November 16, 2022 for further information regarding the Purchase Plan. The Purchase Plan has consecutive, overlapping, twenty-four month offering periods. Each twenty-four-month offering period includes four six-month purchase periods. The offering periods generally begin on the first trading day on or after April 1 and October 1 each year. All employees who work a minimum of 20 hours per week and are customarily employed by the Company (or an affiliate thereof) for at least five months per calendar year are eligible to participate. Under the Purchase Plan, shares are purchased through employee payroll deductions at exercise prices equal to 85% of the lesser of the fair market value of the Company’s common stock at either the first day of an offering period or the last day of the purchase period. If a participant’s rights to purchase stock under all employee stock purchase plans of the Company accrue at a rate which exceeds $25,000 worth of stock for a calendar year, such participant may not be granted an option to purchase stock under the Purchase Plan. The maximum number of shares a participant may purchase during a single purchase period is 3,000 shares. In October 2022, the Company’s shareholders approved an amendment to the Purchase Plan to increase the number of shares authorized for issuance thereunder by an additional 350,000 shares of the Company’s common stock. After such amendment, a total of 2,550,000 shares of the Company’s common stock have been authorized for issuance under the Purchase Plan. During the fiscal years ended May 31, 2023, 2022 and 2021, ESPP purchase rights of 77,000, 101,000, and 279,000 shares, respectively, were granted. For the fiscal years ended May 31, 2023, 2022 and 2021, approximately 211,000, 178,000 and 147,000 shares of common stock, respectively, were issued under the Purchase Plan. As of May 31, 2023, a total of 2,152,000 shares have been issued under the Purchase Plan, and 398,000 ESPP shares remain available for issuance.</p> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation in the form of stock options,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">RSUs, and ESPP purchase rights, included in:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cost of sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">331</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">234</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">70</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Selling, general and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,711</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,721</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">816</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research and development </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">706</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">968</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">215</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net effect on net income (loss)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,748</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,923</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,101</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effect on earnings (net loss) per share:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.10</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.11</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.05</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.11</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.05</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 331000 234000 70000 1711000 1721000 816000 706000 968000 215000 2748000 2923000 1101000 0.10 0.11 0.05 0.09 0.11 0.05 120000 83000 0 1988000 2071000 993000 3102000 8000 P2Y3M18D 760000 935000 108000 715000 P1Y1M6D <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Fair Value. The fair values of the Company’s stock options granted to employees in fiscal 2023, 2022 and 2021 were estimated using the following weighted average assumptions in the Black-Scholes option valuation method:</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected term (in years)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5 - 6</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5 - 6</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">86</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">88</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">72</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Risk-free interest rates</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.12</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.50</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.44</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average grant date fair value</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.29</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.01</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.12</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> P5Y P6Y P5Y P6Y P6Y 0.86 0.88 0.72 0.0312 0.0150 0.0044 6.29 4.01 1.12 <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The fair value of our ESPP purchase rights for the fiscal 2023, 2022 and 2021 was estimated using the following weighted average assumptions:</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31, </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected term (in years) </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.5 – 2.0</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.5 – 2.0</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.5 – 2.0</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Volatility</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">91% – 203</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">% </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">101% – 272</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">% </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">74% – 88</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Risk-free interest rates</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3.97%–4.94</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">% </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.05%–2.44</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">% </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.04%–0.17</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">% </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average grant date fair value</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.60</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.68</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.03</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> P0Y6M P2Y P0Y6M P2Y P0Y6M P2Y 0.91 2.03 1.01 2.72 0.74 0.88 0.0397 0.0494 0.0005 0.0244 0.0004 0.0017 13.60 9.68 1.03 4848000 2248000 <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following tables summarize the Company’s stock option and RSU transactions during fiscal 2023, 2022 and 2021 (in thousands):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td></td><td style="white-space: nowrap;"></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Available</p></td><td style="white-space: nowrap;"></td></tr><tr style="height:15px"><td></td><td style="white-space: nowrap;"></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance, May 31, 2020</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,416</td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#ffffff"><td></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;"></td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Options granted</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(297</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">RSUs granted</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(680</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">RSUs cancelled</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Shares withheld for taxes and not issued</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18</td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Options terminated </p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">455</td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Options expired</p></td><td style="width:1%;white-space: nowrap;"></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(341</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;"></td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance, May 31, 2021 </p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">573</td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#cceeff"><td></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;"></td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Additional shares reserved</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,414</td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Options granted</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(303</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">RSUs granted</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,044</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">RSUs cancelled</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20</td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Shares withheld for taxes and not issued</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(30</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Options terminated </p></td><td style="width:1%;white-space: nowrap;"></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">105</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#ffffff"><td></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;"></td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance, May 31, 2022 </p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">735</td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#ffffff"><td></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;"></td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Options granted</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(110</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">RSUs granted</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(674</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">RSUs cancelled</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">60</td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Options terminated </p></td><td style="width:1%;white-space: nowrap;"></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">16</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#cceeff"><td></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"></td><td class="ffcell" style="width:9%;"></td><td style="width:1%;white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance, May 31, 2023 </p></td><td style="width:1%;white-space: nowrap;"></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">27</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"></td></tr></tbody></table> 1416000 297000 680000 2000 18000 455000 341000 573000 1414000 303000 1044000 20000 -30000 105000 735000 110000 674000 60000 16000 27000 <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following table summarized the stock option transactions during fiscal 2023, 2022 and 2021 (in thousands, except per share data):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Outstanding Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Aggregate</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Intrinsic</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balances, May 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,153</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.17</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">102</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">297</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.78</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Options terminated </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(455</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.31</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(229</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.54</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balances, May 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,766</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.16</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">807</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">303</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.37</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Options terminated </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(105</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.59</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,367</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.28</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balances, May 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,597</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.70</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,290</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">110</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.06</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Options terminated </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(16</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.42</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(730</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.32</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balances, May 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">961</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.67</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,211</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options fully vested and expected to vest at May 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">947</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.66</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,796</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 3153000 2.17 102000 297000 1.78 455000 2.31 229000 1.54 2766000 2.16 807000 303000 5.37 105000 1.59 1367000 2.28 1597000 2.70 9290000 110000 9.06 16000 5.42 730000 2.32 961000 3.67 28211000 947000 3.66 27796000 <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The options outstanding and exercisable at May 31, 2023 were in the following exercise price ranges (in thousands, except per share data):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options Outstanding</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="14" style="width:6%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px">                       Options Exercisable</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">at May 31, 2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px">                           at May 31, 2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Range of Exercise</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Prices</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number Outstanding Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Remaining Contractual Life (Years)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number Exercisable Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Remaining Contractual Life (Years)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Aggregate Intrinsic Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td>1.34</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">41</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.39</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1.34</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">41</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.39</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1.34</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$1.64-$1.86</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">365</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3.53</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1.72</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">291</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3.45</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1.70</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$2.03-$2.40</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">185</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2.14</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">175</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2.48</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2.14</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td>2.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">139</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.12</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.12</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$3.46-$3.93</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">37</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1.11</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">37</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1.11</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$8.00-34.00</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">194</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.97</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9.77</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">41</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.90</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">10.18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$1.34-34.00</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">961</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.02</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3.67</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">620</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2.56</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">18,895</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 1.34 41000 P4Y4M20D 1.34 41000 P4Y4M20D 365000 P3Y6M10D 1.72 291000 P3Y5M12D 1.70 185000 P2Y7M9D 2.14 175000 P2Y5M23D 2.14 2.93 139000 P5Y1M13D 2.93 35000 P5Y1M13D 37000 P1Y1M9D 3.93 37000 P1Y1M9D 3.93 194000 P5Y11M19D 9.77 41000 P5Y10M24D 10.18 961000 P4Y7D 3.67 620000 P3Y4M6D 2.56 18895000 17088000 12542000 152000 620000 1042000 2045000 2.56 2.22 2.26 <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following table summarizes RSUs, PRSUs, restricted shares and performance restricted shares granted to employees and members of the Company’s Board of Directors during fiscal 2023, 2022 and 2021:</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Employees:</em></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Annual RSUs granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">152,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">161,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted-average grant-date fair value of annual RSUs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.03</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.17</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Annual restricted shares granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted-average grant-date fair value of annual restricted shares   </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">RSUs granted in lieu of cash payment for salary reductions and bonus</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">89,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted-average grant-date value of RSU in lieu of cash payment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.21</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Maximum PRSUs to be vested if all revenue goals are achieved</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">80,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">270,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Maximum Performance restricted shares to be vested if all revenue goals are achieved</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted-average grant-date fair value of PRSUs and performance restricted shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.41</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Members of Board of Directors:</em></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">RSUs granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">161,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted-average grant-date fair value of RSUs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.02</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.81</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Maximum PRSUs granted to be vested if all revenue goals are achieved</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted-average grant-date fair value of PRSUs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 152000 120000 161000 8.03 3.17 1.86 8000 8.00 0 0 89000 18000 0 2.50 2.21 80000 270000 24000 8.00 3.41 0 44000 43000 161000 11.35 8.02 1.81 25000 0 8.00 0 <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The following table summarizes the RSUs and PRSUs vested and unvested during fiscal 2023, 2022 and 2021:</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net RSUs and PRSUs vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">240,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">96,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">207,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Shares withheld to settle payroll taxes  </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">178,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">62,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average grant-date fair value of vested RSUs and PRSUs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.47</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.12</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.90</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">RSUs and PRSUs cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average grant-date fair value of cancelled RSUs and PRSUs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.56</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.46</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">RSUs and PRSUs unvested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">345,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">185,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">132,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average grant-date fair value of unvested RSUs and PRSUs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.40</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.88</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Intrinsic value of unvested RSUs and PRSUs (in thousands)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,392</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,554</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">297</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 240000 96000 207000 178000 62000 9000 4.47 3.12 1.90 30000 10000 1000 8.56 2.93 3.46 345000 185000 132000 6.40 3.00 1.88 11392000 1554000 297000 25000 3000 350000 2550000 77000 101000 279000 211000 178000 147000 2152000 398000 <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>14. EMPLOYEE BENEFIT PLANS:</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">EMPLOYEE STOCK OWNERSHIP PLAN:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company has a non-contributory, trusteed employee stock ownership plan for full-time employees who have completed three consecutive months of service and for part-time employees who have completed one year of service and have attained an age of 21. The Company can contribute either shares of the Company’s stock or cash to the plan. The contribution is determined annually by the Company and cannot exceed 15% of the annual aggregate salaries of those employees eligible for participation in the plan. On May 31, 2007, the Company converted the Aehr Test Systems Employee Stock Bonus Plan into the Aehr Test Systems Employee Stock Ownership Plan (the “Plan”). The stock bonus plan was converted to an employee stock ownership plan (“ESOP”) to enable the Plan to better comply with changes in the law regarding Company stock. Individuals’ account balances vest at a rate of 20% per year commencing upon completion of two years of service. Non-vested balances, which are forfeited following termination of employment, are allocated to the remaining employees in the Plan. Under the Plan provisions, each employee who reaches age fifty-five (55) and has been a participant in the Plan for ten years will be offered an election each year to direct the transfer of up to 25% of his/her ESOP account to the employee self-directed account in the Savings and Retirement Plan. For anyone who met the above prerequisites, the first election to diversify holdings was offered after May 31, 2008. In the sixth year, employees will be able to diversify up to 50% of their ESOP accounts. Contributions of $300,000 were authorized for the plan during fiscal 2023, $250,000 for 2022 and $60,000 for 2021. The contribution amounts are recorded as compensation expense in the period authorized and included in accrued expenses in the period authorized. Contributions of 29,832 shares were made to the ESOP during fiscal 2023 for fiscal 2022. Contributions of 26,666 shares were made to the ESOP during fiscal 2022 for fiscal 2021. Contributions of 36,000 shares were made to the ESOP during fiscal 2021 for fiscal 2020. The contribution for fiscal 2023 will be made in fiscal 2024. Shares held in the ESOP are included in the EPS calculation.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">401(K) PLAN:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company maintains a defined contribution savings plan (the “401(k) Plan”) to provide retirement income to all qualified employees of the Company. The 401(k) Plan is intended to be qualified under Section 401(k) of the Internal Revenue Code of 1986, as amended. The 401(k) Plan is funded by voluntary pre-tax contributions from employees. Contributions are invested, as directed by the participant, in investment funds available under the 401(k) Plan. The Company is not required to make, and did not make, any contributions to the 401(k) Plan during fiscal 2023, 2022 and 2021.</p> The stock bonus plan was converted to an employee stock ownership plan (“ESOP”) to enable the Plan to better comply with changes in the law regarding Company stock. Individuals’ account balances vest at a rate of 20% per year commencing upon completion of two years of service 300000 250000 60000 <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>15. OTHER (EXPENSE) INCOME, NET:</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Other (expense) income, net comprises the following (in thousands):</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Foreign exchange (loss) gain</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(111</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other expense, net </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(51</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(3</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">30</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(162</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Other (expense) income, net comprises the following (in thousands):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Foreign exchange (loss) gain</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(111</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other expense, net </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(51</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(3</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">30</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(162</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> -3000 32000 -111000 -2000 -51000 -3000 30000 -162000 <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>16. PRODUCT WARRANTIES:</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company provides for the estimated cost of product warranties at the time revenues are recognized on the products shipped. While the Company engages in extensive product quality programs and processes, including actively monitoring and evaluating the quality of its component suppliers, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The standard warranty period is one year for systems and ninety days for parts and service.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Following is a summary of changes in the Company’s liability for product warranties during the fiscal years ended May 31, 2023 and 2022 (in thousands):</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">  </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at the beginning of the year</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">410</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">494</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accruals for warranties issued during the year </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">420</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">465</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Adjustment to previously existing warranty </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">98</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consumption of reserves </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(624</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(647</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at the end of the year</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">267</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">410</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The accrued warranty balance is included in accrued expenses on the consolidated balance sheets.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Following is a summary of changes in the Company’s liability for product warranties during the fiscal years ended May 31, 2023 and 2022 (in thousands):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at the beginning of the year</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">410</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">494</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accruals for warranties issued during the year </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">420</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">465</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Adjustment to previously existing warranty </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">98</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consumption of reserves </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(624</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(647</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at the end of the year</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">267</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">410</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 410000 494000 420000 465000 61000 98000 624000 647000 267000 410000 <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>17. SEGMENT INFORMATION:</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company has only one reportable segment. The information for revenue category by type, product line, geography and timing of revenue recognition, is summarized in Note 2, “Revenue.”</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Property and equipment information is based on the physical location of the assets. The following table presents property and equipment information for geographic areas (in thousands):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">United States</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,713</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,156</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Asia </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">47</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Europe</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,759</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,203</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">As of May 31, 2023, operating lease right-of-use assets of $6,007,000, $70,000 and $45,000 were allocated in the United States, Asia and Europe, respectively. As of May 31, 2022, the operating lease right-of-use assets of $822,000 and $95,000 were allocated in the United States and Asia, respectively.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">There were no revenues through distributors for the fiscal years ended May 31, 2023, 2022 and 2021.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Property and equipment information is based on the physical location of the assets. The following table presents property and equipment information for geographic areas (in thousands):</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">United States</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,713</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,156</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Asia </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">47</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Europe</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,759</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,203</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 2713000 1156000 44000 47000 2000 0 2759000 1203000 6007000 70000 45000 822000 95000 <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>18. DISSOLUTION OF AEHR TEST SYSTEMS JAPAN:</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">On July 31, 2020, the Company completed the liquidation of ATS-Japan, a majority owned subsidiary. Accordingly, the Company deconsolidated ATS-Japan and recognized an aggregate net gain of $2,401,000 for the period ended August 31, 2020. The net gain was mainly due to cumulative translation adjustment reclassified into earnings of $2,186,000 and the residual income tax effect in connection with the cumulative translation adjustment released into income tax benefits of $215,000.</p> 2401000 2186000 215000 <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>19. EQUITY:</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">On August 25, 2021, the Board of Directors authorized management to take actions necessary for the execution of a $75 million shelf registration. A Registration Statement on Form S-3 was filed with the SEC on September 3, 2021. A Prospectus Supplement for an "At the Market" ("ATM") sale of $25 million of common stock was subsequently filed on September 17, 2021. On October 8, 2021, the Company executed the ATM offering by selling 1,696,729 shares of common stock at an average selling price of $14.73 per share. The gross proceeds to the Company were $25.0 million, before commission fees of $0.7 million and offering expenses of $0.3 million. Another Prospectus Supplement for an ATM sale of $25 million of common stock was subsequently filed on February 8, 2023. The Company partially executed the ATM offering by selling 208,917 shares of common stock at an average selling price of $34.78 per share. The gross proceeds to the Company were $7.3 million, before commissions of $0.2 million and offering expenses of $0.2 million.</p> 75000000 1696729 14.73 25000000.0 700000 300000 208917 34.78 7300000 200000 200000 <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>20. COMMITMENTS AND CONTINGENCIES:</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">COMMITMENTS</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">As of May 31, 2023 and 2022, the Company had restricted money market funds of $150,000 and $80,000, respectively, held by a financial institution, representing a security deposit for its United States manufacturing and office space lease. This amount is included in other assets on the consolidated balance sheets.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">PURCHASE OBLIGATIONS</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company has purchase obligations to certain suppliers. In some cases, the products the Company purchases are unique and have provisions against cancellation of the order. At May 31, 2023, the Company had $26,318,000 of purchase obligations which are due within the following 12 months. This amount does not include contractual obligations recorded on the consolidated balance sheets as liabilities.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">CONTINGENCIES</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">The Company may, from time to time, be involved in legal proceedings arising in the ordinary course of business. While there can be no assurances as to the ultimate outcome of any litigation involving the Company, management does not believe any pending legal proceedings will result in judgment or settlement that will have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">In the normal course of business to facilitate sales of its products, the Company indemnifies other parties, including customers, with respect to certain matters, for example, including against losses arising from a breach of representations or covenants, or from intellectual property infringement or other claims. These agreements may limit the time within which an indemnification claim can be made and the amount of the claim. In addition, the Company has entered into indemnification agreements with its officers and directors, and the Company’s bylaws contain similar indemnification obligations to the Company’s agents.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">It is not possible to determine the maximum potential amount under these indemnification agreements due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. To date, payments made by the Company under these agreements have not had a material impact on the Company’s operating results, financial position or cash flow.</p> 150000 80000 26318000 EXCEL 101 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 102 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 103 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 104 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 248 401 1 false 69 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://aehr.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://aehr.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://aehr.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://aehr.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 5 false false R6.htm 000006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Sheet http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Statements 6 false false R7.htm 000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 000008 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 000009 - Disclosure - REVENUE Sheet http://aehr.com/role/REVENUE REVENUE Notes 9 false false R10.htm 000010 - Disclosure - EARNINGS PER SHARE (EPS) Sheet http://aehr.com/role/EarningsPerShareEps EARNINGS PER SHARE (EPS) Notes 10 false false R11.htm 000011 - Disclosure - CASH, CASH EQUIVALENTS AND INVESTMENTS Sheet http://aehr.com/role/CashCashEquivalentsAndInvestments CASH, CASH EQUIVALENTS AND INVESTMENTS Notes 11 false false R12.htm 000012 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS Sheet http://aehr.com/role/FairValueOfFinancialInstruments FAIR VALUE OF FINANCIAL INSTRUMENTS Notes 12 false false R13.htm 000013 - Disclosure - TRADE AND OTHER ACCOUNTS RECEIVABLE, NET Sheet http://aehr.com/role/TradeAndOtherAccountsReceivableNet TRADE AND OTHER ACCOUNTS RECEIVABLE, NET Notes 13 false false R14.htm 000014 - Disclosure - BALANCE SHEET DETAIL Sheet http://aehr.com/role/BalanceSheetDetail BALANCE SHEET DETAIL Notes 14 false false R15.htm 000015 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS Sheet http://aehr.com/role/AccumulatedOtherComprehensiveLoss ACCUMULATED OTHER COMPREHENSIVE LOSS Notes 15 false false R16.htm 000016 - Disclosure - INCOME TAXES Sheet http://aehr.com/role/IncomeTaxes INCOME TAXES Notes 16 false false R17.htm 000017 - Disclosure - LEASES Sheet http://aehr.com/role/LEASES LEASES Notes 17 false false R18.htm 000018 - Disclosure - BORROWING AND FINANCING ARRANGEMENTS Sheet http://aehr.com/role/BorrowingAndFinancingArrangements BORROWING AND FINANCING ARRANGEMENTS Notes 18 false false R19.htm 000019 - Disclosure - LONGTERM DEBT Sheet http://aehr.com/role/LongtermDebt LONGTERM DEBT Notes 19 false false R20.htm 000020 - Disclosure - STOCK-BASED COMPENSATION Sheet http://aehr.com/role/StockBasedCompensation STOCK-BASED COMPENSATION Notes 20 false false R21.htm 000021 - Disclosure - EMPLOYEE BENEFIT PLANS Sheet http://aehr.com/role/EmployeeBenefitPlans EMPLOYEE BENEFIT PLANS Notes 21 false false R22.htm 000022 - Disclosure - OTHER INCOME (EXPENSE) NET Sheet http://aehr.com/role/OtherIncomeExpenseNet OTHER INCOME (EXPENSE) NET Notes 22 false false R23.htm 000023 - Disclosure - PRODUCT WARRANTIES Sheet http://aehr.com/role/ProductWarranties PRODUCT WARRANTIES Notes 23 false false R24.htm 000024 - Disclosure - SEGMENT INFORMATION Sheet http://aehr.com/role/SegmentInformation SEGMENT INFORMATION Notes 24 false false R25.htm 000025 - Disclosure - DISSOLUTION OF AEHR TEST SYSTEMS JAPAN Sheet http://aehr.com/role/DissolutionOfAehrTestSystemsJapan DISSOLUTION OF AEHR TEST SYSTEMS JAPAN Notes 25 false false R26.htm 000026 - Disclosure - EQUITY Sheet http://aehr.com/role/EQUITY EQUITY Notes 26 false false R27.htm 000027 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://aehr.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 27 false false R28.htm 000028 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 28 false false R29.htm 000029 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 29 false false R30.htm 000030 - Disclosure - REVENUE (Tables) Sheet http://aehr.com/role/RevenueTables REVENUE (Tables) Tables http://aehr.com/role/REVENUE 30 false false R31.htm 000031 - Disclosure - EARNINGS PER SHARE (EPS) (Tables) Sheet http://aehr.com/role/EarningsPerShareEpsTables EARNINGS PER SHARE (EPS) (Tables) Tables http://aehr.com/role/EarningsPerShareEps 31 false false R32.htm 000032 - Disclosure - CASH, CASH EQUIVALENTS AND INVESTMENTS (Tables) Sheet http://aehr.com/role/CashCashEquivalentsAndInvestmentsTables CASH, CASH EQUIVALENTS AND INVESTMENTS (Tables) Tables http://aehr.com/role/CashCashEquivalentsAndInvestments 32 false false R33.htm 000033 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) Sheet http://aehr.com/role/FairValueOfFinancialInstrumentsTables FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) Tables http://aehr.com/role/FairValueOfFinancialInstruments 33 false false R34.htm 000034 - Disclosure - TRADE AND OTHER ACCOUNTS RECEIVABLE, NET (Tables) Sheet http://aehr.com/role/TradeAndOtherAccountsReceivableNetTables TRADE AND OTHER ACCOUNTS RECEIVABLE, NET (Tables) Tables http://aehr.com/role/TradeAndOtherAccountsReceivableNet 34 false false R35.htm 000035 - Disclosure - BALANCE SHEET DETAIL (Tables) Sheet http://aehr.com/role/BalanceSheetDetailTables BALANCE SHEET DETAIL (Tables) Tables http://aehr.com/role/BalanceSheetDetail 35 false false R36.htm 000036 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) Sheet http://aehr.com/role/AccumulatedOtherComprehensiveLossTables ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) Tables http://aehr.com/role/AccumulatedOtherComprehensiveLoss 36 false false R37.htm 000037 - Disclosure - INCOME TAXES (Tables) Sheet http://aehr.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://aehr.com/role/IncomeTaxes 37 false false R38.htm 000038 - Disclosure - LEASES (Tables) Sheet http://aehr.com/role/LeasesTables LEASES (Tables) Tables http://aehr.com/role/LEASES 38 false false R39.htm 000039 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://aehr.com/role/StockBasedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://aehr.com/role/StockBasedCompensation 39 false false R40.htm 000040 - Disclosure - OTHER INCOME (EXPENSE) NET (Tables) Sheet http://aehr.com/role/OtherIncomeExpenseNetTables OTHER INCOME (EXPENSE) NET (Tables) Tables http://aehr.com/role/OtherIncomeExpenseNet 40 false false R41.htm 000041 - Disclosure - PRODUCT WARRANTIES (Tables) Sheet http://aehr.com/role/ProductWarrantiesTables PRODUCT WARRANTIES (Tables) Tables http://aehr.com/role/ProductWarranties 41 false false R42.htm 000042 - Disclosure - SEGMENT INFORMATION (Tables) Sheet http://aehr.com/role/SegmentInformationTables SEGMENT INFORMATION (Tables) Tables http://aehr.com/role/SegmentInformation 42 false false R43.htm 000043 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 43 false false R44.htm 000044 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 44 false false R45.htm 000045 - Disclosure - REVENUE (Details) Sheet http://aehr.com/role/RevenueDetails REVENUE (Details) Details http://aehr.com/role/RevenueTables 45 false false R46.htm 000046 - Disclosure - REVENUE (Details 1) Sheet http://aehr.com/role/RevenueDetails1 REVENUE (Details 1) Details http://aehr.com/role/RevenueTables 46 false false R47.htm 000047 - Disclosure - REVENUE (Details 2) Sheet http://aehr.com/role/RevenueDetails2 REVENUE (Details 2) Details http://aehr.com/role/RevenueTables 47 false false R48.htm 000048 - Disclosure - REVENUE (Details Narrative) Sheet http://aehr.com/role/RevenueDetailsNarrative REVENUE (Details Narrative) Details http://aehr.com/role/RevenueTables 48 false false R49.htm 000049 - Disclosure - EARNINGS PER SHARE (EPS) (Details) Sheet http://aehr.com/role/EarningsPerShareEpsDetails EARNINGS PER SHARE (EPS) (Details) Details http://aehr.com/role/EarningsPerShareEpsTables 49 false false R50.htm 000050 - Disclosure - EARNINGS PER SHARE (EPS) (Details Narrative) Sheet http://aehr.com/role/EarningsPerShareEpsDetailsNarrative EARNINGS PER SHARE (EPS) (Details Narrative) Details http://aehr.com/role/EarningsPerShareEpsTables 50 false false R51.htm 000051 - Disclosure - CASH CASH EQUIVALENTS AND INVESTMENTS (Details) Sheet http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails CASH CASH EQUIVALENTS AND INVESTMENTS (Details) Details 51 false false R52.htm 000052 - Disclosure - CASH CASH EQUIVALENTS AND INVESTMENTS (Details Narrative) Sheet http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetailsNarrative CASH CASH EQUIVALENTS AND INVESTMENTS (Details Narrative) Details 52 false false R53.htm 000053 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) Sheet http://aehr.com/role/FairValueOfFinancialInstrumentsDetails FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) Details http://aehr.com/role/FairValueOfFinancialInstrumentsTables 53 false false R54.htm 000054 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details Narrative) Sheet http://aehr.com/role/FairValueOfFinancialInstrumentsDetailsNarrative FAIR VALUE OF FINANCIAL INSTRUMENTS (Details Narrative) Details http://aehr.com/role/FairValueOfFinancialInstrumentsTables 54 false false R55.htm 000055 - Disclosure - TRADE AND OTHER ACCOUNTS RECEIVABLE, NET (Details) Sheet http://aehr.com/role/TradeAndOtherAccountsReceivableNetDetails TRADE AND OTHER ACCOUNTS RECEIVABLE, NET (Details) Details http://aehr.com/role/TradeAndOtherAccountsReceivableNetTables 55 false false R56.htm 000056 - Disclosure - BALANCE SHEET DETAIL (Details) Sheet http://aehr.com/role/BalanceSheetDetailDetails BALANCE SHEET DETAIL (Details) Details http://aehr.com/role/BalanceSheetDetailTables 56 false false R57.htm 000057 - Disclosure - BALANCE SHEET DETAIL (Details 1) Sheet http://aehr.com/role/BalanceSheetDetailDetails1 BALANCE SHEET DETAIL (Details 1) Details http://aehr.com/role/BalanceSheetDetailTables 57 false false R58.htm 000058 - Disclosure - BALANCE SHEET DETAIL (Details 2) Sheet http://aehr.com/role/BalanceSheetDetailDetails2 BALANCE SHEET DETAIL (Details 2) Details http://aehr.com/role/BalanceSheetDetailTables 58 false false R59.htm 000059 - Disclosure - BALANCE SHEET DETAIL (Details 3) Sheet http://aehr.com/role/BalanceSheetDetailDetails3 BALANCE SHEET DETAIL (Details 3) Details http://aehr.com/role/BalanceSheetDetailTables 59 false false R60.htm 000060 - Disclosure - BALANCE SHEET DETAIL (Details Narrative) Sheet http://aehr.com/role/BalanceSheetDetailDetailsNarrative BALANCE SHEET DETAIL (Details Narrative) Details http://aehr.com/role/BalanceSheetDetailTables 60 false false R61.htm 000061 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) Sheet http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) Details http://aehr.com/role/AccumulatedOtherComprehensiveLossTables 61 false false R62.htm 000062 - Disclosure - INCOME TAXES (Details) Sheet http://aehr.com/role/IncomeTaxesDetails INCOME TAXES (Details) Details http://aehr.com/role/IncomeTaxesTables 62 false false R63.htm 000063 - Disclosure - INCOME TAXES (Details 1) Sheet http://aehr.com/role/IncomeTaxesDetails1 INCOME TAXES (Details 1) Details http://aehr.com/role/IncomeTaxesTables 63 false false R64.htm 000064 - Disclosure - INCOME TAXES (Details 2) Sheet http://aehr.com/role/IncomeTaxesDetails2 INCOME TAXES (Details 2) Details http://aehr.com/role/IncomeTaxesTables 64 false false R65.htm 000065 - Disclosure - INCOME TAXES (Details 3) Sheet http://aehr.com/role/IncomeTaxesDetails3 INCOME TAXES (Details 3) Details http://aehr.com/role/IncomeTaxesTables 65 false false R66.htm 000066 - Disclosure - INCOME TAXES (Details 4) Sheet http://aehr.com/role/IncomeTaxesDetails4 INCOME TAXES (Details 4) Details http://aehr.com/role/IncomeTaxesTables 66 false false R67.htm 000067 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://aehr.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://aehr.com/role/IncomeTaxesTables 67 false false R68.htm 000068 - Disclosure - LEASES (Details) Sheet http://aehr.com/role/LeasesDetails LEASES (Details) Details http://aehr.com/role/LeasesTables 68 false false R69.htm 000069 - Disclosure - LEASES (Details 1) Sheet http://aehr.com/role/LeasesDetails1 LEASES (Details 1) Details http://aehr.com/role/LeasesTables 69 false false R70.htm 000070 - Disclosure - LEASES (Details Narrative) Sheet http://aehr.com/role/LeasesDetailsNarrative LEASES (Details Narrative) Details http://aehr.com/role/LeasesTables 70 false false R71.htm 000071 - Disclosure - BORROWING AND FINANCING ARRANGEMENTS (Details Narrative) Sheet http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative BORROWING AND FINANCING ARRANGEMENTS (Details Narrative) Details http://aehr.com/role/BorrowingAndFinancingArrangements 71 false false R72.htm 000072 - Disclosure - LONGTERM DEBT (Details Narrative) Sheet http://aehr.com/role/LongtermDebtDetailsNarrative LONGTERM DEBT (Details Narrative) Details http://aehr.com/role/LongtermDebt 72 false false R73.htm 000073 - Disclosure - STOCK-BASED COMPENSATION (Details) Sheet http://aehr.com/role/StockBasedCompensationDetails STOCK-BASED COMPENSATION (Details) Details http://aehr.com/role/StockBasedCompensationTables 73 false false R74.htm 000074 - Disclosure - STOCK-BASED COMPENSATION (Details 1) Sheet http://aehr.com/role/StockBasedCompensationDetails1 STOCK-BASED COMPENSATION (Details 1) Details http://aehr.com/role/StockBasedCompensationTables 74 false false R75.htm 000075 - Disclosure - STOCK-BASED COMPENSATION (Details 2) Sheet http://aehr.com/role/StockBasedCompensationDetails2 STOCK-BASED COMPENSATION (Details 2) Details http://aehr.com/role/StockBasedCompensationTables 75 false false R76.htm 000076 - Disclosure - STOCK-BASED COMPENSATION (Details 3) Sheet http://aehr.com/role/StockBasedCompensationDetails3 STOCK-BASED COMPENSATION (Details 3) Details http://aehr.com/role/StockBasedCompensationTables 76 false false R77.htm 000077 - Disclosure - STOCK-BASED COMPENSATION (Details 4) Sheet http://aehr.com/role/StockBasedCompensationDetails4 STOCK-BASED COMPENSATION (Details 4) Details http://aehr.com/role/StockBasedCompensationTables 77 false false R78.htm 000078 - Disclosure - STOCK-BASED COMPENSATION (Details 5) Sheet http://aehr.com/role/StockBasedCompensationDetails5 STOCK-BASED COMPENSATION (Details 5) Details http://aehr.com/role/StockBasedCompensationTables 78 false false R79.htm 000079 - Disclosure - STOCKBASED COMPENSATION (Details 6) Sheet http://aehr.com/role/StockbasedCompensationDetails6 STOCKBASED COMPENSATION (Details 6) Details 79 false false R80.htm 000080 - Disclosure - STOCKBASED COMPENSATION (Details 7) Sheet http://aehr.com/role/StockbasedCompensationDetails7 STOCKBASED COMPENSATION (Details 7) Details 80 false false R81.htm 000081 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) Sheet http://aehr.com/role/StockBasedCompensationDetailsNarrative STOCK-BASED COMPENSATION (Details Narrative) Details http://aehr.com/role/StockBasedCompensationTables 81 false false R82.htm 000082 - Disclosure - EMPLOYEE BENEFIT PLANS (Details Narrative) Sheet http://aehr.com/role/EmployeeBenefitPlansDetailsNarrative EMPLOYEE BENEFIT PLANS (Details Narrative) Details http://aehr.com/role/EmployeeBenefitPlans 82 false false R83.htm 000083 - Disclosure - OTHER INCOME (EXPENSE) NET (Details) Sheet http://aehr.com/role/OtherIncomeExpenseNetDetails OTHER INCOME (EXPENSE) NET (Details) Details http://aehr.com/role/OtherIncomeExpenseNetTables 83 false false R84.htm 000084 - Disclosure - PRODUCT WARRANTIES (Details) Sheet http://aehr.com/role/ProductWarrantiesDetails PRODUCT WARRANTIES (Details) Details http://aehr.com/role/ProductWarrantiesTables 84 false false R85.htm 000085 - Disclosure - SEGMENT INFORMATION (Details) Sheet http://aehr.com/role/SegmentInformationDetails SEGMENT INFORMATION (Details) Details http://aehr.com/role/SegmentInformationTables 85 false false R86.htm 000086 - Disclosure - SEGMENT INFORMATION (Details Narrative) Sheet http://aehr.com/role/SegmentInformationDetailsNarrative SEGMENT INFORMATION (Details Narrative) Details http://aehr.com/role/SegmentInformationTables 86 false false R87.htm 000087 - Disclosure - DISSOLUTION OF AEHR TEST SYSTEMS JAPAN (Details Narrative) Sheet http://aehr.com/role/DissolutionOfAehrTestSystemsJapanDetailsNarrative DISSOLUTION OF AEHR TEST SYSTEMS JAPAN (Details Narrative) Details http://aehr.com/role/DissolutionOfAehrTestSystemsJapan 87 false false R88.htm 000088 - Disclosure - EQUITY (Details Narrative) Sheet http://aehr.com/role/EquityDetailsNarrative EQUITY (Details Narrative) Details http://aehr.com/role/EQUITY 88 false false R89.htm 000089 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://aehr.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://aehr.com/role/CommitmentsAndContingencies 89 false false All Reports Book All Reports aehr_10k.htm aehr-20230531.xsd aehr-20230531_cal.xml aehr-20230531_def.xml aehr-20230531_lab.xml aehr-20230531_pre.xml aehr_ex231.htm aehr_ex311.htm aehr_ex312.htm aehr_ex321.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 107 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "aehr_10k.htm": { "axisCustom": 0, "axisStandard": 21, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1007, "http://xbrl.sec.gov/dei/2023": 36 }, "contextCount": 248, "dts": { "calculationLink": { "local": [ "aehr-20230531_cal.xml" ] }, "definitionLink": { "local": [ "aehr-20230531_def.xml" ] }, "inline": { "local": [ "aehr_10k.htm" ] }, "labelLink": { "local": [ "aehr-20230531_lab.xml" ] }, "presentationLink": { "local": [ "aehr-20230531_pre.xml" ] }, "schema": { "local": [ "aehr-20230531.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "elementCount": 563, "entityCount": 1, "hidden": { "http://aehr.com/20230531": 10, "http://fasb.org/us-gaap/2023": 24, "http://xbrl.sec.gov/dei/2023": 6, "total": 40 }, "keyCustom": 67, "keyStandard": 334, "memberCustom": 39, "memberStandard": 30, "nsprefix": "aehr", "nsuri": "http://aehr.com/20230531", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://aehr.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - EARNINGS PER SHARE (EPS)", "menuCat": "Notes", "order": "10", "role": "http://aehr.com/role/EarningsPerShareEps", "shortName": "EARNINGS PER SHARE (EPS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - CASH, CASH EQUIVALENTS AND INVESTMENTS", "menuCat": "Notes", "order": "11", "role": "http://aehr.com/role/CashCashEquivalentsAndInvestments", "shortName": "CASH, CASH EQUIVALENTS AND INVESTMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS", "menuCat": "Notes", "order": "12", "role": "http://aehr.com/role/FairValueOfFinancialInstruments", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - TRADE AND OTHER ACCOUNTS RECEIVABLE, NET", "menuCat": "Notes", "order": "13", "role": "http://aehr.com/role/TradeAndOtherAccountsReceivableNet", "shortName": "TRADE AND OTHER ACCOUNTS RECEIVABLE, NET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - BALANCE SHEET DETAIL", "menuCat": "Notes", "order": "14", "role": "http://aehr.com/role/BalanceSheetDetail", "shortName": "BALANCE SHEET DETAIL", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS", "menuCat": "Notes", "order": "15", "role": "http://aehr.com/role/AccumulatedOtherComprehensiveLoss", "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "16", "role": "http://aehr.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - LEASES", "menuCat": "Notes", "order": "17", "role": "http://aehr.com/role/LEASES", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - BORROWING AND FINANCING ARRANGEMENTS", "menuCat": "Notes", "order": "18", "role": "http://aehr.com/role/BorrowingAndFinancingArrangements", "shortName": "BORROWING AND FINANCING ARRANGEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - LONGTERM DEBT", "menuCat": "Notes", "order": "19", "role": "http://aehr.com/role/LongtermDebt", "shortName": "LONGTERM DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://aehr.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "-3", "lang": null, "name": "us-gaap:OtherShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - STOCK-BASED COMPENSATION", "menuCat": "Notes", "order": "20", "role": "http://aehr.com/role/StockBasedCompensation", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - EMPLOYEE BENEFIT PLANS", "menuCat": "Notes", "order": "21", "role": "http://aehr.com/role/EmployeeBenefitPlans", "shortName": "EMPLOYEE BENEFIT PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - OTHER INCOME (EXPENSE) NET", "menuCat": "Notes", "order": "22", "role": "http://aehr.com/role/OtherIncomeExpenseNet", "shortName": "OTHER INCOME (EXPENSE) NET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - PRODUCT WARRANTIES", "menuCat": "Notes", "order": "23", "role": "http://aehr.com/role/ProductWarranties", "shortName": "PRODUCT WARRANTIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - SEGMENT INFORMATION", "menuCat": "Notes", "order": "24", "role": "http://aehr.com/role/SegmentInformation", "shortName": "SEGMENT INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "aehr:DissolutionOfAehrTestSystemsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - DISSOLUTION OF AEHR TEST SYSTEMS JAPAN", "menuCat": "Notes", "order": "25", "role": "http://aehr.com/role/DissolutionOfAehrTestSystemsJapan", "shortName": "DISSOLUTION OF AEHR TEST SYSTEMS JAPAN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "aehr:DissolutionOfAehrTestSystemsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - EQUITY", "menuCat": "Notes", "order": "26", "role": "http://aehr.com/role/EQUITY", "shortName": "EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "27", "role": "http://aehr.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "28", "role": "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "aehr:ScheduleOfUsefulLifeForPropertyAndEquipmentTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "menuCat": "Tables", "order": "29", "role": "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "aehr:ScheduleOfUsefulLifeForPropertyAndEquipmentTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockNoParValue", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://aehr.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockNoParValue", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - REVENUE (Tables)", "menuCat": "Tables", "order": "30", "role": "http://aehr.com/role/RevenueTables", "shortName": "REVENUE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - EARNINGS PER SHARE (EPS) (Tables)", "menuCat": "Tables", "order": "31", "role": "http://aehr.com/role/EarningsPerShareEpsTables", "shortName": "EARNINGS PER SHARE (EPS) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - CASH, CASH EQUIVALENTS AND INVESTMENTS (Tables)", "menuCat": "Tables", "order": "32", "role": "http://aehr.com/role/CashCashEquivalentsAndInvestmentsTables", "shortName": "CASH, CASH EQUIVALENTS AND INVESTMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)", "menuCat": "Tables", "order": "33", "role": "http://aehr.com/role/FairValueOfFinancialInstrumentsTables", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - TRADE AND OTHER ACCOUNTS RECEIVABLE, NET (Tables)", "menuCat": "Tables", "order": "34", "role": "http://aehr.com/role/TradeAndOtherAccountsReceivableNetTables", "shortName": "TRADE AND OTHER ACCOUNTS RECEIVABLE, NET (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000035 - Disclosure - BALANCE SHEET DETAIL (Tables)", "menuCat": "Tables", "order": "35", "role": "http://aehr.com/role/BalanceSheetDetailTables", "shortName": "BALANCE SHEET DETAIL (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000036 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)", "menuCat": "Tables", "order": "36", "role": "http://aehr.com/role/AccumulatedOtherComprehensiveLossTables", "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000037 - Disclosure - INCOME TAXES (Tables)", "menuCat": "Tables", "order": "37", "role": "http://aehr.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000038 - Disclosure - LEASES (Tables)", "menuCat": "Tables", "order": "38", "role": "http://aehr.com/role/LeasesTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000039 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "menuCat": "Tables", "order": "39", "role": "http://aehr.com/role/StockBasedCompensationTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "4", "role": "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000040 - Disclosure - OTHER INCOME (EXPENSE) NET (Tables)", "menuCat": "Tables", "order": "40", "role": "http://aehr.com/role/OtherIncomeExpenseNetTables", "shortName": "OTHER INCOME (EXPENSE) NET (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:ProductWarrantyDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000041 - Disclosure - PRODUCT WARRANTIES (Tables)", "menuCat": "Tables", "order": "41", "role": "http://aehr.com/role/ProductWarrantiesTables", "shortName": "PRODUCT WARRANTIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ProductWarrantyDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000042 - Disclosure - SEGMENT INFORMATION (Tables)", "menuCat": "Tables", "order": "42", "role": "http://aehr.com/role/SegmentInformationTables", "shortName": "SEGMENT INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "aehr:ScheduleOfUsefulLifeForPropertyAndEquipmentTableTextblock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31_srt_MaximumMember_us-gaap_FurnitureAndFixturesMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000043 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "menuCat": "Details", "order": "43", "role": "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "aehr:ScheduleOfUsefulLifeForPropertyAndEquipmentTableTextblock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31_srt_MaximumMember_us-gaap_FurnitureAndFixturesMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000044 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "menuCat": "Details", "order": "44", "role": "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000045 - Disclosure - REVENUE (Details)", "menuCat": "Details", "order": "45", "role": "http://aehr.com/role/RevenueDetails", "shortName": "REVENUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31_aehr_SystemsMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000046 - Disclosure - REVENUE (Details 1)", "menuCat": "Details", "order": "46", "role": "http://aehr.com/role/RevenueDetails1", "shortName": "REVENUE (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31_srt_AsiaMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000047 - Disclosure - REVENUE (Details 2)", "menuCat": "Details", "order": "47", "role": "http://aehr.com/role/RevenueDetails2", "shortName": "REVENUE (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31_aehr_ProductsAndServicesTransferredAtAPointInTimeMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000048 - Disclosure - REVENUE (Details Narrative)", "menuCat": "Details", "order": "48", "role": "http://aehr.com/role/RevenueDetailsNarrative", "shortName": "REVENUE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000049 - Disclosure - EARNINGS PER SHARE (EPS) (Details)", "menuCat": "Details", "order": "49", "role": "http://aehr.com/role/EarningsPerShareEpsDetails", "shortName": "EARNINGS PER SHARE (EPS) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "lang": null, "name": "aehr:SharesUsedInBasicNetIncomeLossPerShareCalculation", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "menuCat": "Statements", "order": "5", "role": "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2020-06-01to2021-05-31_us-gaap_EmployeeStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000050 - Disclosure - EARNINGS PER SHARE (EPS) (Details Narrative)", "menuCat": "Details", "order": "50", "role": "http://aehr.com/role/EarningsPerShareEpsDetailsNarrative", "shortName": "EARNINGS PER SHARE (EPS) (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2020-06-01to2021-05-31_us-gaap_EmployeeStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000051 - Disclosure - CASH CASH EQUIVALENTS AND INVESTMENTS (Details)", "menuCat": "Details", "order": "51", "role": "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails", "shortName": "CASH CASH EQUIVALENTS AND INVESTMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31_aehr_CostMember", "decimals": "-3", "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrealizedGainLossOnInvestments", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000052 - Disclosure - CASH CASH EQUIVALENTS AND INVESTMENTS (Details Narrative)", "menuCat": "Details", "order": "52", "role": "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetailsNarrative", "shortName": "CASH CASH EQUIVALENTS AND INVESTMENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31_aehr_GrossUnrealizedLossMember", "decimals": "0", "lang": null, "name": "us-gaap:UnrealizedGainLossOnInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31_us-gaap_AssetsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000053 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)", "menuCat": "Details", "order": "53", "role": "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31_us-gaap_AssetsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RestrictedCashNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000054 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details Narrative)", "menuCat": "Details", "order": "54", "role": "http://aehr.com/role/FairValueOfFinancialInstrumentsDetailsNarrative", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RestrictedCashNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000055 - Disclosure - TRADE AND OTHER ACCOUNTS RECEIVABLE, NET (Details)", "menuCat": "Details", "order": "55", "role": "http://aehr.com/role/TradeAndOtherAccountsReceivableNetDetails", "shortName": "TRADE AND OTHER ACCOUNTS RECEIVABLE, NET (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000056 - Disclosure - BALANCE SHEET DETAIL (Details)", "menuCat": "Details", "order": "56", "role": "http://aehr.com/role/BalanceSheetDetailDetails", "shortName": "BALANCE SHEET DETAIL (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LeaseholdImprovementsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000057 - Disclosure - BALANCE SHEET DETAIL (Details 1)", "menuCat": "Details", "order": "57", "role": "http://aehr.com/role/BalanceSheetDetailDetails1", "shortName": "BALANCE SHEET DETAIL (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LeaseholdImprovementsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherEmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000058 - Disclosure - BALANCE SHEET DETAIL (Details 2)", "menuCat": "Details", "order": "58", "role": "http://aehr.com/role/BalanceSheetDetailDetails2", "shortName": "BALANCE SHEET DETAIL (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherEmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CustomerDepositsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000059 - Disclosure - BALANCE SHEET DETAIL (Details 3)", "menuCat": "Details", "order": "59", "role": "http://aehr.com/role/BalanceSheetDetailDetails3", "shortName": "BALANCE SHEET DETAIL (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CustomerDepositsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2020-05-31_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "menuCat": "Statements", "order": "6", "role": "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity", "shortName": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2020-05-31_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000060 - Disclosure - BALANCE SHEET DETAIL (Details Narrative)", "menuCat": "Details", "order": "60", "role": "http://aehr.com/role/BalanceSheetDetailDetailsNarrative", "shortName": "BALANCE SHEET DETAIL (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2022-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000061 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)", "menuCat": "Details", "order": "61", "role": "http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails", "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2021-05-31", "decimals": "-3", "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000062 - Disclosure - INCOME TAXES (Details)", "menuCat": "Details", "order": "62", "role": "http://aehr.com/role/IncomeTaxesDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000063 - Disclosure - INCOME TAXES (Details 1)", "menuCat": "Details", "order": "63", "role": "http://aehr.com/role/IncomeTaxesDetails1", "shortName": "INCOME TAXES (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000064 - Disclosure - INCOME TAXES (Details 2)", "menuCat": "Details", "order": "64", "role": "http://aehr.com/role/IncomeTaxesDetails2", "shortName": "INCOME TAXES (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000065 - Disclosure - INCOME TAXES (Details 3)", "menuCat": "Details", "order": "65", "role": "http://aehr.com/role/IncomeTaxesDetails3", "shortName": "INCOME TAXES (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2022-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000066 - Disclosure - INCOME TAXES (Details 4)", "menuCat": "Details", "order": "66", "role": "http://aehr.com/role/IncomeTaxesDetails4", "shortName": "INCOME TAXES (Details 4)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2020-05-31", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000067 - Disclosure - INCOME TAXES (Details Narrative)", "menuCat": "Details", "order": "67", "role": "http://aehr.com/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000068 - Disclosure - LEASES (Details)", "menuCat": "Details", "order": "68", "role": "http://aehr.com/role/LeasesDetails", "shortName": "LEASES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000069 - Disclosure - LEASES (Details 1)", "menuCat": "Details", "order": "69", "role": "http://aehr.com/role/LeasesDetails1", "shortName": "LEASES (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "7", "role": "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000070 - Disclosure - LEASES (Details Narrative)", "menuCat": "Details", "order": "70", "role": "http://aehr.com/role/LeasesDetailsNarrative", "shortName": "LEASES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31_aehr_OriginalLoanAndSecurityAgreementMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000071 - Disclosure - BORROWING AND FINANCING ARRANGEMENTS (Details Narrative)", "menuCat": "Details", "order": "71", "role": "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative", "shortName": "BORROWING AND FINANCING ARRANGEMENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31_aehr_OriginalLoanAndSecurityAgreementMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2020-04-23_aehr_SiliconValleyBankMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LoansPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000072 - Disclosure - LONGTERM DEBT (Details Narrative)", "menuCat": "Details", "order": "72", "role": "http://aehr.com/role/LongtermDebtDetailsNarrative", "shortName": "LONGTERM DEBT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2020-04-23_aehr_SiliconValleyBankMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LoansPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "aehr:NetStockBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000073 - Disclosure - STOCK-BASED COMPENSATION (Details)", "menuCat": "Details", "order": "73", "role": "http://aehr.com/role/StockBasedCompensationDetails", "shortName": "STOCK-BASED COMPENSATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "aehr:NetStockBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2020-06-01to2021-05-31_us-gaap_StockOptionMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000074 - Disclosure - STOCK-BASED COMPENSATION (Details 1)", "menuCat": "Details", "order": "74", "role": "http://aehr.com/role/StockBasedCompensationDetails1", "shortName": "STOCK-BASED COMPENSATION (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2020-06-01to2021-05-31_us-gaap_StockOptionMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31_us-gaap_EmployeeStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000075 - Disclosure - STOCK-BASED COMPENSATION (Details 2)", "menuCat": "Details", "order": "75", "role": "http://aehr.com/role/StockBasedCompensationDetails2", "shortName": "STOCK-BASED COMPENSATION (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31_us-gaap_EmployeeStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000076 - Disclosure - STOCK-BASED COMPENSATION (Details 3)", "menuCat": "Details", "order": "76", "role": "http://aehr.com/role/StockBasedCompensationDetails3", "shortName": "STOCK-BASED COMPENSATION (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2020-05-31_aehr_StockOptionAndRSUTransactionsMember", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2022-05-31_aehr_OutstandingOptionsStockOptionTransactionsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000077 - Disclosure - STOCK-BASED COMPENSATION (Details 4)", "menuCat": "Details", "order": "77", "role": "http://aehr.com/role/StockBasedCompensationDetails4", "shortName": "STOCK-BASED COMPENSATION (Details 4)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2020-05-31_aehr_OutstandingOptionsStockOptionTransactionsMember", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31_aehr_Range1Member", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000078 - Disclosure - STOCK-BASED COMPENSATION (Details 5)", "menuCat": "Details", "order": "78", "role": "http://aehr.com/role/StockBasedCompensationDetails5", "shortName": "STOCK-BASED COMPENSATION (Details 5)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31_aehr_Range1Member", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31_aehr_EmployeesMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000079 - Disclosure - STOCKBASED COMPENSATION (Details 6)", "menuCat": "Details", "order": "79", "role": "http://aehr.com/role/StockbasedCompensationDetails6", "shortName": "STOCKBASED COMPENSATION (Details 6)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31_aehr_EmployeesMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "8", "role": "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000080 - Disclosure - STOCKBASED COMPENSATION (Details 7)", "menuCat": "Details", "order": "80", "role": "http://aehr.com/role/StockbasedCompensationDetails7", "shortName": "STOCKBASED COMPENSATION (Details 7)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000081 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)", "menuCat": "Details", "order": "81", "role": "http://aehr.com/role/StockBasedCompensationDetailsNarrative", "shortName": "STOCK-BASED COMPENSATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000082 - Disclosure - EMPLOYEE BENEFIT PLANS (Details Narrative)", "menuCat": "Details", "order": "82", "role": "http://aehr.com/role/EmployeeBenefitPlansDetailsNarrative", "shortName": "EMPLOYEE BENEFIT PLANS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000083 - Disclosure - OTHER INCOME (EXPENSE) NET (Details)", "menuCat": "Details", "order": "83", "role": "http://aehr.com/role/OtherIncomeExpenseNetDetails", "shortName": "OTHER INCOME (EXPENSE) NET (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2022-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000084 - Disclosure - PRODUCT WARRANTIES (Details)", "menuCat": "Details", "order": "84", "role": "http://aehr.com/role/ProductWarrantiesDetails", "shortName": "PRODUCT WARRANTIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:ProductWarrantyDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "-3", "lang": null, "name": "us-gaap:ProductWarrantyAccrualWarrantiesIssued", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000085 - Disclosure - SEGMENT INFORMATION (Details)", "menuCat": "Details", "order": "85", "role": "http://aehr.com/role/SegmentInformationDetails", "shortName": "SEGMENT INFORMATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31_srt_AsiaMember", "decimals": "-3", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000086 - Disclosure - SEGMENT INFORMATION (Details Narrative)", "menuCat": "Details", "order": "86", "role": "http://aehr.com/role/SegmentInformationDetailsNarrative", "shortName": "SEGMENT INFORMATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31_srt_AsiaMember", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "p", "aehr:DissolutionOfAehrTestSystemsTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2020-06-01to2021-05-31", "decimals": "0", "first": true, "lang": null, "name": "aehr:NetGainLossFromDeconsolidation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000087 - Disclosure - DISSOLUTION OF AEHR TEST SYSTEMS JAPAN (Details Narrative)", "menuCat": "Details", "order": "87", "role": "http://aehr.com/role/DissolutionOfAehrTestSystemsJapanDetailsNarrative", "shortName": "DISSOLUTION OF AEHR TEST SYSTEMS JAPAN (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "aehr:DissolutionOfAehrTestSystemsTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2020-06-01to2021-05-31", "decimals": "0", "first": true, "lang": null, "name": "aehr:NetGainLossFromDeconsolidation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-02-08", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000088 - Disclosure - EQUITY (Details Narrative)", "menuCat": "Details", "order": "88", "role": "http://aehr.com/role/EquityDetailsNarrative", "shortName": "EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-02-08", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000089 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "menuCat": "Details", "order": "89", "role": "http://aehr.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - REVENUE", "menuCat": "Notes", "order": "9", "role": "http://aehr.com/role/REVENUE", "shortName": "REVENUE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 69, "tag": { "aehr_AccumulatedOtherComprehensiveLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ACCUMULATED OTHER COMPREHENSIVE LOSS" } } }, "localname": "AccumulatedOtherComprehensiveLossAbstract", "nsuri": "http://aehr.com/20230531", "xbrltype": "stringItemType" }, "aehr_AherTestSystemsShareholdersEquityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Aher Test Systems Share holders Equity" } } }, "localname": "AherTestSystemsShareholdersEquityMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "aehr_AmountOfMinimumNetLiquidityOfCreditFacility": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Minimum liquidity net" } } }, "localname": "AmountOfMinimumNetLiquidityOfCreditFacility", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aehr_AnnualRestrictedSharesGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual restricted shares granted" } } }, "localname": "AnnualRestrictedSharesGranted", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails6" ], "xbrltype": "sharesItemType" }, "aehr_BoardOfDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Board Of Directors" } } }, "localname": "BoardOfDirectorsMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails6" ], "xbrltype": "domainItemType" }, "aehr_CashCashEquivalentsAndInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH, CASH EQUIVALENTS AND INVESTMENTS" } } }, "localname": "CashCashEquivalentsAndInvestmentsAbstract", "nsuri": "http://aehr.com/20230531", "xbrltype": "stringItemType" }, "aehr_CashPaidDuringTheYearForAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash paid during the year for:" } } }, "localname": "CashPaidDuringTheYearForAbstract", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "aehr_CommonStockSharesReservedForFutureIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Remained available for issuance" } } }, "localname": "CommonStockSharesReservedForFutureIssuance", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "aehr_ConcentrationOfSupplyRiskPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONCENTRATION OF SUPPLY RISK:" } } }, "localname": "ConcentrationOfSupplyRiskPolicyTextBlock", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "aehr_ContactorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contactors [Member]" } } }, "localname": "ContactorsMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "aehr_CostMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost [Member]" } } }, "localname": "CostMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails" ], "xbrltype": "domainItemType" }, "aehr_CumulativeStockIssuedSharesEmployeeStockPurchasePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total shares issued under ESPP plan (in thousands)" } } }, "localname": "CumulativeStockIssuedSharesEmployeeStockPurchasePlan", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "aehr_CumulativeTranslationAdjustmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cumulative Translation Adjustments [Member]" } } }, "localname": "CumulativeTranslationAdjustmentsMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "aehr_CustomerDepositsAndDeferredRevenueShortTerm": { "auth_ref": [], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.", "label": "Customer deposits and deferred revenue, short-term", "verboseLabel": "Customer deposits and deferred revenue" } } }, "localname": "CustomerDepositsAndDeferredRevenueShortTerm", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetails3", "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "aehr_CustomerDepositsAndDeferredRevenueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Customer deposits and deferred revenue, short-term]", "verboseLabel": "Customer deposits and deferred revenue, short-term" } } }, "localname": "CustomerDepositsAndDeferredRevenueTableTextBlock", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/BalanceSheetDetailTables" ], "xbrltype": "textBlockItemType" }, "aehr_CustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Three" } } }, "localname": "CustomerThreeMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_DebtInstrumentInterestAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Total interest" } } }, "localname": "DebtInstrumentInterestAmount", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aehr_DeferredTaxAssetsLeaseLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Lease liability" } } }, "localname": "DeferredTaxAssetsLeaseLiabilities", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails3" ], "xbrltype": "monetaryItemType" }, "aehr_DissolutionOfAehrTestSystemsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[DISSOLUTION OF AEHR TEST SYSTEMS JAPAN]", "verboseLabel": "DISSOLUTION OF AEHR TEST SYSTEMS JAPAN" } } }, "localname": "DissolutionOfAehrTestSystemsTextBlock", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/DissolutionOfAehrTestSystemsJapan" ], "xbrltype": "textBlockItemType" }, "aehr_DissolutionOfBusinessAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DISSOLUTION OF AEHR TEST SYSTEMS JAPAN" } } }, "localname": "DissolutionOfBusinessAbstract", "nsuri": "http://aehr.com/20230531", "xbrltype": "stringItemType" }, "aehr_EQUITYAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EQUITY" } } }, "localname": "EQUITYAbstract", "nsuri": "http://aehr.com/20230531", "xbrltype": "stringItemType" }, "aehr_EffectOnNetIncomeLossPerShareBasic": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effect on net loss per share, basic" } } }, "localname": "EffectOnNetIncomeLossPerShareBasic", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "aehr_EffectOnNetIncomeLossPerShareDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effect on net loss per share, diluted" } } }, "localname": "EffectOnNetIncomeLossPerShareDiluted", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "aehr_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriosdForRecognition1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted average period for recognition of costs]", "verboseLabel": "Weighted average period for recognition of costs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriosdForRecognition1", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "aehr_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationsCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average period for recognition of costs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationsCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "aehr_EmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employees Member" } } }, "localname": "EmployeesMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails6" ], "xbrltype": "domainItemType" }, "aehr_EquityIncentivePlan2016Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2016 Equity Incentive Plan" } } }, "localname": "EquityIncentivePlan2016Member", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_EstimatedFairValueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Estimated Fair Value [Member]" } } }, "localname": "EstimatedFairValueMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails" ], "xbrltype": "domainItemType" }, "aehr_EstimatedForfeituresOfUnvestedStockBasedAwards": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Estimated forfeitures of unvested stock based awards, amount" } } }, "localname": "EstimatedForfeituresOfUnvestedStockBasedAwards", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aehr_FairValueAssetsLevelOneToLevelTwoTransfersAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Transfer between Level 1 and Level 2 fair value measurements" } } }, "localname": "FairValueAssetsLevelOneToLevelTwoTransfersAmount", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aehr_FirstAmendmentToLoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "First Amendment to Loan and Security Agreement" } } }, "localname": "FirstAmendmentToLoanAndSecurityAgreementMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_GainFromForgivenessOfPppLoan": { "auth_ref": [], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 11.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gain from forgiveness of PPP loan" } } }, "localname": "GainFromForgivenessOfPppLoan", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "aehr_GainFromForgivenessOfPppLoan1": { "auth_ref": [], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Gain from forgiveness of PPP loan]", "verboseLabel": "Gain from forgiveness of PPP loan" } } }, "localname": "GainFromForgivenessOfPppLoan1", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "aehr_GainLossRelatedToCompletedLiquidation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Gain related to completed liquidation of ATS-Japan" } } }, "localname": "GainLossRelatedToCompletedLiquidation", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aehr_GrossUnrealizedLossMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Gross Unrealized Loss", "verboseLabel": "Gross Unrealized Loss" } } }, "localname": "GrossUnrealizedLossMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails", "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_IncomeTaxBenefitRelatedToDissolutionsOfSubsidiary": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Income tax benefits" } } }, "localname": "IncomeTaxBenefitRelatedToDissolutionsOfSubsidiary", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/DissolutionOfAehrTestSystemsJapanDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aehr_IncreaseDecreaseInCustomerDepositsAndDeferredRevenue": { "auth_ref": [], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Customer deposits and deferred revenue" } } }, "localname": "IncreaseDecreaseInCustomerDepositsAndDeferredRevenue", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "aehr_IncreaseDecreaseInPrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Prepaid expenses and other" } } }, "localname": "IncreaseDecreaseInPrepaidExpenseAndOtherAssets", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "aehr_IncreaseDecreaseInTradeAndOtherAccountsReceivable": { "auth_ref": [], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Trade and other accounts receivable" } } }, "localname": "IncreaseDecreaseInTradeAndOtherAccountsReceivable", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "aehr_InvestorRelations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Investor relations" } } }, "localname": "InvestorRelations", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetails2" ], "xbrltype": "monetaryItemType" }, "aehr_LesseeOperatingLeaseTermsOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating lease term" } } }, "localname": "LesseeOperatingLeaseTermsOfContract", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/LeasesDetailsNarrative" ], "xbrltype": "durationItemType" }, "aehr_MoneyMarketFundMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Money Market Funds", "verboseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails", "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "aehr_NetGainFromDissolutionOfAehrTestSystems": { "auth_ref": [], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Net gain from dissolution of Aehr Test Systems Japan]", "verboseLabel": "Net gain from dissolution of Aehr Test Systems Japan" } } }, "localname": "NetGainFromDissolutionOfAehrTestSystems", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "aehr_NetGainFromDissolutionOfAehrTestSystemsJapan": { "auth_ref": [], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 10.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net gain from dissolution of Aehr Test Systems Japan" } } }, "localname": "NetGainFromDissolutionOfAehrTestSystemsJapan", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "aehr_NetGainLossFromDeconsolidation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deconsolidation net gain" } } }, "localname": "NetGainLossFromDeconsolidation", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/DissolutionOfAehrTestSystemsJapanDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aehr_NetStockBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Net stock-based compensation" } } }, "localname": "NetStockBasedCompensation", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "aehr_NetTransferOfEquipmentBetweenInventoryAndPropertyAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Net transfer of equipment between inventory and property and equipment" } } }, "localname": "NetTransferOfEquipmentBetweenInventoryAndPropertyAndEquipment", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "aehr_NonCashOperatingLeaseExpense": { "auth_ref": [], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Non-cash operating lease expense" } } }, "localname": "NonCashOperatingLeaseExpense", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "aehr_NumberOfAuthorizedSharesIncreased": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of authorized shares increased" } } }, "localname": "NumberOfAuthorizedSharesIncreased", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "aehr_OneCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer One" } } }, "localname": "OneCustomerMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_OperatingLeaseWeightedAverageRemainingLeaseTermDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating lease, weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTermDuringPeriod", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/LeasesDetailsNarrative" ], "xbrltype": "durationItemType" }, "aehr_OriginalLoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Original Loan and Security Agreement" } } }, "localname": "OriginalLoanAndSecurityAgreementMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_OtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive income (loss), net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "aehr_OtherNonoperatingIncomeExpensegross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Other income (expense), net]", "verboseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpensegross", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/OtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "aehr_OutstandingOptionsStockOptionTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Options Stock Option Transactions" } } }, "localname": "OutstandingOptionsStockOptionTransactionsMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4" ], "xbrltype": "domainItemType" }, "aehr_PerformanceRestrictedSharesGrantedBasedOnRevenueTargetThresholdsMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Performance restricted shares granted based on revenue target thresholds maximum" } } }, "localname": "PerformanceRestrictedSharesGrantedBasedOnRevenueTargetThresholdsMaximum", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails6" ], "xbrltype": "sharesItemType" }, "aehr_ProceedsFromPublicOfferingsNetOfIssuanceCostsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Proceeds from public offerings, net of issuance costs, amount" } } }, "localname": "ProceedsFromPublicOfferingsNetOfIssuanceCostsAmount", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "aehr_ProceedsFromPublicOfferingsNetOfIssuanceCostsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Proceeds from public offerings, net of issuance costs, share" } } }, "localname": "ProceedsFromPublicOfferingsNetOfIssuanceCostsShares", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "aehr_ProductLineNetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total Product line [Member]" } } }, "localname": "ProductLineNetMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "aehr_ProductsAndServicesTransferredAtAPointInTimeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Products And Services Transferred At A Point In Time [Member]" } } }, "localname": "ProductsAndServicesTransferredAtAPointInTimeMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/RevenueDetails2" ], "xbrltype": "domainItemType" }, "aehr_PrsusGrantedBasedOnRevenueTargetThresholdsMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PRSUs granted based on revenue target thresholds maximum" } } }, "localname": "PrsusGrantedBasedOnRevenueTargetThresholdsMaximum", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails6" ], "xbrltype": "sharesItemType" }, "aehr_Range1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "$1.34" } } }, "localname": "Range1Member", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails5" ], "xbrltype": "domainItemType" }, "aehr_Range2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "$1.64-$1.86" } } }, "localname": "Range2Member", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails5" ], "xbrltype": "domainItemType" }, "aehr_Range5Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "$3.46-$3.93" } } }, "localname": "Range5Member", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails5" ], "xbrltype": "domainItemType" }, "aehr_RangeFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "$2.93" } } }, "localname": "RangeFourMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails5" ], "xbrltype": "domainItemType" }, "aehr_RangeSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "$8.00-34.00" } } }, "localname": "RangeSixMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails5" ], "xbrltype": "domainItemType" }, "aehr_RangeThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "$2.03-$2.40" } } }, "localname": "RangeThreeMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails5" ], "xbrltype": "domainItemType" }, "aehr_RangeTotalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "$1.34-$34.00" } } }, "localname": "RangeTotalMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails5" ], "xbrltype": "domainItemType" }, "aehr_RestrictedStockSharesIssuedNetOfSharesForTaxWithholding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares repurchased for tax withholdings on vesting of RSUs, share" } } }, "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholding", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "aehr_RsusGrantedInLieuOfCashPaymentForSalaryReductions": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RSUs granted in lieu of cash payment for salary reductions" } } }, "localname": "RsusGrantedInLieuOfCashPaymentForSalaryReductions", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails6" ], "xbrltype": "sharesItemType" }, "aehr_ScheduleOfRestrictedSharesAndPerformanceRestrictedSharesGrantedTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RSUs, PRSUs, restricted shares and performance restricted shares granted" } } }, "localname": "ScheduleOfRestrictedSharesAndPerformanceRestrictedSharesGrantedTableTextBlock", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "aehr_ScheduleOfUsefulLifeForPropertyAndEquipmentTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Useful life for property and equipment" } } }, "localname": "ScheduleOfUsefulLifeForPropertyAndEquipmentTableTextblock", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "aehr_ScheduleOfVestedAndUnvestedTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RSUs and PRSUs vested and unvested" } } }, "localname": "ScheduleOfVestedAndUnvestedTableTextBlock", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "aehr_SecondAmendmentToLoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Second Amendment To Loan And Security Agreement" } } }, "localname": "SecondAmendmentToLoanAndSecurityAgreementMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_ServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Services [Member]" } } }, "localname": "ServicesMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "aehr_ServicesTransferredOverTimeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Services Transferred over Time [Member]" } } }, "localname": "ServicesTransferredOverTimeMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/RevenueDetails2" ], "xbrltype": "domainItemType" }, "aehr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanMaximumSharesThatMayBePurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Maximum number of shares a participant may purchase (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanMaximumSharesThatMayBePurchased", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "aehr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanNumberOfSharesAvailableForGrant": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ESPP Shares available for issuance (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanNumberOfSharesAvailableForGrant", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "aehr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Option exercisable shares (in thousands)]", "verboseLabel": "Option exercisable shares (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "aehr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPerio": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RSUs and PRSUs cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPerio", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails7" ], "xbrltype": "sharesItemType" }, "aehr_ShareBasedCompensationArrangementByShareBasedPaymentAwardsEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RSUs and PRSUs unvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardsEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails7" ], "xbrltype": "sharesItemType" }, "aehr_ShareBasedCompensationArrangementByShareBasedPaymentsAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average market value on the date of the grant of RSU in lieu of cash payment" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentsAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails6" ], "xbrltype": "perShareItemType" }, "aehr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted average remaining contractual life (Years) options exercisable 2]", "verboseLabel": "Weighted average remaining contractual life (Years) options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails5" ], "xbrltype": "durationItemType" }, "aehr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAverageRemainingContractualsTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAverageRemainingContractualsTerm1", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails5" ], "xbrltype": "durationItemType" }, "aehr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted average remaining contractual life (Years) options exercisable 4]", "verboseLabel": "Weighted average remaining contractual life (Years) options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingTerm1", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails5" ], "xbrltype": "durationItemType" }, "aehr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingsContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted average remaining contractual life (Years) options exercisable 1]", "verboseLabel": "Weighted average remaining contractual life (Years) options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingsContractualTerm1", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails5" ], "xbrltype": "durationItemType" }, "aehr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValueRSUsandPRSUs": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average grant-date fair value of unvested RSUs and PRSUs" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValueRSUsandPRSUs", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails7" ], "xbrltype": "perShareItemType" }, "aehr_SharebasedCompensationArrangementBySharebasedPaymentAwardsOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted average remaining contractual life (Years) options exercisable 3]", "verboseLabel": "Weighted average remaining contractual life (Years) options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardsOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails5" ], "xbrltype": "durationItemType" }, "aehr_SharebasedCompensationArrangementBySharebasedPaymentOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted average remaining contractual life (Years) options exercisable]", "verboseLabel": "Weighted average remaining contractual life (Years) options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails5" ], "xbrltype": "durationItemType" }, "aehr_SharebasedCompensationArrangementBySharebasedPaymentsAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Intrinsic value of unvested RSUs and PRSUs (in thousands)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentsAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails7" ], "xbrltype": "monetaryItemType" }, "aehr_SharebasedCompensationArrangementSharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life (Years) options exercisable" } } }, "localname": "SharebasedCompensationArrangementSharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails5" ], "xbrltype": "durationItemType" }, "aehr_SharesUsedInBasicNetIncomeLossPerShareCalculation": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares used in basic net income (loss) per share calculation" } } }, "localname": "SharesUsedInBasicNetIncomeLossPerShareCalculation", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/EarningsPerShareEpsDetails" ], "xbrltype": "sharesItemType" }, "aehr_ShelfRegistrationAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Shelf registration amount" } } }, "localname": "ShelfRegistrationAmount", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aehr_SiliconValleyBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Silicon Valley Bank" } } }, "localname": "SiliconValleyBankMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_StockOptionAndRSUTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option and RSU Transactions" } } }, "localname": "StockOptionAndRSUTransactionsMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails3" ], "xbrltype": "domainItemType" }, "aehr_StockOptionRSUsAndPRSUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option, RSUs and PRSUs" } } }, "localname": "StockOptionRSUsAndPRSUsMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_StockbasedCompensationExpenseRelatedToStockOptionsAndRestrictedStockUnits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Stock-based compensation expense related to stock options and RSUs" } } }, "localname": "StockbasedCompensationExpenseRelatedToStockOptionsAndRestrictedStockUnits", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aehr_StockbasedCompensationRelatedToEmployeeStockPurchasePlan": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Stock-based compensation related to the ESPP" } } }, "localname": "StockbasedCompensationRelatedToEmployeeStockPurchasePlan", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aehr_SupplementalDisclosureOfNonCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash flow information:" } } }, "localname": "SupplementalDisclosureOfNonCashFlowInformationAbstract", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "aehr_SystemsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Systems [Member]" } } }, "localname": "SystemsMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "aehr_TestDuringBurnInMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Test During Burn-In. [Member]" } } }, "localname": "TestDuringBurnInMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "aehr_ThirdAmendmentToLoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Third Amendment to Loan and Security Agreement" } } }, "localname": "ThirdAmendmentToLoanAndSecurityAgreementMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_TwoCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Two" } } }, "localname": "TwoCustomerMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_USTreasurySecurityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "US Treasury Securities" } } }, "localname": "USTreasurySecurityMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "aehr_UStreasurysecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "U.S. treasury securities" } } }, "localname": "UStreasurysecuritiesMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "aehr_UnitedStateTreasurySecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "U S Treasury Securities [Member]" } } }, "localname": "UnitedStateTreasurySecuritiesMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails" ], "xbrltype": "domainItemType" }, "aehr_UnrealizedLossOnInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unrealized Loss on Investments Net [Member]" } } }, "localname": "UnrealizedLossOnInvestmentsMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "aehr_WaferLevelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wafer-level [Member]" } } }, "localname": "WaferLevelMember", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "aehr_WeightedAverageExercisePriceForOptionsExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price for options exercisable" } } }, "localname": "WeightedAverageExercisePriceForOptionsExercisable", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "aehr_WeightedAverageGrantDateFairValueOfCancelledRsus": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average grant-date fair value of cancelled RSUs" } } }, "localname": "WeightedAverageGrantDateFairValueOfCancelledRsus", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails7" ], "xbrltype": "perShareItemType" }, "aehr_WeightedAverageMarketValueOnTheDateOfTheGrantOfAnnualRestrictedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average market value on the date of the grant of annual restricted shares" } } }, "localname": "WeightedAverageMarketValueOnTheDateOfTheGrantOfAnnualRestrictedShares", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails6" ], "xbrltype": "perShareItemType" }, "aehr_WeightedAverageMarketValueOnTheDateOfTheGrantOfPrsus": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average market value on the date of the grant of PRSUs" } } }, "localname": "WeightedAverageMarketValueOnTheDateOfTheGrantOfPrsus", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails6" ], "xbrltype": "perShareItemType" }, "aehr_WeightedAverageMarketValueOnTheDateOfTheGrantOfPrsusPerformanceRestrictedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average market value on the date of the grant of PRSUs, performance restricted shares" } } }, "localname": "WeightedAverageMarketValueOnTheDateOfTheGrantOfPrsusPerformanceRestrictedShares", "nsuri": "http://aehr.com/20230531", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails6" ], "xbrltype": "perShareItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2023", "presentation": [ "http://aehr.com/role/RevenueDetails1", "http://aehr.com/role/SegmentInformationDetails", "http://aehr.com/role/SegmentInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r737", "r738", "r739" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm Id" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r737", "r738", "r739" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r737", "r738", "r739" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r737", "r738", "r739" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r740" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r735" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r735" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r735" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r741" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r735" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r735" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r735" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r735" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r742" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r737", "r738", "r739" ], "lang": { "en-us": { "role": { "label": "Icfr Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r734" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r736" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_AsiaMember": { "auth_ref": [ "r852", "r853", "r854", "r855" ], "lang": { "en-us": { "role": { "label": "Asia", "verboseLabel": "Asia" } } }, "localname": "AsiaMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://aehr.com/role/RevenueDetails1", "http://aehr.com/role/SegmentInformationDetails", "http://aehr.com/role/SegmentInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [ "r852", "r853", "r854", "r855" ], "lang": { "en-us": { "role": { "label": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://aehr.com/role/RevenueDetails1", "http://aehr.com/role/SegmentInformationDetails", "http://aehr.com/role/SegmentInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r325", "r326", "r327", "r328", "r402", "r546", "r592", "r610", "r611", "r665", "r667", "r669", "r670", "r672", "r688", "r689", "r705", "r710", "r717", "r723", "r791", "r836", "r837", "r838", "r839", "r840", "r841" ], "lang": { "en-us": { "role": { "label": "Maximum", "verboseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://aehr.com/role/LeasesDetailsNarrative", "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails", "http://aehr.com/role/StockBasedCompensationDetails1", "http://aehr.com/role/StockBasedCompensationDetails2" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r325", "r326", "r327", "r328", "r402", "r546", "r592", "r610", "r611", "r665", "r667", "r669", "r670", "r672", "r688", "r689", "r705", "r710", "r717", "r723", "r791", "r836", "r837", "r838", "r839", "r840", "r841" ], "lang": { "en-us": { "role": { "label": "Minimum", "verboseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://aehr.com/role/LeasesDetailsNarrative", "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails", "http://aehr.com/role/StockBasedCompensationDetails1", "http://aehr.com/role/StockBasedCompensationDetails2" ], "xbrltype": "domainItemType" }, "srt_NorthAmericaMember": { "auth_ref": [ "r852", "r853", "r854", "r855" ], "lang": { "en-us": { "role": { "label": "North America" } } }, "localname": "NorthAmericaMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r252", "r548", "r586", "r587", "r588", "r589", "r590", "r591", "r691", "r711", "r722", "r747", "r786", "r787", "r793", "r847" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails", "http://aehr.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r252", "r548", "r586", "r587", "r588", "r589", "r590", "r591", "r691", "r711", "r722", "r747", "r786", "r787", "r793", "r847" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails", "http://aehr.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r325", "r326", "r327", "r328", "r395", "r402", "r429", "r430", "r431", "r522", "r546", "r592", "r610", "r611", "r665", "r667", "r669", "r670", "r672", "r688", "r689", "r705", "r710", "r717", "r723", "r726", "r784", "r791", "r837", "r838", "r839", "r840", "r841" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://aehr.com/role/LeasesDetailsNarrative", "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails", "http://aehr.com/role/StockBasedCompensationDetails1", "http://aehr.com/role/StockBasedCompensationDetails2" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r325", "r326", "r327", "r328", "r395", "r402", "r429", "r430", "r431", "r522", "r546", "r592", "r610", "r611", "r665", "r667", "r669", "r670", "r672", "r688", "r689", "r705", "r710", "r717", "r723", "r726", "r784", "r791", "r837", "r838", "r839", "r840", "r841" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://aehr.com/role/LeasesDetailsNarrative", "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails", "http://aehr.com/role/StockBasedCompensationDetails1", "http://aehr.com/role/StockBasedCompensationDetails2" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r403", "r775" ], "lang": { "en-us": { "role": { "label": "Scenario Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://aehr.com/role/RevenueDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r209", "r403", "r743", "r775" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://aehr.com/role/RevenueDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r254", "r255", "r607", "r608", "r609", "r666", "r668", "r671", "r673", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r692", "r712", "r726", "r793", "r847" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://aehr.com/role/RevenueDetails1", "http://aehr.com/role/SegmentInformationDetails", "http://aehr.com/role/SegmentInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r254", "r255", "r607", "r608", "r609", "r666", "r668", "r671", "r673", "r675", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r692", "r712", "r726", "r793", "r847" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://aehr.com/role/RevenueDetails1", "http://aehr.com/role/SegmentInformationDetails", "http://aehr.com/role/SegmentInformationDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r209", "r403", "r743", "r744", "r775" ], "lang": { "en-us": { "role": { "label": "Statement Scenario Axis" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://aehr.com/role/RevenueDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.", "label": "Trade and other accounts receivable, net" } } }, "localname": "AccountsAndOtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r23", "r721" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r165", "r257", "r258", "r695" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "[Accounts Receivable, before Allowance for Credit Loss, Current]", "verboseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/TradeAndOtherAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r677" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r628", "r676", "r727", "r846" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, net" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/TradeAndOtherAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r102" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion of investment discount" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r78", "r126" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses", "verboseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetails2", "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Professional services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r49", "r162", "r565" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]", "negatedLabel": "Less: Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r32", "r33", "r90", "r166", "r561", "r597", "r598" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "[Accumulated Other Comprehensive Income (Loss), Net of Tax]", "periodEndLabel": "Balance at the ending of the year", "periodStartLabel": "Balance at the beginning of the year", "verboseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails", "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r3", "r14", "r33", "r478", "r481", "r514", "r593", "r594", "r763", "r764", "r765", "r772", "r773", "r774" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "verboseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r81" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r438", "r439", "r440", "r604", "r772", "r773", "r774", "r827", "r850" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r57", "r58", "r405" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "ADVERTISING COSTS:" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r433", "r441" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Total stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r167", "r259", "r294", "r297", "r299", "r846" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r167", "r259", "r294" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "[Accounts Receivable, Allowance for Credit Loss, Current]", "negatedLabel": "Less: Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/TradeAndOtherAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Options not included in the computation of diluted net loss per share (in thousands)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/EarningsPerShareEpsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r125", "r164", "r193", "r227", "r242", "r248", "r291", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r472", "r475", "r491", "r557", "r633", "r721", "r733", "r789", "r790", "r834" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r156", "r170", "r193", "r291", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r472", "r475", "r491", "r721", "r789", "r790", "r834" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Member]" } } }, "localname": "AssetsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type Axis" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/EarningsPerShareEpsDetailsNarrative", "http://aehr.com/role/StockBasedCompensationDetails1", "http://aehr.com/role/StockBasedCompensationDetails3", "http://aehr.com/role/StockBasedCompensationDetails4", "http://aehr.com/role/StockBasedCompensationDetailsNarrative", "http://aehr.com/role/StockbasedCompensationDetails6" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BALANCE SHEET DETAIL" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r103", "r104" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Business Description and Accounting Policies [Text Block]", "verboseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r77", "r103", "r104" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "BUSINESS:" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r137", "r558", "r605", "r627", "r721", "r733", "r757" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH CASH EQUIVALENTS AND INVESTMENTS (Details)" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r38", "r159", "r693" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "verboseLabel": "Total cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails", "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "CASH EQUIVALENTS:" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r762" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Total cash, cash equivalents and investments", "negatedLabel": "Total cash, cash equivalents and investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": { "auth_ref": [ "r778" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.", "label": "Cash, Cash Equivalents, and Short-Term Investments [Text Block]", "verboseLabel": "CASH, CASH EQUIVALENTS AND INVESTMENTS" } } }, "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r38", "r100", "r190" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents]", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r2", "r100" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect]", "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r757", "r845" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (Note 20)" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r109", "r323", "r324", "r678", "r785" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common stock reserved for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r724", "r725", "r726", "r728", "r729", "r730", "r731", "r772", "r773", "r827", "r848", "r850" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r80", "r619" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r80", "r619", "r639", "r850", "r851" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r80", "r560", "r721" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.01 par value: Authorized: 75,000 shares; Issued and outstanding: 28,539 shares and 27,120 shares at May 31, 2023 and 2022 respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r114", "r115", "r116", "r117" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans [Text Block]", "verboseLabel": "EMPLOYEE BENEFIT PLANS" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/EmployeeBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EMPLOYEE BENEFIT PLANS" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r34", "r175", "r177", "r185", "r551", "r572" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "[Comprehensive Income (Loss), Net of Tax, Attributable to Parent]", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r9", "r64", "r66", "r175", "r177", "r184", "r550", "r571" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 7.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Less: Comprehensive income attributable to noncontrolling interest" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r89", "r183", "r549", "r569" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "verboseLabel": "ACCUMULATED OTHER COMPREHENSIVE LOSS" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "COMPREHENSIVE INCOME (LOSS):" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r41", "r42", "r69", "r70", "r256", "r677", "r746" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk By Type Axis" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r74", "r143" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "CONCENTRATION OF CREDIT RISK:" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r41", "r42", "r69", "r70", "r256" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration risk" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r41", "r42", "r69", "r70", "r256", "r677" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r65", "r699" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "CONSOLIDATION:" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r380", "r381", "r392" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/RevenueDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r393" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Recognition of contract liabilities" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/RevenueDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r95", "r193", "r291", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r491", "r789" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of sales" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease": { "auth_ref": [ "r830" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 5.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in cumulative translation adjustment before transfers included in determining net income.", "label": "Reclassification of cumulative translation adjustment as a result of dissolution of Aehr Test Systems Japan" } } }, "localname": "CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r748", "r771", "r825" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r748", "r771" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "[Current Foreign Tax Expense (Benefit)]", "verboseLabel": "Current" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r748", "r771", "r825" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "[Current State and Local Tax Expense (Benefit)]", "verboseLabel": "Current" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerDepositsCurrent": { "auth_ref": [ "r135" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The current portion of money or property received from customers which is either to be returned upon satisfactory contract completion or applied to customer receivables in accordance with the terms of the contract or the understandings.", "label": "Customer deposits" } } }, "localname": "CustomerDepositsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BORROWING AND FINANCING ARRANGEMENTS" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r110", "r191", "r351", "r353", "r354", "r355", "r356", "r357", "r358", "r360", "r361", "r362", "r364" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "BORROWING AND FINANCING ARRANGEMENTS" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r28", "r352" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateTerms": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.", "label": "Variable interest rate" } } }, "localname": "DebtInstrumentInterestRateTerms", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r771", "r824", "r825" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r124", "r771", "r824" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "[Deferred Foreign Income Tax Expense (Benefit)]", "verboseLabel": "Deferred" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueAndCreditsCurrent": { "auth_ref": [ "r135" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue or other forms of income in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer.", "label": "Deferred revenue" } } }, "localname": "DeferredRevenueAndCreditsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r759" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred revenue, long-term" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r771", "r824", "r825" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "[Deferred State and Local Income Tax Expense (Benefit)]", "verboseLabel": "Deferred" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r456" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails3" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r62", "r823" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "Inventory reserves" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r822" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Net deferred tax assets (liabilities)" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r62", "r823" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating losses" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r62", "r823" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "[Deferred Tax Assets, Other]", "verboseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r61", "r62", "r823" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax": { "auth_ref": [ "r61", "r62", "r823" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible alternative minimum tax credit carryforwards.", "label": "Alternative minimum tax credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves": { "auth_ref": [ "r62", "r823" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.", "label": "Reserves and accruals" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r457" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "[Deferred Tax Assets, Valuation Allowance]", "negatedLabel": "Less: Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails3" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": { "auth_ref": [ "r62", "r823" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.", "label": "Capitalized research and development" } } }, "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r62", "r823" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "[Deferred Tax Liabilities, Other]", "negatedLabel": "Operating lease right-of-use assets" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Contributions to ESOP" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/EmployeeBenefitPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum amount the employee may contribute to a defined contribution plan.", "label": "Maximum calendar year contribution per employee" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r11", "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r11", "r48" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of defined contribution pension and other postretirement plans.", "label": "Defined contribution plan, description" } } }, "localname": "DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/EmployeeBenefitPlansDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r793" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r404", "r406", "r434", "r435", "r437", "r718" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "verboseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsSharebasedCompensationStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid stock dividends declared for award under share-based payment arrangement.", "label": "Stock based compensation expenses" } } }, "localname": "DividendsSharebasedCompensationStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EARNINGS PER SHARE (EPS)" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r186", "r201", "r202", "r203", "r204", "r205", "r211", "r213", "r215", "r216", "r217", "r221", "r486", "r487", "r552", "r573", "r702" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings (net loss) per share - basic", "verboseLabel": "Basic net income (loss) per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations", "http://aehr.com/role/EarningsPerShareEpsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r186", "r201", "r202", "r203", "r204", "r205", "r213", "r215", "r216", "r217", "r221", "r486", "r487", "r552", "r573", "r702" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings (net loss) per share - diluted", "verboseLabel": "Diluted net income (loss) per share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations", "http://aehr.com/role/EarningsPerShareEpsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r210", "r218", "r219", "r220" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "EARNINGS PER SHARE (''EPS'')" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/EarningsPerShareEps" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r497" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 29.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rates on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails2" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r195", "r449", "r466" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "U.S. federal statutory tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails2" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r820", "r826" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails2" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r466", "r820" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "PPP Loan" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails2" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness": { "auth_ref": [ "r820", "r826" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.", "label": "Controlled Foreign Corporation Liquidation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfBusiness", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails2" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r820", "r826" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Foreign rate differential" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails2" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r820", "r826" ], "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.", "label": "[Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent]", "verboseLabel": "Stock-based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails2" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r820", "r826" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "[Effective Income Tax Rate Reconciliation, Other Adjustments, Percent]", "verboseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails2" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r820", "r826" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "State taxes, net of federal tax effect" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails2" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r820", "r826" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Research and development credit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails2" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Payroll related" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r436" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Unrecognized stock-based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r433" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Income tax benefit related to dissolution of Aehr Test Systems Japan" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock Purchase Plan", "verboseLabel": "Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/EarningsPerShareEpsDetailsNarrative", "http://aehr.com/role/StockBasedCompensationDetails2", "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Information by name of employee stock ownership plan.", "label": "Employee Stock Ownership Plan E S O P Disclosures By Plan Axis" } } }, "localname": "EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/EarningsPerShareEpsDetailsNarrative", "http://aehr.com/role/StockBasedCompensationDetails2", "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Entities identify multiple employee stock ownership plans by unique name." } } }, "localname": "EmployeeStockOwnershipPlanESOPPlanDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/EarningsPerShareEpsDetailsNarrative", "http://aehr.com/role/StockBasedCompensationDetails2", "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "This item represents the number of shares provided to the Employee Stock Ownership Plan (ESOP) during the period.", "label": "Shares contributed to the ESOP during fiscal year (in thousands)" } } }, "localname": "EmployeeStockOwnershipPlanESOPSharesContributedToESOP", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/EmployeeBenefitPlansDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCK-BASED COMPENSATION" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r15", "r153", "r179", "r180", "r181", "r196", "r197", "r198", "r200", "r206", "r208", "r222", "r292", "r293", "r379", "r438", "r439", "r440", "r461", "r462", "r477", "r478", "r479", "r480", "r481", "r482", "r485", "r499", "r500", "r501", "r502", "r503", "r504", "r514", "r593", "r594", "r595", "r604", "r660" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Class of asset." } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r67", "r68" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Fair Value By Asset Class Axis" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r359", "r396", "r397", "r398", "r399", "r400", "r401", "r490", "r519", "r520", "r521", "r708", "r709", "r714", "r715", "r716" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level Axis" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FAIR VALUE OF FINANCIAL INSTRUMENTS" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r359", "r396", "r401", "r490", "r519", "r714", "r715", "r716" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r359", "r396", "r401", "r490", "r520", "r708", "r709", "r714", "r715", "r716" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r359", "r396", "r397", "r398", "r399", "r400", "r401", "r490", "r521", "r708", "r709", "r714", "r715", "r716" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r359", "r396", "r397", "r398", "r399", "r400", "r401", "r519", "r520", "r521", "r708", "r709", "r714", "r715", "r716" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Federal income taxes:" } } }, "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r295", "r296", "r300", "r301", "r302", "r303", "r304", "r305", "r363", "r377", "r483", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r570", "r706", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r779", "r780", "r781", "r782" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails", "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial liabilities at fair value" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r493", "r494", "r495", "r496", "r657" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.", "label": "Foreign exchange gain (loss)" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "FOREIGN CURRENCY TRANSLATION AND TRANSACTIONS:" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Foreign income taxes:" } } }, "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_FormerGainContingencyRecognizedInCurrentPeriod": { "auth_ref": [ "r788" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain recognized in the period that had been disclosed in prior periods as a contingent gain.", "label": "Recognized a gain on loan forgiveness" } } }, "localname": "FormerGainContingencyRecognizedInCurrentPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r107" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfBusiness": { "auth_ref": [ "r474", "r766" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.", "label": "Net gain due to cumulative translation adjustment reclassiefied to earnings" } } }, "localname": "GainLossOnSaleOfBusiness", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/DissolutionOfAehrTestSystemsJapanDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "Selling, General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r94", "r193", "r227", "r241", "r247", "r250", "r291", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r491", "r704", "r789" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "[Gross Profit]", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r0", "r108" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "IMPAIRMENT OF LONG-LIVED ASSETS:" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r194", "r465" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r1", "r91", "r131", "r227", "r241", "r247", "r250", "r553", "r567", "r704" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 13.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "[Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest]", "totalLabel": "Income (loss) before income tax (expense) benefit", "verboseLabel": "Income (loss) before income tax (expense) benefit" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations", "http://aehr.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r194", "r465" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r318", "r320", "r644" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location Axis" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r320", "r644" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r195", "r444", "r450", "r454", "r459", "r463", "r467", "r470", "r471", "r603" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r136", "r149", "r207", "r208", "r235", "r448", "r464", "r574" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 14.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "[Income Tax Expense (Benefit)]", "negatedLabel": "Income tax (expense) benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations", "http://aehr.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r178", "r446", "r447", "r454", "r455", "r458", "r460", "r600" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "INCOME TAXES:" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r820" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "auth_ref": [ "r820" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Research and development tax credit carryforwards" } } }, "localname": "IncomeTaxReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r37", "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r10" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "[Increase (Decrease) in Accounts Payable]", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r10" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r10" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "[Increase (Decrease) in Accrued Liabilities]", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r10" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "[Increase (Decrease) in Inventories]", "verboseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLiabilities": { "auth_ref": [ "r10" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities that result from activities that generate operating income.", "label": "Increase in operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "[Increase (Decrease) in Other Noncurrent Liabilities]", "verboseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseFederalFundsPurchased": { "auth_ref": [ "r151", "r152" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross expenses on the purchase of Federal funds at a specified price with a simultaneous agreement to sell the same to the same counterparty at a fixed or determinable price at a future date.", "label": "Purchase rights under the ESPP" } } }, "localname": "InterestExpenseFederalFundsPurchased", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r133" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 9.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest income (expense), net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r767" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r106", "r696" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r169", "r694", "r721" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetails", "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r139", "r158", "r168", "r306", "r307", "r308", "r547", "r700" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "INVENTORIES:" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r106", "r698" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Raw materials and sub-assemblies" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r47", "r760" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Provision for inventory reserves" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r106", "r697" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r489" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investment securities" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r832" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Supplemental cash flow information related to leases" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r107" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LEASES" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseDescriptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash paid for amounts included in measurement of operating lease liabilities:" } } }, "localname": "LesseeOperatingLeaseDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r833" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Maturity of operating lease liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r513" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Total future minimum operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r513" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r513" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r513" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2028" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r513" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r513" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r513" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r513" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "verboseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r25", "r193", "r291", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r473", "r475", "r476", "r491", "r618", "r703", "r733", "r789", "r834", "r835" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 24.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r85", "r128", "r563", "r721", "r770", "r783", "r828" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "Total liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r27", "r157", "r193", "r291", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r473", "r475", "r476", "r491", "r721", "r789", "r834", "r835" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r24", "r769" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Line Of Credit Facility Axis" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Date the credit facility terminates, in YYYY-MM-DD format.", "label": "Revolving line maturity date" } } }, "localname": "LineOfCreditFacilityExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r24", "r769" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r24" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit, maximum borrowing" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r24" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Balance available to borrow under the line of credit" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "auth_ref": [ "r777" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.", "label": "TRADE AND OTHER ACCOUNTS RECEIVABLE, NET:" } } }, "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/TradeAndOtherAccountsReceivableNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_LoansPayable": { "auth_ref": [ "r21", "r127", "r844" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "PPP loan" } } }, "localname": "LoansPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.", "label": "Property and equipment by geographic region" } } }, "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermDebtAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LONGTERM DEBT" } } }, "localname": "LongTermDebtAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "LONG-TERM DEBT" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LongtermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r160" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r107" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r189" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 28.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r189" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 27.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "[Net Cash Provided by (Used in) Investing Activities]", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r100", "r101", "r102" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 26.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r92", "r102", "r132", "r155", "r174", "r176", "r181", "r193", "r199", "r201", "r202", "r203", "r204", "r207", "r208", "r214", "r227", "r241", "r247", "r250", "r291", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r487", "r491", "r568", "r641", "r658", "r659", "r704", "r732", "r789" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax", "weight": -1.0 }, "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "terseLabel": "Net Income (Loss)", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations", "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity", "http://aehr.com/role/EarningsPerShareEpsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "RECENT ACCOUNTING PRONOUNCEMENTS:" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r63", "r379", "r772", "r773", "r774", "r850" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NoninterestExpenseOfferingCost": { "auth_ref": [ "r134" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Includes offering costs of open-end investment companies, and closed-end funds with a continuous offering period.", "label": "Offering expenses" } } }, "localname": "NoninterestExpenseOfferingCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "[Operating Expenses]", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r227", "r241", "r247", "r250", "r704" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 8.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r510", "r720" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease, cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r508" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Present value of operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r508" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liabilities, short-term" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r508" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liabilities, long-term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r509", "r511" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating cash flows for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r507" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets", "verboseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets", "http://aehr.com/role/SegmentInformationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r512", "r720" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating lease, weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LeasesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "[Operating Loss Carryforwards]", "negatedLabel": "Net operating loss carryforward" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r163" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "All other long term capitalized assets related to property plant and equipment not otherwise previously categorized.", "label": "Test Equipment" } } }, "localname": "OtherCapitalizedPropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location in other comprehensive income.", "label": "Other Comprehensive Income Location Axis" } } }, "localname": "OtherComprehensiveIncomeLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in other comprehensive income." } } }, "localname": "OtherComprehensiveIncomeLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": { "auth_ref": [ "r5", "r179", "r569" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).", "label": "Other comprehensive loss before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r4" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Foreign currency translation (loss) income", "verboseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax": { "auth_ref": [ "r7", "r8", "r90", "r173", "r498" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.", "label": "Reclassification of cumulative translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r5", "r179", "r183", "r448", "r468", "r469", "r499", "r502", "r504", "r549", "r569" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 6.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "[Other Comprehensive Income (Loss), Tax]", "totalLabel": "Total comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r171", "r172", "r290" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Net change in unrealized loss on investments" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherEmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Commissions and bonuses" } } }, "localname": "OtherEmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER INCOME (EXPENSE) NET" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r113", "r120" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "OTHER INCOME (EXPENSE), NET" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OtherIncomeExpenseNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r72", "r555", "r614", "r615", "r733", "r849" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Other long-term liabilities" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r97" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 12.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other (expense) income, net", "verboseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations", "http://aehr.com/role/OtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherShortTermInvestments": { "auth_ref": [ "r73", "r556", "r761" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term investments classified as other.", "label": "Short-term investments" } } }, "localname": "OtherShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r188" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "[Payment, Tax Withholding, Share-Based Payment Arrangement]", "negatedLabel": "Shares repurchased for tax withholdings on vesting of restricted stock units" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r98" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "[Payments to Acquire Investments]", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r99" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "[Payments to Acquire Property, Plant, and Equipment]", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name Axis" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative", "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails", "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetailsNarrative", "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative", "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails", "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetailsNarrative", "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyLoansReceivable": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of loans made to policyholders against the cash surrender value (CSV) or other policyholder funds, and secured by the CSV, policyholder funds or the death benefit provided by the insurance contracts.", "label": "PPP Loan balance" } } }, "localname": "PolicyLoansReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockNoParValue": { "auth_ref": [ "r79", "r792" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r79", "r619" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r79", "r366" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r79", "r619", "r639", "r850", "r851" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r79", "r559", "r721" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.01 par value: Authorized: 10,000 shares; Issued and outstanding: none" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r762" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r6" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuance of common stock under employee plans" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r6", "r601" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 25.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from issuance of common stock from public offering, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromOtherEquity": { "auth_ref": [ "r6" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from the issuance of equity classified as other.", "label": "Gross proceeds" } } }, "localname": "ProceedsFromOtherEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": { "auth_ref": [ "r35" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.", "label": "Proceeds from maturities of investments" } } }, "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantiesDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PRODUCT WARRANTIES" } } }, "localname": "ProductWarrantiesDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_ProductWarrantyAccrual": { "auth_ref": [ "r71", "r333", "r337", "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.", "label": "Warranty", "periodEndLabel": "Balance at the End of the period", "periodStartLabel": "Balance at the beginning of the period" } } }, "localname": "ProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetails2", "http://aehr.com/role/ProductWarrantiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualPayments": { "auth_ref": [ "r338" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.", "label": "[Standard and Extended Product Warranty Accrual, Decrease for Payments]", "negatedLabel": "Consumption of reserves" } } }, "localname": "ProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ProductWarrantiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualPreexistingIncreaseDecrease": { "auth_ref": [ "r340" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the standard and extended product warranty accrual from changes in estimates attributable to preexisting product warranties.", "label": "Adjustments to previously existing warranty accruals" } } }, "localname": "ProductWarrantyAccrualPreexistingIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ProductWarrantiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "auth_ref": [ "r339" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued.", "label": "Accruals for warranties issued during the period" } } }, "localname": "ProductWarrantyAccrualWarrantiesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ProductWarrantiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyDisclosureTextBlock": { "auth_ref": [ "r329", "r330", "r331", "r332", "r334", "r335" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.", "label": "Product Warranty Disclosure [Text Block]", "verboseLabel": "PRODUCT WARRANTIES" } } }, "localname": "ProductWarrantyDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ProductWarranties" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r107", "r161", "r566" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r554", "r566", "r721" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "terseLabel": "Property and equipment, net", "verboseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetails1", "http://aehr.com/role/ConsolidatedBalanceSheets", "http://aehr.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOther": { "auth_ref": [ "r12" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Test equipment" } } }, "localname": "PropertyPlantAndEquipmentOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r12", "r144", "r148", "r564" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY AND EQUIPMENT:" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "verboseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r187", "r298" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Provision for doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Purchase obligation" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TRADE AND OTHER ACCOUNTS RECEIVABLE, NET" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS:" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Reclassifications": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.", "label": "RECLASSIFICATIONS:" } } }, "localname": "Reclassifications", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r36", "r769" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "[Repayments of Lines of Credit]", "negatedLabel": "Line of credit (repayments)borrowings, net" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r76", "r443", "r842" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "PRODUCT DEVELOPMENT COSTS AND CAPITALIZED SOFTWARE:" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r757", "r768", "r843", "r845" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "[Restricted Cash]", "verboseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r138", "r758", "r768" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/EarningsPerShareEpsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Shares repurchased for tax withholdings on vesting of RSUs, amount" } } }, "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r82", "r112", "r562", "r596", "r598", "r602", "r620", "r721" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 23.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r153", "r196", "r197", "r198", "r200", "r206", "r208", "r292", "r293", "r438", "r439", "r440", "r461", "r462", "r477", "r479", "r480", "r482", "r485", "r593", "r595", "r604", "r850" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "REVENUE" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r228", "r229", "r240", "r245", "r246", "r252", "r254", "r256", "r390", "r391", "r548" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "[Revenue from Contract with Customer, Excluding Assessed Tax]", "terseLabel": "Net sales", "verboseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/RevenueDetails", "http://aehr.com/role/RevenueDetails1", "http://aehr.com/role/RevenueDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r150", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r394" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "verboseLabel": "REVENUE" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/REVENUE" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r642", "r690", "r701" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "REVENUE RECOGNITION:" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r147" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Remaining performance obligations" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/RevenueDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "auth_ref": [ "r745" ], "lang": { "en-us": { "role": { "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.", "label": "Remaining performance obligation revenue recognition" } } }, "localname": "RevenueRemainingPerformanceObligationPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/RevenueDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r182", "r193", "r228", "r229", "r240", "r245", "r246", "r252", "r254", "r256", "r291", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r491", "r553", "r789" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Net sales" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of common stock shares" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of common stock price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesCommissionsAndFees": { "auth_ref": [ "r96" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).", "label": "Commission fees" } } }, "localname": "SalesCommissionsAndFees", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesMember": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.", "label": "Net Sales" } } }, "localname": "SalesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Accounts receivable" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/TradeAndOtherAccountsReceivableNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "verboseLabel": "Accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r33", "r829", "r831" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Changes in the components of accumulated other comprehensive loss, net of tax" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, cash equivalents and investments by security type" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "verboseLabel": "Income tax (expense) benefit" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Net deferred tax assets and liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r776" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Earnings per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/EarningsPerShareEpsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Income tax reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Compensation costs related to the Company's stock-based compensation" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r489", "r490" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair value by hierarchy" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r771" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Domestic and foreign components of loss before income tax (expense) benefit" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r22", "r86", "r87", "r88" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "verboseLabel": "Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetailTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Other income (expense), net" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OtherIncomeExpenseNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Liability for product warranties" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ProductWarrantiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r17", "r18", "r52" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Stock option and RSU transactions" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r17", "r18", "r51" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Stock option transactions" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Fair value assumption of the ESPP Purchase Rights" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Fair value assumptions for Option Valuation Model" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r719", "r821" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Unrecognized tax benefits" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r224", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r250", "r256", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r321", "r322", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r707", "r747", "r847" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEGMENT INFORMATION" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r223", "r224", "r225", "r226", "r227", "r239", "r244", "r248", "r249", "r250", "r251", "r252", "r253", "r256" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "SEGMENT INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r96" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r10" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "[Share-Based Payment Arrangement, Noncash Expense]", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKBASED COMPENSATION (Details 6)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Weighted average market value on the date of the grant of annual RSUs" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails6" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Net RSUs and PRSUs vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails7" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility", "verboseLabel": "Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails1", "http://aehr.com/role/StockBasedCompensationDetails2" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rates", "verboseLabel": "Risk-free interest rates" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails1", "http://aehr.com/role/StockBasedCompensationDetails2" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Additional shares reserved (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant]", "periodEndLabel": "Available shares, ending (in thousands)", "periodStartLabel": "Available shares, beginning (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Option exercisable shares (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails5" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Weighted average exercise price for options exercisable | $ / shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails5" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r425" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Total intrinsic values of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period]", "negatedLabel": "Options expired (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r800" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Weighted average exercise price terminated" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Options terminated (in thousands)", "negatedLabel": "Options terminated (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails3", "http://aehr.com/role/StockBasedCompensationDetails4" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross]", "negatedLabel": "Options granted (in thousands)", "terseLabel": "ESPP purchase right granted (in thousands)", "verboseLabel": "Options granted (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails3", "http://aehr.com/role/StockBasedCompensationDetails4", "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Weighted-average grant date fair value", "verboseLabel": "Weighted-average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails1", "http://aehr.com/role/StockBasedCompensationDetails2" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value]", "periodEndLabel": "Aggregate intrinsic value, ending", "periodStartLabel": "Aggregate intrinsic value, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r410", "r411" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number]", "periodEndLabel": "Options outstanding, ending (in thousands)", "periodStartLabel": "Options outstanding, beginning (in thousands)", "verboseLabel": "Options outstanding, ending (in thousands) | shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4", "http://aehr.com/role/StockBasedCompensationDetails5" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r410", "r411" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]", "periodEndLabel": "Weighted average exercise price outstanding, ending", "periodStartLabel": "Weighted average exercise price outstanding, beginning", "verboseLabel": "Weighted average exercise price for options outstanding | $ / shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4", "http://aehr.com/role/StockBasedCompensationDetails5" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r426" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value]", "periodEndLabel": "Aggregate intrinsic value for options fully vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number]", "periodEndLabel": "Options fully vested and expected to vest (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price]", "periodEndLabel": "Weighted average exercise price fully vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/EarningsPerShareEpsDetailsNarrative", "http://aehr.com/role/StockBasedCompensationDetails1", "http://aehr.com/role/StockBasedCompensationDetails3", "http://aehr.com/role/StockBasedCompensationDetails4", "http://aehr.com/role/StockBasedCompensationDetailsNarrative", "http://aehr.com/role/StockbasedCompensationDetails6" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted average exercise price exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted average exercise price granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Axis" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails5" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails5" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term (in years)", "verboseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails1", "http://aehr.com/role/StockBasedCompensationDetails2" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Aggregate intrinsic value for options exercisable |" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails5" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining contractual life (Years) options outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails5" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Weighted average grant-date fair value of vested RSUs and PRSUs" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails7" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Shares withheld for tax and not issued (in thousands)", "verboseLabel": "Shares withheld to settle payroll taxes" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails3", "http://aehr.com/role/StockbasedCompensationDetails7" ], "xbrltype": "sharesItemType" }, "us-gaap_ShippingAndHandlingCostPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.", "label": "SHIPPING AND HANDLING OF PRODUCTS:" } } }, "localname": "ShippingAndHandlingCostPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r129", "r130", "r761" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "negatedLabel": "Short-term Investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "State income taxes:" } } }, "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r154", "r224", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r250", "r256", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r319", "r321", "r322", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r707", "r747", "r847" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Statement Business Segments Axis" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r15", "r30", "r153", "r179", "r180", "r181", "r196", "r197", "r198", "r200", "r206", "r208", "r222", "r292", "r293", "r379", "r438", "r439", "r440", "r461", "r462", "r477", "r478", "r479", "r480", "r481", "r482", "r485", "r499", "r500", "r501", "r502", "r503", "r504", "r514", "r593", "r594", "r595", "r604", "r660" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r196", "r197", "r198", "r222", "r548", "r599", "r606", "r612", "r613", "r614", "r615", "r616", "r617", "r619", "r622", "r623", "r624", "r625", "r626", "r629", "r630", "r631", "r632", "r634", "r635", "r636", "r637", "r638", "r640", "r642", "r643", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r660", "r727" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails", "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative", "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails", "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetailsNarrative", "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity", "http://aehr.com/role/EarningsPerShareEpsDetailsNarrative", "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails", "http://aehr.com/role/IncomeTaxesDetailsNarrative", "http://aehr.com/role/LeasesDetailsNarrative", "http://aehr.com/role/LongtermDebtDetailsNarrative", "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails", "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://aehr.com/role/RevenueDetails", "http://aehr.com/role/RevenueDetails1", "http://aehr.com/role/RevenueDetails2", "http://aehr.com/role/RevenueDetailsNarrative", "http://aehr.com/role/SegmentInformationDetails", "http://aehr.com/role/SegmentInformationDetailsNarrative", "http://aehr.com/role/StockBasedCompensationDetails", "http://aehr.com/role/StockBasedCompensationDetails1", "http://aehr.com/role/StockBasedCompensationDetails2", "http://aehr.com/role/StockBasedCompensationDetails3", "http://aehr.com/role/StockBasedCompensationDetails4", "http://aehr.com/role/StockBasedCompensationDetails5", "http://aehr.com/role/StockBasedCompensationDetailsNarrative", "http://aehr.com/role/StockbasedCompensationDetails6" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r196", "r197", "r198", "r222", "r548", "r599", "r606", "r612", "r613", "r614", "r615", "r616", "r617", "r619", "r622", "r623", "r624", "r625", "r626", "r629", "r630", "r631", "r632", "r634", "r635", "r636", "r637", "r638", "r640", "r642", "r643", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r660", "r727" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails", "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative", "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails", "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetailsNarrative", "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity", "http://aehr.com/role/EarningsPerShareEpsDetailsNarrative", "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails", "http://aehr.com/role/IncomeTaxesDetailsNarrative", "http://aehr.com/role/LeasesDetailsNarrative", "http://aehr.com/role/LongtermDebtDetailsNarrative", "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails", "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://aehr.com/role/RevenueDetails", "http://aehr.com/role/RevenueDetails1", "http://aehr.com/role/RevenueDetails2", "http://aehr.com/role/RevenueDetailsNarrative", "http://aehr.com/role/SegmentInformationDetails", "http://aehr.com/role/SegmentInformationDetailsNarrative", "http://aehr.com/role/StockBasedCompensationDetails", "http://aehr.com/role/StockBasedCompensationDetails1", "http://aehr.com/role/StockBasedCompensationDetails2", "http://aehr.com/role/StockBasedCompensationDetails3", "http://aehr.com/role/StockBasedCompensationDetails4", "http://aehr.com/role/StockBasedCompensationDetails5", "http://aehr.com/role/StockBasedCompensationDetailsNarrative", "http://aehr.com/role/StockbasedCompensationDetails6" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r15", "r79", "r80", "r112" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "ESPP shares issued (in thousands)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r15", "r79", "r80", "r112" ], "lang": { "en-us": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "RSUs cancelled (in thousands)", "verboseLabel": "RSUs cancelled (in thousands)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails3", "http://aehr.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r15", "r112" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "[Stock Issued During Period, Shares, Restricted Stock Award, Gross]", "negatedLabel": "Annual RSUs granted", "verboseLabel": "Annual RSUs granted" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails3", "http://aehr.com/role/StockbasedCompensationDetails6" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r15", "r79", "r80", "r112" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Issuance of common stock under employee plans, share" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r15", "r79", "r80", "r112", "r415" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period]", "negatedLabel": "Options exercised (in thousands)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r53", "r79", "r80", "r112" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Issuance of common stock under employee plans, amount" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [ "r726" ], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Stock Option" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/EarningsPerShareEpsDetailsNarrative", "http://aehr.com/role/StockBasedCompensationDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r80", "r83", "r84", "r105", "r621", "r639", "r661", "r662", "r721", "r733", "r770", "r783", "r828", "r850" ], "calculation": { "http://aehr.com/role/ConsolidatedBalanceSheets": { "order": 25.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "Total shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets", "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r111", "r192", "r365", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r378", "r379", "r484", "r663", "r664", "r674" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/EQUITY" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r505", "r515" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r505", "r515" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r505", "r515" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r756" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "verboseLabel": "BALANCE SHEET DETAIL" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/BalanceSheetDetail" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "auth_ref": [ "r713", "r793" ], "lang": { "en-us": { "role": { "documentation": "Information by timing of transfer of good or service to customer.", "label": "Timing Of Transfer Of Good Or Service Axis" } } }, "localname": "TimingOfTransferOfGoodOrServiceAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/RevenueDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "auth_ref": [ "r713", "r793" ], "lang": { "en-us": { "role": { "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time." } } }, "localname": "TimingOfTransferOfGoodOrServiceDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/RevenueDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r363", "r377", "r483", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r570", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r779", "r780", "r781", "r782" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails", "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r11" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Net unrealized loss on investments", "verboseLabel": "Net unrealized loss on investments" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetailsNarrative", "http://aehr.com/role/ConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r445", "r451" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "[Unrecognized Tax Benefits]", "periodEndLabel": "Unrecognized tax benefit, ending", "periodStartLabel": "Unrecognized tax benefit, beginning" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails4" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r453" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Increases related to current year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails4" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r452" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Increases related to prior year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/IncomeTaxesDetails4" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r43", "r44", "r45", "r141", "r142", "r145", "r146" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "USE OF ESTIMATES:" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r776" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Effect of dilutive securities" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/EarningsPerShareEpsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r212", "r217" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Shares used in per share calculation - diluted", "verboseLabel": "Denominator for diluted net income (loss) per share" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations", "http://aehr.com/role/EarningsPerShareEpsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r211", "r217" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Shares used in per share calculation - basic", "verboseLabel": "Weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperations", "http://aehr.com/role/EarningsPerShareEpsDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "https://asc.fasb.org//610/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "https://asc.fasb.org//710/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "https://asc.fasb.org//712/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org//715/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "https://asc.fasb.org//720/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.14)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org//606/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "b", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org//260/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org//280/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(4)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org//330/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(5)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(4)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(5)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org//830/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "40", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481724/830-30-40-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//842-20/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column G))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column H))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column I))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column J))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column K))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480489/718-40-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480489/718-40-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(5)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.5)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r734": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r735": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r736": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r737": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r738": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r739": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r741": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r742": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r749": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),1(e))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r751": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r752": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r753": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r754": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r755": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r756": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "https://asc.fasb.org//210/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r77": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r777": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//310-10/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r778": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org//320/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r785": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483049/450-30-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-16", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r819": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r820": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r821": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r822": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r823": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r824": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r825": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r826": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r827": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r835": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r840": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r841": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r842": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r843": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r844": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r845": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r846": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r847": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r848": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r849": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r850": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r851": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r852": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r853": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r854": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r855": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "https://asc.fasb.org//220/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 108 0001654954-23-011271-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-23-011271-xbrl.zip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�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

.4/)FF*RXH"@VT??JNE=2)6#T5)B:)E:W^V9BY M$"^#/!'B7*HZJ.'8(W.'GX6IR?%V MC.61@L%HP^H.J?6J32@/RCS2B?ELL*[94-\7\=!US5L/^[RN(,]*$_O4HR3H M"98 +=_(.;0GR2KG?P\PFCJ4:MLY_H_J^ M7C& &L8T3IFW?2;&FU9RY!S8I]'CVI%=>+NNKJBO;DT+-KUQO;0L:DQ6(]Q; M?%)=8SI:[[3M/;D.LN ,NX/K_B.%=_POG3XM8#*@P@;6G09VX91]_ L%M4A' MZ@]Y'I=BY!SB?QF[$.6F6 /D]'@J/I)WIU/5.O'K0"=V/(H+ZV-MX98 $?.? M! %M\;?+GMT2OW))-">HN%NC@AK_W13"D7.2_-?:1?3J)<>X1L4%9#:Z>H\" MB^.[R*(,@=3EF>CRB_CI9G$\O>)N('FQ+>C(.5P'+A)[FL7%>Z[&?=:.[MRH MK:[,R,05FM"N[1)L2DE\+;;\]KC-XWL+7?A5'S@'Q\3-W\W-L2TU>TI%S MP'7T'@:G]I9+)5[ND7, >[;<96%!WCA]\%THI)4:XY'Y*H6!+ZRBS+X/1:/#M$QGK\'*DOOA!;%/7IKGNDI-,Q7W@0_?FIG__ MU1\)]/5=L_MKCV8)2'I!)M+'=4_>^WI;"H7C;9PWJ** MCIP]$%LI 1%_M1'&2L/KWHQ1_Z$*<"@S$*\B 3$6QRL34%Y>*.UV4^)2C)%S MJ$H734,F9F>E"=*0W()+62.LD*B+I@ZC,:2RA=A%1VG68RA$"3-A#MW6?MUV M#%\ID[.W7E=:+4DW$F3D[.$930G&81@=@J4D>A9TY,S!V-ZK*ZNL_D1B\DCL MO\=^V5ZWBB-+$9=^9"GBTH\L15SZD:6(2S^R%''I1Y8B+OW(51*QF PDI*T@ M!8DU.& $ WB@.?E.8#+4(O1EH9LK2LE"5PU;A&44&:\I)+XUPC.9ZX'$MT8B M7@CG)]TL+^(_?EENPUQ.CRFNG(A8-);14?. ;OA99.SP"[K@IT> M=+=]O)+R),C(.60:QP=M?/Y3W@!N*NV6I$<),G+V&+X,+Q:^%\-'4:6.P+,, M[A9TY!Q@'%ZJ>Q^,8W"O)&:K-W(.F VOI!V&V:.97">P(N3U3921+77 M?>HW-NM+*N'JC9P#6QH"/G .+X++G]_F2)6 %&AALM# .W[88/FG"L!(>_'=R/SH;]?_4^ M$38^83^X[7[KW_WQB6S/@'SK/G[MWW\B,(>?23S,1>P@)V\L0OQ<@YG/CQXUNQV+GY CUAKE*MUI&(%V/D'! ?G79V M-.U7JOD"0:_4H(_/98M&$98(+Q#.2HSP>BTZW^$8-K&T9XH(OU(#/SYK(@Y- M62KX J&MU#B/[(:1.OL4KNS8QSE8)TA*/G#E(8]2M3N(8E>=Y M^4;.'I.1%6L:CHK2W;G7[L8=X;[ED^H:T]%Z%Z]#1%YY&WFBEV+D M'.*2\;-E8SDV);R%!UGQX;V[DEB]%K_B>&(?:1Y8/ZXZV46,>C2RF*- 6CI^ M1FXT1ZI4S\*CJ_BXWJ>>HU4N6F5*FW9"!U'_AE\'C3>SS[,AB-!M\^D?KB![%-79O^+,R^.3!#V%"9 M+M!#]^:F?_\U./XIUD8"10)% D4"10)% D4"10)% D4"10)% D4"10*EZD 1 MD][W1=6Q.JFM\.E^4U>D65<(>N;$PK@P4$Z1$;O=J*QK#V9)6&#!%F7I-$QJ M7"CUAG@4V8J.G#T0ZRD!$7^U$5%-H];Q15T"48R1LP=B)Q(08Y$(,P%EO7ZA M="[%*UM2T9%SZ"JZ76MJ%S23\O_2A.G[<&6]UI84D6+B+II*C,;8RQ9DG8YR MV8G1\4WB3)2#MUZK[U=OQ_#G,CF VS7EZC)&M^0JH*34^(RF!N/0XP[A4E+; M"CIR]FAL[-6655: DK@F-OC+]KI5'%F*N/0C2Q&7?F0IXM*/+$5<^I&EB$L_ MLA1QZ4>NDHC%)")Y?9*).<,FO2^F 0\T)]\)3(9:A+XL='-%*5GHJF&+L(PB MXS4-#U=X:G(CD+O93$0/X32EFR6VR.8]13C]B/WY9;L+23ITIKK2O+P4SE56 MT9%SJ+06W@\M"^RR)CCI07>;91(CF%H%Z)08M/5:>)O*?:"-3X/*&\ -I=T2 M+T91T9&SQW ]ON(]CB]U!)YE=+>@(^< X_"VDOM@'(-^)3%;O9%SP&QXQ?\P MS![-Y3J!%=%I2"B+,7(.4 ZO*KQ/_<:F?4DE7+V1+W@$.1*O9HZ@RQ; M_S1W*A*++I;69(["P/4GCOJ#O&G.'(].M/L(X.$55 _\'3W9C\,GZ:S.(4FB M%=WZ.>CQ0_/HTR/(T-(F<"MEGPAFV+)J@OP'MZ8U4G_\OI;_4>[JD*R=BQA> M:YE-(1(@PVMN'^6"WL+D^FP( G,3CT=T2PI!H\1B$;%8K\?'8BS/\JEQV5!J M[1A.9HE-@0SF\ KNF3B,CX>IO/D5=.0<@!R?+A'-92Q16]F1\S -PBNTI^TU M%L!"Z,2H9B0M!($4:WQ:1!QGL%2OE1TY!_7:B,R'J)[&%).&_&"9,-34)C/X M'5DLQ[HV(>9L1M$G;ROP+0?]NIK'5IZ8MB,]O-E3.EO1#95H#EY/T/B@!R;F M@2=EMK<\/OHU"MAST:926K$F"7&"C)P];-OQF40IPK;[ CK422-0*!$KQLC9 MV]O;E4W2/!#9GEU+.C(.8 X/@=NOS]9 M(K;2(^> V,C'ID[?%_,FAUO MIVP\4C!L;5C=(;5>M0GE.1Z/=&(^&^PI+,PG#_Q2C)S#@1^?#$=&&IY@L$O5*#/CX#+AJU6"*\0#@K,\)CU&L[AH4L M[9DBPJ_4P(]/MHA#;I8*OD!H*S7.(U,RI,X^A2L[-WKU/76(QBY=1!#P%W_; M2>]UL>6WNQEVBD5-/'T*&Y [/>Y,6R8RE6/D[(&8L:-9@K)\(VSHY79(_DD[\IO\+-!U7CP.BO=Z4\ETLQ<@XQQOA4[UA.2HG3 M*HR<0U&P9GPEFMAO&0NT1U8'CV&)R@*+ NG-^.FNT9R44F%68>0\%&;T(N'' M>"NEKI10/*0KLW5(2HU9A9'ST)B1\Z3*JP3%)$#>FA9,Q""3I6518[(BCJ4: MMLX8JT3UR:Z"0+7XFT3Z(HLMOSVI_?'3X@[Z(G==KE$/NCOWVMVX(]RW?%)= M8SI:[^(U8]VKT2W/[5*,G(-Y&1_2L5R8$M["@ZSX\-YCEK:BYWD>[?G, ^O' MV;_-IG0"B OC/2B.G[09S6$JU;/PZ"H^KO>IYWQ8H5(S2P1GI)GC4P#BN&>E M?A8>8\5']S[]')DX(%7N,<[@ ">U9"!U'_AE\'C3>SS[,AB-!M\^D?KB![%- M79O^+,R^.3!#V%"9+M!#]^:F?_\U./XIUD8"10)% D4"10)% D4"10)% D4" M10)% D4"10*EZD 1D][W1=6Q5Y*M\.E^4U>D65<(>N:$QG@3$#0UEV.="@OR M=U-,I[395LB@:P]F29ACO,\[]LJBTY3ZQ%\J[>;A5O';>[$IE?8N0,?Q&_]5 M"'"V4@(G_FHC,IM&V=O+M@1GE<%Y%0F1&B)$=K8JU6EH@QQ MW?[#&9O3%?Y7!6FD-0C_D_>6\9]X.[@?G0W[_^I](NR1A/W@MONM?_?')[+] M4/*M^_BU?_^)P&-_)@$83"BJ%%B0T9P2=8*=V%5C!:H&ELJ!1\ I252L*.G0 M9TO5R4*U'&+."%PC;(KP8"YZO%F0F6:HQD2##]D._("EUI]O3OJH9> +P%;6 M>][8M !O3+@PY4\U]D3V['_8A+*4Q(S7JD,=%^DS/QA95OY^I,WC()Z+J;^K*_OOG*%$']VGTY?,O*IE;N$/_ ON\ 7!A M8@ @7*.&8(5&57@2?C+K[9#M/OC%AL/6>(;_PD;PQ*XZZK.O?:>:O=#5U2?8 M%' FTP],94YF'SYW>[\^@AR'(S+\8SCJ?1N2[OT-&3Y]&?9O^MW'?F_XRS_P MJ; @WB"YO,KUX'XXN.O?=$<]F,X(_O,-4#8D@UMRW1W^2F[O!K\/!K"$@U_RGEP7Y\$1]VO6 */T^G,R4S19&H?Y1W[FD_C!'BO(E@MGBCA MY-%Q*_W/AWKM0X:(^8.J%ND94SC>W+#G"11^ M4Y+BC"_.AA1GF<19%TR<$>\1V5!\KE5[3F:Z^6:3&?R6F MJJ0Y> _'*_:HY M&K4_">)SV?*)! "S.:FKC ECE7)TR467BUYI&B3Q_L\UN MDHB%OA@VV909#^9LK.+1@VP*:MB\#KX(ZRPR&-SV+8%)$QZ LSUS0D;-'7WCOG@CV1)705P"O MQ U=6+"Z;D<^8TK4%Q,&_:]T3>2SD:(W"=K>2$')=8UI-R"W%"P)&;849N3L M,9@X7)XM!IMMZ: 09.3L,9@XVIXQ!AOB>6D+X*.X-XTS%G9?!]AUJMJ4T!_H M0Z*"P+K,&RIR=R!O0V$UC$\@.*1\#SRQW:'4>EQH*6RG2_%V4T5'SIY M:.! MSQZS(D,$OB=3M0Y7FRQZ39]RPBH\EK;'4L@55O48&BYK@MYI7 K=R<2B3&;F MC&C&*^5L/3+5;.;FD5Z%'#9)>+PO@EO!EU[0D![,;ESAV6!B/UCT15N^V'U? MMJFR7-L1JE=*S2R@Q1D>%8O@1D@#<\7W%E=TY.QQ&1XIB^!:D+@LBKN!.N19 MU0R>HPR&AFWJ2\\$Z8+Y1[#"(W%+/)+_51>J(0C\R[SQPH.$!UT0U/D*LL1/ MWZPE.9BA' .%.LNVS2HZR=GB0[:#;(@D,C\TR MK%]F>P,K@!.#)W 21_U!QM2@,\TA%F6%\C&K4%H8@NCV\*AA!#='[V6AFRM* MA]1ZU28TG.4\4G]\X<+'!P=_$^HXE-J_H"-GC]/P8%P$UXC$J7!H*3Y.]U@I MX3&["+Z2+(!ZI!U3/]Q%IK2U$K@5\]7WB<"R/FNOL/:VC1;+P\,#T4UIHN2@ M^L/#E8><()[1?[N6VV#VL%C<@=#J4IV78N0(:/@ID0*(5DV]2Q63:(KJEC39=ED2I7 M4*6B(TL1EW[D*HE8Z"MJBY7S&UGJE+*SQL0.M.LR!A:=4.V5]5X182E%QFP: M-X5DL?J^,;&02'M#^7_[!I-GU^#]A+W$WD=?EFG>'IK*19Q\ GE[$ =NG61! M^9/"[4*Y;,:HKR'A)A#K5 ;#7-W]!@%K\+;)[AR0+1;_?'JX07+4.>%R1 O0(R:M=(\$ AHR0+6IP/:9;9 *\#EW_.OD(6Z0N^* M(%@M_B[9O4G"4V43W?\]Z3UPX:5@%[256DL6.!9DY.RQ&!Z12N0M2!^+=456 M)Q1FY,RQ>!$>KDKD6\@"BY<7XC4J+8 S NL[+&G &2$(GLN\D\(C<4DM#!3? MW9JCF(:1(;T/HHRIVZ:N37\69K<=F&$JV_ R<9O*G:Y)+OH12CZ]4.CA MV,U#]^:F?_\UN%RG$*7$M1BX3MSZ,E]<'[[52EQ7$->[Z:Z7B?MIY@+LD'37 MP_V&]T*\;.DRG9K7V(+UT5Q@V_0IG9+QBGQH*;7Z8=JY/&HDM@/8CMWF M\S385MHU>3N0T(YG1<7N-9HGML-:=US4CM3?.:82E7/K"+-#REG2KJ(C2Q&7 M?N0JB5CHJW>=LS;QVCW3S3>;=U#@G:PW[]JR)G*50%O1D:6(2S]RE40L=%2< M5^5_6%J3N8H)B>;,/7=89VG)Q@[IB4AJ9W2\I:X2T^$\&>(WAK ;NL;T&Q?D:C!C!-5TK89Z1ZG5#E,K*@6/ M,@,S,9_M"& 67_E7=.3LX9B8A59I.!;-1;&PD(CFK%A= PJ6X@+%(@C():-A M8TQX7'%Y#3YC!$K+9MJPS4\9)F<^9XQ7(4W<23O7=*6Y,A2 MQ'+D*HM8Q%OQ>ZK[3#-48R*I[M7%:45'EB(N_976G&11#R!.+ M3C6'?,3FBMPS_A,9FY9EOL$Q9"OP*,'BR>)!]VBZ1JN6F-;VZ(MM,$.1PG^N MF43+1LVHZ,B9YUVT:HF9:Q&QE[0!3QSV9$%]G@4&U&X\)::>"80G$>V$TV1C M;W+?-=M>P@V56P[FRPL(WG;,R7=8]RFU"'U9Z.:*4K+054.T"&XI-UMR5EF MY]EWI0K[C+0J6^J:(Y@Q5H+O 7W7"P34\4\CN8CU560V\@E&2ZDU):8EIF-A.CSTF-1+LP?3 MZ<>_14"RT#Z;/7UTPFB.JD$[ M/'":/"LP&V@WVLI%1S:&DMB.A>WP0&SR%,)LL%U7KB*XVD6 =E*_5CDWF3![ MJ9S<\8J.+$5<^I&K)&(1K^8?/O=F,SIA,0SZ8S)7C6=*+-6AC#*!MW2%W]6Q MDN K'--8TQ@K"P8H%/A[$=:WHC;?[GAD/9SQ%.&NSD$QF/5<2#P"(@8&VH'X M_]X:"X\^#/ 776.Z^8/ )],L,-',O[Z$A+4P5YEP#E&$:[I0J%[3/0ZS/42X M\,@-(,P&""I6FS+P0&:Z[T1K.MHUP22\*6M?Q^(YR59,IS8*,G+TB;H2S M;B-*^+)]F'!RBBR1DH%7V&U3MM>MXLA2Q*4?N4HB%O%JS:OW1KLR M*V1,X6N&6Y)@155+A&65P98M:V\K'Z5K#V8975[2J&A35]J=5B&B*1+BPD"\ M$0KQ+"XQ:83+E0#;KH#Q M+P%;(L!VRF_*GP*OLKN@]&Q68Z&EB$N_T%+$PAT9N=V-A\O%0J=8:U+5^149 M6PT2S>"'.9R_LK=@E5!:T9&EB$L_:4 MN5WQ&BG/G"JAM:(C2Q&7?N0JB5C$^XU_YC39E/O&Q'RAV Q&M%JBF7B8T_0C M)RZ6SM=\A$O^ *=]&OD5,:CG55 R!8%0,W%Q\O0A=#@H)H <)8*V$92X%'CZ M"*JWA8.0T)<^[P!V*%)N1.WZ*BKP$]?8]A:\O*@7:F11\9.XD'7:^)%IL87$ M3^)BT2GCIR,VFQKI=P MWIY):DCE<5O1D:6(2S]RE40L=)B.4T.P J%CJ88]HQ;K0_"?I;; DXF,J?-& M*=Q,C5?XIVFM6!+?PC(7,"O^#__#(BQV@:[XX474][@853JWL!G4R)44;ZK) MEOX+%U/?DU+7F#ZX,H*_^A]+PR'0$L\E(-3(HL(MO&3Y'H^D$'!K74@'9B'A M%EXK=8\#4PBXU2.D_9_$?OB',S:G*_RO.M9IJH/XC[H=W(_.AOU_]3X1]BS" M?G#;_=:_^^,3V7X:^=9]_-J__X1FQ,\D@(T)11'4 M,+&KD0IW7!4M"H<^6W#U7:@6:W[DS*E-$32L^(2*%0+][8M*;48E*%*7^JL2>R9[]; 1<(M=K? .NPCQ;J%.M _L^' M&MIO7%ZA=M^'X!Z<+\9S:RV0_1;CAF&XE<\ZUL&:#%3O(*/>/T=G_?N;WOV( M2RE,2,U&I#'7*_[WA?I,S\865;^?J3-XR">BZF_JRO[[YR@VK_LT^O+Y%Y7, M+=R#?W',20/@PL0 0+A&O0&2_N4?*CP)/UGL??"+[5BF\0S_A8W@B5UUU&=? M\4XU>Z&KJT^P*73-H!^8'F6[YY'\"DR&A K@?WP\%=_Z8[ZMV0V_Y]]_ZZW[TC MPQ'\X!M@;YC3Q *BY!K\?OE"+6WB'TKU1BUQ!>\O2QL$8]LWU)Y8V@(/!CAZ MNJ#=EH8#F_X!MMQ$H_8('OU%-R??/Q#XI+J 1SC6DO)A-6-)IUTXG_ ??\X: M5Y-..X4#PY-(_9P,'K]V[_O_ZH[Z@WL7)]]@X?X@@ULR['^][]_VK[OW(]*] MOAX\W8_Z]U_) \CN&E#T:8>84MQ8"1_UY6G8O^\-AY_2GM@NF.P@SB6&R1?5 MUNS![,&" \YPF"-W%TZ.?3^NXS5C"@-]:C%]VP7#BHR0 S1&D9,,N MHV%I\[%P:C9]T6#]I\L)6'OPP^D2D+DZ)VA0!.9;O_C9Q@F A;! .\(R\1O< MP,#'W [^>?;/!X7]]Q[^BP/CWZ\?X"W1TX$RAJFA!:+J.M7?S\_F*Z:PY_V. M7WI0OY/94MO:-RYA"S*5OT%Y@OS%AZ6MX/''AQV MY/KI\;%W?_T'&3UV[X=WZU.1_;M[C?_.\50)YX1%@.TME^#UTK*H 9 -" A. M%_9/G4':SAW37=NF+FYT31UK.NM#OX577UF'09%]5R5C>(O)'+XXTR:4JW#W MO=BYX)CDZ7QX3FX ZRH<+3.8&PZA6:"-#;86F$[/5\B=06]IF:"Z'^8PJ\4" MSV7R0&V3#7@/KS=2M3JSK,%8ZI.:4. MP:U\3KIP]>.3T%>*.S$#?FNKNON*],>"&K9[_PV\&Q]VJ_.ONH#3[(>&05_X M)>Q!2_5_M[#HJPJO!+\()'+.-/1BL'Q.."C7D"#J]-]P?'+=XLSA%6#5X9[- M%]#[''\(+F:82@HL-J!J,=#UP' ME>'+PC3P] =IV7/X*J@R. IM%S#,/'!6:=[X4WA4F&9?[TCRK&J&NR%,&^6] MO>B;Z.)_M\%\,DQ7O[+&3P$DP\I;^!1N'&U(8,76VSTR?/OI.GC(#-=RA%4> M+ !*7+5S0P^?,STG0TK)/5PX2;VM>*;A@ W\L<>!^Q/AG'X%]H[CFHNXH=F( M4^H )'$ ;XO[;^GL6QO\/FP9LF"M-1BVT40NP!GS-.SAI0KNY?UO<-'-\1@) MIX9&.$:>;#J8]6P'U0JU\[%W0*!LLZ/T$1WA%@^^$/IN8;.3-PWL&M6_6'L& M/JK19PKF,VI8_#U=.&O$/QF:CW6&\RY;-I5\=+'\M=M]\.\X%NH5O(_ *X!> M9?R)R9]=WW>&0N752LV8WAPAZRG?JI/ \ ML0@ZZ9$R?RB#$-MF*:NEX+N$J*AK:L'!98#PMZ81N/B\J'@;,QFPT/;2S*7- MZV8VX6\X[\-B@W,$1-I4I,4RBP68"U0.01S1K/+/Z(QZD M/X'%:2*+D&L3[U\;&@@VP2$+2UC,@YRZPU])[_^>^K]U[]"EG-]IVSZFYR/< MSK9[B.5]0;O>+L*-H-5L9G*_@/&] GQ;WQF@;)@#A^UB:8'UAAXY?AJ#EK4T M& - !0I^BA#=>7*06L,H/?C6G8Z]]WO#,ML&E &6\ZF0-N:@NTY>8O M<8&1#<#TZPL,C1^A>*6U3$.;V)O?WG @^SY=-"[0L\%=;LP%M^N=X)\8A)YZ MU@QL)1.^ZAEWW#"%SQFFPZ+H++]W# <2F'(;3G*8%_S>O7,=LJEP35P;B'U@ M86(05F/F]A(.&QW?5\,Y.@B7P*3MS4%5W<8GO6KTS68.RG>?)V/XU#,:GG#$ MT6$D. M.EXIMSOA%W/0H29>,70RAO-Y2L=(H:3&%*#AWE,(R!$O]1,$$'$7%I0H MDZ2AKIU(^$//.\ \ GPQ H;&^K'G\,"@B(*+O0DI>SU=]T[ UP1OX70&@O>L M%O:PH/_WQUR%*?@NG8GY2KG_SGT^7 3^BR<&/@U><>7]@N(&/2.JXM7AHS\(U)R#<<'>@_7Z-&[AYD(*5AFLM1%L' M*4Q;9WLV9[TD\GQN-B61Q[>57+:%ZBN%(.,BA(O1O*)JK9D"%^-Z #;A_>B1 MQYH&M^3ZL7?3'Y''_O#_R\\H#.?Z1@N0(J"XP^Y1L[]?6Q2.&/Q;/OY"3^W; ML VY]> ;SC'YIX34"%=6U/Y@8HQH07&:YB+;//860==* RR M\VAI1PX__VE;SI]L*NY,OH'U2*T_W=7^\_T1PS]P4"H/8->@U^"9UH,G3__^ M-G#V/,!J^-S6,]B7]8MW9]#?V*+L?M7((4OVJKC,IWW%R_?TW;^AH)\MT[;7 MQV; X&8G*+L]K*U-#+&XSN4-(+'%XE@" W&!QM8K0"4$38WH:(I M6S2'T!3N)=SUJ@*@*>P5LT?3Z,T,?-T=AA,Y]BQN9)U_<#7_1"K^GP.#7KN3 MR':1WR=X',)19!9GQ%>%!<_E54,5\%X\J>^.*;SAHM!C1#N_$O^JMY[,HAE^[+O2XK&W0J-A)JR$YG= MZZ_:$%D\I\#^Q55<3'0BA^)VOUUNB-]QOJZ)4W!FNIX,;J)O'I0@A;5;+*H: M#*^KNV_/G$SZH4?C[O5I;'H_%]1"?Q5L&^/99,Y6=I?S?)C,&XG!'LS'8\QP=R"8,S ;S?'6J*35:>.XX;=^4CH9>4<'QMCE>Y@&X[. M]=#9NZ*RO+"N.0X8;V.NVW?=;V'] DM+%Z;-?,#,M\TXNP'7+D;C-&>YVV>\ MP6M4R%=8:H\9S'F-FP+BX3A^HZ8_)M1V9PJ/WH@"SI;&E*. L?I&%E7MI87W M\0F&_33/Q1[R)8Q <%X) !Y#)2:\B?^"5)W,V0=W?I^YFE_AAL_4O1_8L#C1 M9.]:KX.-'CD3'D=U%D$9J\9W-R9CF=\YD7*F(3!?5$X8 9&S-4'50:>N?$ ML!VG &K0-5MQA;G*=P5ZHBV-&BPVP\(M,&>4GLMN0[T#ZQWRKBP:#Y>!,]PB M_#U<0(C./PEQ<0V?'A[N_LC9Q14[DXOE%V\HYL&,E6!:,05]BF2 =8Q#USA< M[.78"S::ELU):;YKB[ =[M+!?.XLQS9\T0U.XI.\9)J@_^R<_-]2U5GDWO+. M!AY94#6=9>?L(&W[#C@,N*WC40S90;^;1RE9*S'XPMA-B%K'JGQ6F6TM%T[H MB)RVPOU\3$+D/^[4UU%=,^3@PO U':^X)E'7VY$%3*>O\#'J4;G=K>E/#S]B MZ<#-US*V3%'3J9&Z9N/@<7?._ZX0&P9E9PRM\$0UEN^%HE2 7' M"(8)GZ*X?"K!K M4HL82#0U&E&:_=542:AI&/#0"T4NV:!JN"JJXB0JSVXBI MX>(A\Y>H/FN=TW0] =E((N*+@&\UI;JZ\H^AM= 9-]W L)P.%IFU\DYX[XT9 MZX@/KS&&)>9%K;SS!WYGCFT3K :Z55Z&(R3X1=#$++UL$]&B:\K^_6^@* >/ M_3SIP4?TC7!ED+LN]$;6Z)H!ZFU>A>CJ&'<";E V9RJ4\6G0#"JW32<]OD1 M3GD;1U((_QM20%ZH,S>G/^WBA)XCN?W=3XG&60 >P77*PA,N.7FRYKN:UA1T M'X 8 &SQ"+6G8!1&CN);B\_P90'(A^W&R,%P]+MZBNU#I$JYE, 'RWS5;&8& MHB'-]XZRWCGXG:6QM%VC:;V0*CLPD$N+L;T U=E73'2#1#M;LC-F2E_8XK(\ M,F:Q!%D&&SP/%JZV WO7M[U@QP;\N846=QG M:X9@A#):)%OLF?IJ6NQ);O($SDNFN'2CF?K2QKCCG+&)V=>?1'24I.:+=N0IE M1RC[YGP1.N>=%=73GG-=J37K.V:-\MHS\ZO0F>^LY9WZS"\Z.^:]X5D1_6!] M>!P\]!Y'?S J)M*"'[#01&YG;"MQ?0"O;-$#*$HG6+LH]S/W(;2$W]:ARO08 MTZ7!E#ZXJ8("TMST0H/Q$BT'E#8_L;XQ5X;V@GJ)K@G \#J:@[H=5>?;7&,L MM86J^74"\,9OL!L)?MQE>4TWT]3N*-C.2&%__WQW$I2;"?S,@9GS0X%9BL[>?#3["KNVOIP(V.?TW&\C*'X]W: M6L5 *O_FROHKA[,TT."'XQX9-6=8]@7.3QL.!&_Z.R?LY@GPFQA6:PQ_K4U_ MDXKV [+)[#2VR4Y'V_X\D6WU%_'6/IS,Z72IT\'LB;W@G39#IEY8#3#&/<)M M- [=1H<98H&E"+"LT-+19BN7*=:.310[99WI#C]2";YJAO2Q?PIWW.W7T&GP;Q^^9 M32>?IDL+N98?/C>VSTTTAG>\3FO[(-EZ&S95]<=ZJA'>+]VWZ;Q[&\8H%;NX M[8?/W\+UYUT@9V;+A]M MV!1![1W:X$T0<#<3@IOE(UVO[<:=(L\"(:U8@&\E!/Q)7S':)MAF:N?#Z ^B M^M@G/O9^Z]T_]3"';_#UOL^*5:7SY"B7Q2-RHUD"_R-W]APN617":[]2VXWI M5?;Q*]<=97M%!W@6$-S07C2\PSV;IAOTY%EP@2(X,XHW.Q8<\&,Y+&_.RW9C M91=<[YKM!F(,6YNZ=4SPFW";G,PW\[1^+*@;)AK#71*6Q=&Y:\ZO2\)+EZ!+ M\/WLQBOWLL0B'& SO](SVZ$+?"/TOWXB'^L_K1/6W$GQ'$&>,>N_C4(^-K8^ M&@R^F6-0H>I&F-][$GRS^9.?J\:]J,%B*LSW#!]J_<32A":>IS7D,V@%?6S_ MM!;4IIS0O;Z9YV;#E.P9:F&(BT5?7>"P17F#BR'W6MB@U/6UFP3O^BSG MT,=9L'"/3V3RY)\#(R9,E0=39V1Z5GKI62V9GG4@/ M[V9WT'7]#>D'SMYI6(SC>#J8G66,[335;)CIQ-FA0;$&X[M4Y!#E'9Y_#(K; MK0M&UW.PE^-_L_)$&#%'IA%3[7Y:*?Y\\SPQ>/0LV7&Z&0X,80T^8V4=F(FS MM-C;O&HZ?48MB5%,V.@LIY7.>-AAS9,(I+'ZU7G<"D7"'RRW@7(!;LDH=G(@ MSVZI.UC':M?YOREI#TYV."S\@C0[#C+F769>;%Q:.(B,J:J;!MV,7'./\SE2 M"D-_S^VT,>.KF($WF+G\)'Y^P<<5,EXZ3.8>7\4QE6"./!; \BIZ\31Y7F3 MY\8$3E&OL/"$SP-?VPVR\U)4B.1G:@*Z%G.-IMH0(!M0N(8\9\*Z-9C9"Z,= M\2Z!'JN,D86I&8Q[@P,I[I;4@B70E@ODB\W=Z +;29R%:0)GR *T !\!J'5/QP(WQ>#>BC;1]?UJ((9;8[]6#$5XZ MV\Q.ZL;QN69EZ,-:#J "IYJK1!'H2+>SUWI87=\ YKS*92"SWZ7$,:Z#5_)R MT^+VSQ:^52W8 .J*ZVQ&HD;!L$ ^XCT2V<9L\R\ @LAFQI@E'LB\, >2K^$GC!CHUQQSKQ9+@V'H MS:LSPYDL^#%&(D&RT)H%XRF%-1L@BZM!6GR FZ?K$;GI_=:[&S R +D>#$>\ M5\9U]Z$_ZM[U_]6[(CW[F,O/ZY XF+ER/50K0D6$;M!$KK)-+U;C36O MNDO7)J=X\0"\YZ*PW*FY[$]_!8K=FL]<\"9.PK1A@^X-89M MSIPW=@>WT QPDTP.DF\/#D_00M$#U%[4_#,*1I++2';I ?[XJ.IY=1P;STG- MGN,[?/5.0V7/HW _K[_DE\U9/_O%Q)CW.HU'\S7GRJ]Y;0=<+RXGVZ_4YI51 M\JQ+UPZU<1:\'8.O !AQS''->Y]+R+EEN'QH=E+C5;-,@_,;--LW$YC!/V&% MXUQ6 M/WRJH[_$_!L3)'G8(1+@-RH\D=TZ6-Y4>=()+J Z7;FKQQ.;6*6=)7)& D[] MP,Q"6"IK^H:NS>@V R4(=;9BZS+ESS"\X_-;&-/+7K,.<>MML$LX]=7CE\"[ M,F<_KT+$]NAZK.!VXW-GB>V!96472_]=MM/T-IB+PK/)^M\>NOU'=F@,;LG= MX/[KV5W_-S@LNL-A+\=:?MMQLAC4[1S.Y,X_D.BV_Q(OTG MH'5S?+]2SXT_4[V[WD2S0&?@UN)7NZGF^J]=*C?+%$"@G*?RNZM[\UGL<]8?88XK9 M8OGMH\05TKM3%C%'#J>M5_V;:&B^I?@I4 M<0OM#W_M/SP@B-"4_Q7^N,-_@*)VC?X<<96X%O!PSA)UG\&4_Q5DI;OXRK]; MBXL/4(WZ=M"5.:?<>3) S=V9;E13W6XWX:>BO[/F34_6>.B5[;%2[C)'IACLQ(_1&;3E ;7XXOI]G8"BQOQU%_4+^'3*"< M YR^KK7,#L\SP-"95]Y\Y5JVJ!']&\UX16[]/-1UFT;7TVV!!OQBHI?-ZP]Q MVQU^\?M#A'[^VISZMRG_:]WAM?^MD;D 5VT:HK;*86,V-L$/HN_]3Y_3FZH M1WY0?^QL!+'I&_:NN:Y1@E_$\ V\-66&E.IP+Q?/>C)]ASDC-? NRKN:2:P- MD4 /"?J#Q;">=TZ/'SR:%<@?8;,:LRO59E8M8D(-BB\U1NN6%E"=;=DPR5NVSA6[Q)$H]8 2>HD)WI/'U+,V^8T(YKL.C*TSC:<1W@HM7#>]FDW,?Y--MSUS MA09G[_K@)Z:%$L!$.+P=.[*9'X?>0780JL MBQ!U&Q[K=_+<+IZ_Q9^=Y^WVR@# [SD27@T5J#YP@*3S!?. P :JL:^%=,%H6"O4E;RFT7E/5>.UQ4D3.BL+ B[I :]+*WRL(,D.:C9 MEN2@ ^2@PQ2@[(Q3- [9L3EN.[&G$P#"R[-]ED:]A)-L^"7O&/*AJ7@!R<&*7ZHK(DB?F"\\N;!#-@E&':6 MVPR),UJP@@)C++CIGY.YP4(.J.[6/7>W#%MO?/[Z@9?<-M-VF-EN-TWV/NKF M&]ESSV/HF[<^]8:ELV+TBK7ZX*LZ5U\Y/]D+!+#5:M?^QE=/FYN6\,SW_)3G1WO58L#(^W,6O*SVOO4X&>=J[!Z'>97$-\ MXP!<1^78Q9,5X>%;)' +V6A^Q;N[N97 &"T(;%J=&,!=WVP*99'%,3K.B]=LMIX+%[7_#W[OG$JTZC8!QB/X#/0SF>L\]&Z3A^_ M?!M^0U:_8ZRSHSEP>"?9[0Z.?@TLMXC-CE7T*&O\QNP^E$WZ7?,ZIF#6AFW] M??\7O]0)+L/^DB&^5=X\!U,YI$KE9%Y[9'@[C00*V\8G[C_ MB]*JA9<+"2HQK\08I][IZV&90AT-S_Y7A0516%TSWM^=\/[N?C/M58 G",N] M9%Z*\#7GMRY8\?=+!=L+K.&@&9+VT[<"L,T%S/R;X]JMGOH&IO]#G>]SJBNY.QU=S]R.LE MA]&.A\?!/?S]NO_JV-HT?+-,PT?1CTLE#XW]@=YM0-RX@ MF/P!VZ$[-;&!L'NU$9P/" KR?Y<&!?58[W#UR*XDK.?9-,Q=39X6K'?P^L[Q MY%\V\"%G]:82<)#W [T?F:Z'OGP#G;_7YK'K(&0U6WV;-T ?7U=:57Q?R;KJE^*.J]JF MP6N%LXJ8S&7$_HUGX$2UG?=-G-T^9^HFOVNKG3*6Y^*N-*9LF;<=$#1\XCT= M7EEJ+J[K%1=.H'NU3^?UKBO<*ZR]TFW*&OP2 , 20?S;@P6:]#]+,%4YRR?@ M_>$$_Q<6DV#!-L;#?;;AJ MS=2BWJ6[:HGK(+KL>?S"M4OI_AWN/'YM_.CA,K7>ZDQK:6@S&SM-/G]NP%', MD@W75IZGV&#< M3<753 KZ0[W(^C+@?5)9?0H_S3>HD_WBY$A@X@6_-DB.-CQ1SR"W8-=.W=$! M*<).W8398.;N7+\&5,1M.KEJML87&=-Y_"M4$$+;X."1;[]2%_G(3@)S:8/, M;/>&GZ'ANMOYRE\^)R=K"R5L#IK=.9DYD_/]7EV*Z%-4<>'KX3_01' MZ9NEIE+2)61 +R@QQ07XL"/2L(XQ\"6[>E>C:VPZ<&*%!1S0[($7,?[G0WWC M>$JI((P?U_@#$\%ZP>ZC)US8R,$5"9U(T&EDB1Q4^F$K^="]N8$;LN MN&U#[."IO54X,R2:&;VI+VM,Z"YR>*W( W[-W@^WEDN7\47I=*3^B!CQ/&MN MA3R])H;-#Y^;E\IEJ_4N\BD@!B3ZMM!W$5ZZ(*Q5IJCH:[251D.BKY#H"]=] M(4P.8=%WH33:[TD?IX: B"7;MXP%E)$;_1!TTYS,ILU@HT7O&,V;A/O"$6FO M->K*Y453N,U6T9&S!VTXSV^G;2(H:!M*IW4A02O&R-F#-IQ/M].D$1.T;>6R M*1YFB^ "\:IL"H+W:.$' ;9@"@&2PWLS,@O%O6ZXPA1I9[:41@172VB0IDIZ M7N(^B/OP8DF[G3P"XKZA7+4O)>XE[N/@/IP?O-N])"#NFTJ[?OC**P+ND_J< M*K$#FX#OJ;DJQ-T]3'AKE@6QX!;40 MTT<,R+9KRF7C2D*VRI -M];WI#>?%K+UCM()R7L6$;(B.I ^?'YP,T2P@KBU(F<8\Y]2&RA M[W"=1?(B=9I*NWGX)BP #"0 MYV8X4Z7G+_>+TO+..L;8FT@&>QBADKD0EY\FZ)8 MN511J'U#J,VJM)KQ/4HRV%ME_%]$]O07 ?]7M6($?27^1<'_93C%?Z>9)C;^ MVU>'+PLBX%^2'DH>CJLW+B-W=^8;RPWGW&D&O:>.2-M*\B$DFB]C)M6(BV9) ME9!HOHS,E1 =S45C46SW!\JJ '#PS_T%+-TRE2$%+%OC=JM^F57QSW456;^3 MA&9P/+!2K&-SZ80V6G"[)K(V)H;?@] AS]1\!M'-M0G6"E7M<[=IW;W7AY65 M$!VO&Z-A[]4SQR2ZZ;6NW%%3=%- V509);+55[,3:K2E$J>L1ULJ<*8W+PR$! 40O0;<-NO!2H&%Q*=% UU;J=?%*@ HULJB@"^>,A86/ MQ -=\U(\/GT!,J&ZMJ8*NDM.35-+<6==12\X:UO.GR@4D:*Q[;;2J4E#0I"1 MLT=K=%*,B&AMM96+"-R!2F&FS&@-)R2&62TBHK5>5VH7,A,K@>G26UKF@@KF MS9#L>W:3B)Y]A7N22U*D7=F1^282\;%.H?"TX%TVDWB(K\?G#DO$5QGQE]'+ MR0J*^%8QDFIE4E7)B?NM'5DHLI*LA*RPD(U<1%\,R,KT* G9R(XB,2 K9CSM@/U!<,E.*_;-Y-@BS::V(Q3')LY\L.C&?#7B1*5$= MLC U&!.3GN ER-N<&GQ44RXO<:><2UP "H-;@(7?!6VO6:YW2;/8=8Z_EKIY MJQ/+6R0ZL?DJ9M5Z3RQ=8^HU01RM9=)UN@\HB[X!ZE6HB):L:U]\GYE) 5%K*1>R^* 5G)^920C5P17PS(2L[G MGF&/?126!/=D2<:JKAI@LKZOJT_D?SZ;YM0FIH7$TE=M"L/ZX4?X(>.,AM%0V89CW%'3 ML.%KELN\M '1\*,I(Q:H^CFCDGJ#+NVEJNLPN(EO9SILJM;4I\(24 _4LTM0F 9, ME:J3N?MU1FCF^P$1A<(%S%#.S9Y2UU?M3FW79&S\L,L9)6B@L_=%LX>\ 9;( M7W=?J+?.H:X]F.VV\,,.G#MW(JN(ITQMZY#YW% NVTVE%G*ZL+?8,_=FZ-QW MF'H9S;UUV0J=NP(RLQ<4_O%*]=4YX=O&[<^+4)AI>+J2%55!Z]$@ZW=3@ANT M^Z RW;,PB:]P>Q?)M3P>_2DD7[7ZQ54BB2R&!XOZ%K[$L@JX2?-(7U3-&1@;&U/9,@/VXO4J MCG;U8>@NV\-ZU0;^HB6&9F>'CF70/" H!1.(]*4-6,//>_DY,-["M#4'?@^V M/1QI#-5X@ED:R\@)GTHQ6@=^C0;:BCF<:XE$<--[H#T0_RQ?RE2)1%V V M_H U<&!3D-URN0B52RM0%F XH88*Q_(M6%P3U=[?A&R_R."'R 56GVE00OW[ MVX",'I86]>];9XT/GR_?N[3^A@NJ,0/H@+Q03>=N-IE%GTU<0H;L*>76X*NJ+QG$3?Q" MM(6&3Z(>P*T!]K^&*SI=>AW#\%$&9:<\WE]TN)*[(M!M:K@=L^&*<%D$5]4P-D!O*!9658>-EEC6&PQN<9ML,(>Q*"Y; DM-JW]T! M;*KK@$#%>QI'S_0%<&D[B(I7ZCW>O].\X,7BOQPQ[N4"+C7.:H%.*Y@.PI!? M&CUPGI.NKQ#T%3_C7M1_ Z)!)[MWUNT[]P2DAK]S1<4NO&S^L$A+O._"9K78 MS#*;=F@*SKY? /.F M\?RY>4YZW%5QQ?5 M!DG!W'&?3"G $#8Y-H^TO3OC&PNWXAX!@P@.2@+VWYCO,>X4(C8*!B"^=&P' MX(A?G*[OG%P7G),;35_B8U(9"U&_,+%M(>Z:S=]]M*B;K>T]=HI#,YTUF\$. M81K. 0P1<^&:FO!Y!R"+0_.GA/R(603P"]CLC\,G]TCM#1\>W-__M'\% J_I M8.O.)2@@/HL7"LICFN8A&6%+MB-78=[>DL/)G$Z7.AW,MC?)\+[&?W'*=NB+O0%1,)NFZ';>2#E3W'H) M@:=.54<-E X(]F/-IC^K[-+J=6F]B)F07KTNK?[INKOXB+>=9>&)0N8GR\(3 M$CJ"IK;+PA.E$J8BX[7!%HX'HA^7 9 M\^':R;U2(+ ^D]<=2"J5ZLM*NWU1"*:;!&-&8 S//8Q ,T@;C%=*JUT,UJ7$ MXE%8_+@;C)%3GC("(TP3?AY$94.I-8[4D''D\),L-R_$R <*.93M=:LXLA1Q MZ4>NDHC%O&W>4,-\T0R\;S*Z H]P[8UJA== E+ M)VPK.K(4<>E'KI*("U 7 MZ_=MCL][^I (*RFKH&RZ!!JQ\WNP&,HGQ@NRGVPZ[1N,'K3A(/"(0]>J/EGJ M<7(--GP&?) -;\&%[O6*X(+U=%J7J[1[QEHHNBW:4K!9$R@S.\HL^>6_!)P1GM&BRT_2*OO-)8EB-+ M$2WKO=8M5O+O\=J?_ M7MH.%NE)QXZ379@DU&-#/;Q7:]*(='Y0O^A(J$NHAT#]3$04R+NLM(*KL=!2 MQ*5?:"EBX8Z,W.ZRVUD^T:K7B;">%36'=EK^SNI'$:C$O.=3%WFS";JISF?D5'EB(N M_3LNN2"7/=MMIX9S !!U*XI"F-QM-/0UO'ER3['/M MO-V0-?BJ#,AP=G^$RW%6@&QV)"#+#\C=12&;B=O'9X)(OT@D0+/VOB-?+&AF M71E27C^EX2I'EB*6(U=9Q&)>/V^*'R,NDGVUT[QJ7:1U W4EFL8=5-:!KS0D MPYTB">Z@Z4&R&3\"*R%9.$CNOH6VPNL0)KB%IH1)$>ZAVPT@,VWR?-RC0KJS MWIJ\M?9B:2VPB3;O]KM8LOZ][RALODVBO&\7O*LE\-2$=6,]EO3E%%M1!IK_ MDC?-F1/5(/0'M2::C9UAM0DESQ;%KMR\93GK<.X.,E,UB[RJ^G)G#K,^\S+0#LGPXTI.B8NSF2NPNQV[HQVY'H@ M?[I;XD\VRH -\HTBOV![SW1A5MZDAGY67.\'6\V^#L,Z\N] 5_P:>XSM?LE> M3N;>Q-.$?^3:AL41>T.YZ'2.DSS\)B#V>B+Q>A?"M,3+#Q/>.YV=^%%%'-D# M[8NX][+0S16E3-2""KEY%2[B0&]YMENQZSP[3G8O4.3*)OX"/?IM[MD2/6&/ M>QA(S*6J-QM[=T,AT._Z4K(TT3:ZP_OPJ#>2ITY?J_8<_]_[SU(#VP<[D7>- MZ7!N6LZ(6B]]XY7R#%)[! __H@.4/A!J3]0%/,2QEI0/#&]+IUW'[1#>&;?4 MVF4*=Z!? ,.F\?RYY:F6Z^[P5X7]27K_]]3_K7O7NQ\-2??^AO3O?^L-1]_P MW[_\P_U>"G9MI/6_2,PR&$[F=+K4Z6 60Q)X&8@ACMD5[4QK1XLCQ,(?P3:9 MF;INON&F=/O!+U_@._!L.]R&AE=4V)^$KM^4Z4%M_8IDO/*J-:R(LUK0,$OG M(]O?YM*&+]L_??*WWUI$:0L_N+&9^(/K&[+R:F*D9&88#\PDO;*SY>OO MVH-9(,Z!=7O_1/LYW)V%$DK>H]Q/FFPJ]2&4Q'%DP7L 91NQ/GDIS1A221&=CH*)<7Q; #)=Q%@7NG<<1U M_/!]1MZL)7RSA._%$;=QJ;M+=()))H+1%:(UQ'XX0;I)(5WFV$C>5- MRSESJ/42I&_+L$25')H5'5F*N/0C5TG$(EZ6M\(23^?#<^* J6LOK551NKF6 MPK:[J,4/-6#**6:?@KDW.1/0\-!PRL.=D4>!JP_4JGVRW@^B546<) MVQA1YPB>R11H==76N6)>H-=$NL,%Q>1&S'PC1LB6WL^JR\VCVKI4:@DZ?LMC MHW!HW1T/N(A08>* N2.2+U:&"(H%S-UJ-((9'H=%EZM23=!B_F3F3%Z]%8)_ M[J\CZE8+#:DCVJ2-UNSJZ)40K()K([2":^JO&)3^.QEG4R^6EX+>7_05GYA% MD5>_X.)B/+?6;[_?C/^P1ZV.=3#Q SE19-3[Y^BL?W_3NQ_Q>HEAY1*;EY'& M7*_XWQ?J,ST;PT'Z_4R=P4,^$55_4U?VWS_'J'!(7S[_HI*YA0KJ+XXY:0#$ MF1@ >M>H5ME=0(4GX2=W:X,\Z@;[9;)W?L+?][)^<.JAB<(7))7U@TLE3ED_ MN-SRW:P?S%]4%A$^]4VRJJ55Y:++1:_&HHL9NY!%A'.HN!&>Y]_(M8AP0[EJ MMPM1+4.",!,0AH?%&K)JD81BSE"\#*=*-$Y8#[@XVE%$DJ>L!UQMXG%%1Y8B M+OW(51*QB!?48J*NW&52'L0 EW8> >7ATOVLU: MMN>1F"\BYB-XDPI11+@X"E_,B[\L(GSJ4AX13A\!B@C7E=:ES'2H-%##TY"3 M!R!D$6&)ULS0>AF>EI,X1B&5K/"^)ED)23I!JSJR%''I1ZZ2B$6\*Q<[E%$. MHRX6$>_D53DNBU&40Z(U([2&]S%)/:X@"R%)V*8)VPA^'F$+(15$Y8IY?3Y4 M!XF_A2R&E*?3-<(9(D@QI&9=:7>*X;V2:,T(K>$U9Y*'")* 5UH[$K(QK)WP M3@J)XP12W9ZX3%(VM7]"(PM$M2C\>Z(OIQ1K%A'3F5.+ )8I_-(T6-4C=3+A M=8^P+A*\,*/RL/3]L:JKQH02>T[A\^_+$Q+M58* _<J->C2F];//X!=Z/9$WC')0!^!(_YHIN3[Q\( MA>-G 1]W+(QWOR\O=W%5NYK1%$Z07VS' HW[N7U.;KO]1_);]^ZI1P:WY+9_ MW[V_[G?O2/]^.'I\^M:['PT__?(/]_.%V(G;=?!FF@'G@ 97;U"JL+3KL^6% M%0-%)>J0&8B&O*)L.'9M+$'&5"=1EZ#C+,T!A(&N>E["^0+GRCD9S0'LX;^$ MS03#PKS7CU5 O'@V:W >P== ,0(TWDSK.X/WTL;S*S )T(;N]+P#CQT'FCK6 M=%:XE&^AZ1I(H#W!,,+7\16W&7RB^SCV^L70J?YJ;JW<^IWF&IP2UF2^@M/> M1EV#NF2Q=-AI@A_AA=H<.ID;VG^6K%(B"!N%O[3Y"GFK'%Q[[S-48X>5.;:I M]UH#>,+GWLRE/L5I MH/I;@(I!!*!^0W'C0)ZP R_G/@<,'!5FY8".]XY87+P%92M(;'-I3>!=P?[4 MZ<9\W\T1_@8:V<&AX9LPEK]MO!GQL9<+;F_!&IEO_CP"KXC;@8:+QMU/[*QP M-NM8SBT*IS]]I;J=1E7)%"$)-BE.B]3)64!OK#'%-FS0ZZ"=,4],<$#K-GZBXE_NK5U%]Q5304(EZ[W)TOV&;U5J81 M;V6F\-0SWU3UX>5A%9>*6?*6BU-?50OZ^LUHKX\GB+ET@CK$W3QLFW"U[FIN MV(YSN%#S#8&[Y=_+Z3-[.NBI*<7[$3R3[R%_HZ6^/+O,GG8CJ=DSG,SI=*G3 MPW10%B(U,@IL_2% $$G[;\ NO)!@%?DT)O\*ER'[X_'0^/">.V\36 MZ]NH4<%L5%D#CFW.\&S:#4OX:>@)TS[0D3AS*Z1^H5RVFX4H]28Q+@S&PZNK MQ3;$GX9;G;E77R(GX?(IE06B*8AN= [X-I%#-40EE".6D3.&0*1PRA4/F%\@E+N" ,H5#3$$4ED<<-(@$(Q-+L7_+GC(EH$@0EQ;$^WLTERF-1000BYG:(FE^^<3L]W<\$8+FE]"JD=22 M$L'T(C9,A:3Y22A+*.]O^"9I?A+ @@-X?]LI2?/+F>:73;E?3OO;3_C*BN#E MAVD6X[FU7I<(!($=&V&LPT4F<%DEH]X_1V?]^YO>_8A'6<*"+,VKF*2$OR_4 M9WHVMJCZ_4R=P4,^$55_4U?VWS_'H#C0E\^_J&1N(6[_XIB3!ER&>+.!&;G& M?<=:0:KP)/SD;J3D4?8YI18D^[F/J3^['V@B]?(N.A169ANKLC/>YQO\!93_IR MQYQ! I8_E-LE%7ZPH*Q?@K["?RW@!]@; 1ME>-4O5C 8ZQ3$NRV$4(&?8'QX MY-!1L2<#@&4Y@T&7%N^W,8619QKV"4/U3G2JVA0[9TSFV,MH9_LQC;5,X;MJ/R.G_@&WF]+G8T MTB%3CB/6DT%#@X-UI[()MF*9%GB!8 =:%FNJY[5V WF'MU+B>X3UW]OJ:JRP M]GSLVQ:=4(WUOPC^=*&NV$F'2S,!0U5=;[/)Q%K2[8Y'BX5E_F#-(H,"F?)^ M2;P]C8W](&&7.VXYE5,V"DO<,>/.!$S>8P^9D:5.:=>8#G!5'M>+N+:,=W7& M./X5O39AG7,R>NS>]$CW_H8,1K_V'DGW^GKP=#\:DL?>=:__6_?+74\A][U1 M=KW"=K8E:29=Y'5;DJZ+1[;B;.UAQ6\YV(WG]:K':$+2H9W9Y"H+0ZG[?DOQ M=HH:'%RBM ?Q7S^M#!(^@3/\U"=UZ9C>#]CME?^$WT$NVS+') ^Z6R<-II9[ M/)YPT20!O4 L2-D[H&SB%(VC+":C->3(%\OM+7BAU$X]/)RXPS#TEGMM^+$& MS->Q'!][J\QUE/;5X>;R LA3(FD;27OY$_DCJ:%$J#(J6Z'WT#.20YAF_" 9?)8VG*QT%E(7-7=RE%#9$&LPY1VC.#91;-3GTY3 MC&!>G),OW;ON_76/#'_M]4;DIC?J]N].$*UL'1^M1**DX9C6RC7\1C%#DQ%?O!6V#S,>,',/;X51R;8(4M,S'OD%&?M!]QR+D?:$6,]X3 M.7R7B;TJQ9$T_";073Y;'_&C^H;D,3B5P#9G)IR]')\AZ?-EK!_JM';*R$CP MVI1^V*.QM]-@6"H'LU!@-;]YBPD7HL'L$4QIZY7::5R-VLI5A%9-.0NGQ!#8 M6^3G)!"X4MJUBY,B0,Q U^^F]1T9Z@O+A%NF"#HKAU'2 ?G>AG8[08X+WC<> M^'*GC?*VK&9H]IU/R;)H'2@.> M."!ZRN'3V1:Q:%?^MO D]!4%E/:V:"CUJ\/;8F^PLP2ZKPK@B\74R@=\ET>V MECVUD@Y8L*7; ]&CEB'WK'Q"DK%84#ZBTXE$-IK*5>WRN$AD^11G 4 3BW&4 M,FCJ;:76CG_:9@V:T_33"@\(MI,&!.':L !TK!YTU7"ZQK3WGZ6VP ALC%"@ M.NW01N/H%0X)!3X\#AYZCZ,_6,YH[_^>^@_?>OL.CP;Z[UZ< M:*!,7DJ>HIA;X#/G)14W^%EJ; D3*)5YCD40I\QSC):@H]IT;NI3HKTL+/.5 MUU@1B^LJ>H):%1KP5[P<6G.6HI6']*\WZ^TI/ HI2@F@;1.$L_!V7 MQHQ!U&B*!R(QX[ZW2PM6<6GQ@DHS6',DW@J6T2A,OE>:^R46/<87$ZLRQ(64 MUG:YJ'6$VRP5'3E[U,5BY&2)NLY5#!J.B"HZO^9TZF2N&=1:,15-/9^=() M M\V:)Q>SQQ11TK*:U6]I*J]46;K]4=.3L@1>+&Y0I\%I*K1Z#,2NBHLZO'Q&U M'5'ULZREP#96+';1SG 9JZR:"K'HZBI^?%R6 ZDTA&-QE'* <+MQ)$-)Q#.C M](5 A-DS:6Z-6&2GG5LC-3=D36D)6&BMHB-GC[Y8K*G,T7>IM#K2<(\:1&15 M_B:3Y?V:\4*8@9D?1,0 M-?Q=I_@7V)'=@,1W[M8TW._*14ASFU@65)R0X$\2N:(A-U;D5"CD-CKY(U?: M\:F0RP6NH]:*%1K=B?"4DAB4BX)44Y-PS B.L6*F&<.QKC1J\?TMI2_N]ZY: M6.K9"<'#EM ?"VI@T[^]K1X[ETD3-8*#)>V:V-K1ZE'9-^-.Z(SK@1GO@'T: M,V[6+I(TI^QP1; 7G'.G2EMX7HG;D<^;/]XM^[^&+?*9:/6IO5L M&O!=7S\^]6Y([Y\/O?MA;YA%E[V=V_] B4O_K6526TDS5612FTQJRPI;,JE- MBE,FM:4RT,T5I8^4 M^=<#IF2*[=>4B\9ASI< 8I6 V@94+%9NCH!JU\2CAHL9Z']05Y:IZ\3B\A 4 M_Z>.>J:Y9V(1;O/9+JT(Q?PJA8(RXR\66S8G_-7$PY^8=O#OJF6IAK,2!*UE MWB=QJ;/3Y<3QQ,,\K[@#C@^V=\1+"JWHR-E#+BY?-AO(M02L-R*H\6R9,\J\ M$JI.L+ZM-A'6)U&B?=*.2VS%*%A05K9FBWT&K48 M/2U$5-6Y&L]BL(/B,QN818,OD4=RD'2M>S]UKM_ZBED^.O@<70VZCU^VVB-=NH&:?ZBR%PRX1)$ M_E)C_Y,Y93*GK.))2#*GK%3BE#EED7+*7 L(2QLR$TBLFX;HR3^=6"RL;7,S MQ<"2TKF2!*Q"(B@6F2I+!#5D8=B(L_3NB,3BE\1W9::$0;_TO[,]%JMRX)8' MH&M,K^%?J6ZV>O,P$4 $%[R$L# 0CE5M, \(MXL!85D7MNR>^TXD>E=$?^]P M;EK.B%HOJ9A4EQ$(7R(X\B4T,X)F)!+82:#9JA^N#B$"-"/&F+**.I&]8:?& M5=RPDW^1,U\6%IU3P]9>*:?]W9O.SDC3\:_SB^U8IO'\^?+[ M[JAW0P:C7WN/Y'KP[>&Q]VOO?MC_K4?N!D,L2.A^+85"I)$">1?IE'ST:N$S M+DW(6M^9=NPZD!,Z;D[&1XLBI"#C]5PUGN'CFD%@OC#TR\(TL%(G5NU4 _U' M3'P=]GO_?8@.KZ+ 2 Y^V%%_*.2-8M]N&[2$KIMO-OG(GNO%"[(H,ADM#.@O M8%IAP.,*Q4J/O4@>^VL.ED.[TWW POO"RM4+Y\Z6PDPO[R; H M_.B_H-)0$Q,0-,](8H)6R#T-[9,JI5U(:8],1]4%DV?DLMREN&)M78$"8G\7 MT2CI[5(NNEST,B^ZF.R"+ZJN&A-V&8'+BK@=8TWLVYU?&%P>M]&2\GZ].%PJ5#9-+CC*=Y\JM7@@CVW:I('O M]"T<$7@VWGX]AI1F5,%MNQW;0WCS HCIMFH?CSWO3M,IQ*I0$H>&7X^,,EU.",[[%(K$I*C;#&8:[ M:_&>#'3M(Q-7DUH;T9)0LTNJ"\V7K$>^%VV+T.\U<:/9$]VTEU:<9,BZ6IO0 M1@K;S,M+O3HG_?OKP;<>&77_V3M!YNEV > DF:=\3;G1O5Y?^(\-B.L:TUOX M.6 N;N;IY71VU3@^"3@D\]2;&U&-*>Y1G-U6_JG&WH-\1,_@3YYKT/VAH_X@ M'^F/!>Q[BK\SZ$QSB"IF^JF_BC+]M) Y:O5:EDEJ?U#5(CW8&U,B?(59"1V1 MTAMEZ=BRB5.TTK%2G$>),S393,C_=8N@MB>@-(KWM91VJRY9.<4#7&2"NUB NU):]<-=\P20 M>E7QMM,Q6 \%7"T N!TY>R ^7AA)9L3)7T4%YOQ \O29A7&.;A ;AL#*0485Y3 M+CM'TK8$=Y=48L\5B7RP:PHZ M?+6/;D.XA*3C9.D%Q_5.IU!X+9EL M;)[L@1U2]$EIU [[C,K',MO/C,F*">/'&A?CN;6>3P0BQ [0CW6P"P/&/AGU M_CDZZ]_?].Y'/%08%BE$G1:+?/'WA?I,S\865;^?J3-XR">BZF_JRO[[YQA4 M#OKR^1>5S"W$XU\<<]+X\)GQPY![A1N$ESY7X4GXR=U R8-"Y;+^0BAJL,'H MY?C#'GI=XE89:WK=M4],\ZAVH"%ZG'[VA9//XE+KU,FL5JL=?0"$4.L"ZYGZ MLT?S Q0\>#=;LSF!#UM*<"X>;$EAV'C^PDLV7B%)&Y*-)Z$C*-]'LO%*)4[) MQBN5.(O#QLLC2$_!W%'U@#%'[4^"^"^JVDI!+KI<]&HLNHA$Y*T:56[#:L%8 M3,*3]A+SDMWU=L^E=^Z5 E76ESB)@)/$=.(<<=*^DC@Y+>F\GI@$G!E,UE'V MSN&Z<$*?JZ>I_>CU%A?U8#TU<2S%S9.8[>O)R-T].R(>LC1O*4;.'(:)Z;@2 MAA4:.7,8)J;+5A.&(E[1/WP>.JI#A71:"KMSRO:Z51Q9BKCT(U=)Q 6XI@KN M_A4&E\?;98GI>:Z(F$G0-:9WYN2@HZ?X9EE%1\[>(1VY2VD*,#S2+5T=KW3Q M +837^&Y9M$]V5GA*U"O0CAE)^(=5+JS3[2#&HE#RYZ,-K901=PX%1TYBPQ6-%>^Y8,W8K-AO0K%A%;X;R6&$SJ'+#5.%R-2F)+O'ME.($T!OLZ M=6BMO=7R/ED:9[6LYHF;+7$-" 4[)9A% 7/B:+H$LP2S:&!. M'+J78):EE*M2F;-Y9$>J+"X)">J,RS;A@L+KR/Y36<#KZLA:Q!)>HM3+;A[9 M;"I3YUG]HABUW"-6$4ZWQF=HR==.N+*(5?*U-YM16.O7=47H1]6ACQ2>.]%T MC;U,W)JO-3IKM*Z.7OH==5FQ2*UJK/[?7RX;]8N?;4*]-V"E6BU,G)MJ\#/+ M)C-X)"O/^G0^/"X87:^& MV="3[,:'@[?)_OUMX#KYL+2H?XT\@ZW:J)\?]H C#G;6\4Y[/..YFT<0K)9XER1N%AIEEX0G M8%'[<&SXP*81+^^JHB-GCL_$/3^/PV=D)-;.Q>-L5G3DS+&8N$UG;ECL"(=% M,9T+7CYJ('Q$#4=3=4&@7-Y-U J/2:=D<&Q3TO 3-P'QQMI,,;([JH",\F*R M&4Y23\G(2!63XE4SJNC(F>O)<+)'2L9&BIB\.H_1=T9$HR-'EXJX-Y&GL82/C77J,N:&<]6B7U#6UP%1 M7YNV74O)?,@> M>*TXMZ\$N!/3+?%(;:I:DSE1C2DLVBO5S<4+%C.96'2JR6A(YMNFG6DX!'YX MS01I>X).LC4:<2Z!4B4+@ZU6.*$F)5L@'6S5);9$QM9.:(5'R5(Z[1- *WB0 MQS @*^T>N)ZKQC-V@2*OJNXFBZB8HZ(:$TEWS%X])ZY4$F4/<>'V#2]W'C[4 MM6WJV+]YLNYZHD[F'Y!ZNY"@2UQ11 #097U'DZ#+"'2)*W\( +IF(V-7J)B> M@6OXG&7J.IT2C[MP;5H+T^)VPIWVGZ4V97\_)^>" +GX6VBGFR!36^%&LQ>F MK>%?![,O2ULSJ"TIDZ49.6MP[B@3D))-\?^S]_;=B2-)OO!7R5,SO>-Z#J81 M[U3WUCF4R]7KV2K;UW;/;.\_?00D1E-"8O1BE_?3/Q&1J1= @$2)*![[O:4 M02@S(WX1&1$9&5&"\Z1'+EQS%IK6D +.,I?;5U2Q'8GJ[ M O- MEPR,]6L+AB5;7=Q>*M7Y:8Q<_(%9,CQS#F LPG,+M[&,5:B,KU3MEYP_DW.H MXN2UGYHQC3MOPAU%@"Q?>%:5@=.5>J'9DL3V_NA?ONMA;LMZ^SQ!G6>YZ;2R M0/"1JOBSPFO!F6;UC/=S,NCMN*WA.V+J>M4$6A$HT" MC3DG?>Z(1BW#X7F)QM-%8\YYHCNBL9LA-S1O-"I4SGWKR'Y4SGTIR08+B!CZ M "Q S^#NII7\\VI;:(ABL2^LTXYUOT9!]SZTJG1:!%U_ M,:-E,-WAL9+M[,*PX.>V[\)S[OO#57 /R957!7W;P NWUU ^Z] ^BO=<=[&MO.J.R,WC\;T6J777A_)5("W):H6 M4-5,1-6:1M5[0E6STM/JRJ%*S?.GKUQW>1@6>5-4" X=1LU1<#I9U+'.)\ZR MU!"O8H&X/&2ETFBTE!.5,QVY<.RULRCMO6&OKAWYO8C]W=.D0AEL&-\H%<'L M"4M+;R?#.:QODK=YTZ[42Y6MRLB%@["[DYU=& A;E9:"(%33Q+ZQ7KA%;08= M[G+G1=D QNF(34?;27>'',M!4GH-]:R<,QVY<-35=E+6^:).O;":FK;U@]3) ME!ZB#X>.#\15!+ G+"J-78WKX#-9*#A@8]\:]243@X]R"9/4:^I5'#S3D0O' M9GU7FWO/V&RTU<.FFJ;XE3XS/'CC__$1&>-)9;$50?GIRE=WVQ/)6/AQ0<)B M? VJR8*P?8Z8BA7C\Q$VK5MV\%)DY,*!FBE>7CA0DXH%K,)H62D@VRP5K!1P M@D+4V3'_!)F4QV%3KU3;BHQ<..)VS$W)"W'UTBK/FH/BNA^2ZM,KUL.NK"Y M5E&R>YQ5H2<5;,XAE:#2;?7*XBWG"\KD Y^L.K\84-8KO>[F=U'W6N.N6U#(3ECKK=^DR]MZJ5;;;%; M[ZI<;5-65$YMN>5Y=?.P4 ]81PF)W9F#12<'P[W7SJP MD#)\2:=WP"8'K?\1&[RQOZ8A1JMMW1@@*ANY?;/03"9!+C5X D]4XW(T'J%4J^-*QL1-FZK/G!B/*Q7FDV MLE)#J[(^%;&4=?L(,D0@02JL;7EE3V>Z]<9FCOUB8(T_G8U]TTP4/_U9-RS7 MH]\EUL-TF>$)O3 R1J#B/#;17SCCENT_3Y@]^)>L3,YQ*'JCRQS^;]]P!*M^ MZ_?OF6?#9[!M@%]OP$O39E-E3['IOQKP5% I%%_!Q4^X+. )[P=ZP^)6K0N' M2UH7/LS^[>N.QQWSC0UTUW"K.6B^8I5HW\O"]PD6+.4C[@!DK*722/,WQ!%* M^@R0\@/0Z7%SE6QI*P_U_Y2"].=G$",7#(0K\#0\Y^T;GP[0K9J7MIV+NRQ) M4;-=Z;4[R6*$=%JA,Y*SS^IJK*L-.T<[13TXW)T)^3/?*D+*1CZ@?^Q[OD/= M J@\K$&J#30'F]D.K5U6P4U'"6"2Y&_ G['D+0C?CQF(-+P* =>LLB^K?@JO M7P&CY&.BK6"4\3)SWP0QMW0DU#?#,J;^%)[;EB%:L]*LMY(9(G16;&B&\CN& M,4FV$(>OMF^"9N3,]4EY(G%UBW5K/RWPBYG&U/!DX5^+^/6&=5M]SZ#<8.!G M9G7@>J@WLRB#%6*R\D@YY-LC#H7%H&W8LOX.^Y<[,NA-^Q*81JU2KS6V4@0K M#S"56F&MF;S"RJ8Z 7?>R="1M>W!$JTMU9748;7YA<-ELZ@K7: M5D6QPW*QL\'$B>:S0;73!6]]8.K#[[$ *WNZ_I^GRYO;S]>W3Z+::U*QUV8] MTY@1P?\VTY_YY0#L\>^7^AA>\@$LKU?]S?W;QPW*.O/IQU]U-G$0UG_Q[&$= MG$1B V@A+.^/Y=I__5F'-^&3Z7[P/NJM@S#R[F!GSSX7DR[M3AH;)E0 VLB^ M2^X8DN!C;[9)IWA6X5;M!K=@>O7M%'XOJPNMW(H;[7K6#< >C\$TBFT M42D_H?\#9"4""!2^OJSPZYM;'\7A-MGG7X7;#;?PPOG9KK2W0["6N0NRPFO7 M6LE8W@+* FJ)B,)6'AB_B-G=!&E:SGSH 29J$W+UR'%@4^$YT*AID%W!J)5G M+]LRYQ#^3Z.9S"P,Q@CRSWQG9H,?*(@J:.6R*2@+<'M\C.%%K'3XLV^"5T.Q M&50,-C%)*!OU(S(W%E'69 ^@T#!.=66/R(+1>MUV!8-AP"]JM''Q'W_IUNNU M7VX>KNA?VB_OV2,7*&ETZ^'W.-O.+_!)^!3Y@2YI5#O_K&IZP9L" GW"0@2%%- &NPZ'O!)ZE"P;8=V:_6MQQ)\:,U"^US0%Q MJ+(;BSUS"_>("C/&[)4C?[ACB( ?>P9+$,@ +X*=H@6.K/X,'SV3)-)@.$KL MW2\F'[\DEQ:?)<]JN"+44KG/6/= G/,C'O#/A#484!(%A(+ WI$('*. M]7B00PHUDE/K_.*RF<,OY;20CG.$J[(K,([A+\O0B<(VY@0(6+LB\NG"/!"P MIOXJ ;X\04DLV+4,##\";4!YB'CHU#<]8V:^H8_ER3,1GC95P15=A&<1E_B@ MZ\,>&E%3+N4B1K2 ]7K4@/,]CHUO@4W5-(9D9YNV]7R) M\?W18H3@@B:&B2,?(YTI0+(04EHB*<@\_'..,^J+]=."!3/51[AYB)"ZB\M% M;?=[];$:!&M %#F%E0&6-8+V"4"F2$(\)(%&Q/& TD>KSP M]"NJAMC,YZVXQ* 5N+HX'8#^ B%(.UCN$:CO.)^GP!ODCSO7 SY[%L!ZW!Q ML+71NH7TQPICX^/ "=M\P8YC%E ;E *VK_\T3-9NJA1T'N8RN,*K";E\."0 MP_9=X.;4AMW6EJFW SK\DFIN@.PV++&!TZM>=-!*,%B5%1Z)26TK MEWP@N5%;N=\M!\S,9PL#G&"C? )%.D8;TS;-+T*AK.PL5Q!$%O<:LY95BJ0466\[JRN>\EAPPQI4BFJ.V3O SF*L+/B*^^1O_?DW,.S M]P%[<^D*=3)*_@!R-_0=!WT*U27OK.ZVI,IJ.YP5U.LR)9ZT-S=@4Z^5;N99L_%@>[5U6M&46IF MM>%_4LM54S.7#K1*ZKJW]>4K51SH(X^2'C9P53K0Q^1 )^>UYBVK13K0G?4F MV=$YT.4Y1VFFG=YVD>Q UTL'NG '.OEZVF::/8^*OI7:L?>L+C5SJ9E/3S.7 M#K1*ZEJK)1]!9\@65,2#[I6M.TH/6@&9W(<'G?F&G;(>M-8^01>Z/.DH#;73 MVR^27>B&8B[T"=9E[&W4-*1(%[K>:1]W8<;H@HS:%Z R%Y/#6W!X,1=Y[N!] M5KR.YN U)'Q^QBW=I M0@%U[:)"5]VIX$[J"EGHI9N[6=7C1;>YQ<:UF[B:- MN(PF)D.E;;SH$B9LA[(@'?X$+S3BA=78^V+W["94JDXN9T6-/-M**R,W?VM\ M9'-!([QRYW*<$][@ C(96%Q!WAP"VQ?GN_JZ$-%.WC&R@&G,>^5XK6P*?)ZD MD&T&1M^0;IQ2T1_YVC0^X>W X[ZP%RX\*%^!"Q07T&,K<[CG.Y:[>*\8O W7 MP"M2_ ?,PA(LEU=DX6=X,TCWO8GMB&M]ON49)GTY?_T5/PF<&AS:]T3UL_CU M6;JR9[MSTYF_4ATOQ98P=;IV/'=?6@ZU,)(HE.F%51#27S6V?6?5FY(!%MPD M3:$N%4V8*ZZP1-G@#21!,?*2IL '\$HRW61-G):\)XZ?ABNH%EH<*O[?E7!8:0)0+=^<3CJZDJLGD % M/]=92ZO4NSWF8O%1E C8+P:^8>*=R?GMA,ISB8W6AM\!["Z'N!^9HDC60O,4 M_1FT UT4QAO+N/C?L>C@B#V*V@6II @64&%@,PTG[)5V1:"[6,AG/J3*(^(4 MBRXP4VD.VD$>^A-P?1$.2(@_!<^<."E;PSL%JW7FY\;?/]W6#!^+>V:5H5DA^YW M8U$)'VQCH-]P?F<5*T>=K(MR"+29#GBLB -5P+"H2@E-VF7/ M+1I+A:=?X M$;QM#-!-+3(3$BB"D-CP[R?PYVP&@\U!2F?U2D=K)"('O[\R=><[ H\34?_7 MMH!H]SH.]JROHF1 J2#7=X&0(0*2*6G/@IH$1#M1D]<2=3-HRZ(0GQL1U/6, MF6\&J\(%X^O0RJ\$1,5W2$Y$!%Y%U]])DKU@B9$TN/-6K.%232&\G(]"A./, M]#=Z$'<5JE&!.U)%UG,0E:==WZ'RQ'NI<5B0YW#>%0X;987#=14.\S$C,M12 ML2WS;6G3E2*/'EQHO)H^J39PT$"AZ60-XCX!POD*"A!K)P0;.8II4*(#:X]3 M73FL=RRT 9F7.AJN(-PP!-6\P1I-]4"AP."P*;FD;,+:/7/NKAVJ*@(>J:^@ M=H [X1PUC6_12\@==1QT]VA#%DOA"]IRYCO@$KK">R5+1!0%(L^RP@(-N/0V M;R+K )V:R![*$&O)GP-2" M%4>F$(Y.ZAQV0'F^!+LRUN<26]%1>;F1Y4'UNVA;1?LECB_";[0G2S+,%8SQ M+>/?/AE[GMC5AH8S]*<@:T!SJHGE4H$:P2I +)_%?=S8<%6VV+J & MSL<16RT)<4)O/W(:0_F:FVTPG; XEA@HVJH#]"%.ARB*$><%MLS$ MH*A?V/%!.!]\*JA%[2.DTAW!]T,/UN3""V>Z,4+0(M L=*LH$L?A'R/UI?-F MP2N:QT10[P]UVJ)K1DH9MOW1HNK$2FI86@W<3 3*@FL6]P+PAW.>70Q00=$I M"F>*MT_MD0'O$IL]HEL?#A$E0?,,5!BKF:80N4 MAG!0DEV0L>^0AERD)J&LG'2PK[#(34'K-!I2LUM"W7J$B5Y4)[2P6 MV=^HSQ%-_;/L'G1C13&E:/2LIS.ME-.9]KN/K>IR5\. BXSKPTGQ?E(A&^XK MV>\H.Z!AP?Q/M"M(:C(@PZ4X2FJX<#%9=3V;=3YQ/LQ'"?\I)]P7\WT(IDM? M/L%D/U.P1Z13S#'^TN7##R/?07/HW<=.M;'H>48^^]+1D)=$JA%()VT^I$=B M2T] ^,HN,NG-$Q)6_%F.^@"#PBI1&\5!?'/[)8;B>]_A(8POZ[CLY:H$/ZF_ M^V2PBVF3)2ZL4#1;-U2;9\D5#+5M)>&TJNV55?/>^C)/?O/NM-M;U.KN++87 MR5[((\^IIS2B"_2:$'QAPL1EOQ(%@'&>\V7F:U!*36R>BA91;63\RX7RE M5V]KO4):/U#I?2H'2<6 *3(D/1^78N-FX$(,=7?"QO#@7,W/6#9EIATIJ>1D M@1''U%!32-&\BE3N%J,L-*%KWVEKDU'>N:%!$!6]45B(]9_OM%I\"5_N;I\N M'V_^]QI>CVM@],&7_K>;KW]\6&(5^]9_^.WF5H1J65*L]@\,V%S/Z9\#4C9S MQ+C$3B;LU(N$#FK_)$HFYO7N/96U9.?F[*R7[#PE=FJ*L3/C&60Q:Q9#K22 \L?5 D/WHA?SD&KM-.IB^)7A+]/(BN MYOW>Z%@R=)=EIM"B)ZP"#8^FLG^[5\LG4G@O#R%SN"#2;:PO**L 0TLH+4(I M<[?"_4%):Y10.D8H)1?@VSB8GB.4.IWE@]%#,S3U@EIAK;130_=;'S@EW9 ( MCK3?ONF8TNZ];1K6;S8Z^JB7;UB_$:,%BU\=61GI)R]/K$*F!V3)/)A+NEJ^ MQ+>_6#];'>P/Z:Q&L#_%!)4** Z(+1M\HT3R/7AJUTZDN5[@0M!05 M F7*F>0@."L;FV\K.'@*_/1JY]+00&NJY^(INVVT%<'M*4M,JS")P?N6^A*HW+Z&;/F ]_-]+U934A$(G^,>=Y%^?:V6F[S];@471OGH^L<0'NU3^FLN MM6.U#,*W1P@51H) M%T"/JKKR?/+*X8M_)E_LS9#:\ID//+S%;MJ8Y+])^DIMT!OM?BLU5O53JS(0 M@X>[?P+76?_V,_MR<]N_O:*_'A[ZM[]=?[N^?7K\<#Q%0>]BI0W;E!=3FR_5 MLE!A\ZN-172L$7OD0\HI8OVPJU7^BY\"OZ4/OEO:@R]@A2"@QB M_]!-D[^Q3[KUG5W(WSW^XU/P<)7=^X[KZZ(F#+Y[_J7S\Z0B.Z(ND#_#'USH M[V5M$]AD'=3L%\9[68SXQ39?2,-CL:Z5M4:TE1OZGUAQXL\[4&N&I9LXO;XU M"B@33O0;E<%9VOQA[+OQ%=#6\+[((C;?]!_H,'T*JB%=Z9C\DUVCK:A(TJPF M7&@/*I+8#A!'4D=62-)?=$-448W*TT15FK 2E?Q"3Z#GD%85+[HS7Z3I#2N' M)Z9PR?HP_ <6UR);%S R]+!:$U:.@@U&%CQ=F L,TJW]A&-SV&FH<*6LXH,E MG]U8;5(<'5 FLMZ3IC#%PA!8G0>HL# *E=U#EOZ"LWDQ1EB^9V*_ M@Z)(4S!!GK%R"!4?@RD/Z;)36-+O153]HB)G(T,6NQ8<0-G01S!'EYOP+RK_ M+BOU!7QALB NF4%5]AB5J-;ENW&P$1_KOBDE+U;]5T#&]CVLE4:US"+0I*,# MP(=, NT=*\#N8;%7TQ86V(P*N0'>1D&PLT MO(_/W,BI8X$5+"CCOOLH:M=SI"SI':F)@&!36]:L=EH_+28\ M8M%UR0H#2Y"]D0J@"I!8D5*, _:AQU"S6"/=82- %\J=CDC#!\,2.'% +**E M(DONT>6^N?K[J!I$:5Q[8"+DJ:PYUL(:^3R8@DP&?6.C^7IQC783)^1&XAUU M.QB)^IC1AB<*=M2B\NAE7=D"ZLHVR[JR:XI]Y&:H[LM2;%9D@9M42Q&_^&(X M(-)]K/47;&)9SL.V)TG9<:*&'< -" MDXL%R?#L,VVF-ON[;T9+2MS8J3RK,9=S#AO7Q(!O059F8']1/;XHL=[H M:%YF0L\G@]PL_CY%?!8?2Y:BB_[[L-BC$*7(*0A,/B$49-D)DV79Y5KA7*V, M]@@@BJGFBL1=O:QVNI>E976R%@F9YF15UGI9P*=/[T4G)EFP-'J#8,E?&]$< MQ@O#!Q6E16EA?X;E*0,':@C&HPVR%I7A)M,%D7'U7O:5&LE:R/%*PE2J03A? MZ':(ZLG1 FGZJU15YOIEN2!D&VL^LR4OS?AJK4A#OE&MMWZJ+)6G% QR4Q@T MS]-5?,IC_:UBU]_!]].?G]_/;_YS?L)*U&5N3E287MIUAURJ4'I<.V0M***X M%IU89F6XV&W.>4V!LIIF9N&,NF)JN/YAB;$8/"CQ3 MO7Y\#4B?3DI=M@D0AFJ\/P/H83X3_B=, Q8HY238B((4#:Q:;1H@7B.P?,Q;]7VGI;QHVF7C9H0(Z)T9BGZ4XK/GX_^P.7_ M]N&+ZY=^OUH)=MU*439^Y0/(V MM-Z'QFH=G\9*: 8:E]6)+KINCAS]%132,Y9?E[%6$?4,Z]6C&+Y2[7^L'S\S M#;+#1!L6$VO*OU %^;F&\/& &(:$.<=(-;:RHM8)HL$ 9>G(('G0)3BT]Z+N M"0L;?<+]Z-7%D1U6:K5F8IU?HITCRN];-BA=X,.0 MVI.&/)&%Q\*N!<5V6%Q]L+IU-?ROL*=1"72P@-..57,\/*U7V=>[V]\NGZX? MOK'/UY^>CNN8M ]&K\EDD>>%0U)[@&\?VN! 9^.>SHT^9 MB39*<-!Y?W]/1DMH@820 DS1.4_D8J<*H;;(?"F$MD):J.&X5IZUX MV)HB=3 9]UX$_+>5*:W2[O12:F=C/#XTL(+5DX[A: A90WDPB);1U'!=VZ%6 M,R)L/UH@_YQ-=PM/A60D$XBL?D[NQ-SO1&WN 97OGC]RDKVS4DOR:RG&S#:4 M3ON@1U#D>PR]4-"O^@_7C_A) -%*1%W M0_1?9C-@C6@.258@J(V@#0WU=\0S8?K:I -;D!7<^D5/>H).GJ=JHLL>GNZO_OOS4?[S^S*[NOMU?WS[V MGV[N;H_(:'WT@'R7(K(_C!$^[%Q)O=!BW_%7X0<=^'RYCY U"=8)[ IDZ]7B7)R":@%J/@*K]P5T8B!"-# MHE(S;M\4/[?<,7=$Q\BD1DT+_ X&HC& *:@C83TPT-!E+N@Q:E1G>=B-TAC# MFZF_NS!;;'?5W*L,]+S$:!I 12O[51BMB'FN IKAK@/((@W0/(>'!05D-#:. MM]RAT4>+,GDNJ%$WTWCKP7 MX;20V9T>]56C$FG9G$;QMF-EU[&3@4[9=:QD9]EU[%S9678=BTTF-7(DSV@Q M&("F\WR83)'J .?:<*DD>DGT\R#Z 74C"_Y/C":"IFE1\TJ\46/9>?'@2R^) M7A+]#(A^R,! R>52M$JBET3?CSX[9-T\/#\@'U@W52N,IW@;I4XC<[/8\+X3 M4OMN_(BT3LY8DT<]?)1\$G0M3J7S*)#<6,XT5I#U)>@60%=/SM]+:"NK(.A4 MK(&OU,BJ@JZ7"+J$!K0*@JZSO@"HTJ; WNI3/P)Z#.NY$EP[%AE_L2L +UQ1 ML3ET3>H\C8KL53,"4?M-L*MOC?ISS)(B=&#QTRH=K30U%!FY>/AF[GI_//"M ME_!59.3BX9M<>'25H:,V?+M:6SGPJAD(>> NUYVAJ'HJKU10V1E%L)\M*T4! M<=Q#$ZI.(W,5^E!. _Z"H'Z.N*N&E'9JZZ54A5Y5I0 H(P#)=4!7V5DJ"T"O MO;[1>RD I0#$!"#Y\L4J2TUE :AK)]BM,!:Y.DU15$;B3O/$]$Q'+EE\\B.? M$XO5=/=ON2=;BN!M?BR;:EA#>\K9A6F[[GL5"'?:+0(7R_RLOSU+U8V ;W2M M8\D6RZ6?9J>YN1]RB&Z!)2B+ >5BF;%TMWJ/H.Q%%<%+4)XA*!<+PZ6[NGL# MI5;1:NM/Q50 9>FPEJ;N>1"Z9/')$[IDL7);QMX6Z@Q7T779!W3[0 M78TJBZER/[.$ZLD3NF3QR1.Z9+%R&\Z>TL$7*@2 $VD,5:#5$5V:R-RJ= $VAAF]-_G&TV W]/KW#??:Q5$_I;*LC8$E*+ MD$I.3UT7GMP/I,HLZ:.$5/)]DW7!Q;U JK8^)T;IK7I/ON'"5OW9,'V/CTHQ MV$@,-NZ^MEX,)"/R$(2>[$"?H&-$79[56JK6BQ8FK'[Q(I6)NO[D/5J6S)6<"6Y[L<*L=_'6I+X 9I@AAU3 M7[CY5J$&14-]9B#L9'^;F>Y0R2'#PI[?MO.F?CO)S[Z#0B.;P"2*W&(7/&<4 MM-E*DL-8,^B%)EUS?8S6=]5:_G15<[UN-W/[-]EH#R=W1W/#&?6M$T@ M/;F$+GE#0O:(>[)C[\.7/82SIR]^QWYDV[?AZW63V_"MU!&9,[Z.CB#U2JVC M;:%KNKW,"4='1Y->+UG[SJLMT5&,%I&E<5A<]+EH_\;=Y'92__9!^7''?)/" M*YNYN'/]IF+#2=U!C>>P#S+\T #-Z<$:L;$MMFG%OPP7>_L.1&MX[.06G_'0 M,;#3FA[VLI)O>S5,$[O33KFGO@;N+_6U%W0G@R:9UC$=ZUO8TFY!(4LR1"UV M%SNFU6M:FUV+3FA@-&/CVA?.[JE?X<#WL*TUF&1>K'V;V.]6[.+);6SG5*X8 M,!P/A\.))%]0R]0_Z-:6R^_3BI^09/'OL5;3K>W]P;VHN]"V M:H:+5ZLM(! M>W\X0:ABV@*VJA0M"D73N3$W9*_O%=M73TOND;LY_81/%$S@2S3^W?AW2:PH M>5*0;6M[+[DUK.CB&& UD$5]BIV@_T_T&-09%I- A_ 2;':.S0?A)]064&>O M%'I$&,/?^G/0 A#I1WV:?]#20%^D]*_J:9D3\#>F:QZ@=)-0*7I> ;OD1_B@ M-L>82YUF%'H&VK>QUVIM[C;WD$Y%55^M56W:OT=K*[DL^L5YUIUJU ME6NU-!=@SKY37OIW,W<6VQY')@Y)?;+MLL9TT7+5!H']$K2GER[ %S["8DI? M8,)N (>M39&.EBP%"FR]FQ?Y6R=HA1F"M.6Z&^RY6E4[BCWWW<=_A)VZ^Z[K M3X7#J=8D$U1#-&O4YGV!6O'!-^Y-1(/PF$,JC5PWH67U?&=N:DS--^EO3L.) M,J$,?X2=:,5#HE,Z28,^G(@9Q<:.%-+"S^0/J"=U1GG$MZ0UQ';G.K>#JQ[Z M(++&*383Q_;HLN&Y;*.M/ 9075((XHD[TY3VZ\$C&"< LU S6)_8%JO5%@4 M*EC7*URZR=BU.GJGC1K3]CW7 ^XCY1 $HAF]C$N,HE[IH&T]V\%C+WJ#8W!P M(BKLV7C!7X(B= U4^_* @B:$VA'UM0^_P1>&C%R>627DGBO;ZHJ@C9BL\"7P MUV,?';RH+?V 3_070[8[IQ#Y$"?]ALWIK6>4%S&5<'BTFI>'5Q\L_[#!,#!, M<-ZJ+/HWB1B(L.XB50(QF6(;>!>I("1%!P?$TJVA 7QXT1U#]E#';R0QV,Q! M>8.=FHU-'SF& +F(\?PE'/,] W(;[AR.PA^QB_#C^"]&P@_2PQ;W<>7FNU*O M)0X7!KQFNNO!0EXXQ=N-'V(_JD0(7=K1)3WFA0@^E'J*5"5&_NQ0O[*$V<_1 M&R?#4;?)=Z,I%@K;+K? #1#P\8WEO ME_0N\3D2&V@R](5IZ/*9[@C3!)^/M?6B&:$Z!968[D)&IJ9P-M7'_H/A?K_\ MXH"X!Y8F>P "S*,(5RI@Y.#C8WS<"!Y'>B'.0BIEVQ1M\; !VL: W[X9W*0W MR)H34N\2QQ=@A3_]O?H(4W1(.-_8_W''OAS:_@SM<;!4.,9N/11.AT]UPZ+M M&@&*NR#,!*M62N6U!.!0AP9Z78 @V/$1E'ER-<;;U#;JF6LYIK=1C\S=>_T- MJWJ1@1L_1PBMIIBI]X3:+*UW>D+C^I[.V[W&SBD*"3#]@J813I$OFDKAQI>X M12_9;JB0Y :'K%T1/@*=A[MA&(.-K+ZQ;9KV*_ZUI!;UB'@;B<.'8J0[GNJQ MD-"!?TL.ZB(-)4FOM1J/P&\N&G. M]!%*'OJN\%*1H;*B(630IW@VF#C1?%:GI&OI)/PR+2F@T\Z>FD]DT'\<#1G:R^$Y)6!_I@+72!:XI RW4Q:X1O96RJ7 M';O *6-O[7HC>!G&FS=G/AK0JFHQ'K(09)12H C 3T:TEB_;-[/;9)O)UE)J MYK)L+1UGKY*M"!28WI!^6__>=WA8R/L2C(_N!OU!-ZF(\),"\#AE8"8G3:RZ MI'!LP%S?B:,$IH+ 3/8M=K=&E %FIUXH,%4L!BKSZ)83XUQ%8'W" M7*'AT[ MC$ A-###,DBPW%"<&E6M6($J@5D0,#-7-SM.8&K5U@95XQS\7DY%%MOP(\_.C?&E%0+X+%_983#![[OT>1$5FZO]&=VMN M+%'K(>!Z7S"=OOP,+ _E:N>BA>UJO2RO>I3@32Y7!?!FVP]'\9(.1!XM8U.][Z^MO'Q)OG>6#"K;Z=E%(X/*&T%$F MDN_[AA KKPB=#';**T(E.\LK0N?*SO**T.'Q<[C[$F+S9H]5YR5&VSJT09RI8>)#^Z5EV^W4#E@+1?TNXX $6R MG_"D7W)0E2+U:BW318=2K:LNMYD[-9V-W&9N]5O*;2FW!Y/;S-V#ST9NL]?0 M+^5VCS;^^DSI_&S\-3>T2B6S2LDL'95KC5JR3!5CU2MSSZ"WG-CQTZ+^22+6 MAB[03@I(&6+5:XV$3()EX=LD&Z0PI/^TO062\TQ.66DD-S$LQJ501@ZTA'2P M3%IC0P?L1+1&XEVN4FN9UEQ2;VU@E0;NI-*J*T=2=6L M]I+NC)6FSAF;.LEUH]1VD':^.EEK;:,Q-O0E3T%CU)-OF98:XWPU1DK'<+6= MH]TU1H)SM%YC;.A'GH+&J%6U97/L\*Y1P<=&Y>UV5>]8:HUZLL+:L6?UT5VS M;%3;&U0R*2\)*P3@[(;G"0.X5VUO4 RPQ*]"^,UN!ITP?K5JXNGTN=USWSEU M_O_]?O/T![NYO;J^?;KYQS6[_]J_S:.S:+$MB&\L=C?T;, QJ]=J[4IB-U?\ MAEW_V\=&T3<6.GG8K1JOY-,]=7TV<^P7T9Z<.O@BLB:V.>).V-0>GS!&7-Q] M)^L1[[!CW_+P?7,]8RL +NO2]73/]VSG;?%+= <@ZXJT&CPT@DO.*%#I^9.O:\QRH* MZ0 ,\(7CN[*PA&@T_&,&O, ^P//K0@:_&J89UH:(];WVX1,JQ] 6T^,_N#,T M7"Z[R -_J45Z'(O8U1H4+*T7"/R=>U']AQ@-_N9BK_(I/"]_+-H3DP,%3Y) M5)G< 9CW-L.MS7QC+W@0A9W/10]VV1G>]0?_POG*-MJBO3(/Z1Q6O6 N=UYP MYM20.S8=^#KS*^C =3S=Q M.6E;;F_Q<*/OWHUC;H[.)\Z?@LTAEY')R+GDS?:*B$J[\94^,V!\L:T]<%PZ M'WVQG2^^YSO\QG5]%/F,VV4MMEF&U8PJW6:W4JLM>RN!\H"ESW%Y NXR&W". M:!;S(?5GR+G $" *&TI: 'C1&1T&32=V*R=BXY-Q2A='XGJEOH;$WD3W9&-Y M"D?HADEU1E+HFJXXJNR+#UI "*O0[@%I=6P]+GXCU;[8$6!L*]J"4G<:W#/$ M#^2O:<[X4DIWQIO<'$0;GH?7 1L=CJ5A#&M><YN4-YPJX"CJKVZ@@ MG#$W\ ]2;P,.S/?I2]RT7FT9:\77 $]0(<)(P:XW&HF7P/_X0]FJ'9\4E,;A M(U*',UNB>#IJJ^R1\T2D/_!G S9A0@-6F5J/2II Y.>.P[Q!G#$A@EKO%G M8%- XA5KR'$3SU)@*7-WARP%EN9\$1"I%UC?QK63N%ZCYM_%U$Z*D([S@NW< MG\*/X.7)QD1\$T8<@'7' $>PQJ'814> $GC;BB)+>,'5F]B^"Y^X[Y.+)A7J M=*RND5143:3PR&?P1421SE) M9T3-SH9U&OXV P_X<@#Z\ONE/H:7?&"Z^:J_N7_[F"6 +M_&IQ]_U=G$09GZ M"X"H#O C-H ZO$)Y ^_[UY]U>!,^F>Z-YEMC+;F8EC:LCVKM)%EL-73>';Q; M58@KD-:\"G&)R5_B4Q]T\,J"#VC7$Y\(7'9;6Y;JRG8VNJ>#RRW9V@_VR0U. M>[,!=R?J) ON$126$:;ACJ5E%"X<_4DWT8*JA/70, *Y32!WR\<+KR7:279# M:G$W)%8\M&^-8"=_BFWD.8=9;\GXE;:1&XHK6)L47,WHO5PVEMV7X+@9E*Y6 M:6H;]*[*#;:Q$V%% +3EBU445A;\GU#*0;1&^F!'*+,7Z4*;['PD'8WL78 3 MSTE^S)XEMC6O\"<;"^.@S>: " MH&'03!XXT&.$YQRAV^X6U!1F&^@>1BL3=(=H4IGF48(W';O9+S3M#;M?@J!C M3JKWL";3'F$JUDY!S0DWQ;F I_^0,4W+]BBV>F( SMY58">CPKW7#43FD_[C MGTA?V\0H!'R0;'+D9/'OG@1T+"HV/*:DPVTJ4']2,%7?]I5JUP<,!@9P/BAN MMI9OH)RJ"@Y@+,ZX\]"T:Z)KVV([AZ#=>LNXEYS,J1+JKY%1])N<4=]HKF]3 ME!AM/( IK8B:W4=89V_7&Y)BL-I)[6F==F(0]F 2O9<@;*NS>V)K*:M*R>K" M%MX?C0QDJVX&62E!HM4I"6]*'Q8'$^2($U*D?6]B8_)&3ELT'JALT%?V M1#RL4PS!=K+?[#^YHX7&)EY>'"X>W,;K9 MVQ4?[>'"[M>,CT7)GO#IP@H%G-Q,)'?#8I_'"[!R^&K>A#AW)5S,\8/ZL=MT MX*MO41=V8*$EE,S:*'1;IMX=@W^<'*.MGU:,-OERY,%#.X7&:#N- Q\X*@*? M$Y+5J;',4Y^^NOU.W'UR]S//;NZS<*D/L&".C(]L&I MS5?PE]Z;S\:FK:_G=JGO4F'\QY#//"P *++%L)"2GE+V91_5 M/4*ZYE6A8[>R,"?9NSH_RVRY[H56>U=@X8L[WW,] "YB7 JPDNV,3Q<[JRK* M%#.!O:]891(?L-M(^.:@_'+)I5,6A%*YJ2=YPKLHY4YE'LFB]"63E&;2\S-6 M./4.R:92P:J'"WM=++JG,I1O+*"47A,:V[>^WBDVI_5WR&4W(QC[F*RK'3 WEX M$#L)+#X%)#:\".3D='^ZHK74:U:GU,AJ-EOL+C:I5QNS"UT7 U>,MOJ=&R[6 MDSM1*X>D$L,+&*XG7]!1%,.A9[I)F] Y_0N@G;]JMWMYUH,:1G.W?DY:@)0Q M=DYMN>B;=@>HFC\NAL!N%"/6ZMV=J_.?]*85D:/G]1R5;Q=M<+4V/&.Y>GP M;1]W[+NUY'J1JMH;:K2V82^V737^JHHI\3O*@:K.J^9O MO;?WSCXJH%QY@T.Q8-NZ8$4 RWW%*UJ[][HXG8VOM#!4M##*T_02;.7()8O+ MD<^9Q2HZI2F9Z9H*]%(9F#FKW3:ZZL3GA7:CL4532ZK MIRAFB\Y,+S%\C!BNMXX)P[EGIG=KZJ4LE;ZTVL;.J2WW'$6U/Y^IYJ9OE'W['- WI%X)]J&O84/?=B[Q\ST5K6AGNMR MIB.7ID:9F:XZW_:3F9Y\DTA5>^.@O87+1+&";8?D=E='@,4#9*9KU=;Z=$<% ML'8.(Y?6A+*!BS(S7>G,].2[2(5I_ -EIFN51GOSWF9E;OH>#E,5"[>IE9M> MK];+N_2*C%S:&.5Y>@FV7()8N/PBU-R4VOJT OE8&YNUG?:"3F2*H4 M/2PH-UVKM,J:;D?IBC:2JZ8KBMF"_I]]0#;NE- MJVWNG-IRSW'DDL4G/_(YL5A%;[K,3C^X7]WI=1./R^JQX[*&0K9>8=GIFJ:> MF:?4R(KZ)UIR'=Z#X5>A[/1>M5;>!U=DY-+4*+/35>?;?K+3-;7T]<&RTS=0 MS66F6#&F0W(1W2. X@&2TUO5IGK](\]TY-*84#9N42:G*YV2/;'YA<64]T:8KY%(5++K6N4KRQH'3V7GM]^\5%Y[01=T[/ M09D>B4-;3RZ^KBB*"_5>&]4,]0 40%*)X44,MX\)P[DGN->[E;JF7D/S)QH^*;FY=!*]UY15VAY!H+QP7NHKW\,J7^ M**'=/0%H]Y^?'?ZL>SS_*$"GTNFIAVPRZ7[V!O;H#?]7A\W\(TT266E8OBYG MN?1)/A,1]P%HV.!] ]L9<8=6#@SY4*,WTKO9XOLDL6JUGP!Z .N9/D(F_N>[ M&IJ=8DV)YNJ[N$A,9H.)$U%FM:'[;H7)-C#!"([EU;&GZ_]YNKRY_7Q]^_2! MA5F-0IZ&@$WN $N;W4QC1A3_VPR4[N7 X?KW2WT,+_G =/-5?W/_]C&+J2[? MQJ*B5P.SBL N%2DFK=Y)KE28DA!U V>!WM',@^Z8P7P\!_7/\M*[PT%W6,LWT[;96F!)[N]^F@#"I,-F M1Z20_EI(C$57C;URAS/#8A[\?FR;IOV*OPIR@=D,;0]&K''9!3UG^RZ\U*W M0T,.RF/&01J086RD>_K[#T)6YG"S'S2'C%NM]F*ZPN1CKT U:)LPJO6?[^K% MVB][-YCV[2U/1L*V"@FJU18,K78&0RO<&**9?KF[?;I\O/G?ZP^,ILKH@R_] M;S=?__BP! ?VK?_PV\VMV'%8TIN#B$E,%Y4<$QQKYL.QG69ZV/^R !VQO>F MS-K.%(N,L'?[TF^)Z?YG(T'KV+"Y-,VIT0*589:@\)FS\2\U^G]YL;-Y(IHR M58.J ZE=M6]-T:MZB^8#V/#JD08AQWB?)>S@*8+JE;M^G;B\4/^(4)F[F M,A%F+GE\,CP.#B.8/(U@#WRJ&Q;R&L-8&&?U=9-]-<:<7?S!=<=]7W+_=+D? M[!2,E'G)Z9/AM-3E,:>TU.6GQN-2EY?<+W7YZ7,Z/&5GX3$[HW-VQ7B\:[[C M;BD;Z:D6K0Q7V\AWUHK)HXAMP@6W:VXTE5VLEP>7A/*K6T$\YDY,)!WT-BR(G@1F_V,I(6.O!I=D'6FD?'*M](+9'Y8AR,(F.!;F6 MB'I22]^Z340"A8JYN_M7K=IN7L)_NVT5"':F(Q%/6>$L/[B2WC3Z$3BTXN-,IBY8K,G+A MH&[5#@OJ@H([]5X9W5%DY,*C.^W=#86MHSO9#NE#*\'=(,;3J#9;I9EP?&9" M*T-9CCUIU*+-A+*])P M?E21+ZU;1KX4&;GPR->&'?TR(5J9Z%>]&C5+*,W:(S)KLV:!%*A;]V7:UJM: MF=ZDR,C% SMKSMY^@)VKT= IC09%1BX\"M;)QVC((Q*6;ZX3.&W=TF X/H.A MDZ'R\AZ=L=)@*&-AJL7"XAE@N4AUNC2VLY[S?;%]Y]BM]UZC%$8U1BX^Y)?U MM*4X7!<5\8M2O$L4GQ2*ER-^VUQ06 -H90)^K:I6+^WW([3?FRIIUM)B.).1 MBX_W94WCW(LEG&MV?!GM4V3DPJ-]W5P,AMV"?6XA5QM+AD$+P<[=GF MPL(J,"L3ZM&J6IG;I:[MEGXXE#4%IB"5NJ^3H489YU%FY.+C/%GS#XH'=6DG MG.+(A0=Y>KO;"?NZV+@NJE-:!L=I&72RU@@NWMDJ+8,RSJ5:G.LP);RZU5KM MLM&$_ZI ,!5&7M.100&S((>>$>L+M6;-\7LT?AQ5;$SKK<^N3>Q:<8:BH SB M5A<^0=?EMA:+CK$ZMZM=+2.#Y+HYTU7W4?"K;8BF*U MJM8M38TR"G<4V6;8Y*&,PJTPB!M@;HYL'[2&LA;QTA3SB<-EKBAB>[IY5)&X M7GMSJ[A16L6G8A4WM[EWL [ERL3B0)>75P^.T$+N9"[[N!=]6_!!=;N,QI7& MQXIX7-:,C0*%H:"(7+N^ON!T:7RP-[](;_BVO_2)-$9AB6KXM9YCCL;J\2H#*L$?#N0[.% M[WZ:<.8A*I@1<(V](-M<9H^9+7C+N-0S(_;*'<[^FHK$;N8CM8*4)'=OK'O8 M7>T187T>BAF16%L XD>M4ZEUNY5:;=DVK:P@1B8XC\"OZW3E3"M588;+LS#H^_ M'!!-%'WT(OY#WPCO,"SV8#/?^VQ M;_H;:V@TCP9[U5W6K-8TAB:J6\U!P12KJR0S<64SWQE.@-DL71.MW!.7_83M MT;6M)UQ;=H31_4U1,^D+33X[KJN]4*U26Z5$TE>;;(]K:J\65MIL):_6I4?$ MOKI"6->K#G?^]X%^F.BC9:42[.=LAHX#;?4K]O25H=A:(83/O)-?C=^X"Z8%+C]"@+TK1'8&T1#:\@7O_T--!'\\824?H(Q M/YGV\/L[QL%>F,&[/0>-$NE* -. "_C'GXW.N*8U=W9G4IR!L6V:]BL:+N3/ M,->?PF_@W2Y[>/S=K;![\3].N)A A2'S9M%J$YYX%@O Q/9Z;]QN7/IN22 MNH%M@_I:M][^XR_=NM;YQ66?;-#*^.5GPP%0V/#D6N/J@W#3%B)NN9-,H(H% ML(H[?@2L>8Y)DHHI#&QGQ!WR4F$I'VIQE]_D8S$IFAY;G))T=&NUGP @W#1G M^@A/I7#S@4&$/YJ86?-.5! O,%2R[U#T9+1).G0O0[AE"-SESB^Q3"RM%E_" ME[O;I\O'F_^]AM?C&AA]\*7_[>;K'Q^66,6^]1]^N[G]P! _+&&8CW^ ]D+#I25DE=+:!3KU(Y*#:2Z)D8L[ZWH.F)3LW9V>]9.E')Q[]O#[C>OZ?/29@A+BA$F$>&(A M'WR,PLN_.;;K[A(Z3SEP4H!YYSAR\8!-*1*7<(ZL*&!3#K448-XYCEP\8%,N M5B<<]"L*V+:F)&!W;3Q9C!43G"I=!J>+9,IF3O*"(+ MQ2?XY62S;'@I:YU$;7LT?OUOW_#>;BR0.1\_=.^\"7>>)KHE#P_I3"M,LUDX M<*0O/P,NO@ L-DFZ23]@[%9K95''XX1TSE;-R4"Z4=7*ZU]'">F.EJ_=4%0D3\E]6>PJL*6Q1;E!@ITIF3\[N"C)V>@*L.<<1\X+ MDI<*K.4<1SX9_IU(@&!I\Q/KC.?:'1XTQV*4+A8+V&4W6[ 4O^G.=^Z1B7AG M/4TX&HUW8_@'[6]WX^3-+P^?O]SZ%!EY#_AMYA(G* J__\<=>Z2[DVS0O2QQ MJ\;(>P@&)'L1FP8#2MP>D_<>3^5@AL5,@_MHV R!TFPF0C3(!N;JINZ\@:4S M\H?BHA9>7!C8EJ_JT;!S?$S'7D/-D'R1:VM;(('UP_B,3?65Y#7N_$5 M2*N,IWZQG4<2U8=04G>)VO3*L(TZ(^_!!DBV7;>R ?:)4TW-\.+QA3?"R 88 M!FGV@"+2<,IRV,HG?6+KL@+N'H[ECMV@5VID98-Y^21-* WD[:I J+=;*36R MJH!>;#Z\BX5T4H"NKR_"K[3YM;>0RS?]AS'UIZ(NA:QZ]<)="L",F6[B<=(+ MM\ ,>[:!Z@P(S/3AQ( /RV2*/5Q>V+#)UBH!OW65!HY#W@-#EW;RO+:I\XK7=*H"HT\LG$KM6,M82;_6\51 M$=@<2X"K?;CT2W)#5FR792+F^:(RN<_2/I(J"T=EH]I4+W9ZIB/OX0 A^6AW M'VF6FR'YV,]GMPT(G!BBE96E4UON.8Y8+OAE3958=LH8:O.R'L(OV;NZ:LT;$^BXJ^"9\IEJ=_-K_ALF#"=4:). MIY:D5FVTE!-4I496%MH;YEB?&[2[U=IR^U\%\54B>Q'9W0T['IP;LK5J5[V< M##7#1?/WV6(MD\N4=I4&6DKZ.V\'_U@AV8+WRV<_%?N\+BG M_YV_P?8^-H:8HH@7\J:KTA79 'U%YL] 8P0A 8\<1N:%'B,5'1X;+C"6X19' MKT6M42UF87%>%B&]FBV^3F*U5OL)%"O(P4P? MC> WZ"S#2P6D$BW#=W$9FLP&$R>:SVJ;?KVZM;H]\M$:0CBCS!^SZ9]O#[.\9!]&;P.\_!<*J< M)OS"DU/L::T.[^VL)1-$$?9PD'[3M%\!X$P*C#^%W\"[7= 1G(4W?X4^DF%& M_,"7RV$C.H>/JY *Z8] D6@?0F&/*)RKJ*=R-R3=:F40DR"3C[W"E$.AYL*^ MK83):,Y*6%!;D<+*;CX$V@MDP(2%6/_Y3JO%E_#E[O;I\O'F?Z_A];@&1A]\ MZ7^[^?K'AR56L6_]A]]N;H6.9$E*\@^N.^P:!&+$ONEOK*%5#DC8S)JZA$XF MZ-2+1 XJN21*WO<_?[ZY_2V^E ,X#B4[-V=GO63G*;%34XR=:L:3;\$13#3P M%(E'''\D9,6Q3>;"9_O+_1"N2I#[L5,=M++TI$(C%X_F7O(A9$(4^@C1W&N7 M8%9GY#V .7-_OB,$<[W641+-:J;<":JQ5\.;3+A)(7B7>Y[)L46/8YLF\_0? M\(!2$G+*LMG-7#0O43;=>]T8?;&=)_W'/Y&GMHGA.VR1E2BYN]P;ZJC9*>M, M1][#KI&Y&_&!D=FNE\!49^3"@5FO)=^MR6K.[ ^8:K; 5#-T$^3HL+6I@/*4 M#J,[8FEAL$<1"3B6_,#NQB?![)K,W0C4Q:Q6 M8E:AD?=@[VQ\?*0@9I6$[+&'8D)K9R'K1A'1.!*'0NMEKH.UZEK;LA]P-[X* M&/20ST7,5ELY&5)J9&41EOE2Y6$15J_V&B7"CA!A]5KR:>$Z(V'O"&M4F^KI ML*,(;03WHQ05C!.RN+5NYL+>^5C<[MITK5M;O\XC(708W7X:@6ZVSFV"]8I!6>Q-^PZ^G,M-\X9]2+D-W[ MSG "$L#N3=VJLKD1M(U'6'RR#^(SDH49L0NBCA;HVFFP"WP7OJ1>^V7N&_I, M^^5]A0'DAQ.FQ][O!._/N%2L,CD_+-!;O [?X'%GBH9SIK1XX,\&*!51#?(19TOJA<%?7T!AL,?++AL;F(B%-_OI%8]\Z#N&9W!A MM%__@$%!?^&KIX;KXHO@_]\"!S!LS+0N%;FLTT[; I0 MGV!I8$[%.&=4)L*MLFL=N!=[\#+Q09CCT/1''(L!P\M,N(#=[B>&$7.!D+Y@-@,# 2C0SC]O@],5#WF,EU6,$8:"\H M+,;!S<,:Z0[-DP;CL,4:6&+4L]E,QYW8F,'[JNQWP*NSS.R*D&W1FRD@,LH# M^+'/DW#5894)$!:?]B879\5_<&=H(%<<8P@OX?_V=1.'[K9^"D3)Y*X+(\N_ M*,(^I4+ND:N:)#E#@#LPR271PZ$,PG#$3>+B&*FVB"%;/&;JT5/X]P*$0/7! MKR,B65XX-EDH+I$P^(V8AT]$U&-PD%]$[P::N@MK8OIPZ,!*814Z<"]^-^^'JJ42C<;D'4I%S5(VP[<9+1R<5/J^PZ\?[ M^TA#R0UN%8M2+H_LN/7L>K=DOBGHKBW5.\D5R"HKJ)*]/?#14D6K)5^ZJ1"< MTDF3O?W;T9*FWDDN#2/EOX(NZ8P/T44RWRIS35.JZ/!M);JTS\&NK*.KN8+^ MF7-/-Z(_?H6ZDX^$]A&$% 1)M2)VHK&6!K_TI6>N>*7VTM-*M:T1O,RI;8JO MOIFLCF.;:WPC310V@R:E.!HO6 M2DX-#&@:&2.K*;=&]VM=1=V9P(86%.F_Z(:)06Q0Q;0Q[&)!]U)DE2PM25Z' M3W4##+U@W#D[KUI\ZZFT7D*+'DKV"E)SC+%"PG_B%A\;'JF #3H*#9KUFM;, MX>#B5]=S;.L9=$B5A1'_3]>WUU]NGBC4__CAUY_E,VH%_9=.*.[^>7O]\/A? M-_='_,284=Q,!JM- M\Q(GL!!Q)4T%^G]F!'H6"8#@/=\Y%DG#',! -C(K[(M"@6*WX$"Y"GFX=!N)@PF$B"!@P&MGD3A51RX!+2S$7>KA>="+OGZ\>X^6#+^ MD%NT\]"6+F-A ^YAY(:@_R9.GL0ADQMPUM1?8T=$ 3-EW.?&&ADOQ@B0Y$H@ M8X0;X\)L 'BR\"0 C\5C 6\Z(/F)SBQ(Q-"0XQ9V/1--(:44TN$6(/'5ENY1 M)(J+;=NJ[!;4C$QQ"X8-3PD=0BV6H:#@2MA9CJ1'#\81!)5A*_@)R),]U"7! MD0QB_\9?1F(A*23LR=BI"M(6 Y(&,AQF0N='(=P<7XJWX7CR*3G#1_T%2.7* ML]\ Y9)27^B$ZPV5+-)BRL5T](']@L=',/]_^T Z#YD8'?*$RZ%%@#2XQABV M&5'ZU24I"1=/T 2?2CW#T>J9 VD9SVFD]G,^&Z![2&9TYRW^T&YG-(U:2HR3'*R%F&6P M"R3V7EQ!DZV[=!R&)O6TN"_2( S7K%COQI?L#[O>]NKE:@G6B4X#BG-D4 _8 MV1)DDF+?H<, %@G^FX?V@S@HBV$*R2A3 / ?\N1T%/S03?UE@DC6>Y5NHQX8 M8(3>J3[B@4XCB5Z&[4(7XGK2B]N5=KN]X8OK"R_6$E[21M^!_R1;35";"4ENH?TPOA+C#7UQ_XCGM$.*:MA6Y-+FWV"5 MEC5]T>]&I'XF-:%ZON-+B MFRWZ7;CD[^_G,O@H)0/MXQ%N$*%U"!K%GI**P[0:S!\RQD8L4K#H.@OM%GL_ M^L6&%>3QH7,3>XL(9SY*(U+^2K[P!J4*#_(?9$?Z*WM$F-9ZW78%]RZ9;)@X MY-BG <'[?K%-V/E@_T4S]M+3?\S1")X$JD?+653[0JL*/X8&#:UKZ=C'7($* MJEWQ,-$.Y^#&HHM1\#8VV?D@!;; ZB)G_8:0&;CNU\("08/+M%W?26VJXV+:$E/\V07TO!\+_54!7[ND4WK&&B.>G.-Z^=O MU1VNVWQ(E;+;?.XU2LIN\WNZ3EM"1\5^UF6W^9-B9]EM_J3867:;SS+++[8# M$\%HI+Q:=0$6O?N>/8.K6][43;BI>Y$:V&YL[1%()ESYCL.MX=L3'DN)M_\& M;/@*#/G$Q_#,D_YC^\NU, !\'K]ENT&5XDUH_K[$3.;;W1M76=HK9"*DE,4N M%(;7"I64'/7)<-9V()6D:5JA2DG-BD4BOB+#*R*LHA;0UQB "M1'S<%$#<3I M,I/1N&;A)>L.P;H5FG#C+ O*PEX=H7W>X I-)O6W?IM=B<4CM=)*B J(;M>B M:L\0;:W?H//&Z+:>\VD:G0M8; 61[8_,/EV-%YGCJX;+B?L;UQ&<.YX,A7^ M^W67%X'?.#WE?$QP2T?;UHVYBT);!++UI8A7HNR,O.\C1N8*1;AQ2>/]*T*M MO;F=NJLJS%A]K]@,@^3,FJW#OO>.C06D_JGCI4[O;:_I-.TJNW^X^_S[U1/[ M9__AH7_[='.M[+W -:EY,I/.#;/PN>M1B0#,T',]3&.;"5*S5T%K*B@G[X#@ M73A'9+U%&=O/%J5@RY)I\M=8<\>8S3 )[I\3PYRKX]:S+2T-42<\U7L(? MBB0\CV;Z[.A3<2T$_AAB/3"W(E.)J8*2O,.-5_@,SQ95E>!AC@7"2*QIU."% ML#3#$XGEMH5I<*X_FYD&=]SDHD%R_?## 8B>'MRET\?C,,\NF/-8-TP?R:'3 M/12DIV/H)O-=O+.#Q,LV,+ X9=R1@;=?1(IATMH#5%!I"GDU*;S4$R(FI)!IZ .#B/Q* MLQSP,%.P>A3BX7HZE@R++2DJQA7>[T21<>550N2I95@Q;K.\S? M0EQ$Z7;*A/]]I$/TBXR'T0LK4SQ.S70E"E^)3N/.,7OD.K@X&WAHHJM />5RG-("IO5>@D<)G^1J?2DQ]N+@TU.O/9.:N7*2YB(Z%0MW MR)J-L:@'Q;<4E89#)[3D)T&-E#+0FY]_2,[^,^2I* F:AW352^6LR,C%PW'K ML!WQ/89T U)+/%;9 MR&C,86.OM]=O[.5UFM.%8>UX#H=5@&'&2S:J)[X'A?+#V+!LB2*J(Z\HJ"^O M>V G)=S%]5@[%>9../?<(HNZK[YEM'TV/']&/^F!SVP'0UKKKQDE),!WZK7. MH)?G!:1.E3U>__;M^O:)W=Q^N7OXUG^ZN;L]TAM(V*W&MLPWNE?A$*5%FKJ@ MO2@[;5A"D01-".2E(X9==IYM1W2O>IOQ2IC-;QH6_/7,\=+0;"+Z6<$<9;Y0 M\'MY7PG?6T&(BSL$='\)0'YK>YS5*T$Q_M,L?6C5^^ AB^&B^ M1=<% ?ST]ILDAS'L8TAVTZL<@Z;>Z':+N,H!V\<,=BS!)KPI-)-%W2.V W<& MV*\QO%@V>7-QAV/4:RGH^(0JC!8K91]*XKJ6Z%MF/I[?GTKPLUF16<+*<3E;: 3O0E0Z&V@\A[0J<&EO =4 MLO,D[P$=,OOJ=XM:ACYZ>&E>K6"5XFGE#:VY*O[Y)[7.=-[^_/TQ(09%-CTV M%/*PJ7A@UM_RK!T,5P9$*QUM@[+/9Q3^5!U1BPV40I>:I M5-\U]#)]J7CEVUZI?%W'^Q,Y\8U/!]S9L[@TU;OG3 [BE7QS,Z[E!?,.(F [5O(^!P55R-J=1JR[XB?%BKK%K.2F6]QO4M M>DF=Y61,7 ]ET:Q84K+ 9W4WBEY4<[FD "WJE3N 0)/RBT1"&*87S9WL5!C% M)7'Y8@58']F=<5F)NLJ6$%\7Q:5W1WWR*T10LO&F2\@XQAR-&%QM$++CJJ\>Q/P!YXG;&2XGF,,?,]VHN+Q:XHE"P$( M2B9K44)P83M8:DKPQCF5U"_JL^&"]^KC-._&??CDB;O>HR@!OH?& ]TJ^WSS M^'CW]7?,]V5W7UC_^K\>V-/UXQ-[_./QZ?K;(_M[_[Y_3*G =Q;[NV^&&*G- MU=ZGXOPF1VG"3TT#;+]1F.S9?WJ\_+L.SU68SJ;ZOVR'ROJ_6O"XZP]<8V3H M#NK@X=!V,.',?)M_.PA_/%T]?!\A--;* #]Y?G;X,SS&L,,D=GA>HYXW[D5" M .;-N@1BK_X')L@O#ZC)JLM*#)PN9HU#176DA8+)5>6MQ??=<+62)2 M:<-UO^HN4-O E.V1S[&XS-"?^J:.BHUYV.S4%"S2HPHT0$ST-XRQ06H2?@,J M HLWKMOEDGM;96CI$I#QSGK4L9S])]\U+)ZYGUL"#;5N.YF&E%H^P61R@!QV M8S"H>PSS]!^,4W<(T<[!LKA8WJOA3<1MB0R$(_M $BWVX@&W^-A8:R5TMX*A M:'_SI/_X)$9YX"9*R),=4X"P/S^&0K8U5;56(DT/=UVQ8>+-KD#Y/%Y?X2./?.:147WQKO_T[=U[YNHB)_ZO]58X M86S&84^G.'64#YH'[LW\WSZ\$;80,:FY>6B=8"( CCO@/7[8C8,C;!Q$G)76 M 4P"AAMS*F(Y>&,NARG /]/9W4SK9:?5(NV(_^XN"3OM*23RH$-@?O#'1'>" M0G>>4B"F8,]?U;M M%$",-.RO(\ ]OOR>.S3IC(N]N?TR+P#WX9*;U3G?[NY-A7MIM9DZ]<:P*2Y5I!RUHV]:Y?J6M1 MJ>VF5[_P@>/C=B@T:$,(4-C_37<\0S?-W75ILN$$QE(]9CC5#Z=+Z[5NI:3EKTF3_(@/7B].DG152EZ!(U^J7Y'IN&8%= ME!)=CK'NID23K\AG6.0>E&CZ6HMQ$P-_*G![XJY4BM_8:&Y=8X 0LX^ N2* M(J'/W!H:W-VG\XAAGJN[;]]NGK"NP"/KWWZ&OV^?;FY_N[Z]4KC!Z;N/L6FK M-;5,)Z!A!\%YUV:B8P@28^S47!3V)?X&;B]Z7&SL6Z-U$KTRPV\1@P_A0%>4 MWK1=,$=KU=(#9"NFNC)]JYBI=I-G.G]&4V'@;5-?5QW,*4L'F:3@GNL9GB]* M1CA<5A0075I=,*$H"#WB,]LUA!6'0;KY(R% B3_&SJUABUK0UVA74 Z!.!'$ MW1G;6E)48;'ZBC <@V/"C)57E!&+=Q_O?W^X^J_^XS6[^_3UYC>J7J*^Z"X6 M+9GYSG""9[=1/V"RGX;<\3!.'K83KK(;^ L#MT.=6A;/]46."WWP2M%,&2 + MUCSA8Z*+CLA!ZUT=(_&N!R^T,']GKOX%W>0']\);.'M;U"[I$ME,OB^5EB\F M)WT7DF'K:'"[TM"ZR3H$&U$G$?QU8@PG1"X\C,#@ECR%C4I_:'54G][$G9>I MD8V\M[U LFC)CFRH'!\"3X*<451Y9(6D@4R&W65A U=.\.9V=+4FMT;BICKH M8]&?VIC2J1/^+]KSP+\7VWP1FM'DSZ(=-CH7=+ZD.R SV"/8"J0#5#DUOO8= MEURY@3P:BK4F1P\!O+\!G7V#GO4=9#*Q5WI(ONE1UVMF^QX=RF!LV<+6UU[8 M')SF%;34D0NIQ&/7(00''#3%"ZE(/J;<+&('6Y #^UW7$Q[[X1U+!00&N"_]#Q2'RN M[[W<#,!5$%N' #P)B\ZP^@UH2"IZ)8V5&,?L%PX,QIG;LOT[>G.FR<.^\J), MDF&-T5CA =[$>H:F;DQ%J25,6WIV.#V %@Y* O@U1!"26*F:I;ZV(NK(ZDWT MKD#JIOJ(A^>J4E_+[8V>HRT5J\@(1'H+6S.5*X@.3><'BDV3*"X.4='^)!1BCJ*E $ MKH&E@V!%(PZ$GH)\T-JF^@]CZD_A":R)1!I'L [\%4YG<2Y?Q0Z93B!2/:9D M,<-^[=FBJ?O,,>QE$@L(AHR2-A-:U^+#H>$,_:GK"?T=WRI(+$@BASXR+YP( MX!E6!D)>@:_? D #(+'(7 QI\57%5D%:%PF%1E9,^QKPJW2M&R4$2O5:2="] ML#C?I7@[=BFT-YT2C "-KE'QZ<+_3T+ M"'+]HIM^Z*2/0O )ES-8["Q<;/5XEGGG.W&/AHN5\E$E2C01>ZPQ"PD MC7( MLL''[%JDYL"&>2'"8C*/5+O^[RCY%E4SA21["H[*6-M'W2_01E@>L7P8*R1',1AT* MH(2412.,6_0\O2->%?65T[,.UDS%U:(1*%Z/IITLX.M*)Y33,33YI_X O8&( MKH\B5(J^49S$2%.MUVBBL1G$72IBHN#W&A(JT^E"F<1:8;K-JDG&89(\1\94I[CI@5 4%] MA^-B$.G/;R$90WO9"<6*CA\M\MD)VPSE,&8\.T'U[N/5JB0,[@RX2HX7Q0%< M-/$,=Q(8-YB2C\T[1>&7SP[I .^!+\-BX;##]E%O:8UHN_>!QVX(P<3E*7'R=Q_1+;; M=%)TYSSKEO%_0?A&K/4)7(T1.!@Q)3:WO^C>W/X2(R)&2A9VBR3/-#O=, DI MVD3TI:/.(U ZPTCIQ+R-11*XIZ!CYB]X#:/5)@E+^HJEF0$;H>/,-Y'?V"X2 MKR(K)HB:P(ZF$Z)P[\>4.+(]=->V0/MAC/$[;GJTTR[\H++A.A0#YP[>U"#P MICY5&:56@4(*K9:C\Z/N+$PT!].KW@U.,O^;6Q:'+0;6]S@SK.^51+V59B5? M2!5^]>5.*N7W%8S7"2LQ'N #]34QA *T:'OQ\"*D9^"E3PSMQ!T!@C_F;497 M(.FK"%]S>9>H>R=DDUU-'!CCT?!18<*<8AKT[[X%NW"8MCEW_J!;XJ 7T8_Y MD3(2_LV1-!&S%AE]#D?C@,WK=VFOBAX/^!2UB$7YQS4'RP&1P:"J9Y@+M\)4 M4^8[R,LPD)>K:BPPA+FJ>[H7ZX& B;01V)>/ M3L!N;0^]"A.\%C N8>/&TJ$CS6%PL=YER3?4NQGC7LVDUJ=FT6C6Z1U=9]KU$P./*=F"OPLWE-S22<-\\OO#X8K>H,/81F)\& M$D3DTP7KI2]!6,!,Q50>V O1=+QW[!]OL>MT\/& +UVB6Q]12KC[BZ^GW$]I M"W_CW).=J2A[7UXC/9DM5M,"(&K5&/K0$N&6>YQV:0DT%8%6#X!6KP8D>V-W MKQ8L311+"M@PLRXI@ZR,M=N\1F/MAL!MAL5H&N0'IC M!LN.8MJ$X.S(F:;\L[LH>^R-_#DQVA+?%NE>[( MA&]0O>*DZ,-^M5OV_J<[:COYN7A+\Z=]%+)N+E5QSJGC1U#2<7[08L9*$ 1W M SV;/XUSM4X:!0VB1#O5(A%>#-@>.2<'ZX?,8"/=W*T>-17/!V_%8J-^6*47 M[OXE&(\"C,<'\%+Y'3/>BL5&8X_*+_"#2N =!?".#\RDZ(37C=GG Q[=LCQ2 M&AX2;7E'I) EZVFU@&"=9NUG[&L_Y_\ M1T.K3KPI0JM^47]_46_!_W67('96@%I#J?Y4M(T1B2H29)]$A9S<$+6WKN5Y M"5ZSV>D)P6N"DFJ<-X)2*$,WO\CFH<+;E&5'9:]$?1]^\BJHV>ATFCU@8Z-7 MKS5_YC^TVF5=2%43]$_SO%&SBCQS/4^HXY_+^D$U&*K9"MI(!U0]+UUZPK]O M+!B6NLI;= 74,.BF)8I$R:EQT2D"E MD =MG3/50BD>"P"F>7'FX8 USMS-0H76R"J?*\L[X-XKYU8L/$!Z"T])1E'+ M1_B$A_<%@RJ]IZ^QQ#]K6@O)W?QY.'D>>HYY24^'0&Q=],X;B!G(%$88Q#T+ M>;Z"58Q"6)Z\*I/_[/5JY+?$/KKL]2[%AR&HVA=:K415-G)]Q48M,E005$>I M,*W7ZU&)-EFM!2_[F+8H":A[[)-OF%15Y*K"FK4:^V\=E.$3=QQ]R"OLB\.Q M5T6%70$YX"66H9]\$$Q*<1=)V^K^3.UO+OF/[O=ZB,K.A;9\S'..J$RGTA?# M ?R1"R!Z2Q#@L/Q:K8U1JUIW!2@+!^(1Z4FMB23N:A1NU$((=B^T!2J4!ZT@9#780,*@HI:+>:O]BZT,S],6DNE MIXGA+(,Q;(1;%V@L]6%&>:]3^DIK01]JM0OMW,^GT@E$35#95XZE0B3^_JY; M!+\&H:]>"3W@Q?.IW_0WBUT[QO"[:Y]!=$X2L4&6=6T19=J%=N:'!2L(E( R M42NS11AKI&/L8<)U=F^[?/3_MW>MSVDC2?Q?F?)6[9$K[.B!>3B[J9*Q,,0$ M*$22]7W9&D .C1Z@'E(MH01D"\., SZ=?=T]_3T=.O&J6R ME]:I'(J85!!/_4QA,X&>!TXT'7JB0VYR&-D[:[B$"SC1HCR$\,&)94(="XTX$8:5D-1*Q?$4S_/V$6F&'(6]D?G(@>MQSV!.QFE M5A&$2JTL1>A7"\6L4I!._8!C%YE",=MT_']69VL)* FAG%4+TJD?6>PB4PPY M.VEUMB[].9)%62M(IWXBL85"08Y;+K+"L+!)*>?P,LM!+]:G M,%E3*$CGPXHD1&O3CWE%55Z\.A#?9?'S8RTB"[9(@I$LG%"PQ8)TZH6;5L_=?M4]+!(_U^^+D?\]U ^ MI8)TZC'M'51:R9?9H%U+3##%(I1SWJ*;7ZQ:BRNAEQ\!Y7XEND.\J?)<+Z<;;W)6Q4KODBOR&S=QN3[99-*['R*ZGA& M7&R@>RI:,]1NU]>+[XEH6O#>2J7UFK94D,YARZU46DT.VZ!JO;Z"TEG59L,= M.%PK78MK9?BZ()]CHENIM))2MD&$!;]#Z;Y$V-/E\HFH81DB/A$%$Y'@VK]E7]JKAO7R)/ M>EADM[^O??Y(/H,D$' @!W'BL+E0_X6KNP;"%D\QH4;P*L' MM=$(JY?F]X!@-YR)_O2\M3.:S6UGCKV&=!KO*B<+$K1BXNI;P_80F[ISV?T% MVP]EY/(<(RF?J_PY]:1 .*1C% XIIG"$W4,.3CC>3G-(ON:0CE)S2&LUQQ9] MP3K!QQ 7L8J^7&ETMQ<(CBA?"T780^*Q-0-CM$ZZ:D(YEFC-;9,XD]SI'@@8 MM3I:OH7HK]M^F[J#CLLRZN]XB[Y#7]E >JW>/ +2#_ OR[2F"[HZ7=UD76&A MR=,4OY87>UT&=:5]G+RH8V,T]SITHS8Q?PPARVP#9]ZV8C^;^T@[-Y1C_>9Q M=V[88^.&@V@@ &KE3FT<6ZW_38KF#A)022P]SRW\__14WU:Z>8JE6$;"]K__5I7$R@<'+954CX0/>&10NQ3Y#)_FIL[R-<1: MK8(*#?HFZZ\CR_*E5*U5*SR ^&K4TAY0U^>V[86\E^*@UQ0NHW"@S@R/X@'F-4:G& MW\U0,8E" LS2"\QN+.Q>*=4H=EG@[V:)?9>S%<5^G:;Q =PU7JPS2X"[_*HH MP#3QA3I8X@4ALT2YRY7*"J57<- M9+M-$9-X0-6<@I22N#RU[$!6,@69P+>1A+R"?"O_9K_! VF;@^-DB3.X?\)K M#V0),D$@*%6,_&9Z=0\0XSHY0<3V=S&257^7.%&1<9T?,BI/^[=Y, M4<9U>5*65S]:*=;V@#&)QY.)N/+KL!F"3)1#<,RI))5S*LF'E$ZODOC0F2P; M?FYG5/6",ZT*7XL0DDN\2]F#&Y+CQ02D9'P\(8XI+^]_H M,S:IVF-G,2/Z)1N/7 =9-GTQG>FFXYW7S QLLG>Q;4.1;ACN(&*BGQ,RFD0Z M.](ASQL[TF_I2*?:F8 >I"R88<@@(3/*GX.CR!^.:UOF=_J7LM\W9=C%WR_\ MB:9%*#/2O^^U?$HC-:1^(5KUR'?+SYJK?N.,OC25[7Y$(.F"Y;_]^< M:F1/2;,J4?Y-'M#/XG5A'-X#\ZJ8P*UO]=?(:\# ;^R(-9GNK6%0I)?O! JH MP@']",\=5D1UZY53Q#H"LZNJ=##]!/H #_4)-I[ +L/DC59Y]!' MF/T(GKL3RZ8$&J>IBM+)W;L#Y^(FL/I5OV1+:H_Y]G<"EE0EZ%'+@)7QYX64 M0KZGHC;[5'%J Z0]:@/U\\KEJB3JV4-9JD"6^,HC+XV0=PX0=HT0KU='[%3 M/J3;Q&;A_1 MH*EJ*@*9H1*C@57"+M(QW>C,J*FR8-=C.=$"#'@VT[$-ELVP?L(VRG&).W=U MK],]_=0B8(J7I)Q]]*";IDXWG+=72)L1\T<1_1>&&EYA)H>U/S*,11&!F<6\ M-H1#$5"L([?H/52P99WY522<^=![ FKUBRP3:T*FL%WSJZ+32:D%!P,"II\5 M-@,T2Y]C/ZW/\?R*K8:^Z!5;M]A>.,AFYH5_>1J9XYEW.@C&6O "C7D>/]M, M4L*9W%5Q_?O!Q1!>Q%>!"0)_A>[4H08QPPI?@PT_W;8^+:"J"8RD\SX1>\I> M4F A.X%4F(S749;1S DIJ<,[X2M*LRE>T,=G6V7PA;BK,Z;[)G!M_B&V.]?9 M\UA/![;)?8$+N4+_%1=QNP\(/N,0"N)Q-]!;)=S]>[(,^@I8XZTM![[+/43^ MNQ'W$[A)O#9?H?AZXN2]"P7/0);&A#5]38/P:ZCU]JY93 \BZM9D9P8T7Q%N MOL$G9_L$FR\KQ2)0*6,"#8AKY)8X4BG;QX.-5/QXQG8_+_[+="(_*U?AAA8U M)-.M?OOZS<6F>5Y?6,K6'3)FM2!7*H.D8I*X;^M9_SL>!4XGCO\B5WHCXWYC M+5"%&*S+3M#7A0J2R.*F)]Z]>4IS9>1H!3ZHG8XZ:#+ONM?J/+S5(OQ*A18% M*Y'58F4U>-)9@ULJ^Z2]$L,?8*5>P]J!YX6Y[HE7=W?GM1FNS8;2;]TJZ$[I MJ%KSA0O3&QV:G;/^@KKM5J^I= 9O5! C/4A+'O4>@!R1CGP]F=IX;F/4-J=F7JSP]7/6)YC8],V#T?*'J,\S MM[7]B8Z9V%B./M:-PQ>;O,YYUO=O-6?6!PL'9@CNU6ZCT5YUZ^G)UA=,,D;4A!R^9.1USK.VS_FC" M;2N/:N?P"7K6Z7O1 TWK)[;'3# ,O- SWTV=[IS[RU=-X8'Y4T[,?.S%P4.L35?A,G(A M(TB%!TIR4P,@3")YCUO.]HKM766G[\'O0F#;7M,5T':Z^N=<7 M)[">[I:AHM"+YPE(\BPUG-$3/9;%Q!L4/OQU"D%/:<7AE5)P=O*# MAT_A71B#8?:1-V@/KZB/G$FMI#^)6S/7XA'G-+NXU[PY%B?*7,7Z;]-(5'>) M>)7';!/M@RB&S0+":!YL _51XBY8AOLXV 5SV-[?K<(93&>SS7T4A]$2%N%N M#?\CZ3_R-:G3I>R@4G4MNW+^E4!*!'F\0,)960VXY"!3 I0E7!1<8$DY Z47 MY*@,65*I:HL=.5&5:&.PE^I55 ^D!"4MN,AAKYGP(>)],$U3,^RQB4:W#4;# MT=CHL&4@!S [-*)NZ;IS4\N_Q^&\XA@Z%C);OT.$K([/UM'(;K%I([W#AF/K MXY=0N:AM7]9%GM#$^4H990G&FYJ8KWBT\I31) 1<%P:)LVDG+ MIJ!(U[[TW]K<]OQ!.8"[[1I6J^W;"VZ/&7SF);F%F5HE1RX8Q6\ORJNYJ9S6 M/RK_%U!+ P04 " #2@!Q70I67Z!(' "G&P #@ &%E:')?97@S,3$N M:'1MU5EM;]NV%OXKO!XV)("=Q,F"#8YGP$F4U%@;%XY[T=XO RT=65PD42,E M.]ZOWW-(^26)TZ6WWI!^<4OR\+R?YQPJW:3,TEXW(1GUNJ4J4^I)2LQO='_2 M;A_@L'OH=[O_:;4N=5AEE)5U?_1.VI),J]7K'GIF$QTM MA"T7*?W2& D%)=GXFIX,^Z(]E%1BE)E9$5.W&MJSZDSI. [>,9:;21>>Q_$R:J;TR!- MU_&L76D?B4;*1(H9-YFB2D& (&IXVHFS3I]0VD3$J9[;980-315 1T*0Y$VO M-[1L;@3*+I5YHNTKC-6/!V+\P+ ?OOOYN/W3F:VC46,@IZ:.8X7EGMUW5@^$ M-.3\"W^I24KL!P%@D9-4V81O,%F&RN3JY'6D;)AJ6^$>UZS1J7=T871($;:M MV(-?(T*@O/."^S"1^91$'^4PJE)0M$]DJWVZ1UZ+]FGD5WZIN&WD/L#,7W#- M;,3=QX%U>;&@^(&@&(+8SL?9 J&XE?7)LY<4U7 HKSL_'C*S-'6+\FBR\)R M!TQ_'Y8F8V8H*_OR*PQ>$X*+:TD>#G5EP !U,E/651^H*'=\N,NNZW:S]@VE MTL6LQL.UWYLU+O"A0@U#%ZM3%;DAV%83JR(EC6(#E$=MAT8YD&XW:0=I];5!1F0+Y85V3"4-M(J> :]E3RM$[4J0) M3JC@_&,2C",^%9"GJ@"J? O)$.Z+8";3RE41>XKB&#U4S6"CW=(+5RWC!:C@ ME]O;HXL]+J*BK6_"$UV5SVOP$MR2*VKB"2/^^X%*3):SBTMG\IZ /F?,_!L( M7X1:]IYYZF$>D>M&YTZVAO$+*I@Q6X=A9=B/&P"YA6NF\>8PQ"\[\+(A&/U1 M 5_!>N^9*S$2 K7UB+I6'-,9N>D^?_CBV?=:)=*NN@E7I4L@BAQ<.7_44++ M#']':3WJ/Z)O?K6+7F72-'JG7S'VN2=GM,RPYKI>N'PWH[PN'8[3%W24)WU^ MI9U$KR^UL2L0=QM@F>%!5Q)]!IPF&FV"SR,%_1R3/>0"L, RUN!?GCB6"4Q_ M5 KJNV2M\M ]"O:_D>FNCP<0]U2%P/%PRF-NJ ANK@%X-67-2=XQHOJ>YC#5 M=6/W1%X^AKXH>/5 Y)\&6TI,1KAH:55ASP:Z[N&X@FBAU38]K%M@NJTRN "N MD=6 MI5YNN"_@?F>NHC+![:/O&T#X-"UDQ(/S+XVC!NMBEHHDY.ZT76[B(%H>> :G M1]_SE]G#,MIR>,)GYXO.D^/SX>@R&+7.A^/Q\%U'3%(9WHEV<2_24 MKQ_:0W'=_W0C@M'@XM?;XGM)^C*# M-ZBWKK]>]?>8L17CF$/BBT11+()["BL>U<703PZ[K/&]]_XE!2AZ(F?_H0O7 M7L(/E]EN<<#]':WW%U!+ P04 " #2@!Q7^^FT8\^ #;B>VP'*C&SCA$D"&4SOI/W2 M6:0CM+6D578E,/WU?S]\,^J(F,*\*Z['HVE'M)I9+G*5D!4I M+871B4QK_5ZV/L=4C9OA;X.2M#S6N/8^#-__VMD]V!4?O,F;(40TL[NNR.DN M;\A8S=..$UGK_Y#.;-;MG69]<7 11LTCEM&SN='IO#_X]'9X,9R*L]9)NW=: M+>Z(#G6:-ZSZDSI.LOL,9:+B56=7;B+-7*4=2'U9,WQ$E\R6'9>#R71X/;ST MIL/Q2(ROQ>7;X>!:7 ]'WNARZ+W'$G8'DZ=L?"F]/OXRN?G%&TW%="QN!I=. MN[-F^T@>LY+3MP-QXTTNO-'@IC'^]'[PJ_ NIR\2!W$89L.Z>$=I2GDD+D[$ M3:;2V[KPR>0J7(D\DGGG0(+V9L__R:MU(H8BD@L2AA:*ED"$/%)6R#0M9(S% M3)MQKS<.J2-V(,>VV=I7:8C,E;D"'Y7Z<1& )YR^97T= 5,F M7HD,/N-PE2OMCFBD3*"8<9TIBA@$"**&IYTXZ_3QI8U$&.NE74?8 MT%P!Q20$25XL]8:6]:U V;4RC[1]A;'Z\41,'QCVPW<_M5O_[=HJ&A4(/#;793M]NU;RB6+F85'F[\7J]P@3<5:ABZ6!VKP(W'MIA9%2AI%!N@2M1V M:)0RI\(RDKHLMPYV7:UJ2U (0[<[E$DDBU_$DB$&9CDE-HB,$R6^;[2L49:) TW6LX& M:8)U9) K2LY4K/(5@_8^L9RG+H@N/F6*/2#=:M0.TNXJ@[+"9,@/ZYJ,[VL3 M. 5J M!6RT>WKA?S-XQ?4<&,V=KW"\-^W +(/5P3 MC3N'(;Y+@I?UP>AS 7P%ZZ,GCH1("-36#G6E.*8S#@ROFC@I(59OA;BJM1?X>^_H]=]"J3IM8__P=CG[MR!NL,JV_JA=3G[[63Z/6Y-O8>Q-T"6":XT.5$7P"GF4:;X/U 03_'Y BY M "RPC#7XGR>.=0+3YT)!?9>L1>J[2\'Q-S+=>;@ <4]5"!P/ISSF^HK@Y@J M[Z>L)N0P5=U2DL5Z1=A=1KJL5/D@%Q"[@T#_R6OS:JU_!3]U MA%?,"T!0^Z>Z:#?;9X=];,S=[%GQFB$KR31L)GTXI-/L;KV8_@$=@)].0&?? M.WO%OL&/XQU9Y'J]X)ZRRY6E"O((IYO?UP#(<9S)@.??/[;NV@L>J=YL$>06;1],9Y<#2:-B_%T.O[0$=\U MW3_1RNZ$NZY5EIZ=,X-3>RK>#4:CP?2M>XS].!R]>T)@J\T'W"9^F"\[Y64\ M\$)<=U^C-SMKZG_3YBT=#B3E?Q@QQ$=,["JH'FVO'>:4$'\9*5JO, J-RY'D M,+5]]+&\G('O1@)+]3;WMTK@\4,W;(* 'XP,A__3AOL[7O\O4$L#!!0 ( M -* '%>0H9X+# 8 '49 . 865H#,R,2YH=&WM66M/VT@4_2NS MD;JB4@;\?H0TD@D.1$""$E/1_5*-9ZZ341W;:SL+V5^_=QP"(:6KKC:T6BT? ML, S<^ZY=^[CD'3G]2+M=>? 1*];RSJ%'H-Y^1GN34,_Q,7NT?IM]Q=*3W.^ M7$!6$UX"JT&0926S&0E/SX+)%:MJ*"GM=8_68'$N5J2J5RE\:$7A;42#R^'9 MJ$-22.IC,AB/H@[1M:(FM5Q 13*X(V6^8%FKURTVY]0N.AW^%JZWKH_107 U MO/S4V3UX3*Z"R=D036C%_3&IX;ZF+)6SK%/*V;P^1N"J+O-LU@MOSX/7IXV3TJ>N3)=))G-:WDG]!I+#=_)FPATU5GU^Z"E3.9==!JJ_=K%E?% M,=D!VY,?'&,/Y98C_7 2#0?#?A -QR,R'I#^^3 G#VF X"D;]87"Y6?M6 %Z+\_7-9'H3C"(2C7.DA-^7 ML@35[RMEZ(*YN'XCWC^R!+TM9*X3PGL]9-H.-"[IO6H1E8NV%S)#3 M@C50'"^%R0QC(S-2+?E\U[]GKC!9(M&BA*JAA$=8FA*$0M_P#+XOD&+5T$ED MQC*N7J,-(1MKB@)N6J9K?W*,24.C>C&.A[L]_%\-A/U@G:*O'1(L9TOD:7CK M"WR%N56S.(4-8)R7 @=[53".N=/1&LC.2Y/[^$Z*>HY+VKL65DF:%DRH?/O0 MTEH*M=Q SD$-Y([>%!@NX/V+#RT!Z>=:0 R>G3A $P,XM9@+U(OUF#J> V!R MA[FZUMH K0W:VCO5HHYJL0LF8L8.)V,IZW),J3Z5XB)5I*W-'U1$Y"SZ-2#@9]B^FX]%+QAU;,YCKZ=0P-0Q, M[,24N1RHZT#BN5XL?)'L^*(;CX'!1_G]=^#;KN_9G');&.AGPF@<&^AL8@)S M$Y\;W&WMM39>#V"A^\PU\[FJ M:^S?4@WGIIGWYQ(2'#FKY!Y!QDD@Q1$%Y!E@#+A!-5. M(;,O;YKH31.]::(W3;1O3701CD9A=-[TF>OAZ.)-%OW'9-'NH'A31J^EC#ZB M(B%/\@B[]Z!I]["EE :/ ^!!P>Q=(SU94%8#SO-E5JOI^C^23&3SLY9+D9J\ M>0FS7,5AK9,D?QBRK 22Y341@)I"X(1.\?FH-K;T@PKGHX;HYXN%K"HUOY66 M00U5Y!4\%R3>=XJ0M1I#08-U2 ZV=[QO-U8W%%&@Q8 "@^=HK6P^_8]7J!T2 M*$&EF&UL4$L! A0#% @ TH <5Z!E]--V+@ Q4# !4 ( ! MZBP &%E:'(M,C R,S U,S%?9&5F+GAM;%!+ 0(4 Q0 ( -* '%=++4I\ M-H$ %JV!@ 5 " 9-; !A96AR+3(P,C,P-3,Q7VQA8BYX M;6Q02P$"% ,4 " #2@!Q7RLR4 DUI !"V 4 %0 @ '\ MW 865H&UL4$L! A0#% @ TH <5T@P2SA&Z?0( @' . " :@6 P!A96AR7V5X M,C,Q+FAT;5!+ 0(4 Q0 ( -* '%="E9?H$@< *<; . M " 5$9 P!A96AR7V5X,S$Q+FAT;5!+ 0(4 Q0 ( -* '%?YRW[N( < M "<< . " 8\@ P!A96AR7V5X,S$R+FAT;5!+ 0(4 Q0 M ( -* '%>0H9X+# 8 '49 . " =LG P!A96AR7V5X =,S(Q+FAT;5!+!08 "@ * '4" 3+@, ! end